Title of Invention

"TRICYCLIC SPIROPIPERIDINE OR SPIROPYRROLIDINES AND PROCESS FOR PREPARATION THEREOF"

Abstract A tricyclic spiropiperidine or spiropyrrolidines of formula (I) wherein R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in treatment of chronic obstructive pulmonary disease, asthma, rheumatoid arthritis and multiple sclerosis.
Full Text Novel tricyclic spiropiperidines or spiropyrrolidines .
The present invention relates to novel compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C) and Cys-Cys (C-C) families. These are distinguished on the basis of a single arnino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peplide 2 (NAP-2).
The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins la and ip (MIP-lot and MIP-1
Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1 , CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
In accordance with the present invention, there is therefore provided a compound of formula

wherein
mis 0, 1, 2, 3 or4;
each R independently represents halogen, cyano, hydroxyl, Cj-Cg alkyl, Ci-Cg haloalkyl, Cj-Cg alkoxy or sulphonamido (-SO2NH2);
either X represents a bond, -CH2-, -O- or -C(O)- and Y represents a bond, -CH2-, -O- or -C(O)-, or X and Y together represent a group -CH=C(CH3)- or -C(CH3)=CH-, and Z represents a bond, -0-, -NH- or -CH2-, provided that only one of X, Y and Z can represent a bond at any one time and provided that X and Y do not both simultaneously represent -O- or -C(0)-; n is 0, 1 or 2;
each R independently represents halogen or Cj-Cg alkyl; q is Oor 1;
R3 represents -NHC(O)R10, -C(0)NRIIR12 or -COOR12a; R , R , R , R and R each independently represent a hydrogen atom or a Cj-Cg alkyl group;
s 0,1 or 2;
9 each R independently represents halogen, cyano, hydroxyl, carboxyl,
Cj-Cgalkoxy, Cj-Cs alkoxycarbonyl, Cj-Q haloalkyl, or C]-Cg alkyl optionally substituted by at least one substituent selected from carboxyl and Cj-Cg alkoxycarbonyl;
R10 represents a group Ci-Cealkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, adamantyl, Cs-Cg cycloalkenyl, phenyl or a saturated or unsaturated 5- to 10-memberedheterocyclic ring system comprising at least one ring heteroatorn selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, Cj-Cs
Ci-C6 alkoxy, Cj-Q alkylthio, Cj-Cg alkylcarbonyl, C\-C$ aikoxycarbonyl, phenyl and
-NHC(O)-R°, or
R represents a group -NR R or-O-R ;
R and R each independently represent (i) a hydrogen atom, (ii) a 3- to 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatorn selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, Ci-Cgalkyl, Ci-Cghydroxyalkyl andCj-Cg haloalkyl, (iii) a C\-C(, aLkyl group optionally substituted by at least one substituent selected from halogen, amino (-NH2), hydroxyl, Cj-C6 haloalkyl, carboxyl, Cj -€5 alkoxy, Ci-Cg aikoxycarbonyl, Cj-Cg alkylcarbonylamino and a 3- to 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatorn selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo (=0), Cj-Cg alkyl, Cj-C6 hydroxyalkyl and C|-C6 haloalkyl, or
(iv) C]-Cg alkylsulphonyl, or
1 1 12
R and R together with the nitrogen atom to which they are attached form a 4- to 7-
membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom and that is optionally fused to a benzene ring to form a 8- to 1 1-membered ring system, the heterocyclic ring or ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, amido (-CONH2), Cj-Cg alkyl, Cj-Cg hydroxyalkyl, Cj-Cg alkoxy, Cj-Q aikoxycarbonyl, Cj-Cg haloalkyl, Cj-Cg alkylarnino, di-Cj-Cg alkyiamino, alkylcarbonyl, C-C5 alkylcarbonylamino, Cj-Cg alkylaminocarbonyl, di-Cj-Cg alkylaminocarbonyl, phenyl, halophenyl, phenylcarbonyl, phenylcarbonyloxy and hydroxydiphenyhnethyl;
Rl2a represents a hydrogen atom or a Ci-Cg alkyl group;
R13 represents a Cj-C6 alkyl, amino (-NH2) or phenyl group;
R14 and R each independently represent a hydrogen atom, or a group Cj-Cg alkyl, Cj-Cg alkylsulphonyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyctic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted as defined above for R , or
R and R together with the nitrogen atom to which they are attached form a 4- to 7-mernbered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom, the heterocyclic ring being optibnally substituted by at least one hydroxyl; and
R represents a hydrogen atom, or a group C]-Cg alkyl, phenyl or a saturated or
unsaturated 5- to 10-membered heterocyclic ring system comprising at least one ring
heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally
substituted as defined above for R ;
or a pharmaceutically acceptable salt or solvate thereof.
In the context of the present specification, unless otherwise stated, an alkyl or alkenyl substituent group or an alkyl moiety in a substituent group may be linear or branched. The alkyl moieties in a di-alkylamino or di-alkylaminocarbonyl substituent group may be the same or different. A haloalkyl or halophenyl substituent group will comprise at least one halogen atom, e.g. one, two, three or four halogen atoms. A hydroxyalkyl substituent may
contain one or more hydroxyl groups but preferably contains one or two hydroxyl groups.
In the ring substituted by R , R may be attached to any suitable ring carbon atom
including the carbon atom of (CH2)q. When R and R or R and R represent a 4- to
7-membered saturated heterocycle, it should be understood that the heterocycle will

contain no more than two ring heteroatoms: the nitrogen ring atom to which R and R
14 R and R are attached and optionally a nitrogen, oxygen or sulphur ring atom. In the
definition of R (or R , R or R ) it should be noted that the saturated or unsaturated
5- to 10-membered heterocyclic ring system may have alicyclic or aromatic properties.
11 12 Similarly, in the definition of R or R , a 3- to 6-membered saturated or unsaturated ring
optionally comprising at least one ring heteroatom may have alicyclic or aromatic properties. An unsaturated ring system will be partially or fully unsaturated.
In an embodiment of the invention, m is 0 or 1.
Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), cyano, hydroxyl, Ci-Q, preferably GI-€4, alkyl (e.g. methyl, ethyl, n-propyl, isopropy!, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Q-Q, preferably C\-C^, haloalkyl (e.g. trifluoromethyl), Cj-Cg, preferably C[-C4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy) or sulphonamido.
In an embodiment of the invention, each R independently represents halogen, Cj-Cg, preferably C)-C4, alkyl or Cj-Q, preferably Cj-C4, haloalkyl.
In another embodiment, each R independently represents fluorine, chlorine, methyl or trifluoromethyl.
Combinations ofX and Y of particular interest include any one or more of the following:
In an embodiment of the invention, X and Y have the meanings shown below:

In an embodiment of the invention, Z represents a bond, -0- or -CH2-.
Combinations of X, Y and Z of particular interest include anyone or more of the following:
In an embodiment of the invention, X, Y and Z have the meanings shown below:

In another embodiment ofthe invention, X, Y and Z have the meanings shown below:

In still another embodiment ofthe invention, X, Y and Z have the following meanings:

Each R" independently represents halogen (e.g. chlorine, fluorine, bromine or iodine) or Cj-Q, preferably C]-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
In an embodiment of the invention, n is 1 and R represents halogen, particularly fluorine.
In an embodiment of the invention, R represents -NHC(O)R .
In another embodiment of the invention, R represents -C(O)NR R ,
R , R , R , R and R each independently represent a hydrogen atom or a Cj-Cg, preferably, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
In an embodiment of the invention, R , R , R , R and R each independently represent a hydrogen atom or a methyl group.
In another embodiment of the invention, R , R , R and R each represent a hydrogen

atom and R represents a methyl group.
In an embodiment of the invention, R , R , R , R and R each represent a hydrogen atom.
In an embodiment of the invention, t is 0, 1 or 2.
9 Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine),
cyano, hydroxyl, carboxyl, Cj-Cg, preferably C\-€4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), Cj-Cg, preferably Cj-C alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl or n-butoxycarbonyl), Cj-Cg, preferably Ci-C4, haloalkyl (e.g. trifluoromethyl), orCj-C, preferably Q-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents) independently selected from carboxyl and Cj-Cg, preferably Cj-C4, alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl or n-butoxycarbonyl).
9 In an embodiment of the invention, each R independently represents halogen, cyano,
hydroxyl, carboxyl, Cj-Q, preferably Ci-C4, alkoxy, Cj-Cg, preferably C\-C^, alkoxycarbonyl, Cj-Cg, preferably C|-C4, haloalkyl or Cj-Cg, preferably Cj-C4, alkyl.
9 In another embodiment of the invention, each R independently represents halogen,
hydroxyl, carboxyl, methyl, methoxy, methoxycarbonyl or trifluoromethyl.

carbon atom to which either the oxygen atom or the group R is bound, as indicated by the
R9 is preferably bound to a carbon atom located in the para position with respect to the carbon atom to which either the oxygen atom asterisks in the partial structure shown below:
R10 may represent a group Cj-Ce, preferably Cj-C alkyl group (e.g. methyl, ethyl, n-propyl, isopropyi, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C2-C&, preferably C2-C4, alkenyl, C3-Q cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), adamantyl, Cs-Cg cycloalkenyt, phenyl or a saturated or unsarurated 5-to 10-membered heterocyclic ring system comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each of which (i.e. each of the recited groups and the ring system) may be optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from nitro, hydroxyl, oxo, halogen (e.g. fluorine, chlorine, bromine or iodine), carboxyl, Cj-Cg, preferably ,alkyl (e.g. methyl, ethyl, n-propyl, isopropyi, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Cj-Ce, preferably C-Cn, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), Cj-Cfi, preferably Ci-C4, alkylthio (e.g. methylthio or ethylthio), Cj-Cfi, preferably C\-C^, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), C\-C^, preferably Cj-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), phenyl and -NHC(0)-R13.
The saturated or unsarurated 5- to 10-membered heterocyclic ring system in R may be monocyclic or polycyclic (e.g. bicycllc), examples of which include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, thtadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl, pyridinyl and combinations of any two or more there.
In an embodiment of the invention, R represents a group CfC6 alkyl, Cj-Ce cycloalkyl, phenyl or a saturated or unsaturated 5- to 6-membered heterocyclic ring system comprising at least one ring heteroatom (e.g. one or two ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each of which (i.e. each of the recited groups and the ring system) may be optionally substituted by one, two, three or four substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, Ci-Cg, preferably Ci-C4, alkyl, C\-C6> preferably €[-€4, alkoxy, C-C6, preferably C\-C^t alkylthio, Ci-C6, preferably Ci-C4, alkyJcarbonyl, Cj-Cg, preferably Cj-C^ alkoxycarbonyl, phenyl and -NHC(O)-R13.
In another embodiment of the invention, R represents a group C]-Cg alkyl, Cj-Cg cycloalkyl or phenyl, each of which may be optionally substituted by one or two substituents independently selected from halogen, Cj-Cg, preferably GI-€4, alkyl and Cj-Cg, preferably C]-C4, alkoxy.
In still another embodiment of the invention, R represents Cj-Cg alkyl, cyclopentyl or phenyl.
Alternatively, R may represent a group-NR R or-O-R .
14 15
R and R each independently represent a hydrogen atom, or a group Cj-Cg, preferably
C]-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Cj-Cg, preferably C-C alkylsulphonyl (e.g. methylsulphonyl, ethylsulphonyl, n-propylsulphonyl, isopropylsulphonyt, n-butylsulphonyl, isobutylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl or n-hexylsulphonyl), phenyl or a saturated or unsaturated 5- to 10-mernbered heterocyclic ring system comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each group (i.e. each of the recited groups including the ring system) being optionally substituted as defined above for R (that is, optionally substituted with one or more (e.g. one, two, three or four) substituents independently
selected from nitro, hydroxyl, oxo, halogen (e.g. fluorine, chlorine, bromine or iodine), carboxyl, , preferably C\-C^ alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C\-C(, preferably Cj-C/j, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C\-C6, preferably C]-C4, alkylthio (e.g. methylthio or ethylthio), C\-C^ preferably Cj-€4, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyi or n-hexylcarbonyl), Ci-Cg, preferably Ci-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), phenyl and -NHC(0)-R ),
or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom (e.g. pyrrolidinyl, piperidinyl, morpholino, piperazinyl or thiomorpholinyl), the heterocyclic ring being optionally substituted by at least one hydroxyl (e.g. one or two hydroxyls).
14 15 In R or R , the saturated or unsaturated 5- to 10-membered heterocyclic ring system
may be monocyclic or polycyclic (e.g. bicyclic), examples of which include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazoly!, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl, pyridinyl and combinations of any two or more thereof.
In an embodiment of the invention, R and R each independently represent a hydrogen
atom or a C]-Cg alkyl or C]-Cg alkylsulphonyl group, each group being optionally substituted as defined above for R , or R and R together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom, the heterocyclic ring being optionally substituted by at least one hydroxyl.
14 15
In a further embodiment, R and R each independently represent a hydrogen atom or a
14 15
Ci-Cg alkylsulphonyl group, or R and R together with the nitrogen atom to which
they are attached form a 5- to 6-membered saturated heterocyclic ring that is optionally substituted by at least one hydroxyl.
In a still further embodiment, R14 and R1 each independently represent a hydrogen atom or a methylsulphonyl group, or R and R together with the nitrogen atom to which they are attached form a pyrrolidinyl or piperidinyl ring optionally substituted by one hydroxyl group.
R represents a hydrogen atom, or a group Cj-Cg, preferably C\-C^, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl orn-hexyl), phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, each group (i.e. each of the recited groups including the ring system) being optionally substituted as defined above for R (that is, optionally substituted with one or more (e.g. one, two, three or four) substituents independently selected from nitro, hydroxyl, oxo, halogen (e.g. fluorine, chlorine, bromine or iodine), carboxyi, Cj-Q, preferably C[-C^, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Cj-Cg, preferably C[-C4, alkoxy (e.g. mechoxy, ethoxy, n-propoxy or n-butoxy), Cj-Ce, preferably €1-04, alkylthio (e.g. methylthio or ethylthio), Cj-Q, preferably C\-C$, alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl or n-hexylcarbonyl), Cj-Cg, preferably Cj-C^ alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), phenyl and -NHC(O)-R 3).
In R , the saturate-) or unsaturated 5- to 10-membered heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic), examples of which include pyrrolidinyl, piperidinyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl, pyridinyl and sombinations of any two or more thereof.
R andR each independently represent
(i) a hydrogen atom,
(ii) a 3- to 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group
(examples of which include cyclopropyl, cyclobutyl, cyciopentyl, cyclohexyl,
bicyclo[2.2.l]heptyl, phenyl, pyrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl,
tetrazolyl, pyrimidinyl, thienyl, furanyl, tetrahydrofuranyl and combinations of any two or more thereof), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, Ci-Cg, preferably Cj-C5, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-buty], n-pentyl, 1,1-dimethylpropyl or n-hexyl), CrC6, preferably Ci-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3) and C]-C6i preferably Cj-C^ haloalkyl (e.g. trifluoromethyl), (iii) a Cj-Cfi alkyl group optionally substituted by at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), amino(-NH2), hydroxyl, Cj-C preferably haloalkyl (e.g. trifluoromethyl), carboxyl, Cj-Cg, preferably Cj-C alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), Cj-Q, preferably Q-C^ alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), Cj-Cg, preferably C]-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonytamino) and a 3- to16-membered saturated or unsaturated ring optionally comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group (examples of which include cyclopropyl, cyclobutyl, cyciopentyl, cyclohexyl, bicyclo[2.2.1 jheptyl, phenyl, pyrolyl, imidazolyl, pyridinyl, pyrazinyl, pyridazinyl, tetrazolyl, pyrimidinyl, thienyl, furanyl, tetrahydrofuranyl and combinations of any two or more thereof), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, oxo (=0), Cj-Ce, preferably Cj-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
tert-butyl, n-pentyl or n-hexyl), Cj-Cg, preferably Ci-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH,-CH2CH2CH2OH or -CH(OH)CH3) and Ci-C6, preferably Cj-C4)
haloalkyl (e.g. trifluoromethyl), or
(iv) Ci-C6, preferably CfC^ alkylsulphonyl (e.g. metl'iylsulphonyl or ethylsulphonyl), or R and R together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom (e.g. pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl) and that is optionally fused to a benzene ring to form a 8- to 11-membered ring system (e.g. dihydroisoquinolinyl or dihydroisoindolyl), the heterocyclic ring or ring system being optionally substituted with at least one substituent (e.g. one, two.three or four substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amido (-CONH2), C\-C(>, preferably Ci-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Cj-C6, preferably C^C^ hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3), Cj-Cg, preferably C\-Cq, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), Cj-Cg, preferably Cj-C^ alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), Cj-C6f preferably C]-€4, haloalkyl (e.g. trifluoromethyl), Cj-Cg, preferably C[-C 11 12
In an embodiment of the invention, R and/or R represents a 3- to 6-membered
saturated or unsarurated ring optionally comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group, the ring being optionally
substituted with at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, Cj-Ce, preferably Ci-C5, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 1,1-dimethylp.ropyl or n-hexyl) and C]-C6, preferably C |-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3).
11 12
In a further embodiment of the invention, R and/or R represents a 3- to 6-membered
saturated or unsaturated ring optionally comprising at least one ring nitrogen atom and optionally further comprising a bridging group (in particular, cyclopropyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, phenyl, pyrrolidinyl and tetrazolyl), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, C[-C$ alkyl and C]-C2 hydroxyalkyl.
11 12
In an embodiment of the invention, R and/or R represents a Cj-Cg alkyl group
optionally substituted by at least one substituent (e.g. one, two, three or four substituents independently) selected from amino, hydroxyl, Cj-Cg, preferably Cj-C^ alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), Cj-Cg, preferably Ci-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), Cj-C6, preferably C\-C^, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino) and a 3- tc 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen and oxygen and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, oxo, Ci-Cg, preferably C\-Cq, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C|-C6, preferably Cj-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3) and C|-C6, preferably C]-C4> haloalkyl (e.g. trifluoromethyt).
II 12
In another embodiment of the invention, R and/or R represents a C|-Cg alkyl group
optionally substituted by at least one substituent (e.g. one, two, three or four substituents
independently) selected from amino, hydroxyl, Ci-C4alkoxy, Ci-C2 alkoxycarbonyl,
i
Cj-C2 alkylcarbonylamino and a 3- to 6-merabered saturated or unsarurated ring optionally comprising one or two ring heteroatoms selected from nitrogen and oxygen and optionally further comprising a bridging group (in particular, cyclopropyl, bicyclo[2.2.1]heptyl, phenyl or tetrahydrofuranyl), the ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from oxo (e.g. to form a 2,5-dioxoimidazolidinyl ring) and Ci-C2 alkyl.
11 12
In an embodiment of the invention, R and R together with the nitrogen atom to which
they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom (e.g. pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl) and that is optionally fused to a benzene ring to form a 8- to 1 l-membered ring system (e.g. dihydroisoquinolinyl or dihydroisoindolyl), the heterocyclic ring or ring system being optionally substituted with at least one substituent (e.g. one, two,three or four substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amido, Cj-Cg, preferably C]-C4, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), Cj-C6, preferably Ci-C4, hydroxyalkyl (e.g. -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH(OH)CH3), Ci-C6, preferably CrC4, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C]-Cg, preferably C]-C4, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), Cj-C^ preferably Ci-C4, haloalkyl (e.g. trifluoromethyl), di-Cj-Ce, preferably Cj-C4, alkylamino (e.g. dimethylamino), €[-€$, preferably Ci-C4, alkylcarbonylamino (e.g. methylcarbonylamino or ethylcarbonylamino), di-Ci-Cg, preferably Cj-C4, alkylaminocarbonyl (e.g. dimethylaminocarbonyl), phenyl, halophenyl (e.g. fluorophenyl or chlorophenyl), phenylcarbonyloxy and hydroxydiphenylmethyl.
11 12
In an embodiment of the invention, R and R together with the nitrogen atom to which
they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom and that is optionally fused to a
benzene ring to form a 9- to 10-membered ring system, the heterocyclic ring or ring system being optionally substituted with one or two substituents independently selected from fluorine, hydroxyl, amido, C^ alkyl, C\-C2 hydroxyalkyl, Ci-C2aUcoxy, C\-Ci alkoxycarbonyl, C\-Ci haloalkyl, di-C]-C2 alkylamino, C]-C2aIkylcarbonylamino, di-Cj-C2 alkylaminocarbonyl, phenyl, chlorophenyl, phenylcarbonyloxy and hydroxydiphenylmethyl.
In another embodiment of the invention, R and R together with the nitrogen atom to which they are attached form a heterocyclic ring or ring system selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dihydroisoquinolinyl and dihydroisoindolyl, the heterocyclic ring or ring system being optionally substituted with one or two substituents independently selected from fluorine, hydroxyl, amido, methyl, hydroxymethyl, 2-hydroxyethyI, methoxy, methoxycarbonyl, trifluoromethyl, dimethylamino, methylcarbonylamino, dimethylaminocarbonyl, phenyl, chlorophenyl, phenylcarbonyloxy and hydroxydiphenylmethyl.
12a R represents a hydrogen atom or a Ci-Cg, preferably C\-C^, alky! (e.g. methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) group.
12a In an embodiment of the invention, R represents a hydrogen atom or methyl group.
R represents a C]-€5, preferably C\-€4, alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), amino or phenyl group.
In an embodiment of the invention:
each R independently represents halogen or C|-Cg alkyl;
either one of X and Y represents a bond and the other of X and Y represents an oxygen
atom and Z represents -CH2-, or X represents -CH2-, Y represents an oxygen atom and Z
represents a bond;
R4, R5, R and R7 each represent a hydrogen atom and R represents a hydrogen atom or a
d-Cg alkyl group;
t is I or 2; and
each R independently represents hydroxyl (e.g. in the para position with respect to R ) or
halogen (e.g. either in the para position with respect to R or in the para position with
respect to -O-).
In an embodiment of the invention:
rn is 0 or 1;
each R independently represents fluorine, chlorine, methyl or trifluoromethyl;
either X represents a bond, -CH2-, -O- or -C(O)- and Y represents a bond, -CH2-, -O- or -C(O)-, or X and Y together represent a group -CH=C(CH3)-, and Z represents a bond, -O-, or-CH2-, provided that only one of X, Y and Z can represent a bond at any one time and provided that X and Y do not both simultaneously represent -O- or -C(O)-;
n is 0 or 1;
2 R represents fluorine;
q is 0 or 1;
R3 represents -NHC(0)R10, -C(O)NRNR12 or -COORJ2a; R , R , R , R and R each independently represent a hydrogen atom or a methyl group;
t is 0, 1 or 2;
9 . each R independently represents halogen, hydroxyl, carboxyl, methyl, methoxy,
methoxycarbonyl or trifluoromethyl;
R represents a methyl, cyclopentyl, phenyl or a group -NR R ;
II 12
R and R each independently represent (i) a hydrogen atom,
(ii) a 3- to 6-membered saturated or unsaturated ring optionally comprising at least one ring nitrogen atom and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent selected from hydroxyl, C]-C5 alkyl and Cj-C2 hydroxyalkyl, (iii) Cj-Q alkyl group optionally substituted by at least one substituent selected from
amino, hydroxyl, Cj^alkoxy, C(~C2 alkoxycarbonyl, C[-C2 alkylcarbonylaminoand a 3- to 6-membered saturated or unsaturated ring optionally, comprising one or two ring heteroatoms selected from nitrogen and oxygen and optionally farther comprising a bridging group, the ring being optionally substituted with at least one substituent selected from oxo and Cj-C2 alkyl, or (iv) methylsulphonyl, or
R11 and R1 together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom and that is optionally fused to a benzene ring to form a 9- to 10-membered ring system, the heterocyclic ring or ring system being optionally substituted with one or two substituents independently selected from fluorine, hydroxyl, amido, C|-C2 alkyl, C\-Ci hydroxyalkyl, C\-C alkoxy, Cj-C2 alkoxycarbonyl, C[-C2 haloalkyl, di-Ci-C2 alkylamino, C(-C2 alkylcarbonylamino, di-Cj-C2 alkylaminocarbonyl, phenyl, chlorophenyl, phenylcarbonyloxy and
hydroxydiphenylmethyl;
12a R represents a hydrogen atom or a methyl group; and
14 15
R and R each independently represent a hydrogen atom or a Cj-Cg alkylsulphonyl
14 15
group, or R and R together with the nitrogen atom to which they are attached form a
5- to 6-membered saturated heterocyclic ring that is optionally substituted by at least one hydroxyl.
In an embodiment of the invention: m is 0 or 1;
R represents halogen;
either X represents a bond, -CH2-, -0- or -C(O)-and Y represents a bond, -CH2-, -O- or -C(O)-t or X and Y together represent a group -CH=C(CH3)-, and Z represents a bond, -0- or -CH2-, provided that only one of X, Y and Z can represent a bond at any one time and provided that X and Y do not both simultaneously represent -O- or -C(0>;
n isO;
qisOorl; ;
R3 represents -NHC(0)R10, -C(0)NRHR12 or -COORl2a;
R4, R5, R6, R? and R8 each independently represent a hydrogen atom or a methyl
group;
is 0 or 1;
R represents halogen, hydroxyl, methoxy or trifluoromethyl;
10
R represents methyl;
R and R each independently represent hydrogen, methyl, cyclopropyl, hydroxyethyl or aminoethyl, or R and R together with the nitrogen atom to which they are attached form a morpholinyl group, or form a pipendinyl group substituted by hydroxyl; and R represents a hydrogen atom.
Examples of compounds of the invention include:
^-(2-{[(2S)-3-(5-Chloro-r//,3/Aspiro[l-ben2ofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
JV-(2-{[(2S)-3-(5-Chloro-lW,3//-5piro[l-benzoftiran-2,4'-piperidin].l>-yl)-2-hydroxypropyl]oxy}-4-fluorophenyl)acetamide,
Ar-(2-{[(2S)-3-(5-Chloro-l>//,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)'2-hydroxypropyl]oxy}-4-methoxyphenyl)acetamide,
//-(2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide,
//-[2-{[(2S)-3-(5-Chloro-r//)3//-spiro[l-benzofuran-2,4>-piperidin]-r-yl)-2-hydroxypropyl]oxy}-5-(rrifiuoromethyl)phenyl]acetamide,
2- {[(2S)-3-(5-Ch!oro-1 'H,3H-spiro[ I -benzofuran-2,4 '-piperidin]-1 '-yl)-2-hydroxypropylJoxyj-N-cyclopropylbenzamide,
2-{((2S)-3-(5-Chloro-l'//,3//-spiro[l-benzoruran-2,4'>-piperidin]-r-yl)-2-hydroxypropyl]oxy}-Ar-cyclopropyl-4-fluorobenzamide,
2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzofuran-2,4 -piperidin]-l'-yl)-2-hydroxypropyl]oxy}-N-cyclopropyl-4-methoxybenzamide,
N-(2- {[(26)-3-(5-Chloro-1 '#,3//-spiro[l -benzofuran-2,4 '-piperidin]-1 '-yl)-2-hydroxy-2-methylpropyl]oxy}-4-hydroxyphenyl)acetamide trifluoroacetate,

Ar-(5-Chtoro-2-{[(2S)-3-(6-chloro-l'//,3//-spiro[2-benzoftiran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
Ar-(2-{[(2S)-3-(6-Chloro-r//,3//-spiro[2-benzofurari-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-fluorophenyl)acetamide,
N-(2- {[(2S)-3-(6-Chloro- 1 '//,3#-spiro[2-benzofiiran- 1 ,4 '-piperidinj- 1 '-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
//-(2-{[(2S)-3-(6-Chloro-r//,3//-spiro[2-benzoajran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)acetamide,
2-{[(2S)-3-(6-ChIoro-r//,3//-spiro[2-benzofijran-l,4'-piperidin]-r-yl)-2-hydroxypropy^oxyJ-A^-cyclopropyl^-fluorobenzamide,
N-(2 {[(2S)-3-(5-Fluoro-l '//,3//-spiro[2-benzoftiran-l,4'-piperidin]-l '-yi)-2-hydroxypropyl]phenyl)acetarnide,
^-(4-Ch!oro-2-{[(2S)-2-hydroxy-3-(3-oxo-r//J3//-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)propyl]oxy}phenyl)acetamide,
A^-Cyciopropyl^- {[(2S)-2-hydroxy-3-(l '//,3//-spiro[2-benzofljran-l,4'-piperidin]-r-yl)propyljoxy} benzaraide,
A^-(4-ChIoro-2-{[(2S)-2-hydroxy-3-(r//)3//-spiro[2-benzofijran-l,4'-piperidin]-l'-yl)propyl]oxy}phenyl)acetarnide,
N-(5-Ch\oro-2 {[(2S)-2-hydroxy-3-(l '//,3//-spiro[2-benzoftiran-l,4'-piperidin]-r-yl)propyl]oxy} phenyl)acetamide,
Ar-(2-{[(2S)-2-hydroxy-2-methyl-3-(r//J3//-spiro[2-benzoajran-l,4'-piperidin]-r-yl)propyl]oxy} -4-methoxyphenyl)acetamide,
-[2-{[(2S)-2-Hydroxy-3-(l'//,3//-spiro[2-benzofuran-l,41-piperidinJ-r-yl)propyl]oxy}-5-(trifluoromethyl)phenyl]acetamide,
-(2-{[(2S)-2-Hydroxy-3-(2-methy!-l>//-spiro[indene-l>4>-piperidin]-r-yl)propyl]oxy}phenyl)acetamide,
hydroxypropyl]oxy}phenyl)acetamide,
-(2-{[(2S)-2-Hydroxy-3-(2-oxo-r//-spiro[l-benzofuran-3,4>-piperidin]-l>-yl)propyl]oxy}phenyl)acetamide,

2-{[(2S)-3-(5-Chloro-r//,3//-spiro[l-benzofliran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy}-Af-cyclopropyl-4-hydroxybenzamide,
2-{[(2S)-3-(5-ChIoro-l'//,3//'-spiro[l-benzofiiran-2,4'-piperidin]-r-yl)-2-hydroxy-2-methylpropyl]oxy}-/V-cyclopropyl-4-hydroxybenzamidc,
/VC(4-hydroxy-2-{[(2lS)-2-hydroxy-3-(r//,4//-spiroL"chromene-3,4'-piperidin]-r-yl)propyl]oxy} phenyl)acetamide,
2-{[(2S)-3-(5-Chloro-l '//,3//-spiro[l-benzoftiran-2,4'-piperidin]-r-yl)-2-hydroxy-2-methylpropyl]oxy}-4-hydroxy-jV-rnethylbenzarnide (trifluoroacetate),
2-{[(2S)-3-(5-Chloro-r/f]J//-spiro[l-benzofuran-2,4'-piperidin]-r-y!>2-hydroxy]oxy} -4-hydroxy-//-methylben2amide,
N-(2- {[(2,5>3-(5-Chloro-1 '//-spiro[ 1 .S-benzodioxole^^'-piperidin]-1 '-yl)-2-hydroxypropyljoxy) -4-hydroxyphenyl)acetamide trifluoroacetate,
//-(2-{[(25}-3-(5-Chloro-l'//-spiro[l,3-ben2odioxole-2)4'-piperidin]-lp-yl)-2-hydroxy-2-methylpropyI]oxy} -4-hydroxyphenyl)acetamide trifluoroacetate,
//-(4-Hydroxy-2-{[(21S)-2-hydroxy-3-(l1//-spiro[l,3-benzodioxole-2,41-piperidin]-ll-yl)propyl]oxy}phenyl)acetamide trifluoroacetate,
M(4-Hydroxy-2-{[(2lS)-2-hydroxy-2-methyl-3-(r//-spiro[l,3-benzodioxole-2)4'-piperidin]-l'-yl)propyl]oxy}phenyl)acetamide trifluoroacetate,
//-(2-{[(2S)-3-(5-Chloro-rH,3/ir-spiro[2-benzofuran-I,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide,
//-(2-{[(2S)-3-(5-Chloro-r//,3//-spiro[2-benzofuran--l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
2-{[(2S)-3-(5-Chloro-l '//,3//-spiro[2-benzoruran-l ,4'-piperidin]-l '-yl)-2-hydroxypropylJoxyl^-hydroxy-Mmethylbenzamide,
2-{[(2S)-3-(5-Chloro-rA',3Ar-spiro[2-benzoruran-l,4'-piperidin]-r-yl)-2-hydroxy-2-methoxypropyljoxyJ-McycIopropyl^-hydroxybenzamide,
2-{[(2S>3-(5-Chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy)-4-hydroxy-//-(2-hydroxye(hyl)benzamide,
//-(2-Aminoethyl)-2- {](2 S/-3 -(5-chloro-1 '/7,3//-spiro[ 1 -benzoruran-2,4 '-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide,
2-{[(2S)-3-(5-Fluoro-r//,3//-spiro[l-benzofiiran-2)4'-piperidin]-I'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-Ar-methylbenzamide,
yV-(2-{[(2S)-3-(5-Fluoro-r//,3//-spiro[l-benzoiliran-2,4'-piperidin]-J'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetarnide,
^-(2-{[(2S)-3-(5-FJuoro-r//,3//-spiro[1-benzoftiran-2,4'-piperidinJ-r-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
Ar-[2-({(2S)-3[(2S)-5-Chloro-r//,3//-spiro[l-benzofuran-2,3'-pyrrolidin]-r-yl]-2-hydroxypropyl}oxy)phenyl]acetamide,
-[2-({(2S)-3[(2R)-5-Chloro-l'//13//-spiro[l-benzofuran-2,3'-pyrrolidin]-r-yl]-2-hydroxypropyl}oxy)phenyl]acetamide,
N-[2-( {(2S)-3-[(2S)-5-Chloro-l '//,3//-spiro[ I -benzofuran-2,3 '-pyrrolidin]-1 '-ylJ-2-hydroxypropyl}oxy)-4-methoxyphenyI]acetamide)
M[2-({(2S)-3-[(2R)-5-Chloro-l'//,3//-spiro[l-benzofliran-2,3'-pyn-olidin]-r-y!]-2-hydroxypropyl}oxy)-4-methoxyphenyl]acetaraide,
2-{[(2S)-3-(5-Chloro-l'//',3/:/-spiro[l-benzofiuran-2)3'-pyrrolidin]-l>-yl)-2-hydroxypropyljoxy) ^-hydroxy-A^-methylbenzamide,
2-{[(2S)-3-(5-Chloro-r//,3//-spiro[I-benzoftiran-2)4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoic acid (trifluoroacetate),
3(S)-l-(2-{[(2S)-3-(5-ChIoro-r//,3//-spiro[l-benzoftjran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoy!)pyrrolidin-3-ol,
3(R)-'[-(2-{[(2S)-3-(5-Chloro-l'//I3//-spiro[l-benzofliran-2J4>-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrroIidm-3-ol,
3-{[(2S)-3-(5-Chloro-t'//,3//-spiro[l-benzoftjran-2,4>-piperidin]-r-yl)-2-hydroxypropyi]oxy}-4-(morpholin-4-ylcarbonyl)phenol,
2-{[(2S)-3-(5-chloro-rH-sp:':c[lI3-ben2odioxole-214'-piperidinJ-l'-yl)-2-hydroxypropyl]oxy}-N-methylbi. rzamide trifluoroacetate,
A^-(2-{[(2S)-3-(6-chloro-3,4-di:iydro-l'H-spiro(chromene-214'-piperidin]-r-y!)-2-hydroxypropyi]oxy}phenyl)acetamioe trifluoroacetate,
/V-(2-{[(2S)-3-(6-chloro-3,4-dihydro-l'H-spiro[chromene-2J4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-fluorophenyl)ficetamide trifluoroacetate,
2-{[(2S)-3-(6-chloro-3,4-dihydro-rH-spiro[chromene-2,4'-piperidin]-r-yI)-2-hydroxypropyljoxy} -N-methylbenzamide trifluoroacetate,
A^-{2-{[(2S)-3-(6-chloro-354-dihydro-lrH-spiro[chromene-2,4'-piperidin]-r-yl)-2-hydroxypropyi]oxy}-4-hydroxyphenyi)acetamide trifluoroacetate,
Ar-(2-{[(2S)-3-(6-chloro-3,4-dihydro-rH-spiro[chromene-2,4'-piperidin]-r-yl)-2-hydroxy-2-methylpropyl]oxy'}-4-hydroxyphenyl)acetamide trifluoroacetate,
Af-[2-({(2S)-3-[(2R)-5-cKloro-l"//,3^-spiro[l-benzofuran-2,3'-pyrrolidin]-r-yl]-2-hydroxypropyl}oxy)-4-hydraxyphenyl]acetaraide,
//-[2-({(2S)-3-[(2S)-5-chloro-l"//,3//-spiro[l-benzofuran-2,31-pyrrolidin]-l'-yl]-2-hydroxypropyl}oxy)-4-hydroxyphenyl]acetarnide,
3-{[(2S)-3-{5-Chloro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-I'-yl)-2-hydroxypropyl]oxy}-4-(pyrrolidin-l-ylcarbonyl)phenol,
l-(2-{[(2S)-3-(5-Chloro-r//)3//-spiro[l-benzofurar.-2,4'-piperidin]-r-yl)-2-hydroxypropyIJoxy}-4-hydroxybenzoyl)piperidin-4-ol,
(3S)-l-(2-{[(2S)-3-(5-Chloro-r//J3//-spiro[l-benzofuran-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoyl)pyrrolidin-3-ol,
3-{[(2S)-3-(5-Chloro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-(piperidin-I-ylcarbonyl)pheno(,
(3S)-1 -(2- {[(2S)-3-(5-ChIoro-1 '//,3//-spiro[2-benzo ruran-1,4 '-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ol,
]-(2-{[(2S)-3-(5-Chloro-l'Ar,3/ir-spiro[2-benzoruran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-4-oI,
-[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(triftuoromethy!)-rJ/y,3//-spiro[l-benzofuran-2J4'-piperidin]-r-yl]propyl}oxy)phenyl]acetamide,
(3S)-l-(2-{[(2S)-3-(5-Chloro-l '/f,3//-spiro[l -benzofuran-^'-piperidin]-! '-yl)-2-hydfoxypropy^oxyJ^-hydroxybenzoylJpyrroIidinO-ylbenzoate,
(3S)-1 -(2- {[(2S)-3-(5-ChIoro- \ '//,3//-spiro[ I -benzofuran-2,4'-piperidinj-1 '-yt)-2-hydroxypropyl]oxy}-4-f]uorobenzoyl)pyrrolidin-3-ol,
(3S)-l-[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(trifluoromethyl)-r//',3//-spiro[l-benzofuran'-piperidinj-l'-yljpropylJoxyenzoylJpyrroIidin-B-ol,
(3S)-l-(4-Fluoro-2-{[(2S)-2-hydroxy-3-(r//,3//-spiro[l-benzofuran-2J4'-piperidin]-
1'-yl)prop y 1] oxy} benzoy l)pyrrolidin-3-o 1,
4-Fluoro-2-{[(2S)-3-(5-f]uoro-l>//,3//-spiro[l-benzofuran-2,4'-piperidin]-i'-yl)-2-
hydroxypropyl]oxy} benzole acid (hydrochloride),
(3S)-l-(4-Fluoro-2-{[(2S)-3-(5-fluoro-r//,3//-spiro[l-benzofuran-2,4'-piperidinJ-r-yI)-2-bydroxypropyl]oxy}benzoyl)pyrrolidin-3-ol,
M[(3S)-l-C2-{[(2S)-3-{5-Ch[oro-J'//J3//-spiro[l-benzofuran-2,4'-piperidin]-r-y[)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)pym)lidin-3-yI]aeetarnide,
2-{[(2S)-3-(5-Chloro-i'//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-methylbenzoic acid hydrochloride,
(3S)-l-(2-{[(2S)-3-(5-Chloro-r//J3//-spiro[]-benzofuran-2,4t-piperidin]-l'-yl)-2-hydroxypropyl]oxy]}-4-methyIbenzoyl)pyrrolidtn-3-ol,
2-{[(2S)-3-(5-Fluoro-I>//)3//-spiro[l-benzo{\iran-214v-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-methylbenzoic acid hydrochloride,
(2S)-l-(5-Chloro-r//J3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-3-(2-{[2-(hydroxymethyl)morphoUn-4-yl]carbonyl}-5-methylphenoxy)propan-2-ol,
(3S)-l-(2-{[(2S)-3-(5-Fluoro-r//53//-spiroi;i-benzofuran-2,4'-piperidin]-r-yO-2-hydroxypropyljoxyJ^-methylbenzoyOpyrrolidin-S-ol,
2-{[(2S)-3-(5-Chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-l'-y|)-2-hydroxypropyl]oxy}-A^-f[(4R)-2,5-dioxoimidazo[idin-4-y[JmethyI}-4-hydroxybenzamide,
l-(2-{[(2S)-3-(5-ChIoro-lI//>3//-spiro[l-benzofuran-2>4'-piperidinJ-r-yI)-2-hydroxypropyI]oxy}-4-hydroxybenzoyl)-3-(trifIuoromethyOpyrroIidin-3-ol,
3-{[{2S)-3-(5-Chloro-l1//,3//-spiro[I-benzoruran-2]41-piperidin]-r-yl>2-hydroxypropyIJoxy}-4-{[3-(trifluoromethy!)pyrroiidin-l-yl]carbonyl} phenol,
Ar-[2-(Acetylamino)ethyl]-2- {[(2S)-3-(5-chloro-1 '//,3//-spiro[ 1 -benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide,
Ar-(5-ch[oro-2-{[(25)-3-(5-chloro-t'//',3//-spiro[l-benzoruran-214'-piperidinJ-r-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)acetamide,
(3S)-N-(5-chloro-2-{[(^-3-(5-chloro-rAr,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenyl)-3-hydroxypyrrolidine-l-carboxamide,
(3S)-Ar-(2-{[(25)-3-(5-chloro-I'//,3//-spiro[l-benzofuran-2)4'-piperidin]-r-yI)-2-hydroxypropyl]oxy} phenyl)-3-hydroxypyrrolidine-1 -carboxamide,
//-(2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy) pheny l)-4-hydroxypiperidine-1 -carboxamide,
N-(2- {[(25>3-(5 -Chloro-1 7/,3tf-spiro[ 1 -benzo furan-2,4'-piperidin] - l'-y l)-2-hydroxypropyl]oxy}phenyl)urea trifluoroacetate,
Ar-(2-{[(2S)-3-(5-ch[oro-lf//,3//-spiro[l-b€nzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy}-4-hydroxyphenyJ)urea trifluoroacetate,
//-(2-{[(25)-3-(5-Chloro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy]-4-fluorophenyl)urea trifluoroacetate,
^-{[(2-{[(25)-3-(5-Chloro-r//,3/:/-spiro[l-benzofuran-2,4'-piperidin]-l1-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)araino]carbonyl}methanesulfonamide trifluoroacetate,
(4>S}-2-(2-{[(2^-3-(5-Chloro-lI//>3//-spiro[l-ben2oftiran-2,4l-Piperidm]-l'-yl)-2-hydroxypropyl]oxy}-4-bydroxybenzoyl)isoxazolidin-4-ol trifluoroacetate,
(4tf)-2-(2- {[(2^-3-(5-Chloro-1 W,3//-spiro[ 1 -benzoforan-2,4'-PiPeridin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxyben2oyI)isoxazolidin-4-ol trifluoroacetate,
(4JS)-2-(2-{[(21S)-3-(5-Chloro-l'//(3//-spiro[l-ben2ofuran-2I4'-piperidin]-l1-yI)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-rnethylisoxazolidin-4-ol trifluoroacetate,
(4^)-2-(2-{[(25)-3-(5-Chloro-IW,3//-spiro[l-benzofuran-2,4'-piperidin]-lt-yl)-2-hydroxypropyl]oxy}-4-hydroxyben2oyl)-4-methylisoxa2olidin-4-o[ trifluoroacetate,
2-{[(2^-3-(5-chIoro-l'//,3//-spiro[l-benzoairan-2,4l-piperidin]-l'-yl)-2-hydroxypropyljoxy} -/^-(methylsulfonyObenzamide trifluoroacetate,
2-{[(2.Sl)-3-(5-chIoro-r//,3/f-spiro[l-benzofuran-2J4'-piPeridin]-l1-yl)-2-hydroxypropyl]oxy}-iV-l//-tetrazo[-5-yibenzamidebis(trifluoroacetate),
3-{[(25)-3-(5-chloro-r//,3//-3piro[l-benzoruran-2,41-piperidin]-r-yl)-2-hydroxypropy!]oxy}-4-{[(3jl?)-3-(dimethylamino)pyrrolidin-l-yl]carbonyl}phenol bis(trifluoroacetate),
3-{[(25)-3-(5-chIoro-r//,3//-spiro[l-benzofuran-2,4l-piperidin]-r-yl)-2-hydroxypropyljoxyJ-ICCS-CdimeJhylaminojpyrrolidin-l-yljcarbonylJphenol
bis(trifluoroacetate),
(35')-l-(5-ch[oro-2-{[(26)-3-(5-chloro-r//,3//-spiro[l-ben2ofuran-2,4l-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ol trifluoroacetate,
3- {[(25>[email protected] '//,3//-spiro( 1 -benzofuran-2,4'-pipertdin]-1 '-yl)-2-
hydroxypropyl]oxy}-4-{[(35)-3-methoxypyrrolidin-l-yl]carbonyl}phenol trifluoroacetate,
-{[(2iS)-3-(5-cbloro-l'//,3//-spiro[l-benzoruran-2J4'-piperidin]-l(-yl)-2-
hydroxypropyl]oxy}-4-{[(2/Z)-2-(hydroxymethyl)pyrrolidin-l-yl]carbonyl}phenol trifluoroacetate,
3-{[(2^-3-(5-chloro-l'//,3//-spiro[l-benzoruran-2,4'-piperidin]-l'-yi)-2-hydroxypropyljoxy}-4-{[(25)-2-(hydroxymethyl)pyrrolidin-l-y!]carbonyl} phenol trifluoroacetate,
3-{[(2lS)-3-(5-chIoro-ll//,3//-spiro[l-benzofuran-2)4'-Piperidin]-l'-y[)-2-hydroxypropyl]oxy}-4-{[3-(hydroxymethyl)pyrrolidin-l-yl]carbonyl} phenol trifluoroacetate,
l-(2-{[(2tSO-3-(5-chloro-r/3r,3//-spiro[l-benzofuran-2,4'-piperidm]-r-y[)-2-hydroxypropylJoxy}-4-hydroxybenzoyl)-D-prolinamide trifluoroacetate,
//-(4-hydroxy-2- {[(2S)-2-hydroxy-3-(l'H,3H-spiro[ 1 -benzofuran-2,4'-piperidinJ-1 '-yl)propyl]oxy}phenyl)acetamide trifluoroacetate,
M(4-hydroxy-2- {[(2S)-2-hydroxy-3-(5-methyI-1 'H,3H-spiro[ 1 -benzofuran-2,4'-piperidin]-r-yl)propyl]oxy}phenyl)aceiarnide trifluoroacetate,
M(5-chloro-2-{[(2S)-2-hydroxy-3-(rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)propyljoxy) -4-methoxyphenyl)acetamide trifluoroacetate,
M(5-chloro-4-hydroxy-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2J4'-piperidin]-1 r-yl)propyl]oxy} phenyl)acetamide trifluoroacetate,
(3S)-N-(2- {[(2S)-3-(5-chloro-1 'H,3H-spiro[l -benzofuran-2,4'-piPeridin]-1 '-yl)-2-hydroxypropyl]oxy) -4-methoxyphenyl)-3-hydroxypyrrolidine-1 -carboxamide trifluoroacetate,
(3S)-N.(2-{[(2S)-3-(5-chloro-llHF3H-spiro[l-benzoftiran-2,4'-piperidin]-r-yl>2-hydroxypropyl]oxy}-4-hydroxyphenyl)-34iydroxypynx>lidine-l-carboxamide
trifluoroacetate,
(3S)-l-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-
r-yl)propyi]oxy}benzoyI)pyrrolidin-3-ol trifluoroacetate,
2-{[(2S)-3-(5-chloro-lrH,3H-spiro[l-benzofijran-2,4'-piperidin]-r-yO-2-hydroxypropyl]oxy}-5-methylbenzoic acid hydrochloride,
2-{[(2S)-3-(5-chloro-l1H)3H-spiro[l-benzofuran-2,4l-piperidin]-lr-yl)-2-hydroxypropyI]oxy}-4-methoxybenzoic acid hydrochloride,
(3S)-I-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[t-ben2ofuran-2f4l-piperidin]-l1-yl)-2-hydroxypropyI]oxy}-5-rnethylbetizoyl)pyrrolidin-3-ol tnfluoroacetate,
(3S)-l-(2-{[(2S)-3-(5-chloro-rH)3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yJ)-2-hydroxypropyl]oxy}-4-methoxybenzoyl)pyrroIidin-3-ol trifluoroacetate,
5-chloro-2-{[(2S)-3-(5-chloto-llH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride,
(3S)-l-(5-chloro-2-{[(2S)-3-(5-chIoro-l1H]3H-spiro{l-benzofuran-2,4l-piperidin]-l)-yI)-2-hydroxypropyl]oxy) benzoyl)pyrro[idin-3-ol trifluoroacetate,
2- {[(2S)-3-(5-chioro-1 'H,3H-spiro[I -benzoHjran-2,4'-p iperidin]-1 '-yl)-2-hydroxypropyl]oxy}-5-fluorobenzoic acid hydrochloride,
(3S)-l-(2-{((2S)-3-(5-chloro-]'HJ3H-spiro[l-benzof\iran-2,4'-piperidin]-i'-yl)-2-bydroxypropyl]oxy}-5-fluorobenzoyI)pyrrolidm-3-ol trifluoroacetate,
Af-(2-{[(2S)-3-(5-chloro-rH,3H-spiro[ 1-benzofuran-2,4'-piperidin]-1'-y!)-2-hydroxypropyl]oxy}phenyl)pyrrolidine-l-carboxamide trifluoroacetate,
Methyl 4-(acetylamino)-3-{[(2S)-3-(5-chloro-l'H,3H-spiro[t-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyIJoxy}benzoate trifluoroacetate,
4-(acetylamino)-3-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}benzoic acid trifluoroacetate,
//-(2-{[(2,y)-3-(5-chloro-3'-fluoro-l1//,3//-spiro[l-ben2ofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropy!]oxy}-4-hydroxypheny[)acetamide,
2-{((2S)-3-(5-chIoro-l'H)3H-spiro[l-benzofuran-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxypropyl)benzamide,
2- {[(2S)-3-(5-chloro-1 'H,3H-spiro[l -benzofuran^^'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxy-l,l-dimethylethyl)benzamide,
2- ([(2S)-3-(5-cbloro-1 'H,3 H-spiro[ 1 -benzoftiran-2,4'-piperidin]-1 '-yi)-2-hydroxypropyl]oxy}-N-cyclopentyl-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofUran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-methoxyethy])benzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzoruran-2,4'-piperidinJ-r-y[)-2-
i
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxyphenyl)benzarnide,
M(tert-butyi)-2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2>4t-piPeridin]-r-yl)-2-hydroxypropyI]oxy}-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzof\jran-2)4'-piperidin]-lr-yl)-2-hydroxypropyljoxy} -4-hydroxy-N-(2-hydroxy-1 -methylethyl)benzamide,
2- {[(2S)-3-(5-chloro-1 'H,3H-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-y[)-2-hydroxypropyl]oxy}-4-hydroxy-N-isobutylbenzamide,
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-ben2ofuran-2,4'-piperidin]-r-yI)-2-hydroxypropyl]oxy}-4-hydroxy-N-(4-hydroxycycIohexyI)benzamide,
2- {[(2S)-3-(5-chloro-1 'H,3H-spiro(; 1 -benzoruran^^'-piperidin]-1 '-y!)-2-hydroxypropylJoxy}-N-(2,3-dihydroxypropyl)-4-hydroxybenzamide1
2-{[(2S)-3-(5-chloro-l1H,3H-spiro[l-benzofuran-2,4'-piPeridin]-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxyethyl)-N-methylbenzamide,
Methyl Ar-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyJ)serinate,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-N-(I-ethylpropyl)-4-hydroxybenzamide,
2-{[(2S)O-(5-chloro-rH,3H-spiro[l-benzofuran-2,41-piperidinJ-]l-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(tetrahydroruran-2-ylmethyl)benzamide,
2-{[(2S)-3-(5-chioro-l'H,3H-spiro[;i-benzofuran-2)4l-piperidin]-r-yl)-2-hydroxypropyljoxy} -4-hydroxy-N-[ 1 -(hydroxymethylj-dimethylpropyljbenzamide,
2-{[(2S)-3-(5-chloro-l'HI3H-spiro[l-benzofuran-2)4r-piperidin]-r-yl)-2-hydroxypropy[]oxy}-N-{[(IS,2R,5S)-6,6-diraethylbicyclo[3.1.1]hept-2-yI]methyl}-4-
hydroxybenzamide,
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyljoxy} -4-hydroxy-N-[ 1 -(hydroxymethyl)-2-methylpropyl]benzamide,
hydroxypropyl]oxy}-4-{[4-(2-hydroxyethyl)piperazin-l-yl]carbonyl}phenol, 3-{[(2S)-3-(5-chloro-l'H;3H-spiro[l-benzoi\iran-2,41-piperidin]-JI-yl)-2-hydroxypropyl]oxy}-4-{[3-(hydroxymethyl)piperidin-l-yl]carbonyl}phenol, 2-{[(2S)-3-(5-chIoro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yO-2-hydroxypropyl]oxy}-N-[5-(l,l-dimethylpropyl)-2-hydroxyphenyl]-4-hydroxybenzamide)
2-{[(2S)-3-(5-chloro-rH>3H-spiro[l-benzofuraa-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-[3-(l-hydroxyethyI)pheny[]benzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzoftaran-2)4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-N-(cyclopropylmethyl)-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H13H-spiro[l-benzofiaran-2,4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-pyrrolidin-1-ylbenzamide,
//-[(JR,4S)-bicyclo[2.2.I]hept-2-yl]-2-{[(2S)-3-(5-chloro-ltH,3H-spiro[!-ben2of\aran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide,
4-(4-chlorophenyl)-1 -(2- {[(2S)-3-(5-chloro-1 'H,3H-spiro[ 1 -benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-4-ol,
2- {[(2S)-3-(5-ch!oro-1 'H,3H-spiro[l -benzofiiran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxy-l-phenylethyl)benzamide,
l-(2-{[(2S)-3-(5-chloro-l1H)3H-spiro[I-benzofuran-2)4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-phenylpiperidin-4-ol,
3-{[(2S)-3-(5-chloro-l'HJ3H-spiro[l-benzoftiran-2,4l-piPeridin]-l'-yI>2-hydroxypropyl]oxy}-4-(3,4-dihydroisoquinolin-2(lH)-yJcarbonyl)pheno],
3-{[(2S)-3-(5-chloro-lrH,3H-spiro[l-benzoftjran-2J4!-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-{[2-(hydroxymethyl)piperidin-l-yl]carbonyl}phenoI,
1 -(2- {[(2S)-3-(5-chloro-1' H,3 H-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-N,N-dimethylprolinamide>
Methyl (4R)-l-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuraa-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyI)-4-hydroxyprolinate,
(3R>1 -(2- {[(2S)-3-(5-chloro-1 'H,3H-spiro[ 1 -benzo^uran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-3-ol,
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4I-Piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxycyclohexyl)benzamide,
3-{[C2S)-3-(5-chloro-rH,3H-spirQ[l-benzofuran-2)4l-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-phenylpiperidin-l-yl)carbonyl]phenol,
3-{[(2S)-3-(5-chloro-!1H,3H-spiro[l-benzofliran-2J4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-(thiomarpho[in-4-ylcarbonyl)phenol,
I-(2-{[(2S)-3-(5-chloro-llH,3H-spiro[l-benzoftiran-2)4>-piperidin]-l1-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoy()piperidin-3-ol,
2-{[(2S)-3-(5-chIoro-l'H13H-spiro[I-benzoairan-2,4l-piPeridin]-l'-yl)-2-hydroxypropyl]oxy}-N-(cyclopropylraethyl)-4-hydroxy-N-propylbenzamide, 2-{[(2S)-3-(5-chloro-]tH,3H-spiro[l-benzofiiran-214'-piPeridin]-Jl-yl}-2-hydroxypropyl]oxy}-4-hydroxy-N,N-diisobutylbenzamide,
3-{[(2S)-3-(5-chloro-l'H,3H-sPiro[l-benzoftiran-2)4 Ar-(2-tert-butoxyethyl)-2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4l-piperidinJ-r-yO^-hydroxypropylJoxyJ^-hydroxy-N-isobutylbenzamide,
3-{[(2S)-3-(5-ch]oro-l'H13H-spiro[l-benzofUran-2,4l-piperidin]-l'-yl)-2-hydroxypropyljoxy} -4-[(4-fluoropiperidin-l -yl)carbonyl]phenol,
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-pipendin]-r-yl)-2-hydroxypropyljoxy} -4-[{4,4-difluoropiperidin-1 -yl)carbonyl]phenol,
2-{[(2S)-3-(5-chloro-rH)3H-spiro[l-benzofuran-2]4'-piperidin]-ll-yt)-2-hydroxypropytjoxyJ-N-phenylbenzamide,
3-{[(21S}-3-(5-chloro-l'//)3//-spiro[2-ben2ofuran-l)4r-piperidin]-l'-y[)-2-hydroxypropyl]oxy}-4-({(2/2)-2-[hydroxy(diphenyl)methyl]pyrrolidin-l-
yl} carbonyl)phenol,
2- {[(2S)-3-(5-chIbro-1 7/,3//-spiro(2-benzofuran-1,4'-piperidin]-1 '-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-Af-(2-hydroxyethyl)-Ar-methylbenzamide,
3- {[(25)-3-(5-chloro-1 '#,3//-spiro[2-benzofuran-1,4'-piperidin]-1 '-yl)-2-
hydroxypropyl]oxy}-4-(pyrrolidin-l-ylcarbonyI)phenol,
3-{[(2lSO-3-(5-chloro-l'//,3//-spiro[2-benzoruran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyljoxy) -4- {[4-(2-hydroxyethyl)piperazin-1 -yljcarbonyl} phenol,
3- {[(2^-3-(5-chloro-1 '//,3//-spiro[2-benzofuran-1,4'-piperidin]-1 '-yl)-2-
hydroxypropyljoxy) -4- {[3-(hydroxyrnerhyl)piperidin-l -yljcarbonyl} phenol,
4-(4-chlorophenyl)-l-(2-{[(2)-3-(5-chloro-rM3//-spiro[2-benzoruran-l)41-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-4-ol,
3-{[(26)-3-(5-chloro-l'//J3//-spiro[2-benzoruran-l)4'-piperidin]-l1-yl)-2-hydroxypropyljoxy}-4-{[4-(hydroxymethyl)piperidin-l-yljcarbonyl} phenol,
l-(2-{[(25)-3-(5-chloro-l'//,3//-spiro[2-benzofliran-l)4l-piperidin]-l'-ylJ-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-phenylpiperidin-4-ol,
3-{[(25}-3-(5-chloro-r//,3//'-spiro[2-benzofuran-lI4l-piperidm]-ll-yl)-2-hydroxypropyl]oxy}-4-(3,4-dihydroisoquinolin-2(l//)-ylcarbonyl)phenoI,
3-{[(25)-3-(5-chloro-l'/fJ3//-spiro[2-benzofljran-iJ4l-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-{[2-(hydroxymethyl)piperidin-l-y!]carbonyl}phenol,
3-{[(25)-3-(5-chloro-l'//,3//-spiro[2-benzofliran-l,4l-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-{[3-(dimethylamino)pyrrolidin-l-yl]carbonyl}phenol,
l-(2-{[(2^-3-(5-chloro-l'Ar,3//'-spiro[2-ben2oruran-l,41-piperidin]-r-yI)-2-hydroxypropyI]oxy}-4-hydroxybenzoyl)-//,A'-dimethylprolinamide,
2- {[(2^)-3-(5-chloro-1 '//,3//-spiro[2-benzofuran-l ,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}-//-cyclohexyl-4-hydroxy-A^-(2-hydroxyethyl)benzamide,
Methyl (4J«)-l-(2-{[(25}-3-(5-chloro-r//,3//-spiro[2-benzofuran-l,41-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyI)-4-hydroxyprolinate,
I -(2- {[(25)-3-(5-chloro-1 '//,3 -spiro[2-benzof aran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-3-oI, ,
3-{[(2lS)-3-(5-ch[oro-l'//,3Ar-spiro[2-benzofuran-l,4l-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-phenylpiperidin-l-yl)carbonylJphenol,
3-{[(21S)-3-(5-chloro-l'//,3//-spiro[2-benzof\iran-l,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-(thiomorpholin-4-ylcarbonyl)phenol,
I -(2- {[(25>3-(5-chloro-1 7/,3//-spiro(;2-benzofuran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyljoxy}-4-hydroxybenzoyl)piperidin-3-ol,
2-{[(2^-3-(5-chloro-lr//)3W-spiro[2-benzofuran-l,41-piperidinJ-r-y[)-2-hydroxypropylJoxy}-Ar-(cyclopropylmethyl)-4-hydroxy-A'-Propylbenzaraide) 2- {[(2^-3-(5-chloro-1 W,3//-spiro[2-benzoiuran-1,4'-piperidinJ- l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-A',/V-diisobutylbenzamide)
3-{[(21S)-3-(5-chloro-l'//)3/f-spiro[2-benzofuran-lI4'-piperidin]-r-yi)-2-hydroxypropyl]oxy}-4-(J,3-dihydro-2//-isoindol-2-ylcarbonyl)phenol,
JV-(2-/err-butoxyethy!)-2-{[(2,S)-3-(5-chloro-l'//)3//-spiro[2-benzofiiran-l,4'-piperidin]-r-yI)-2-hydroxypropyl]oxy}-4-hydroxy-//-isobutylbenzamide,
3-{[(25)-3-(5-chloro-l'//)3//-spiro[2-benzoftjran-l)41-piperidin]-l'-yl)-2-hydroxypropylJoxy}-4-[(4-fluoropiperidin-l-yl)carbonyl]phenoI,
3-{[(25}-3-(5-chloro-r//,3/f-spiro[2-benzoftjran-J)4l-piperidinJ-r-yl)-2-hydroxypropylJoxy}-4-[(4,4-difluoropiperidin-l-y])carbonylJphenol,
2- {[(2,S>3 -(5-chloro-1 '//,3//-spiro[2-benzoruran-1,4'-piperidin]- l'-yl)-2-hydroxypropylJoxy}-4-hydroxy-A^-(2-hydroxypropyl)benzamide,
2-{[(2lS)-3-(5-chloro-l'//,3/f-sPiro[2-benzofuran-l,41-piPeridinJ-l'-yl)-2-hydroxypropyljoxy} -4-hydroxy-A^-(2-hydroxy-1,1 -dimethylethyl)benzamide, 2-{[(21S 2- {[(2vS>3-(5-chloro-1 '//,3/f-spiro[2-ben2oftiran-1,4'-piperidinJ-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-/V-(2-methoxyethyl)benzamide,
2- {[(2.y)-3-(5-chloro-17/,3//-opiro[2-benzofuran-1,4'-piperidinJ-l '-yl)-2-hydroxypropyI]oxy}-4-hydroxy-M(2-hydroxyphenyl)benzamide,
2-{[(2i}-3-(5-chloro-l'y/,3//-spiro[2-ben2ofuran-l)4l-piperidin]-r-yl)-2-
hydroxypropyljoxy} -4-hydroxy-yV-(2-hydroxy-1 -methylethyObenzamide,
2-{[(25)-3-(5-chloro-l1/3r,3//-spLro|;2-benzof\iran-l,4l-piperidin]-ll-yl)-2-hydroxypropynoxy}-4-hydroxy-Ar-isobutylbenzamide,
2- {[(25)-3-(5-chloro-1 7/,3#-spiro[2-benzofuran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-Af-(2-hydroxyethyl)benzamide,
2-{[(2J)-3-(5-chloro-l'//;3//-spiro[2-benzcifuran-ll4'-piperidin]-l'-yl)-2-hydroxypropyI]oxy}-4-hydroxy-/*/-(4-hydroxycyclohexyl)benzamide,
2-{[(2^-3-(5-chloro-l'j'y'13//-spiro[2-benzofljran-l)4l-piperidin]-l1-yl)-2-hydroxypropyl]oxy}-//-(2,3-di'hydroxypropyl)-4-hydroxybenzamide,
Methyl N-(2-{ [(26)-3-(5-chloro-l'//,3//-spiro[2-benzofuran-l,4'-piperidin]-ll-y])-2-hydroxypropyl]oxy} -4-hydroxybenzoy[)serinate,
2-{[(2,y)-3-(5-chloro-l'//,3//-spiro[2-benzofuran-l,41-Piperidin]-r-yl>2-hydroxypropyl]oxy}-A'-(l-ethylpropyl)-4-hydroxybenzamide,
2- {[(25)-3-(5-chloro-1 '//,3//-spiro[2-benzofuran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-A'-(tetrahydrofiaran-2-ylraethyl)beazamide, 2- {[(2 J)-3-(5-chloro-1 r//,3//-spiro[2-benzofuran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxy-A-[l-(hydroxymethyl)-2,2-dimethylpropyl]benzamide,
2-{[C2-3-(5-chloro-r//,3//-spiroi;2-benzoftiran-l)41-piperidin]-l1-yl)-2-hydroxypropyl]oxy}-4-hydroxy-//-[l-(hydroxymethyl)-2-methy[propyl]benzamide,
2-{[(2ly)-3-(5-chloro-r//,3//-spiro[2-benzofiiran-l)41-PiPeridin]-l'-yl)-2-hydroxypropyI]oxy}-4-hydroxy-yV-[3-(l-hydroxyethyl)phenyl]benzamide,
2-{[(2J)-3-(5-chloro-l'//,3//-spiro[2-benzofliran-l,4'-piperidin]-l'-yl)-2-hydroxypropyI]oxy}-Ar-(cyclopropyImethyl)-4-hydroxybenzamide,
2-{[(2ly)-3-(5-chloro-r//,3//-spiro[2-benzofiiran-l)4'-piperidin]-r-yl)-2-hydroxypropyljoxy} -4-hydroxy-/V-pyrrolidin-1 -ylbenzatnide,
-[(l/?J4l!T)-bicyclo[2.2.1]hept-2-yl]-2-{[(2lS)-3-(5-chloro-l1//l3//-spiro[2-benzoftiran-1,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy) -4-hydroxyberizamide,
2-{[(2,y)-3-(5-chloro-l'//,3//-spiro[2-benzofliran-l,4l-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxy-,V-(2-hydroxy-l-phenylethyl)benzamide,
2-{[(25)-3-(5-chloro-r//,3//-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-Ar-(2-hydroxycyclohexyl)benzamide,
l-(2-{[(25)-3-(5-chloro-liy/,3//-spiro[l-benzofliran-2,4l-piperidin]-]l-yl)-2-hydroxypropyl]oxy}-4-hydroxyben2oyl)pyrrolidine-3-carboxaraide trifluoroacetate,
1 -(2- {[(25)-3-(5-chloro-17/,3//-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-L-prolinarnide trifluoroacetate,
2-chloro-5-{[(25)-3-(5-chloro-l'//,3//-spiro[l-benzofuran-2,4'-piperidinj-l'-yl)-2-hydroxypropylJoxy}-4-{[(3/?)-3-(dimethy!amino)pyrrolidin-l-yl]carbonyl}phenol bis(trifluoroacetate),
2-chloro-5- {[(2lS)-3-(5-ch!oro-1 '//,3//-spiro[l -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-{[(3/J)-3-(hydroxymethyl)pyrroiidin-l-yl]carbonyl}phenol trifluoroacetate,
2-chIoro-5- {[(2lS)-3-(5-chloro-1 'H,3H-splro[ 1 -benzofijran-2,4'-piperidinJ-1 r-yl)-2-hydroxypropyl]oxy}-4-{[(3J)-3-(hydroxymethyl)pyrrolidin-l-yl]carbonyl}phenol trifluoroacetate,
2-chioro-5- {[(26)-3-(5-fluoro-1 '//,3/f-spirof 1 -benzoftiran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyljoxyj -4-(pyrrolidin-1 -ylcarbonyl)phenol trifluoroacetate,
-(2-{[(2R)-3-(5-FIuoro-r//,3//-spiro[l-benzoruran-2,4'-piperidinJ-r-y0.2-hydroxypropyljoxy} -4-raethoxyphenyl)acetamide,
Methyl 2-{[(2S)-3-(5-fluoro-ry/,3//-spiro[l -benzofuran-2,4'-piperidinj-l '-yl)-2-hydroxypropyljoxy) benzoate,
2-{[(2S)-3-(5-Fluoro-r//,3//-spiro[l-benzoruran-2,4'-piperidinJ-l'-yl)-2-hydroxypropyl]oxy}benzoic acid (hydrochloride),
(3S)-l-(2-{[(2S)-3-(5-Fluoro-r//13f/-spiro[l-benzoftiran-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoyl)pyrrolidin-3-ol,
3-{[(2S)-3-(5-Fluoro-r//,3//-spiro(l-benzofuran-2,4'-piperidin]-r-yl}-2-hydroxypropy|]oxy) -4-(pyrrolidin-1 -ylcarbonyl)phenol,
yV-(4-fluoro-2- {[(2^-3 -(5-fluoro-1 'y/,3//-spiro{ 1 -benzoruran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}phenyl)acetamide,
JV-{5-chJoro-2-[3-(5-chloro-;'^;j//-spiro[l-benzofuran-2)4'-piperidin]-r-yl)-2-hydroxypropoxy]-4-hydroxyphenyl}cyclopentanecarboxaraide,
Ar-{5-chloro-2-[3-(5-fluoro-y'//,J//'-spiro[I-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropoxy]-4-hydroxyphenyl}cyclopentanecarboxaraide,
A'"-{5-chloro-4-hydroxy-2-[2-hydroxy-3-(y7/,J//-spiro[l-benzofiiran-2,4'-piperidin]-l'-yl)propoxy]phenyl}cyclopentanecarboxamide,
V-(5-Chloro-2- {[(2,S>3-(5-chloro-17/,3//-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyljoxy} -4-hydroxyphenyl)ben2amide trifluoroacetate,
//-(5-Chloro-2- {[(25)-3-(5-fluoro-17/,3//-spiro[ 1 -benzofuran-2,4F-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-hydroxypheny[)benzamide trifluoroacetate,
-(5-Chloro-2-{[(21S)-3-(5-chloro-r//J3//-spiro[l-benzofuran-2J4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)urea trifluoroacetate,
Af-(5-Chloro-2-{[(2.y)-3-(5-nuoro-r//33//-spiro[l-ber^ofuran-2,4l-piperidin]-l>-y])-2-hydroxypropyljoxy) -4-hydroxypheuyl)urea trifluoroacetate,
//-(5-chloro-2-{[(25)-3-(5-nuoro-]1//J3//-spiro[l-benzoruran-234'-piperidin]-]'-yl)-2-hydroxypropyljoxy) phenyl)urea,
A^-(5-chloro-2-{[(2lS1)-3-(5-chloro-l'//,3//-spiro[l-benzoraran-2J4'-piperidin]-lt-yl)-2-hydroxypropyl]oxy}phenyl)urea,
^-(2-{[(2ly)-3-(5-fluoro-l1//)3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyljoxy} phenyl)urea,
Ar-(2-{[(2tS)-2-hydroxy-3-(r//>3//-spiro[l-benzoruran-2,4l-piperidin]-l'-yl)propyl]oxy}phenyl)urea,
A-(4-fluoro-2-{[(26')-3-(5-fluoro-rAr,3v[/-spiro[l-benzoruran-2,4'-piperidinJ-r-yl}-2-hydroxypropyl]oxy}phenyl)urea,
-(4-nuoro-2-{[(2^-2-hydroxy-3-(l'//,3//-spiro[l-beiizoruran-2,4'-PiPeridin]-l'-yl)propyl]oxy}phenyl)urea, and pharmaceutically acceptable salts and solvates of any one thereof.
The present invention further provides a process for the preparation of a compound of
formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined above which
comprises,
(a) reacting a compound of formula

1 2
wherein m, R , n, R , q, X, Y and Z are as defined in formula (I), with a compound of
formula
wherein R , R , R , R , R , R , t and R are as defined in formula (I); or (b) reacting a compound of formula
wherein m, RJ, n, R2, q, X, Y, Z, R4, R5, R6, R7 and R8 are as defined in formula (I), with a compound of formula
wherein R , t and R are as defined in formula (I), in the presence of a suitable base; or
(c) when R represents -NHC(O)R , reacting a compound of formula
wherein m, R , n, R , q, X, Y, Z, R , R , R , R , R , t and R are as defined in formula (I), with a compound of formula
wherein L represents a leaving group (e.g. a hydroxyl group or a halogen atom such as
chlorine) and R is as defined in formula (I); or
(d) whenR represents -C(0)NR R , reacting a compound of formula

wherein L represents a leaving group (e.g. a hydroxyl group or a halogen atom such as chlorine) and m, R1, n, R2, q, X, Y, Z, R , R , R , R , R , t and R are as defined in formula (I), with a compound of formula (IX), NHR R , wherein R and R areas
defined in formula (I); or
(e) when R3 represents -NHC(O)R10, R'° represents -NR14R15 and R14 and R15 both
represent hydrogen, reacting a compound of formula (VI) as defined in (c) above with potassium cyanate;
and optionally after (a), (b), (c), (d) or (e) forming a pharmaceutically acceptable salt or solvate.
The processes of the invention may conveniently be carried out in a solvent, e.g. an organic solvent such as an alcohol (e.g. methanol orethanol), a hydrocarbon (e.g. toluene) or tetrahydrofuran, dimethylformamide, N-methylpyrroIidinone or acetonitrile at a temperature of, for example, 0°C or above such as a temperature in the range from 0, 5, 10, 15or20°C to 100, 110 or I20°C.
Certain compounds of formula (II) are novel. Thus, the present invention further provides an intermediate compound of formula
wherein R is selected from fluorine, chlorine, methyl and trifluoromethyl; s is 1 or 2; q is
'
0 or 1; w is 0 or 1; and R is fluorine.
Specific examples of compounds of formula (IIA) include:
5-fluoro-3//-spiro[ 1 -benzofuran-2,4'-piperidine]



5-methy[-3//-spiro[l-benzofxiran-2,4l-piperidine]



5-(trifluoromethyl)-3//-spiro[l-benzofuran-2)4'-piperidine]
5-chloro-3'-fluoro-3//-spiro[l-benzofuran-2,41-piperidine] F

5-chloro-3//-spiro[l-benzoruran-2,3'-pyrrolidine] -O

-chIoro-3,4-dihydrospiro[chromene-2I4'-piperidine]
Other compounds of formula (II) and compounds of formulae (III), (IV), (V), (VI), (VII), (VIII) and (IX) are either commercially available, are known in the literature or may be prepared using known techniques.
For example, compounds of formula (II) in which m is 1, R is chlorine or fluorine, n is 0, q is 1, one of X and Y represents a bond and the other of X and Y represents an oxygen atom and Z represents CH2, may be prepared according to the following reaction schemes in which DMF denotes dimethylformamide, EtOH denotes ethanol, DME denotes 1,2-dimethoxyethane, i-Pr denotes isopropyl, THF denotes tetrahydrofuran, KOtBu denotes potassium tert butoxide and HOAc denotes acetic acid.: (A)

(Figure Remove)
Compounds of formula (II) in which m is 1, R is chlorine, n is 0, q is 1, X represents CH2, Y represents an oxygen atom and Z represents a bond, may be prepared according to the fallowing reaction schemes in which THF denotes tetrahydrofuran: (E)
Compounds of formula (II) in which m is 1, R is chlorine, n is 0, q is 0, one of X and Y represents a bond and the other of X and Y represents an oxygen atom and Z represents CH2, may be prepared according to the following reaction scheme in which DMF denotes dtmethylformamide and EtOH denotes ethanol: (G)
(Figure Remove) Compounds of formula (II) in which m is I, R is methyl, n is 0, q is 1, one of X and Y represents a bond and the other of X and Y represents an oxygen atom and Z represents CH2, may be prepared according to the following reaction scheme in which DMSO denotes dimethylsulphoxide:


Process routes (C), (D) and (H) above are novel.
Thus, the present invention further provides a process for preparing a compound of formula (IIA) as defined above in which s is I, which comprises reacting a compound of formula
wherein L represents a suitable leaving group (e.g. an electron withdrawing group such as a halogen atom) or an alkoxy, particularly methoxy, group, L represents a suitable leaving group such as a halogen atom and R is as defined in formula (IIA), with a
compound of formula
20
wherein R represents a protecting group such as a benzyl group or a group -C(0)-Q-R in which R represents an alky! (e.g. Cj-Cg alkyl, particularly terbutyl) or aryl (e.g.

phenyl) group and q, w and R 3 are as defined in formula (1IA) to form a compound of formula
followed by a cyclisation reaction and then removal of the protecting group R .
It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the reagents may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience(1999).
The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tarrrate, citrate, oxalate, methanesulphonate or/j-toluenesulphonate.
Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.
The compounds of formula (I) have activity as pharmaceutical, in particular as modulators of chemokine receptor (especially MlP-lct chemokine receptor) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).
Examples of these conditions are:
(1) (the respiratory tract) airways diseases including chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudo-membranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
(2) (bone and joints) rheumatoid arthritis, seronegative spondyloarthropathies (including
ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease,
Sjogren's syndrome and systemic sclerosis;
(3) (skin) psoriasis, atopical dermatitis, contact dermatitis and other eczmatous
dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus,
Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous
eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
(4) (gastrointestinal tract) Coeliac disease, proctitis, eosinopilic gastro-enteritis,
mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have
effects remote from the gut, e.g., migraine, rhinitis and eczema;
(5) (other tissues and systemic disease) multiple sclerosis, atherosclerosis, Acquired
Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus,
erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic
syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary
syndrome and idiopathic thrombocytopenia pupura;
(6) (allograft rejection) acute and chronic following, for example, transplantation of
kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host
disease;
(7) cancers, especially non-small cell lung cancer (NSCLC) and squamous sarcoma;
(8) diseases in which angiogenesis is associated with raised chemokine levels; and
(9) cystic fibrosis, stroke, re-perfusion injury in the heart, brain, peripheral limbs and
sepsis.
Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
tn the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
The invention also provides a method of treating an inflammatory disease which comprises administering to a patient in need thereof a therapeulica Uy effective amount of a compound of formula (I), or a.pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
The invention still further provides a method of treating an airways disease which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I) may be in the range from 0.001 mg/kg to 30 mg/kg.
The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (1), or a
pharmaceutically acceptable salt orsolvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.
The invention will now be further explained by reference to the following illustrative
examples, in which !H NMR spectra were recorded on Varian Unity Inova 400. The
central solvent peak of chloroform- (6n 7.27 ppra), acetone- (§H 2.05 ppm), DMSO-c4
(5n 2.50 ppm), or methanol- (8n 4.87 ppm) were used as internal standard. Low
resolution mass spectra and accurate mass determination were recorded on a Hewlett-
Packard 1100 LC-MS system equipped with APCI /ESI ionizations chambers.
A!J solvents and commercial reagents were laboratory grade and used as received.
The nomenclature used for the compounds was generated with ACD/IUPAC Name Pro.
The abbreviations or terms used in the examples have the following meanings:
BuLi : butyllithium
DCM : dichlorometharte DEAD : diethyl azodicarboxylate DMAP : 4-dimethylaminopyridine
DME : 1,2-dimethoxyethane
DMF : tyW-dimethylformamide
DMSO : dimethyl sulfoxide
Et2O : diethyl ether
EtOAc : ethyl acetate
EtOH : ethanol
HOAc : acetic acid

KotBu
MeCN
MeOH
NMP
TEA
TFA
THF
TMSC1

potassium tert butoxide
acetonitrile
methanol
1 -methyl-2-pyrrolidinone
triethylamine
thrifluoroacetic acid
tetrahydrofuran
chlorotrimethylsilane

SELECTFLUOR fluorinating reagent (Aldrich)
Chemical name: [l-(chloromethyl)-4-fluoro-l,4-diazoniabicyclo[2.2.2]octane
bis(tetrafluoroborate)]
PS-Carbodiimide : a resin-bound coupling agent
Chemical name: N-cyclohexylcarbodiimide-N'-propyloxymethyl polystyrene
Examples
Intermediate compound: 5-Chloro-3/f-spirofl-benzQfuran-2,4'-piperidinc|
Method A: This compound was prepared as described by Effland, R. C; Gardner, B. A; Strupczewski, J.,J. Heterocyclic Chem,, 1981,18, 811-814.
ethodJ3: o
i) l-Oxa-6-azaspiro[2.5Joctane-6-carboxylic acid, 1,1-dimethylethyl ester
Potassium t-butoxide (31g) was added to a stirred suspension of trimethylsulfoxonium iodide (60.8g) in 1,2-dimethoxyethane (250ml) at 20°C. After 1 hour, the mixture was added portionwise over 30 minutes to a stirred solution of 4-oxo-l-piperidinecarboxylic acid, 1,1-dimethylethyl ester (50g) in 1,2-dimethoxyethane (50ml) at 0°C. After a further 2 hours, water (500ml) was added and the mixture extracted with tert. -butyl methyl ether (2 x 500ml). The organic extracts were washed separately with saturated sodium bicarbonate solution (250ml), combined, dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was co-evaoprated with toluene (100ml) to give the sub-title compound (43.25g, 81 %) as a solid. 'H-NMR (400 MHz, CDC13): S 1.46 (9H, s), 1.43-1.48 (2H, m), 1.75-1.84 (2H, m), 2.69 (2H, s), 3.38-3.47 (2H, m), 3.70-3.75 (2H, m).
(ii) 5-Chlorospiro[l-benzofuran-2,4'-piperidine]-l'-carboxylic acid, 1,1-dimethyI ester
A solution of iso-propylmagnesium chloride in tetrahydrofuran (2M, 106.6ml) was added dropwise over 15 minutes to a stirred solution of 2-bromo-4-chloro-l-fluorobenzene (42.5g) in anhydrous tetrahydrofuran (250ml) at 0°C under nitrogen. After a further 15 minutes; a solution of l-oxa-6-azaspiro[2.5]octane-6-carboxylic acid, 1,1-dimethylethyl ester (43.2g) in anhydrous tetrahydrofuran (50ml) was added followed by copper(I)bromide dimethyl sulphide complex (0.4g). The mixture was stirred at 40°C for 18 hours, cooled to 20°C, diluted with water (300ml) and extracted with with tert.-butyl methyl ether (2 x 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in 1,2-dimethoxypropane (200ml). Potassium terf.-butoxide (22.8g) was added and the mixture stirred at 40°C for 16 hours then at 50°C for 24 hours. Further potassium tert.-butoxide (5.7g) was added and stirring continued at 50°C for 2 hours then at 55°C for 4 hours. Water (500ml) was added and the mixture extracted with te/V.-butyl methyl ether (2 x 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure to give the sub-title compound (47.45g, 67 %) as an oil. 'H-NMR (400 MHz, CDCI3): 5 1.47 (9h, s), 1.67 (2H, td), 1.85-1.93 (2H, m), 2.94 (2H, s), 3.39 (2H, td), 3.65-3.80 (2H, m), 6.67 (1H, d), 7.06 (1H, d), 7.10 (1H, s).
iii)5-ChIorospiro(l-benzofuran-2,4'-piperidine]
Concentrated hydrochloric acid (23ml) was added to a solution of 5-chlorospiro[l-benzofuran-2,4'-piperidine]-l '-carboxylic acid, 1,1-dimethyl ester (46.43g) in tetrahydrofuran (230rnl). The mixture was stirred at 50°C for 6 hours, cooled to 20°C, diluted with water (230ml) and extracted with ten.-butyl methyl ether (2 x 230ml). The aqueous phase was adjusted to pH >10 by addition of 50wt.% sodium hydroxide solution and extracted with tert.-butyl methyl ether (3 x 300ml). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in tetrahydrofuran (240ml), concentrated hydrochloric acid (12ml) was added and the mixture stirred at 20°C for 16 hours. Precipitated solid was filtered and dissolved in water (100ml). The solution was adjusted to pH >10 by addition of 50wt.% sodium hydroxide solution and extracted with tert.-butyl methyl ether (3 x 100ml) to give the title compound (13.3g, 45 %) as a solid.
'H-NMR(400 MHz, CDC13): 5 1.69-1.76 (2H, m), 1.83-1.87 (2H, m), 2.78-2.84 (2H, m), 2.98-3.03 (4H, m), 6.65 (1H, d), 7.04 (1H, d), 7.13 (lH,s). APCI-MS: m/z 224/6 [M+H]+
Intermediate compound: 5-Fluoro-3//-3piroU-benzofuran-2.4'-p|peridinef
Method A:
i) 1 '-Benzyl-5-fluoro-3/T-spirof l-benzofuran-2,4'-piperidine]
To a stirring suspension of magnesium strip (763 mg) in diethyl ether (7 mL) was added a crystal of iodine followed by (0.4 mL of 2-(bromomethyl)-l,4-difluorobenzene under nitrogen. The reaction mixture was initiated with a high intensity heat gun, 2-(bromomethyl)-l,4-difluorobenzene 5.0 g, 24.25 mmol) in diethyt ether (7 mL) was added slowly maintaining gentle reflux. After addition was completed the reaction mixture was stirred at reflux for 100 min, cooled to room temperature. To this reaction mixture a solution of l-benzylpiperidin-4-one (4.57 g, 24.25 mmol) in diethyl ether (12 mL) was added dropwise with vigorous stirring. After addition was completed the reaction mixture was left at room temperature overnight, Aqueous NFUCl solution was added and stirred at
room temperature until hydrolysis was completed, extracted with diethyl ether. The organic layer was washed with HiO, dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% NhLtOH) to give intermediate l-benzyl-4-(2,5-difluorobenzyI)piperidin-4-ol (2.74 g) containg large quantities of unknown impurities. To a suspension of NaH (55%, 1.12 g, 26.0 mmol) in toluene (10 mL) was slowly added a solution of l-benzyl-4-(2,5-difluorobenzyl)piperidin-4-ol in toluene (15 mL). After addition was completed the reaction mixture was stirred at 110 °C (in a pre heated oil bath), after 5 min, DMF (9 mL) was added and stirring was continued at reflux temperature for 2h. The reaction mixture was cooled to room temperature, H2O (20 mL) was added and extracted with ethyl acetate. The organic layer was dried over NajSC^, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (190 mg).
'H-NMR (CDC13,400 MHz): 5 7.39-7.26 (m, 5H); 6.88-6.76 (m, 2H); 6.67 (dd, J =• 4.2, 8.7 Hz, 1H); 3.59 (s, 2H); 2.99 (s, 2H); 2.68-2.47 (m, 4H); 2.03-1.94 (m, 2H); 1.86-1.76 (m, 2H). APCI-MS: m/z 298(MH+).
(ii) 5-Fluoro-37/-spiro[l-benzofuran-2,4'-piperidine]
Ethyl chloroformate (65.6 mg, 0.604 mmol) was added to a solution of 1 '-benzyl-5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidin] (150 mg, 0.504 mmol) in toluene (2 mL) and the reaction mixture was refluxed overnight. The reaction mixture was cooled to room temperature, diluted by addition of toluene, washed successively with aqueous NaHCCb and H20. The organic layer was dried over Na2SC>4, filtered and concentrated in vacuo. The residue was dissolved in ethanol (3.5 mL), aqueous KOH (800 mg, KOH in 0.8 mL fyO) was added and the reaction mixture was stirred at reflux temperature overnight, cooled to room temperature, ethanol was removed in vacuo. Aqueous layer was extracted with Et2O, combined ether layer was washed with 3N aqueous HC1. Combined aqueous layer was made pH 10 by addition of aqueous NaOH. The basic solution was extracted
with ethyl acetate. The combined organic layer was washed with H20, dried over Na2S04, filtered and concentrated. The residue was purified by HPLC (10-55% CH3CN in H20, 0.1% NH4OH) to give the titled compound (49 mg).
'H-NMR (CD3OD, 400 MHz): 5 6.92-6.87 (m, 1H); 6.81-6.75 (m, 1H); 6.64 (dd, J= 4.2, 8.7 Hz, 1H); 3.08-2.98 (m, 4H); 2.89-2.81 (m, 2H); 1.91-1.83 (m, 2H); 1.78-1.71 (m, 2H). APCI-MS: m/z 208(MH). .
(i) 4-((5-Fluoro-2-methoxyphenyl)methylJ-4-hydroxy-l-piperidinecarboxylic acid, 1,1-dimethylethyl ester.
A solution of iso-propylmagnesium chloride in tetrahydrofuran (2M, 130ml) was added dropwise over 30 minutes to a stirred solution of 2-bromo-4-fluoroanisole (34.2ml) in anhydrous tetrahydrofuran (400ml) at 30°C under nitrogen. After a further 16 hours at 30°C,. copper(I)bromide dimethyl sulphide complex (0.4g) was added followed by a solution of l-oxa-6-azaspiro[2.5]octane-6-carboxylic acid, 1,1-dimethylethyl ester (56.2g) in anhydrous tetrahydrofuran (110ml). After a further 3 hours at 30°C, the solution was cooled to 20°C, diluted with water (600ml) and extracted with ten. -butyl methyl ether (600ml) then ethyl acetate (600ml). Combined organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure to give crude sub-title compound (86 g) as a solid. APCI-MS: m/z 240 [M+H-(CH3)2CCHrC02]+
(ii)5-FIuorospiro[l-benzofuran-2,4'-piperidine] hydrochloride
Hydrobromic acid (48%, 60ml) was added to a solution of the crude 4-[(5-Fluoro-2-methoxyphenyl)methyl]-4-hydroxy-l-piperidinecarboxylic acid, 1,1-dimethylethyl ester in acetic acid (300ml). The mixture was heated at reflux for 5 hours. Further hydrobromic acid (48%, 60ml) was added and reflux continued for 24 hours. The mixture was cooled to room temperature, added to water (2 1) and extracted with tert.-butyl methyl ether (2 x 500ml). The aqueous phase was adjusted to pH > 10 by addition of 50 wt.% sodium hydroxide solution and extracted with tert.-butyl methyl ether (21+1 I). Organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residual oil was dissolved in tetrahydrofiiran (200ml), concentrated hydrochloric acid (13 ml) was added and the solution evaporated under reduced pressure. The residual solid was crystallised from tetrahydrofuran / tert.-butyl methyl ether (4:1, 500 ml) to give the title compound (20.0 g, overall yield 31 %).
'H-NMR (CD3OD, 400 MHz): 5 1.86-1.98 (2H, m), 2.03-2.07 (2H, m), 3.05 (2H, s), 3.16-3.27 (4H, m), 6.61 (1H, dd), 6.74 (IH, dt), 6.81 (IH, dd). APCI-MS: m/z 208 [M+H]*
Intermediate compound: 3//-Spirofl-benzofuran-2,4'-piperidinel
This compound was prepared as described by Effland, R. C; Gardner, B. A; Strupczewski, J., J, Heterocyclic Chem., 1981,18, 811-814.
Intermediate compound: 5-Metliyi-3//-spirofl-benzofuran-2,4-piperidiiie|

(i) 6-benzyI-l-oxa-6-azaspiro[2.5]octane
Sodium hydride (55 % suspension in mineral oil, 1.57 g, 35 mmol) was washed with heptane, dried in the stream of nitrogen and suspended in dry DMSO (10 ml). A solution of trimethylsulfoxonium iodide (4.8 g, 22 ramol) in DMSO (45 ml) was added dropwise under nitrogen. After stirring for 20 min a solution of i-benzylpiperidin-4-one (3,78 g, 20 mmol) was added dropwise. The mixture was stirred overnight at room temperature, then poured over ice (200 g), and extracted with dichloromethane (2 x 200 ml). The combined extracts were washed with water (3 x 100 ml) and dried over Na2SO4. The solvent was removed i. vacuo. The residue was dissolved in diethy! ether, and the insoluble material was removed by filtration. Evaporation of solven afforded pale-yellow oil (2.95 g, 73 %). 'H-NMR (CDClj, 400 MHz): S 7.2 - 7.4 (m, 5HJ- 3.57 (s, 2H); 2.5 - 2,7 (m, 4H); 1.85 (rn, 2H); i.55(m, 2H).
(ii) J-benzyl-4-(2-fluoro-5-methylbenzyl)piperidin-4-oI
To a solution of 2-bromo-l-fluoro-4-methylbenzene (0.76 g, 4 mmol) in THF (15 ml) at -70 °C under Ar a solution of n-BuLi (1,6 M in hexane, 2.5 ml, 4 mmol) was added dropwise. The reaction mixture was stirrred at -70 °C for 1 h, then BFs'EtiO (0.5 ml, 4 mmol) was added. After stirring for 20 min at -70 °C , a solution of 6-benzyl-l-oxa-6-azaspiro[2.5]octane (0.41 g, 2 mmol) in dry THF (5 ml) was added dropwise. The stirring was continued for 2 h at -70 °C, then the reaction mixture was quenched with sat. aq. NtUCl (20 ml). The layers were separated, the aqueous layer extracted with THF. The combined organic layers were dried over NaiSO-i. The solvent was removed in vacuo. Diethyl ether (50 ml) was added to the residue, folowed by a 2 M HCI in Et20 (5 ml). The precipitate was collected, washed with Et20, and dissolved in minimal volume of methanol (ca. 5 ml). Water (50 ml) was added, and pH adjusted to 10 by addition of 2 M aq. NaOH, The mixture was extracted with ethyl acetate (2 x 25 ml), and the combined organic extracts were dried with Na2S04. Evaporation of solvent afforded brownish oil. APCJ-MS:m/z314[M-f-Hr
(iii) r-benzyl-5-mcthyI-3//-spiro[l-benzofuran-2,4'-piperidine]
To a suspension of NaH (55% in mineral oil, 200 mg, 5 inmpl) in toluene (10 mL) was slowly added a solution of crude l-benzyl-4-(2-fluoro-5-methylbenzyl)piperidin-4-ol in toluene (15 mL). After addition was completed, the reaction mixture was heated to 110 C and stirred for 5 min. DMF (9 mL) was added and stirring was continued at reflux temperature for 10 h. The reaction mixture was cooled to room temperature, poured into water (50 ml), and extracted with ethyl acetate (2 x 25 ml). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash chromatography (ethyl acetate / n-heptane) to give the subtitle compound (240 mg, 41 %). 'H-NMR (CDC13> 400 MHz): 5 7.2 - 7.4 (m, SH); 6.8 - 6.9 (m, 2H); 6.64 (d, /= 10.8 Hz, 1 H), 3.54 (s, 2H); 2.91 (s, 2H); 2.4 - 2.7 (m, 4H); 2.24 (s, 3H); 1.92 (m, 2H); 1.78 (m, 2H). APCJ-MS: m/z 294 [M+H]+
(iv) S-methyl-S/f-spirofl-benzofuran--piperidine]
To a solution of r-benzyl-5-methyl-3//--spiro[l-benzofuran-2,4'-piperidine] (0.12 g, 0.41 rnol) in dichloromethane (3 ml) was added 1-chloroethyl chloroformate (87 mg, 0.61 mmol). The solution was stirred at room temperature overnight. The solvent was removed i. vacuo. The residue was dissolved in methanol (3 ml), and the solution was heated at 70 °C for 2 h. The solvent was eeporated, and the residue treated with diethyl ether. The precipitate formed was collected by filtration, washed with diethyl ether, and dissolved in methanol (1 ml). Water (25 ml) was added, and pH was adjusted to 10 by addition of 2 M aq. NaOH. The mixture was extracted with dichloromethane (2 x 25 ml), and the combined organic extracts were dried overNa2S04. Evaporation of solvent afforded brownish oil (64 mg, 77 %).
'H-NMR (CDClj, 400 MHz): 8 6.95 (s, 1H); 6.90 (d, y= 8 Hz, 1 H); 6.64 (d, /= 8 Hz, 1 H); 3.11 (m, 2H); 2.95 (s, 2H); 2.85 (m, 2H); 2.26 (s, 3H); 1.88 (m, 2H); 1.72 (m, 2H). APCI-MS: m/z 204 [M+H]+
Intermediate compound: 5-(Trinuoromethvl)OH-smVofl-bcn2ofuran-2.4'-piperidinel
(3) l-Benzyl-4-(2-nuoro-5-(trinuoromethyI)benzyI]piperidin-4-ol
To a stirring suspension of Mg strips (308 rag) in Et2O (5 mL) was added a crystal of iodine followed by 0.3 mL of 2-(bromomethyl)-l-fluoro-4-(trifluoromethyl)benzene under argon. The reaction was initiated with a high intensity heat gun, then 2-(bromomethyl)-l-fluoro-4-(trifluoromethyl)benzene (2.5 g, 9.73 mmol) in Et^O (5 mL) was added slowly (maintaining reflux). After addition was completed the reaction mixture was refluxed for 50 min, cooled to room temperature. A solution of l-benzylpiperidin-4-one (1.84 g, 9.73 mmol) in Et2O (10 mL) was added slowly with vigorous stirring. After addition was completed, the reaction mixture was left at room temperature for 50 min, saturated aqueous NH4CI solution was added and stirred at room temperature untill hydrolysis was finished, extracted with ethyl acetate. The combined organic layer was washed with water, dtied over NajSO^, filtered and concentrated. The residue was purified by silica gel flash chroma to graphy (0-1% methanol in dichloromethane, 0.2%NH,fOH) to give the subtitled compound (720 mg). APCl-MS: mJz 368 (MH+).
(II) r-Benzyl-5-(trifluoromethyl)-3H-spiro[l-benzofuran-2,4'-piperidlnej
To a suspension of NaH (55%) (127 mg, 2.91 mmol) in toluene (4 mL) was slowly added a solution of l-benzyl-4-[2-fluoro-5-(trifluoromethyI) benzyl] piperidin-4 (715 mg, 1.94 mmol) in toluene (5 mL) at room temperature. After addition was completed the reaction mixture was stirred at 110 °C for 5 min, then DMF (3 mL) was added and the reaction mixture was stirred at reflux temperature for 40 min, cooled to room temperature, fyO (3 mL) was added, extracted with eihyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (380 mg). 'H-NMR (CDCI3l 400 MHz): 5 7.45-7.23 (m, 6H); 6.82 (d, J = 9.0 Hz, 1H); 3,60 (s, 2H); 3.02 (s, 2H); 2.70-2.45 (m, 4H); 2.00 (m, 2H); 1.85 (m, 2H). APCI-MS:m/z348(MH+).
(ill) 5-(Trifluoromcthyl)-3H-spiro(l-benzofuran-2,4'-piperidine]
To a solution ofl'-benzyl-S-CtrifluoromethyO-SH-spirol-benzoruran^^'-piperidin] (280 mg, 0.806 mmol) in toluene (3 mL) was added ethylchloroformate (0.093 mL, 0.967 mmol) and the reaction mixture was stirred at reflux temperature overnight, cooled to room temperature, diluted by addition of toluene and washed with aqueous NaHCOs and water successively. The organic layer was dried overNa2SO,i, filtered and concentrated. The residue was dissolved in ethanol ((4 mL), aqueous KOH (1.14 g KOH in 1.2 mL of HjO) was added and the reaction mixture was refluxed overnight, cooled to room temperature, ethanol was removed in vacuo. Aqueous layer was extracted with Et2O, combined ether layer was washed with 3N aqueous HC1. Combined acidic layer was made pH 10 by addition of aqueous NaOH. The basic solution was extracted with ethyl acetate. The combined organic layer was washed with water, dried over NaaSO,), filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NKtOH) to give the subtitled compound (156 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.29 (s, 1H); 7.39 (d, /= 8.4 Hz, 1H); 6.82 (d, J= 8.4 Hz, 1H); 3.10-3.00 (m, 4H); 2.89-2.81 (m, 2H); 1.94-1.86 (m, 2H); 1.82-1.74 (m, 2H). APCI-MS:m/z258(MH+).
(i)/^-Butyl4-[(trimethylsilyl)oxyJ-356-dihydropyridine-l(2/0-carboxylate
Intermediate compound: 5-diloro-3'-fluoro-3//-spirofl-benzofuran-2,4'-piperidineI
(Figure Remove)
To a solution of tert-butyl 4-oxopiperidine-l-carboxylate (10.13g, 50.84mmol) in DMF under argon was added TMSC1 ( 7.74 ml, 61.27mmol) followed by Et3N (17 ml). The mixture was stirred at 80°C overnight, The solution was cooled to ambient temperature and then diluted with heptane, washed with cone, aq NaHC03 and water. The organic layer was then dried over sodium sulphate, filtered and concentrated. Chromatographic purification on silica gel (EtOAc:pethroleum ether 40-60 1:9) gave 9.6g (69 %) of an oil which solidified on standing.
'H-NMR (CDClj, 300 MHz): 8 4.79(m, IH); 3.87(01, 2H); 3,520,7= 5,8 Hz, 2H); 2.1 l(m, 2H); 1.47(s, 9H); 0.19(s, 9H). APC1-MS: m/z 272 (M+H)+.
(il) ferf-Butyl 3-fluoro-4-oxopIperidine-l-carboxylate
To a solution of /e/7-Butyl 4-[(trimethy[silyl)oxy]-3,6-dihydropyridine-l(2//)-carboxylate ( 9.52 g, 35,07 mraol) in CHjCN under argon was added selectfluor reagent (13.7 g, 38.6 mmol) and stirred at room temp, for 2 h. The reaction mixture was diluted with EtOAc (1000ml), washed with dilute brine, water, dried over sodium sulphate, filtered and concentreated in vacuo. Chromatographic purification on silica gel (MeOH:EtOAc, from 0:1 to 2:98) gave 5.35g (70%) of an oil, which solidified on standing. 'H-NMR (CDCh, 300 MHz): 8 4.73 - 4.94 (m, IH), 4.14 - 4.23 (m, 2H), 3.30 - 3.20 (m, 2H) 2.49 - 2.66 (m, 2H), 1.50 (s, 9H) APCI-MS:m/z218(M+H)+
(Hi) te^Butyl4-(5-chloro-2-fluorobenzyO-3-fluoro-4-hydroxypiperidine-l-carboxylute
To magnesium turnungs covered with ether was added a small amount of a solution of 2-(bromomerhyt)-4-chloro-l-fluorobenzene in diethyl ether and the reaction was intiated by a high inlesisty heat gun. To the refluxing mixture was added the remaining solution (150ml) dropwise maintaining the reflux. After all the solution was added the mixture was stirred until! the reflux was ceased. A solution of tert-butyl 3-fluoro-4-oxopiperidne-l-carboxylate in diethytether(50m!) was added slowly. The resulting mixture was sitirred for
further 4 s at room temp., then it was quenched by slow addition sat. aq ammonium chloride (125m). It was extracted with EtOAc (2 x ISOmml), washed with brine, water, dried over sodium sulphate, filtered and concentrated. The resulting residue was purified on silica gel (heptane - Et20 4:1-2:1) to give 1.6Lg (18%) of subtitle compound. .'H-NMR (CDC13 300 MHz): 5 6.74 (s, 1H), 7.15 (s, 1H), 7.10 - 7.14 (m, 1H), 4.85 - 5.02 (m, 1H), 3.78-3.88 (m, 2H), 3.50 (m, 2H) 2.74 (s, 2H), 1.63 - 1.67 (m, 2H), 1,44 (s, 9H) APCI-MS: m/z 362 (M+H/
(iv)rerr-Butyl5-chloro-3'-fluoro-l'//,3//-spiro[l-benzofuran'2,4'-piperidine]-r-
carboxylatc
To a suspension of NaH (60% in mineral oil, 1.38 g, 4.35 mmol) in benzene (30 ml) was added a solution of /er/-butyl 4-(5-chloro-2-fluorobenzyl)-3-fluoro-4-hydroxypiperidine-l-carboxylate in benzene (50mml) and the mixture was heated to reflux. DMF 20(mml) was added and refluxing continued for 6hrs. The mixture was cooled to rt and poured into water and extracted with ETOAc. The organic layer was dried over sodium sulphate, filtered and concentrated. The residue was purified by chromatography on SiO2 (ethylacetate: n-heptane) to give the product (10 mg, 26%). APCI-MS m/z 342 [M+H]+
(v) 5-Chloro-3'-fiuoro-3/f-spiro[l-benzofuran-2j4'-piperidineJ
A solution of tert-butyl 5-chloro-3'-fluoro-l'H,3H-spiro[l-benzonaran-2,4'-piperidine]-r-carboxylate in DCM/TFA (20mt, 5:2) was stirred at room temp, for 2 h. the solvent was removed in vacuio, the residue diluted with EtOAc and washed with sat. aq. NaHCOj, and water. The organic layer was dried over Na2SO4, filtered and concentrated to give the title compound (60mg). APCI-MS m/z 242 [M+H} +
Intermediate compound: 4#-spirofchromene-3,4'-Dipcridine|
(i) Ethyl l-benzyl-4-(2-fluorobenzyl)piperidine-4-carboxylate
Ethyl !-benzylpiperidine-4-carboxylate (2.47 g, 10 mmol) was dissolved in tetrahydrofuran (20 mL) and cooled to -78°C. Lithium bis(trimethylsilyl) amide (11 mL, 1.0 M in tetrahydrofuran) was added slowly, and stirred for 30 minutes. 2-fluoro-benzylbromide (1.34 mL, 11 mmol) in 5 mL tetrahydrofuran was added slowly. The resulting solution was allowed to reach room temperature and stirred overnight. The reaction was quenched with ammonium chloride (aq, sat) and partitioned between water and ethyl acetate. The organic layer was washed with brine and dried over magnesium sulphate, filtrated and concentrated. The crude material was purified on silica (heptane/ethyl acetate), to give 2.7 g (77%) the subtitle compound as a colourless oil. APCI-MS: m/z 356 [MH+]
(ii) [l-Benzyl-4-(2-fluorobenzyl)piperidin-4-yl]methanol
A stirred solution of ethyl l-benzyl-4-(2-fluorobenzyl)piperidine-4-carboxy[ate (1.85 g, 5.2 mmol) in diethyl ether was cooled on ice/sodium chloride. Lithium aluminium hydride (5,8 mL, 1.0 M in diethyl ether) was added drop wise. After stirring at room temperature for 2 hrs the mixture was re-cooled on ice, quenched with water/sodium hydroxide (10%) and stirred at room temperature for 1 hrs. The solids were filtered off, and the organic layer was dried over disodium sulphate, filtrated and concentrated. The crude material was purified on silica (dichloromethane/ethanol) to give 1.0 g (61%) the subtitle compound. APCI-MS: m/z 314 [MH+]
[iii) 1 '-Benzyl-4//-spiro[chromene-3,4'-piperidine|
Sodium hydride (350 mg, 7.0 mmol, 50% disp in oil) was washed three times with heptane, under nitrogen atmosphere, and then dissolved in tetrahydrofuran (50 mL). A solution of [I-benzyl-4-(2-fluorobenzyl)piperidin-4-yl]methanol (Ig, 3.2 mmol) in tetrahydroftiran (30 mL) was added and the resulting mixture was refluxed for 3 hrs. The cooled solution was partitioned between water and ethyl acetate and the organic layer was dried over magnesium sulphate and concentrated. The crude product was purified on silica (dichloromethane/ methanol) to give 0.83 g (89%) of the subtitle compound. APCI-MS: m/z 294 [MH+]
(iv)4/f-Spiro[chromene-3,4'-piperidinej
1 '-benzyl-4//-spiro[chromene-3,4'-piperidine] (800 mg, 2.7 mmol) was dissolved in methanol (100 mL). Acetic acid (5 mL) and palladium on activated charcoal (cat amount,
10%) was added. Reaction in a Parr apparatus at 35 psi for 18 hrs, followed by filtration, evaporation and HPLC purification on CIS (acetonitrile/water) yielded 500 mg (92%) of the title compound.
'H-NMR (400 MHz, DMSO-d5) 5: 8.86 (1H, bs); 7.10-7.05 (2H, m); 6.85 (1H, dt); 6.76 (1H, d); 3.93 (2H, s); 3.15-3.01 (4H, m); 2.71 (2H, s); 1.66-1.51 (4H, m)
APCI-MS :m/z 2 04 [MH+]
Intermediate Compound: 6-Chloro-3,4-dihvdrosDiro[chrojTiene-2,4'-piperidtnel
(i) r-Benzyl-6-chlorospiro[chromene-2,4'-piperidin]-4(3//)-one
A solution of l-(5-chloro-2-hydroxyphenyi)elhanone (1.7 g, 10 mmol), 1-benzylpiperidin-4-one (2.08 g, 11 mmol) and pyrrolidine (1.07 g, 15 mmol) in methanol (2 ml) was heated
at 70 °C for 3 h. After cooling to room temperature, the reaction mixture was poured into water (20 ml), and extracted with ethyl acetate (50 ml). The organic layer was washed with 1 N aq. HCI (2 x 50 ml), 2 N aq. NaOH (50 ml), and water. Drying over Na2SCU and evaporation of solvent afforded subtitle compound as orange-coloured oil (2.61 g, 77 %). APCI-MS: m/z 342 [M+H]+
(ii) l'-BenzyI-6-chloro-3,4-dihydrospiro[chromcne-2,4'-piperidine]
To a stirred suspension of AIC13 (3.04 g, 22.8 mmol) in dichloromethane (75 ml) tert-butylamine - borane (1:1) (3.98: g, 45.8 mmol) was addeo at 0 °C, and the stirring was continued for 15 min at this temperature to obtain a clear solution, A solution of I'-benzyl-6-ch[orospiro[chromene-2,4'-piperidin]-4(3#)-one (2.61 g, 7.6 mmol) in dichloromethane (15 ml) was added dropwise. The stirring was continued for 2 h at 0 °C and for 3 h at room temperature. The reaction mixture was quenched by dropwise addition of 0.1 N aq. HO. After the gas evolution has ceased, the layers were separated. The organic layer was washed with 0.1 N HCI (2 x 50 ml) and brine (50 ml), and dried over Na2SO4. The solvent was removed in vacuo to afford subtitle compound as colourless solid (1.63 g, 65 %). APCI-MS; m/z 328 [M+H]
(iii) 6-Chloro-3,4-dihydrospirofchromene-2,4'-piperidtne] hydrochloride
A solution of r-benzyl-6-chloro-3,4-dihydrospiro[chrornene-2,4'-piperidine] (1,63 g, 5.0 mmot) and 1-chloroethyl chloroformate (1.07 g, 7.5 mmol) in toluene (5 ml) was heated with reflux overnight. The solvent was removed vacuo, the oily residue dissolved in methanot (10 ml) and heated with reflux overnight. The solvent was removed in vacuo, and the residue treated with diethyl ether (50 ml). The white precipitate was collected by filtration, washed with diethyl ether and dried to afford the subtitle compound as white powder (0.58 g, 49 %).
'H-NMR (cocb, 400 MHZ).- 5 7.07 (d, /= 10.0 HZ, 2H); 7.63 (d,y = 8.4 HZ, IH); 3.2-
3,5 (m, 4H); 2.77 (t, /= 6.6 Hz, 2H); 1.9 - 2.2 (m, 4H); 1.88 (t, J = 6.6 Hz, 2H). APCI-MS: m/z 238 [M+Hf
Intermediate compound: e-ChlorQ-ff-spirofZ-benzofuran-M'-piperidinel
(i) l'-Benzyl-6-chloro-3/f-spiro{2-bcnzofuran-l,4'-piperidin]-3-one
To a solution of 2-brorao-4-chlorobenzoic acid (2.35 g, 10.0 mmol) in tetrahydforuran (THF) (15 mL) was added, a 1.6 M solution in hexane, n-butyllithium (Parham, W.E; Egberg, D. C; Sayed, Y. A; Thraikill, R. W; Keyser, G. E; William, M. N; Montgomery, M. C; Jones, L. D., J. Org. Chem., 1976, 41, 2628-2633) (20 mL, 32.0 raraol) slowly at -78 °C under nitrogen. After addition was complete the reaction mixture was stirred at -78 °C for 3 hours (h). Then a solution ofl-benzylpiperidin-4-one (3.78 g, 20.0 mmol) in THF (10 mL) was added slowly to the reaction mixture at -78 °C. After addition was complete the reaction temperature was raised to room temperature and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into a mixture of water (H20) (60 mL) and diethyl ether (60 mL), layers were separated. The aqueous layer was extracted with diethy! ether (2 x 20 mL). The aqueous layer was acidified with aq 6 M HC1 to pH 2 and boiled for 1 h, cooled to 0 °C, pH was adjusted to 10 by addition of aqueous sodium hydroxide (NaOH) (6M) and rapidly extracted with trichloromethane (CHCl^). The organic layer was washed with H20, dried over sodium sulphate (NaaSC^), filtered and concentrated in vacuo to give sub-titled compound (1.22 g) and it was pure enough for the next step.
'H-NMR (CDClj, 400 MHz): 6 7.84 (d,J= 8.2 Hz, 1H); 7.51 (dd, J= 1.7, 8.2 Hz, 1H); 7.45-7.25 (ra, 6H); 3.67 (s, 2H); 3.00 (br.d;7 = 9.4 Hz, 2H); 2.61 (br.t,J = 11.2 Hz, 2H); 2.32 (br, s, 2H); 1.74 (d, J = 12.2 Hz, 2H). APCI-MS:m/z328(MH+).
(ii) lVBenzyl-6-chloro-3#-spiro[2-benzofuran-l,4'-piperidine]
To a solution of I'-benzyl-6-chloro-3//-spiro[2-benzofuran-l,4'-piperidine]-3-one (1.1 g, 3.35 mmol) in THF (15 mL) was added 1 M solution of borane (Marxer, A; Rodriguez, H. R; McKenna, J. M; Tsai, H. M.,/ Org. Chem., 1975, 40, 1427-1430) complex in THF (7 mL, 7.0 mmol) slowly at 0 °C. After addition was complete, the reaction mixture was kept at room temperature for 30 minutes (min), then kept at reflux overnight, cooled to
0 °C and 6M aqueous hydrochloric acid (HC1) (3.5 mL) was added slowly. The reaction
mixture was kept at reflux for 5 h, cooled to 0 °C, pH of the reaction mixture was adjusted
to 10 by addition of aqueous NaOH 6M and the whole was extracted with ethyl acetate.
The organic layer was washed with HaO, dried over Na2S04, filtered, and concentrated in
vacuo. The residue was purified by silica gel flash chromatography (0-30% ethyl acetate
in petroleum ether) to give the sub-titled compound (900 mg).
'H-NMR (CDC13) 400 MHz): 5 7.44-7.22 (m, 6H); 7.18 (m, 2H); 5.03 (s, 2H); 3.60 (s,
2H)2.87 (br.d,/= 10.5 Hz, 2H); 2.45 (br.t,y- 11.2 Hz, 2H); 2.00 (br.s, 2H); 1.79 (d,J =
ll.2Hz.2H).
APCI-MS:m/z3l4(MH>).
(iii) 6-Chloro-3//-spiro(2-benzofuran-l,4'-piperidine]
To a solution of r-benzyl-6-chloro-3//-spiro[2-benzofuran-II4'-piperidine] (850 mg, 2.7 mmol) in dichloromethane (CHjC^) (8 mL) was added chloroethyl chloroformate (Yang, B. V; o'Rourke, D; Li, ]., Synlett, 1993, 195-196) (772 mg, 5.4 mmol) slowly at 0 °C. After addition was complete the reaction mixture was stirred at 0 °C for 30 min. The volatiles were removed in vacuo, residue was dissolved in methanol (10 mL) and kept at reflux for 40 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-6% methanol in dichloromethane, 0.2% ammonium hydroxide (NH4OH)) to give the titled compound (170 mg) and l'-benzyl-6-chloro-3H-spiro[2-ben2ofbran-l,4'-piperidine] was recovered (200 mg).
'H-NMR (CD3OD, 400 MHz): 8 7.29-7.21 (m, 3H); 5.00 (s, 2H); 2.99 (m, 4H); 1.90-181 (m, 2H);1.70(m,2H). APCI-MS:m/z224(MH+).
Intermediate compound: 5-Fluoro-3ff-spiro(2-benzofuran-1.4'-piperidine[
(iv) l'-Benzyl-5-fIuoro-3//-spiro[2-benzofuran-l,4'-piperidin]-3-one
This reaction was performed as described for (i) above using 2-bromo-5-fluorobenzoic
acid (2.19 g, 10.0 mmol), 1 -benzylpiperidin-4-one (3.78 g, 20.0 mmol), n-butyl lithium
(n-BuLi) (20 mL) and THF (20 mL) to give the sub-titled compound.
'H-NMR (CDCIj, 400 MHz): 5 7.58-7.23 (m, 8H); 3.68 (s, 2H); 2.98 (m, 2H); 2.59 (m,
2H); 2.28 (m, 2H); 1.74 (m, 2H).
APCI-MS: m/z 312(MH+).
(v) r-Benzyl-5-fluoro-3//-spiro[2-benzofuran-l,4'-piperidine] This reaction was performed as described for (ii) above using 1 '-benzyl-5-fluoro-3//'-spiro[2-benzofuran-l,4'-pipertdin]-3-one(200 mg, 0.642 mmol), borane THF complex IM solution (1,34 mL, 1.34 mmol) and THF (3 mL) to give the sub-titled compound (148 mg). 'H-NMR (CDCI3j 400 MHz): S 7.41-7.27 (m, 5H); 7.08 (dd, J= 4.8, 8.3 Hz, 1H); 6.97 (m, IH); 6,89 (m, 1H); 5.08 (s, 2H); 3.60 (s, 2H); 2.87 (m, 2H); 2.46 (m, 2H); 1.97 (m, 2H); 1.88(m,2H). APCI-MS: m/z 298(MhT).
(vi) 5-Fluoro-3/f-5pin>[2-benzofuran-l,4'-piperidine]
This reaction was performed as described for (iii) above using 1 '-benzyl-5-fluoro-3//-
spiro[2-benzofuran-l,4'-piperidine] (145 mg, 0.487 mmol), cbloroethyl chloroforrnate
(0.07 mL) to give the titled compound.
'H-NMR (CDjOD, 400 MHz): 67.18 (dd, .7=4.9, 8.1 Hz, IH); 7.03-6.96 (m, 2H); 5.01 (s,
2H); 3.09-2.93 (m, 4H); 1.91-1.81 (m, 2H); 1.73-1.66 (m 2H).
APCI-MS: m/z 208(MH+).
Intermediate compound: {(25V2-methYloxiran-2-Yl]methyl 3-nitroben2enesulfonate
Prepared as described by Eriksson, T.; Kiingstedt, T.; Mussie, T, Published International Patent Application No. WO 01/98273.
Example 1
hydroxypropyl|oxy}phenyl)acetamide
Step I: A^2-[(2S)-Oxiran-2-ylmethoxyJphenyl}acetarnide
A mixture of /V-(2-hydroxyphenyl)acetamide (l.Slg, 10 mmol), (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (2.59 g, 10 mmol) and cesium carbonate (Cs2CO3) (3.9 g, 12 mmol) in dimethylformamide (DMF) (30 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H^O. The organic layer was dried over NajSO^ filtered, concentrated and the residue was purified by silica gel flash chromatography to give the subtitled compound (1.34 g).
'H-NMR (CDC13, 400 MHz): 5 8.40 (m, IH); 7.90 (br.,s, IH); 7.05 (m, 2H); 6.92 (m, IH); 4.37 (dd, J = 2.5, 1 1.3 Hz, IH); 3.98 (dd, J = 5.9, 1 1.3 Hz, IH); 3.40 (m, IH); 2.97 (t, J = 4.8 Hz, IH); 2.81 (dd,7= 2.7,4.8 Hz, IH); 2.20 (s, 3H).
Step II:
A^-(2-{((2S)-3-(5-Chloro-17/)3J-spiro[l-benzofuran-2,4)-pipendin]-l'-yl)-2-
hydroxypropyljoxy}phenyl)acetamide
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidme] (36 mg, 0.16 mmol) and jV-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (33 mg, 0.16 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane containing 0.2% ammonium hydroxide) to give the titled compound (25 mg). 'H-NMR (CDC13, 400 MHz): 6 7.82 (d, /= 4.8 Hz, IH); 7.22 (m, IH); 7.13 (m, 2H); 7.05 (d,/= 7.5 Hz, IH); 6.98 (m, IH); 6.74 (d, J = 8.6 Hz, IH); 4.49 (m, IH); 4.08 (d, J = 4.8 Hz, 2H); 3.70 (m, 2H); 3.43 (m, 4H); 3.12 (s, 2H); 2.20 (m, 7H). APCI-MS:m/z433(MHi).
Example 2 Ar-(2-{[(2S)-3-(5-Chloro-r/r,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-
hydroxypropyl]oxy}-4-fluorophenyl)acetamide
Step I: A^-Fluoro^-hydroxyphenyOacetamide
A mixture of 5-fluoro-2-nitrophenol (5 g, 31.8 mmol), acetic anhydride (4.86 g, 47.7
mmol) and platinum on carbon (5%, 200 mg) in methanoi was hydrogenated at 35 psi for 3
hours. The catalyst was filtered off and the residue was purified by silica gel flash
chromatography to give the subtitled compound (4.7 g).
'H-NMR (CD3OD, 300 MHz): 8 7.56-7.51 (m, 1H); 6.61-6.50 (m, 2H); 2.15 (s, 3H).
APCI-MS:m/zl70(MH+).
Step II: yV-{4-Fluoro~2-[(2S)-oxiran-2-ylmethoxy]phcnyl}acetamide
A mixture ofAr-(4-fluoro-2-hydroxyphenyl)acetamide (1.69 g, 10.0 mmol), (2S)-oxiran-2-
ylmethyl-3-nitrobenzenesulfonate (2.59 g, 10.0 mmol) and CsjCCh (4.87 g, 15.0 mmol) in
DMF (15 mL) was stirred at room temperature for 2 h. The reaction mixture was
partitioned between ethylacetate and H20. The organic layer was dried over Na2S04
filtered and concentrated. The residue was purified by silica gel flash chromatography to
give the subtitled compound (1.35 g).
'H-NMR (CDC13] 400 MHz): 5 8.33-8.29 (m, 1H); 7.71 (br. S, 1H), 6.74-6.66 (m, 2H);
4.39-4.36 (m, 1H); 3.95-3.90 (m, 1H); 3.41-3.39 (m, 1H); 2.99-2.97 (m, 1H); 2.80-2.79 (m,
1H).
APCI-MS: m/z 226 (MH+).
Step III: A^-(2-{l(2S)-3-(5-Chloro-l'/f,3//-splroll-benzofuran-2,4'-piperidin]-l'-y[)-2-
hydroxypropylJoxy}-4-fluorophenyl)acetainide
A mixture of 5-chIoro-3//-spiro[l-benzofbran-2,4'-piperidine] (45 mg, 0.201 mmol) and A/-{4-fluoro-2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (45.3 mg, 0.201 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromalography (0-3% methanoi in dichloromethane, 0.2% NH4OH) to give the titled compound (33 mg). 'H-NMR (CDC13, 400 MHz): 8 8.52 (s, 1H); 8.20 (dd, J = 6.4, 8.9 Hz, 1H); 7.18 (s, 1H); 7.13 (dd, 7=2.0, 8.5 Hz, 1H); 6.74 (dd, 7=2.6, 8.6 Hz, 1H); 6.69 (d,J = 8.6 Hz, 1H); 6.59 (dd, /« 2.6, 9.8 Hz, 1H); 4.48 (m, 1H); 4.17 (dd, 7 = 3.7, 9.8 Hz, 1H); 4.00 (dd, 7= 2.2, 9.8 Hz, 1H); 3.79 (m, 2H); 3.59 (br.d, J *> 1 1.7 Hz, IH); 3.38 (m, 1H); 3.27 (m, 1H); 3.12 (s, 2H); 3.05 (m, IH); 2.48 (m, IH); 2.37 (m, IH); 2.24 (s, 3H); 2.17 (m, 2H). APCI-MS:m/z451
Example 3
A'-(2-{[(2S)-3-(5-Chloro-r//,3Jcr-spiro[l-benzofuran-2,4'-piperidinI-l'-yl)-2-
hydroxypropyl]oxy}-4-methoxyphenyl)acetamide
Step I:
/V-(2-Hydroxy-4 methoxyphenyl)acetamide
2-Nitro-5-methoxyphenoI (prepared from 3-methoxyphenol, R. J. Maleski, Synthetic Communications, 1993, 23, 343-348) (48.5g,0.287 mol) dissolved in THF (1.5 L) was hydrogenated at ambient temperature over night with 10% palladium on carbon (10 g) until 20.3 L of hydrogen was consumed. After filtration and evaporation the residue was suspended in degased water (1 .7 L) and acetic anhydride (42.5 mL) was added with stirring. The mixture was heated to 60 °C for Ih and then cooled to room temperature. The volatiles were removed in vacuo and the solid was washed thoroughly with water and dried in vacuo to give brick-red crystals (41,7 g, 80 %).
'H-NMR (400 MHz, CDC!3): 6 8.98 (s, 1H); 7.34 (br.s, 1H); 6,81 (d, 1H); 6.58 (d, 1H); 6.44 (dd, 1H); 3.78 (s, 3H); 2,26 (s, 3H)
Step II: 7V-{4-Methoxy-2[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide
//-(2-Hydroxy-4-methoxyp'henyl)acetamide (18.12 g, 0.1 mol) and (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (25.92 g, 0.1 mol) were dissolved in dry DMF (75 mL) and stirred under nitrogen (N-t) on an ice-bath. Cesium carbonate (35.8g, 0.1 Imol) was added and the stirring under Nj was continued at ambient temperature overnight. The mixture was poured into ethyl acetate (1L) and water (250 mL). The organic phase was washed with water (3 x 250 mL), dried over NajSO^, filtered and concentrated in vacuo to give an orange solid crude product (29 g), which was recrystallized from ethanol (100 mL) and washed with ether to give white crystals. More white crystals were obtained from the mother liquor, after evaporation and recrystillazition from 2-propanol. Total yield 15 g (63%).
'H-NMR (CDCI3): 5 8.22 (d, 1H); 7.64 (bs, 1H); 6.53 (dd, 1H); 6.50 (d, 1H); 4.34 (dd, 1H); 3.92 (dd, 1H); 3.79 (s, 3H); 3.38 (m, 1H); 2.96 (t, 1H); 2.78 (dd, 1H); 2.20 (s, 3H)
Step III:
Ar-(2-{[(2S)-3-(5-Chloro-lW,3Jff-spiro[l-benzofuran-2,4'-piperidinj-l'-yI)-2-hydroxypropylJoxy}-4-methoxyphenyl)acetamide
A mixture of 5-chIoro-3//-spiro(l-berizofaran-2,4'-piperidine] (200 mg, 0.894 mmol) and A/'-{4-methoxy-2[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (212 mg, 0.894 mmol) in ethanol (5 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (400 mg). 'H-NMR (CD3OD, 400 MHz): 8 7.74 (d,/= 8.9 Hz, 1H); 7.13 (m, 1H); 7.04 (dd,y=2.3, 8.5 Hz, 1H); 6.65 (d, J = 8.5 Hz, ;H); 6.61 (d, J = 2.7 Hz, !H); 6.51 (dd, J = 2.7, 8.8 Hz, 1H); 4.17 (m, 1H); 4.08 (dd,7= 5.4, 10.0 Hz, 1H); 3.98 (dd,/= 6.3, 9.9 Hz, 1H); 3.79 (s, 3H); 3.03 (s, 2H); 2.72 (m, 4H); 2.62 (m, 2H); 2.15 (s, 3H), 1.95 (m, 2H); 1.84 (m, 2H).
APCI-MS:m/z46l (MhT).
Example 4 Af-(2-{[(2S)-3-(5-ChIoro-l'/f53//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-4-hydroxyphcnyl)acetamide
To a cold (0 °C) solution of ?/-(2-{[(2S)-3-(5-chtoro- -spiro[l-ben2ofuran-2,4-piperidinj-l '-yI)-2-hydroxypropyl]oxy}-4-methoxyphenyi)acetamide (380 mg, 0.82 mmol) in dichloromethane (8 mL) was added 1M solution of boron tribromide (BBrj) in dichloromethane (2.47 mL, 2.47 mmol) slowly. After addition was complete the icebath was removed and the reaction mixture was stirred at room temperature for 2 h 30 min. The reaction mixture was cooled to 0 °C and methanol (2 mL) was added slowly with stirring for 10 min. The volatiles were removed in vacuo. The residue was dissolved in large volume of ethyl acetate, washed successively with aqueous sodium hydrogencarbonate (NaHCOj) solution and water. The organic layer was dried over Na2S04, filtered, concentrated and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% NH^OH) to give the titled compound (155 mg). 'H-NMR (CD3OD, 400 MHz); 5 7.57 (d, J= 8.7 Hz, IH); 7.14 (m, 1H); 7.04 (dd, J = 2.3, 8.5 Hz, IH); 6.66 (d, J = 8.5 Hz, IH); 6.48 (d, J = 2.5 Hz, 1H); 6.32 (dd, 7 = 2.5, 8.6 Hz, IH); 4.17 (m, IH); 4.06 (dd, J = 3.4, 9.8 Hz, IH); 3,93 (dd, J = 6.2, 9.8 Hz, IH); 3.03 (s, 2H); 2.70 (m, 4H); 2.59 (m, 2H); 2.13 (s, 3H); 1.95 (m, 2H); 1.84 (m, 2H). APCI-MS :m/z447(MH>).
Example 5
^-(2-{K2S)-3-(5-Chloro-l'jy)3/f-spiro[l-benzofuran-2,4'-piperidin]-r-yl>2-hydroxypropyl]oxy}-5-(trifluoromethyl)phenyl]acetamide
Step I:
Ar-f2-{[(2S)-2-Methyloxlran-2-yllmethoxy}-5-(trifluororaethyl)phenyl] acetamide
A mixture of 2-nitro-4-(trifluoromethyl)phenol (310 mg, 1.5 mmol), palladium on carbon (10%, 125 mg) and acetic anhydride (306.3 mg, 3.0 mmol) in methanol was hydrogenated for 2 h at atmospheric pressure. The catalyst was filtered off, the filtrate was concentrated in vacuo to give crude Ar-(2-hydroxy-5-(trifluoromethyl)phenyl]acetamide (331mg). A part (219.16 mg, 1.0 mmol) of vV-[2-hydroxy-5-(trifluorcmethyl)phenyl]acetamide was treated with [(2S)-2-methyloxiran-2-yl]methyl3-nitrobenzenesulfonate (273.27 mg, 1.0 mmol) in the presence of Cs2C03 (406.25 mg, 1.25 mmol) in DMF (5 mL) at room temperature for 5 h. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over NaaSO,), filtered, concentrated. The residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum ether) to give the subtitled compound (230 mg).
'H-NMR (CDClj, 400 MHz): 5 8.86 (s, IH); 8.00 (br.s, IH); 7.29 (m, IH); 6.97 (d, J = 8.5 Hz, IH); 4.23 (d,/= 11.0 Hz, IH); 4.04 (d, J= 11.03 Hz, IH) 2.93 (m, IH); 2.81 (d, J= 4.6 Hz, IH); 2.22 (s, 31H); 1.42 (s, 3H).
Step II:
Af-[2-{[(2S)-3-(5-ChIoro-l'/r}3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-5-(trifluorornethyI)phenyl]acetamide
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidtne] (35 mg, 0.155 mmol) and A'-^-I^SJ^-methyloxiran^-ylJmethoxyJ-S^trifluorometliyOphenyl] acetamide (45 mg, 0.155 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (28 mg). 'H-NMR (CD3OD, 400 MHz): 5 8.40 (d,7= 1.8 Hz, IH); 7.40 (dd,y= 1.4, 8.7 Hz, IH); 7.18 (d, J= 8.6 Hz, IH); 7.13 (m, IH); 7.03 (dd, / = 2.2, 8.5 Hz, IH); 6.63 (d, /= 8.5 Hz, IH); 4.13 (d, 7=9.3 Hz, IH); 3.98 (d, .7=9.3 Hz, IH); 2.99 (s, 2H); 2.78 (m, IH); 2.68 (m, 3H); 2.58 (m, IH); 2.22 (s, 3H); 1.88 (m, 2H); 1.78 (m, 2H); 1.32 (s, 3H). APCI-MS:m/z513(MH+).
Example 6
2-{[(2S)-3-(5-Chloro-l'//,3-spiro[l-benzofuran-2,4'-piperidin|-l'-y))-2-hydroxypropyl]oxy}-N-cycIopropylbenzamide
Step I: TV-Cyclopropyl-Z-hydroxybenzamide
A mixture of of methyl salicylate (4.36 g, 28.69 mmol) and cyclopropylamine (1.64 g) wa; heated in a sealed tube at 80-100 °C for 3h. An additional 0.5 g of cyclopropylamine was added and heated at 70 °C overnight. T he volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography to give the subtitled compound (2.71 g). 'H-NMR (CDC13, 400 MHz): 5 12.40 (s, 1H); 7.40 (m, 1H); 7.38 (m, 1H); 7.01 (m, 1H); 6.81 (m, 1H); 6.48 (br.s, 1H); 2.85 (m, 1H); 0.98 (m, 2H); 0.82 (m, 2H).
Step II: yV-Cyclopropyl-2-[(2S)-oxiran-2-ylmethoxy]ben2amide
A mixture of//-cyclopropyl-2-hydroxybenzamide (270 mg, 1.52 mmol), (2S)-oxiran-2-ylmethyI-3-nitrobenzenesulfonate (378 mg, J.68 mmol) and cesium carbonate (645 mg, 1.98 mmol) in DMF (4 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over NajSOo, filtered and concentrated. The residue was purified by silica gel flash chromatography (40% heptane in ethyl acetate) to give the subtitled compound (354 mg), 'H-NMR (CDC13, 400 MHz): 5 8.22 (dd,/= 1.8, 7.8 Hz, 1H); 7.95 (br.s, 1H); 7.42 (m, IH); 7.10 (m, 1H); 6.93 (d,J= 8.3 Hz, 1H); 4.44 (dd,7= 2.5, 10.7 Hz, 1H); 4.08 (dd,/ = 5.1, 10.8 Hz, lH);3.40(m, IH); 3.04-2.95 (m, 2H); 2.83 (dd, 7= 2.7,4.5 Hz, IH); 0.86 (m, 2H); 0.65 (m, 2H).
Step III:
2-{[(2S)-3-(5-Chloro-lW,3//'-spiro[l-ben2ofuran-2,4'-piperldinJ-r-yl)-2-hydroxypropyI]oxy}-N-cyclopropyIbenzamide
A mixture of 5-chloro-3//-spiro[l-benzoruran-2,4'-piperidine] (9 mg, 0.04 mmol) and /V-cyclopropy!-2-[(2S)-oxiran-2-yunethoxy]benzamide (9.4 mg, 0.4 mmo!) in ethano! (1.5
mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH 'H-NMR (CD3OD, 400 MHz): 5 7.92 (m, 1H); 7.47 (m, !H); 7.13 (rn, 2H); 7.05 (m, 2H); 6.65 (d, J= 8.5 Hz, 1H); 4.23 (dd, J = 3.0, 9.4 Hz, 1H); 4.16 (rn, 1H); 4.09 (dd, J = 5.5, 9.4 Hz, 1H); 3.03 (s, 2H); 2.93 (m, 1H); 2.70 (br. S, 4H); 2.60 (d,J = 6.3 Hz, 1H); 1.96 (m, 2H); 1.85 (m, 2H); 0.81 (m, 2H); 0.69 (m, 2H). APCI-MS:m/z457(MH+).
Example 7
2-{[(2S)-3-(5-Chloro-l'/f,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-
hydroxypropylJoxy}-A/-cyclopropyl-4-iluorobenzamide
Step I: Ar-CycIopropyl-4-fluoro-2-hydroxybenzarnide
A suspension of methyl 4-fluoro-2-hydroxybenzoate (510 mg, 3.0 mrnol) in cyclopropylamine (5 mL) was stirred at room temperature overnight when it became a clear solution. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-30% ethyl acetate in petroleum ether) to give the subtitled compound (493 mg).
'H-NMR (CD3OD, 400 MHz): 5 12.65 (s, 1H); 7.28 (m, 1H); 6.69 (dd,7= 2.6, 10.4 Hz, 1H); 6.56 (ddd, 7= 2.6, 8.0, 10.4 Hz, 1H); 6.30 (br. S, 1H); 2.88 (m, 1H); 0.98 (m, 2H); 0.66 (m, 2H). APCI-MS:m/z 196(MH+).
Step II: 7V-Cyclopropyl-4-fluoro-2-(oxiran-2-ylmethoxy)benzaniide
A mixturte of jV-cyclopropyl-4-fluoro-2-hydroxybenzamide (195 mg, 1.0 mmol), (2Soxiran-2-yimethyD-nitrobenzenesulfbnate (259 mg, 1.0 mmol) and Cs2C03 (390 rng, 1.2 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The organic layer was dried over . Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-30% ethylacetate in petroleum ether] to give the subtitled compound
(I50mg).
'H-NMR (CDCJj, 400 MHz): 8 8.24 (dd, /- 7.0, 8.8 Hz, IH); 7.80 (br. s, IH); 6.82 (ddd, J
= 2.3, 7.6, 10.2 Hz, IH); 6.66 (dd,/- 2.3, 10.2 Hz, IH); 4.45 (dd,/- 2.4, 10.7 Hz, IH);
4.05 (dd, /= 5.1, 10,7 Hz, IH); 3.40 (m, IH); 3.00 (m, 2H); 2.84 (dd, 7 = 2.6,4.8 Hz, IH);
0.86 (m,2H); 0.65 (m,2H).
APCI-MS:m/z252(MH*).
Step HI:
2-{{(2S)-3-(5-Chloro-l,3-spiro(l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropylJoxy}-N-cyclopropyl-4-nuorobenzanude
A mixturte of 5-chloro-3-//-spiro[l-benzofuran-2,4'-piperidine] (30 mg, 0.134 mmol) and Af-cyclopropyl-4-fluoro-2-(oxiran-2-yImethoxy)benzamide (33.6 mg, 0.134 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH-)OH) to give the titled compound (36 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.97 (dd,/= 6.9, 8.7 Hz, IH); 7.14 (m, IH); 7.05 (dd, / = 2.3, 8.5 Hz, IH); 6.96 (dd, 7 = 2.4, 10.4 Hz, IH); 6.82 (ddd;/ = 2.4, 8.0, 10.4 Hz, IH); 6.66 (d, /= 8.5 Hz, IH); 4.24 (dd, /= 3.0, 9.4 Hz, IH); 4.17 (m, IH); 4.10 (dd, /= 5.5, 9.4 Hz, IH); 3.05 (s, 2H); 2.82 (m, IH); 2.71 (br. s, 4H); 2.60 (d, /= 6.3 Hz, 2H); 1.99 (m, 2H); 1.88 (m, 2H); 0.83 (m, 2H); 0.58 (m, 2H). APCI-MS: m/z 252 (MH+).
Example 8
2-{((2S)-3-(5-Cliloro-r//,3/f-spiro[l-benzofuran-2,4'-piperidinj-l'-yl)-2-hydroxypropyl]oxy}-N-cvdopropyl-4-methoxybenzamide
Step I;
Ar-CyclopropyI-2-hydroxy-4-methoxybenzamide ,
A suspension of methyl 2-hydroxy-4-methoxybenzoate (5.1 g, 28.0 mmol) in cyclopropyl
amine 24 mL) was stirred at room temperature for 5 days. The volatiles were removed in
vacuo and the residue was purified by silica gel flash chromatography (0-60% ethyl acetate
in petroleum ether) to give the subtitled compound (1.8 g).
'H-NMR (CD3OD, 400 MHz): 5 7.61 (d,/= 8.8 Hz, 1H); 6.42 (m, 2H); 3.80 (s, 3H); 2.80
(m, 1H); 0.80 (m, 2H); 0.62 (m, 2H).
APCI-MS:m/z208(MH+)
Step II: A'-CycIopropyl-4-methoxy-2-[(2S)-oxiran-2-yIniethoxyJbenzamide
A mixture of jV-cyclopropyl-2-hydroxy-4-methoxybenzamide (700 mg, 3.38 mmol), (2S)-oxiran-2-ylmethy!3-nitrobenzenesulfonate (876 mg, 3.38 mmol) and CsjCOs (1.31 g, 4.05 mmol) in DMF (12 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-80% ethyl acetate in petroleum ether) to give the subtitled compound (1-0 g).
'H-NMR (CDClj, 400 MHz): 6 8.20 (d, J= 8.8 Hz, 1H); 7.85 (br.s, 1H). 6.63 (dd, /== 2.3, 8.8 Hz, 1H); 6.45 (d,/= 2.3 Hz, 1H); 4.42 (dd,y = 2.5, 10.8 Hz, 1H); 4.05 (dd.y- 5.2, 10.8 Hz, 1H); 3.82 (s, 3H); 3.40 (m, 1H); 3.00 (m, 2H); 2.83 (dd, J= 2.6,4.8 Hz, 1H); 0.88 (m, 2H); 0.68 (m, 2H). APCI-MS: m/z 264 (MH+).
Step III:
2-{[(2S)-3-(5-Chloro-l'//,3//'-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-A^-cyclopropyl-4-methoxybenzamide
A mixture of 5-chloro-37/-spiro[l-benzofuran-2,4'-piperidine] (100 mg, 0.447 mmol) and Ar-cyclopropyl-4-methoxy-2-[(2S)-oxiran-2-ylmethoxy]benzamide (117.7 mg, 0.447 mmol) in ethanol (3 mL) was stilted at 80 °C overnight. The volatiles were removed in

vacuo and the residue was purified by silica gel flash chromatograpy (0-1.5% methanol in dichioromethane, 0.2% NH4OH) to give the titled compound (145 mg). 1H-NMR (CDC13,400 MHz): 5 8.18 (m, 2H); 7.12 (m, 1H); 7.09 (dd, J= 2.3, 8.5 Hz, 1H); 6.70 (d, J = 8.5 Hz, 1H); 6.63 (dd, 7= 2.3, 8.8 Hz, 1H); 6.44 (d, J = 2.3 Hz, 1H); 4.19 (dd, J- 3.3, 9.4 Hz, 1H); 4.13 (m, 1H); 3,97 (dd,/ = 5.0, 9.4 Hz, IH); 3.88 (s, 3H); 3.02 (m, 3H);2.92(m, IH); 2.81 (m, IH); 2.63 (m, 3H); 2.53 (dd,/= 3.6, 12.4 Hz, lH);2.04(m, 2H); 1.88 (m, 2H); 0.85 (m, 2H); 0.06 (m, 2H). APCI-MS:m/z487(MH*).
Example 9
Af-(2-{[(21S Step I: 2-MethyI-l,3-benzoxazoI-6-ol
To a stirred solution of l-(2,4-dihydroxyphenyl)ethanone (20 g, 131 mmol) in pyridine (80 mL) hydroxylamine hydrochloride (9.1 g, 131 mmol) was added over a period of 15 min in small portions at room temperature. The reaction mixture was stirred for 20 h and then diluted with water (600 mL) and extracted with ethyl acetate (2 x 250 mL). The combined organic extracts were washed with water (2 x 250 mL) and 5 % aqueous HC1(250 mL). The solvent was removed in vacuo. Water (200 mL) was addded to the residue and then concentrated in vacuo, then toluene (200 mL) was added and concentrated in vacuo. The residue was dissolved in a mixture of acetonitrile (150 mL) and dimethylacetamide (25 mL). The solution was cooled to 5 °C, phosphorus oxychloride (20.4 g, 12.2 mL, 133 mmol) was added dropwise allowing the temperature to exceed 10 °C. After the addition was complete, the reaction mixture was stirred at room temperature for 1 h and then it was slowly poured into a mixture of sodium carbonate (55 g) and ice (ca 800 g). After the ice melted, the resulting slurry was filtered and the solid collected was washed with water (2 x 150 mL). The product was dried in vacuo to afford a yellow powder (14.4 g, 97 mmol, 76%),
'H-NMR (400 MHz, DMSO-d*): 5 9.68 (br. s, 1H), 7.38 (d, /« 8.5 Hz, 1H), 6.94 (d, /= 2.2 Hz, LH), 6.74 (dd, J = 8.5, 2.2 Hz, 1H), 2.50 (s, 3H).
Step II: 2-MethyI-l,3-benzoxazol-6-yl benzoate
To a stiired suspension of 2-methyl-l,3-benzoxazol-6-ol (2.99 g, 20 mmol) in dichJoromethane (50 mL) was added triethylamine (4.05 g, 5.58 mL, 40 mmol). A solution of benzoyl chloride (3.09 g, 2.56 mL, 22 mmol) in dichloromethane (20 mL) was added dropwise over ca. 10 min. The reaction mixture was stirred at room temperature for 2.5 h, then washed with water (2 x 50 mL), and dried over Na2SO4, filtered and concentrated in vacuo to give the subtitled compound as a colourless solid (5.05 g, 20 mmol).
'H-NMR (400 MHz, CDC13): 5 8.22 (m, 2H), 7.66 (m, 2H), 7.53 (m, 2H), 7.40 (d, 1H), 7.16(dd, 1H), 2.65 (s, 3H). APCI-MS: m/z 254 [MH*].
Step III: 4-(Acerylamino)-3-hydroxyphenyI benzoate
To a solution of 2-methyI-l,3-benzoxazol-6-yl benzoate (5.05 g, 20 mmol) in THF (100 mL) a mixture trifluoroacetic acid/water (4 ml/10 mL) was added. The reaction mixture was stirred at room temperature for 16 h, then saurated aqueous NaHCO3 (150 mL) was added. The mixture was extracted with ethyl acetate (150 mL), dried over Na2S04, filtered and concentrated in vacuo to give the subtitled compound.
'H-NMR (400 MHz, acetone-d6): 6 9.76 (br.s, 1H), 9.32 (br.s, 1H), 8.15 (m, 2H), 7.71 (m, 1H), 7.60 (m, 2H), 7.47 (d, 1H), 6.85 (m, 1H), 6.75 (m, 1H), 2.20 (s, 3H). APCI-MS: m/z 272 [MH*].
Step IV: 4-(Acetylamino)-3-{[(2S)-2-methyIoxiran-2-yl]methoxy}phenyl benzoate
This compound was prepared from 4-(acetylamino)-3-hydroxypheny! benzoate (2.71 g, 10 mraol) and [(2S)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate using the standard procedure and l-methylpyrrolidin-2-one as a solvent. Flash chromatography on silica gel (ethyl acetate/n-heptane) afforded the subtitled compound as a colourless solid (1.31g, 3.9
mmol, 39 %).
'H-NMR (400 MH2, CDC13): 8 8.41 (d, IH), 8.18 (m, 2H), 7.91 (br.s, IH), 7.63 (m, IH),
7.50 (m, 2H), 6.83 (m, IH),4.15 (d,/ = 10.8 Hz, IH), 4.03 (d,J= 10.8 Hz, IH), 3.99 (d, J
- 10.8 Hz, 1H), 2.92 (d, J = 4.6 Hz, IH), 2.78 (d, J = 4.6 Hz, 1H), 2.22 (s, 3H), 1.48 (s,
3H).
APCI-MS: m/z 342 [MH+].
Step V:
Af-(2-{[(2.y)-3-(5-ChIoro-17/)3//-spiro{l-benzofuran-2,4'-piperidinJ-l'-yl)-2-hydroxy-2-inethylpropyl]oxy}-4-hydroxyplienyl)acetamide trifluoroacetate
A solution of 5-chtoro-3//-spiro[l-benzofuran-2,4'-piperidine] (20.0 mg, 0.09 mraol) and 4-(acetylamino)-3-{[(2iS)-2-methyIoxiran-2-yl]methoxy}phenyt benzoate (30.5 mg, 0.09 mmol) in methanol (2 mL) was refluxed for 3 h. The reaction mixture was cooled to room temperature, and 1 drop of 20 % NaOH in ethanol was added. The mixture was stirred at room temperature for 3 h. The solvent was distilled off under reduced pressure, The residue was purified by HPLC ("Kromasil" column; eluant: [acetonitrile + 0.1 % trifluoroacetic acid (TFA)Avater + 0.1 % TFA]) to afford a colourless solid (41 mg, 0.07 mmol, 79 %).
'H-NMR (400 MHz, acetone-d«): 5 8.67 (br. s, IH), 7.71 (d, J = 7.0 Hz, IH), 7.22 (s, IH), 7.12 (dd, J - 2.3, 8.5 Hz, IH), 6.75 (d, J = 8.5 Hz, IH), 6.59 (d, J = 2.6 Hz, IH), 6.42 (dd, J = 2.6, 8.6 Hz, IH), 4.03 (d, IH), 3.97 (d, J = 9.7 Hz, IH), 3.92 (br.s, IH), 3.82 (br. s, IH), 3.70 (d,y = 13.6 Hz, IH), 3.52 (m, 3H), 2.1 - 2.5 (m, 4H), 2.10 (s, 3H), 1.51 (s, 3H). APCI-MS; m/z 461 [MH*].
Example 10
yV-(5-ChIoro-2-{[(2S)-3-(6-chloro-r/7,3//-spiro[2-benzofuran-l,4'-piperidinI-l'-yl)-2-hydroxypropyl]oxy}phenyl)acetamide
Step I: //-(5-ChIoro-2-hydroxyphenyl)acetaniide
To a suspension of 2-amino-4-chlorophenol (1.43 g, 10.0 mmol) in methanol was added acetic anhydride (0.945 mL, 10.0 mmol) and the reaction mixture was stirred at room temperature for 2 h. The volatiles were removed in vacuo to give the subtitled compound
(1-5 g).
'H-NMR (DMSO-d6, 400 MHz): 5 10.20 (br.s, IH); 9.21 (s, IH); 8.00 (d,7= 2.6 Hz, IH);
6.94(dd,y=2.6,8.7Hz, IH); 6.84 (d, J=8.7Hz, IH); 2.02 (s, 3H).
Step II: A/-{5-Chloro-2-[(2S)-oxiran-2-ylmethoxy]phenyI}acetamide
A mixture of ./V-(5-chloro-2-hydroxyphenyl)acetamide (500 mg, 2.69 mmol), (2S)-oxiran-2-ylmethyl3-nitrobenzenesu!fonate (697 rag, 2.69 mmol) and Cs2CO3 (1.04 g, 3.22 mmol) in DMF (10 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-50% ethyl acetate in petroleum ether) to give the subtitled compound (600 mg). 'H-NMR (CDCI3, 400 MHz): 5 8.47 (d, /= 2.3 Hz, IH); 7.93 (br.s, IH); 6.98 (dd, J= 2.3, 8.7 Hz, IH); 6.83 (d, J~ 8.7 Hz, IH); 4.36 (dd, /= 2.4, 11.3 Hz, IH); 3.94 (dd, /= 6.1, 11.3 Hz, lH);3.39(m, lH);2.98(m, IH); 2.81 (dd, .7=2.7, 4.8 Hz, IH); 2.22 (s, 3H). APC1-MS: m/z 242 (MH+).
Step III:
A^-(5-Chloro-2-{[(2S)-3-(6-cliloro-y'flr,3//r-spiro[2-benzofuran-l,4'-pipendin]-l'-yI)-2-hydroxypropyl]oxy}phenyl)acetamide
A mixture of 6-chloro-3//-spiro[2-benzoruran- l,4'-piperidine] (26 mg, 0.116 mmol) and A^{5-chloro-2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (28 mg, 0.116 mmol) in
ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (28 mg). 'H-NMR (CDjOD, 400 MHz): 5 8.18 (d,/= 2.4 Hz, IH); 7.30-7.20 (m,, 3H); 7.10-7.00 (m, 2H); 5.02 (s, 2H); 4.23 (m, IH); 4.14 (dd, J = 3.1, 9.9 Hz, IH); 3.99 (dd,7= 6.5, 9.9 Hz, IH); 2.93 (m, 2H); 2.63 (d, J= 6.3 Hz, 2H); 2.55 (m, 2H); 2.21 (s, 3H); 2.00 (m, 2H);
1.73(ra,2H).
APCI-MS: m/z 467 (MH+).
Example 11
A'-(2-{[(2S)-3-(6-Ch!oro-l'//,3/f-spiro[2-benzofuran-lJ4'-piperidinJ-l'-yl)-2-
hydroxypropyl]oxy}-4~fluorophenyl)acetamide
A mixture of 6-chloro-3//-spiro[2-benzoruran-l,4'-piperidine] (30 mg, 0.134 mmol) and Af-{4-fluoro-2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (30 mg, 0.134 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (40 mg). JH-NMR (CD3OD, 400 MHz): 5 7.90 (dd, J= 6.2, 8.9 Hz, IH); 7.29-7.20 (m, 3H); 6.89 (dd,7= 2.7, 10.5 Hz, IH); 6.67 (m, IH); 5.02 (s, 2H); 4.23 (m, IH); 4.13 (dd, 7*3.1, 9.9 Hz, IH); 4.01 (dd, J = 6.3, 9.9 Hz, IH); 2.93 (m, 2H);'2.69-2.50 (m, 4H); 2.20 (s, 3H); 2.00 (m, 2H); 1.73 (br.d, 7= 13.5 Hz, 2H). APCI-MS: m/z 45 1(MH*).
Example 12
hydroxypropyl]oxy}phenyl)acetamide
A mixture of 6-chloro-3//-spiro[2-benzoruran-l,4'-piperidine] (25 mg, 0.111 mmol) and Af-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (23 mg, 0.111 mmol) in ethanol (2 ml)
was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methahol in dichloromethane, 0.2% NtLiOH) to give the titled compound (20 mg).
'H-NMR (CD3OD, 400 MHz): 8 8.00 (dd, 7= 1.3, 8.0 Hz, IH); 7,30-7.20 (m, 3H); 7.12-7.05 (m, 2H); 6.93 (m, IH); 5.01 (s, 2H); 4.22 (m, IH); 4.14 (dd, 7= 3.3, 9.9 Hz, IH); 4.00 (dd, 7 =• 6.4, 9.9 Hz, IH); 2.94 (m, 2H); 2.69-2.52 (m, 4H); 2.20 (s, 3H); 2.01 (m, 2H); 1.74 (br.d,J=13.5Hz, 2H). APCI-MS:m/z433(MH+).
Example 13
hydroxypropyl]oxy}-4-methoxyphenyl)acetamide
A mixture of 6-chloro-3#-spiro[2-benzofuran-J,4'-piperidine] (46 mg, 0.205 mmol) and //-{4-methoxy-2[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (48.6 mg, 0.205 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NKtOH) to give the titled compound (80 mg). 'H-NMR (CDjOD, 400 MHz): 5 7.75 (d, J = 8.9 Hz, IH); 7.29-7.20 (m, 3H); 6.64 (d, / = 2.7 Hz, IH); 6.51 (dd, J= 2.7, 8.9 Hz, IH); 5.02 (s, 2H); 4.44 (m, IH); 4.12 (dd,/= 3.3, 10.0 Hz, IH); 3.98 (dd, J = 6.2, 10.0 Hz, IH); 3.80 (s, 3H); 2.96 (m, 2H); 2.68-2.50 (m, 4H); 2.18 (s, 3H); 2.00 (m, 2H); 1.74 (br.d, /= 13.2 Hz, 2H). APCI-MS:m/z461(MH+).
Example 14
2-{[(2S)-3-(6-ChIoro-l'/f,3/f-spiro(2-benzofuran-l,4'-piperidin]-l>-yJ)-2-hydroxypropyl]oxy}-jY-cycIopropyI-4-fluorobenzamide
Amixtureof6-chloro-3Ar-spiro[2-benzoruran-l,4'-piperidine](25 mg, O.JH mmol) and //-cyclopropyl-4-fluoro-2-(oxirari-2-ylmethoxy)benzamide (28 mg, 0.111 mmol) in ethanol
was stirred at 80 °C overnight. The volatilcs were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% NH 'H-NMR (CD3OD, 400 MHz): 8 7.98 (dd, y= 6.9, 8.8 Hz, IH); 7.29-7.20 (m, 3H); 6.98 (dd, 7- 2.4, 10.8 Hz, IH); 6.82 (ddd,./- 2.4, 8.0, 8.8 Hz, IH); 5.01 (s, 2H); 4.25 (dd, /= 3.1, 9.4 Hz, IH); 4.19 (m, IH); 4.11 (dd, J= 5.5, 9.4 Hz, IH); 2.92 (m, 3H); 2.59 (m, 4H); 2.01 (m, 2H); 1.73 (m, 2H); 0.80 (m, 2H); 0.69 (m, 2H). APC!-MS:m/z477(MH+).
Example 15
//-(2{((2S)-3-(5-Fiuoro-l'^,3Jff-spiro(2-benzofuran-l,4'-piperidin]-r-yO-2-
hydroxypropyljphenyl)acetamide
A mixture of 5-fluoro-3//-spiro[2-benzofuran-l,4'-piperidine] (15 mg, 0.072 mmol) and
/Vr-{2-[(2S)-oxiran-2-yImethoxy]phenyl}acetamide(15mg, 0.072 mmol) in ethanol(1.5
mL) was stirred at 80 C overnight. The volatiles were removed in vacuo and the residue
was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2%
NH 'H-NMR (CD3OD, 400 MHz): 6 7.99 (dd, J= 1.2, 8.0 Hz, IH); 7.18 (dd, J = 4.9, 8.0 Hz,
IH); 7.11-6.90 (m, 5H); 5.00 (s, 2H); 4.27 (m, IH); 4.13 (dd.7- 3.2, 9.9 Hz, IH); 3.99
(dd,./- 6.4, 9,9 Hz, IH); 2.99 (m, 2H); 2.72-2.52 (m,4H); 2.20 (s, 3H); 2.02 (m, 2H); 1.73
(br.d,/=13.6Hz,2H).
APCI-MS;m/z415(MH*).
Example 16
jV-(4-Chloro-2-{[(2S)-2-hydroxy-3-(3-oxo-l'JHr,3/f-spiro[2-benzofuran-l,4)-piperidin]-r-yl)propyl]oxy}phenyl)acetanude
Step 1: /V-(4-Chloro-2-ltydroxyphenyl)acetamide
To a suspension of 2-amino-5-chlorophenol (i.Olg, 7.0 mmol) in methanol (10 mL) was added acetic anhydride (1.08 g, 10.55 mmol) and the reaction mixture was stirred at room temperature for 30 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (hexane:ethyl acetate 5:2) to give the subtitled
compound (1.19 g).
'H-NMR (DMSO-d6j 400 MHz): 5 10.29 (br.s, 1H); 9.26 (br.s, 1H); 7.77 (d, /= 8.6 Hz, 1H); 6.86 (d,y = 2.4 Hz, 1H); 6.80 (dd,/- 2.4, 8.6 Hz, IH); 2.12 (s, 3H). APC1-MS: m/z 186(MH+).
Step II: 7V-{4-ChIoro-2-[(2S)-oxiran-2yJmethoxy]phenyJ}acetamide
To a mixture of (2S)-oxiran-2-ylmethyl3-nitrobenzenesulfonate (3.37 g, 13.25 mmol), N-(4-chloro-2-hydroxyphenyl)acetamide (2.46g, 17.23 mmol) and Cs2C03 (6.48g, 19.88 mmol) was added DMF (20 mL) at 0 C and the reaction mixture was stirred at 0 °C for 3h. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried overNa2SO,i, filtered and concentrated. The residue was purified by silica gel flash chromatography (hexane:ethyl acetate 3:2) to give the subtitled compound (2.36 g).
'H-NMR (CD3COCD3, 400 MHz): 8 8.67 (br.s, 1H); 8.30 (d, 7= 8.7 Hz, 1H); 7.07 (d, / = 2.3 Hz, 1H); 6.95 (dd, / = 2.2, 8.7 Hz, IH); 4.46 (dd, / = 2.3, 11.5 Hz, 1H); 3.94 (dd, / = 6.6, 11.5 Hz, IH); 3.34 (m, IH); 2.87 (dd, J = 4.3, 5.0 Hz, IH); 2.73 (dd, J = 2.7, 5.0 Hz, lH);2.18(s, 3H).
Step III
A^(4-Chloro-2-{[(2S)-2-Jiydroxy-3-(3-oxo-l'//,3/f-spiro[2-ben2ofuran-l,4'-piperidin]-]'-yI)propyl]oxy}phenyI)acetamide
A mixture of 3#-spiro[2-benzoruran-l,4'-piperidin]-3-one (Marxer, A; Rodriguez, H. R; McKenna, J. M; Tsai, H. M., J. Org. Chem., 1975, 40, 1427-1433) (61 mg, 0.3 mmoi) and A'-{4-chloro-2-[(2S)-oxiran-2ylmethoxy]phenyl}acetamide (72.5 mg, 0.3 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the
residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (40 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.93 (d,y= 7.7 Hz, 1H); 7.84 (m, 2H); 7.71-7.61 (m, 2H); 7.13 (d, J = 2.0 Hz, 1H); 7.00 (dd,/= 2.0, 8.5 Hz, 1H); 4.58 (m, 1H); 4.13 (m, 2H); 3.86 (m, 2H); 3.65-3.45 (m, 4H); 2.64 (m, 2H); 2.20 (s, 3H); 2.06 (m, 2H). APCI-MS:m/z 445(MH+).
i
Example 17
Ar-CycIopropyl-2-{[(2S)-2-hydroxy-3-(l'/r,3/^-spiro[2-benzofuran-l,4'-piperidlnj-r-
yl)propyljoxy}benzamide
A mixture 3//'-spiro[2-benzofiiran-l,4'-pipendine] (Marxer, A; Rodriguez, H. R; McKenna, J. M; Tsai, H. M., J. Org. Chem., 1975, 40, 1427-1433) (46.5 mg, 0.246 mmol) and A^-cyclopropyl-2-[(2S)-oxiran-2-ylrnethoxy]benzarnide (57,4 mg, 0.246 mmol) in ethanol (3 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NJ-LtOH) to give the titled compound (55 mg). 'H-NMR (CDCb, 400 MHz): 5 8.43 (d, y = 1.8 Hz, 1H); 8:20 (dd, J= 1.8, 7.8 Hz, 1H); 7.40 (m, 1H); 7.30 (m, 2H); 7.23 (m, 1H); 7.18 (m, 1H); 7.08 (t, 7= 7.5 Hz, 1H); 6.93 (d, J " 8.2 Hz, 1H); 5.10 (s, 2H); 4.20 (m, 2H); 4.00 (dd, /= 5.0, 9.3 Hz, 1H); 3.02 (m, 2H); 2.85 (m, 2H); 2.69 (m, 1H); 2.58 (m, 2H); 2.02 (m, 2H); 1.82 (d, 2H); 0.85 (m, 2H); 0.63 (m,2H). APCI-MS: m/z 423(MH*).
Example 18
A^-(4-ChIoro-2-{|(2S)-2-hydroxy-3-(l'//,3/r-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)propyl]oxy}phenyl)acetamide
A mixture 3#-spiro[2-benzofuran-l ,4'-piperiduie] (38 mg, 0.2 mmol) and /V-{4-chloro-2-[(2S)-oxiran-2ylmethoxy]phenyI}acetamide (48.3 mmol) in ethanol (3 mL) was stirred at

80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1,5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (35 mg).
'H-NMR (CDClj, 400 MHz): 5 8.05 (d,J= 8.7 Hz, 1H); 7.29-7,18 (m, 4H); 7.10 (d, J= 2.2 Hz, 1H); 6.94 (dd, J = 2.2, 8.7 Hz, 1H); 5.08 (s, 2H); 4.26 (m, 1H); 4. 16 (dd, /= 3.0, 10.0 Hz, IH); 4.01 (dd, J = 6.4, 9.9 Hz, IH); 2.97 (m, 2H); 2.69-2.52 (m, 4H); 2.19 (s, 3H); 2.07 (m,2H); 1.73 (m,2H). APCI-MS: m/z 433(MH+).
Example 19
yl)propyl]oxy}phenyl)acetamide
A mixture 3/f-spiro[2-benzofuran-l,4'-piperidine] (63 mg, 0.33 ramol) and /^-{ [(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (80 rag, 0.33 mmol) in ethanol (5 mL) was stirred at 77 °C for 4h. The volatiles were removed in vacuo and the residue was purified by silica gei flash chromatography (0-3% methanol in chloroform) to give the titled compound (77 mg).
'H-NMR (CDC]3, 400 MHz): 5 8.50 (m, IH); 7.3 1 (m, 3H); 7.18 (m, IH); 6.98 (m, IH); 6.83 (m, IH); 5.10 (s, 2H); 4.10 (m, IH); 4.03 (dd, IH); 3.91 (dd, IH); 2.97 (m, IH); 2.76 (m, 2H); 2.60-2.43 (m, 3H); 2.20 (s, 3H); 2.05-1.89 (m, 2H); 1.60 (m, 2H). APCI-MS: m/z431(MH+).
Example 20
Ar-(2-{l(2S)-2-hydroxy-2-methyl-3-(rJHr,3r-spiro[2-benzofuran-l,4'-piperidin]-r-yl)propyl]oxy}-4-methoxyphenyl)acetamide
Step I: [(2S)-2-MethyloxiranyIJmethyl3-nitrobcnzcnesulfonare
To an oven-dried 1000 mL three-necked flask was added powdered activated molecular sieves (8.0 g, 4A) and CHiCl2 (440 mL), D-(-)-diisopropyl tartrate (4 mL, 14.2 mmol) and 2-methyl-2-propene-l-ol (20 mL, 240 mmol) was added and the mixture was cooled to -20 °C. Titanium tetraisopropoxide (3.5 mL, 11.9 mmol) was added with a few mL of CH2C12 and the mixture was stirred at -20 °C for 30 min. Cumene hydroperoxide (75 mL, 430 mmol) was added dropwise over 1.5 hours maintaining the temperature at -20 °C. The mixture was stirred at this temperature overnight. Trimethyl phosphite (40 mL, 340 mmol) was added dropwise over 5 hours maintaining the temperature at -20 °C. Triethyiamine (50 mL, 360 mmo!) and 4-dimethylaminopyridine (DMAP) (3.48 g, 28.5 mmol) was added followed by a solution of 3-nitrobenzenesulphonyl chloride (47 g, 212 mmol) in CHaCk (400 mL). The temperature was raised to -10 °C and the mixture was stirred at this temperature overnight. After removing the external cooling vessel, the reaction mixture
was filtered through celite. The organic phase was washed with 10% tartaric acid (500
mL), saturated NaHC03 (300 mL) and brine (300 mL). The organic layer was dried over
magnesium sulphate (MgSO-i) and concentrated in vacuo to give 150 g of a yellow oil.
The crude material was purified by silica gel flash chromatography (0-50% ethyl acetate in
heptane) to give the subtitled compound (48.8 g).
'H-NMR (CDCI3, 400 MHz): 5 8.79-8.75 (m, 1H); 8.52 (ddd, / = 1.1, 2.3, 8.3 Hz, 1H);
8.25 (ddd,/= l.l, 1.8, 7.8 Hz, 1H); 7.81 (t, J= 8.5 Hz, IH);4,28 (d, J = 11.3 Hz, 1H);
4.05 (d, J = 11.3 Hz, IH); 2.73 (d, / = 4.4 Hz, 1H); 2.67 (d, 7=4-4 Hz, 1H); 1.56 (s, 3H).
Step U: yV-(4-Methoxy-2-{((2S)-2-methyloxiran-2-yl]nicthoxy}phenyl)acetamlde
A mixture of [(2S)-2-methyloxiran-2-yi]methyI3-nitrobenzenesuIfonate (2.04 g, 7.46 mmol), //-(2-hydroxy-4-methoxyphenyl)acetamide ((1.04 g, 5.74 mmol) and Cs2C03 (2.80 g, 8.61 mmol) in DMF (12 mL) was kept on stirring at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2SC>4, filtered and concentrated. The residue was purified by silica gel flash chromatography (ethyl acetate : hexane 1:1) to give the subtitled compound (1.19 g).
'H-NMR (CDCI3, 400MHz): 8 8.20 (d, J = 8.8 Hz, IH); 7.72 (br.s, IH); 6.52 (m, 2H); 4.12 (d,y= 11.0 Hz, IH); 3.98 (d,y= 11.0 Hz, IH); 3.77 (s, 3.H); 2.91 (d,y=4.7Hz, IH); 2.77 (d,y=4.7 Hz, IH); 2.20 (s, 3H); 1.48 (s, 3H).
Step III:
jV-(2-{[(2S)-2-Hydroxy-2-methyI-.3-(l'^,3//-spiro[2-benzofuran-l,4'-piperidinJ-l'-
yJ)propyl]oxy}-4-merhoxyphenyl)acetamide
A mixture of 3//-spiro[2-benzofuran-l,4'-piperidine] (57 mg, 0.3 mmol) and N-(4-methoxy-2-{[(2S)-2-methyloxiran-2-yl]methoxy}phenyl)acetarnide (75.4 mg, 0.3 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH-tOH) to give the titled compound (70 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.65 (d, y = 8.8 Hz, IH); 7.28-7.15 (m, 4H); 6.61 (d, J = 2.7 Hz, IH); 6.50 (dd, J = 2.7, 8.8 Hz, IH); 5.10 (s, 2H); 3.99 (d, J = 9.2 Hz, IH); 3.90 (d, J= 9.2 Hz, IH); 3.79 (s, 3H); 2.88 (m, 2H); 2.73-2.53 (m, 4H); 2.16 (s, 3H); 2.00 (m, 2H); 1.63(m, 2H); 1.31 (s, 3H). APCI-MS:m/z441(MH+).
Example 21
A^-[2-{[(2S)-2-Hydroxy-3-(i'/^,3J7-spiro[2-ben2ofuran-l,4'-pipendin]-l'.
yl)propyl]oxy}-5-(trifluoromethyl)phenylJacetamide
Step I: Af-{2-[(2S)-Oxiran-2-yImethoxy]-5-(trifluoromethyl)phenyI]acetamide
A mixture ofvV-[2-hydroxy-5-(trifluoromethyl)phenyl]acecamide (282 mg, 1.28 mmol), (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (331.5 mg, 1.28 mmol) and Cs2CO3 (487.5 mg, 1.28 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash
chropatography (0-40% ethyl acetate in petroleum ether) to give the subtitled compound
(150mg).
'H-NMR (CDCb, 400 MHz): 8 8.72 (br.s, IH); 7.90 (br.s, IH); 7.31 (m, IH); 6.97 (d, IH); 4.46 (dd, 7 = 2.4, 11.3 Hz, IH); 4.00 (dd, /= 6.3, 11.3 Hz, IH); 3.44 (m, IH); 3.00 (d, 7= 4.5 Hz, IH); 2.80 (dd,./- 2.7, 4.8 Hz, IH); 2.25 (s, 3H).
Step II:
Af-[2-{[(2S)-2-Hydroxy-3-(r//,3/r-spiro[2Tbenzofuran-l)4'-piperidinJ-r-
yI)propyljoxy}-5-(trifluorornethyl)phenyllacctarnide
A mixture of 3//-spiro[2-benzoruran-l,4'-piperidine] (47.3 mg, 0.25 mmol) and N-[2-[(2S)-oxiran-2-ylmethoxy]-5-(trifluoromethyl)phenyl]acetamide (69 mg, 0.25 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NH Example 22
7V-(2-{[(2S)-2-Hydroxy-3-(2-merhyl-l'^-spiro[indcne-l,4'-piperidJn]-l'-
yl)propyl|oxy}phenyl)acetamide
A mixture of 2-methylspiro[indene-l,4'-piperidine] (Efange, S. M. N; Khare, A. B; Foulon, C; Akella, S. K; Parsons, S. M.,J.Med. Chem., 1994, 37, 2574-2582) (82.5 mg, 0.35 mmol) and Ar-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (72.5 mg, 0.35 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (80 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.84 (m, 2H); 7.28 (m, 2H); 7'.16 (m, 2H); 7.07 (m, IH); 6.98 (m, IH); 6.53 (br.s, IH); 4.58 (m, IH); 4.14 (m, 2H); 3.90-3.49 (m, 6H); 2.45 (m, 2H); 2.19 (s, 3H); 1.99 (s, 3H); l.40(br.t,/= 14.0 Hz, 2H). APCI-MS:m/z407(MH+).
Example 23
vY-(2-{[(2S)-3-(2,3-Dihydro-l'/f-spirQ[indene-l,4'-piperidin]-l'-yl)-2-
hydroxypropyljoxy}phenyl)acetamide
A mixture of 2,3-dihydrospir6[indene-l,4'-piperidine] (Efange, S. M. N; Khare, A. B; Foulon, C; Akella, S. K; Parsons, S. M.,J. Med. Chem., 1994, 37, 2574-2582; Chambers, M. S; Baker, R; Billington, D. C; Knight, A. K; Middlemiss, D. N; Wong, E. H. F., J. Med, Chem., 1992, 35, 2033-2039). (78.3 mg, 0.35 mmol) and N- {2-[(2S)-oxiran-2-y[methoxy]phenyl}acetamide (72.5 mg, 0.35 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromelhane, 0.2% NH^OH) to give the titled compound (65 mg).
'H-NMR (CD3OD, 400 MHz): 8 7.82 (m, IH); 7.26-7.12 (m, 5H); 7.06 (m, IH); 6.98 (in, IH); 4.50 (rn, IH); 4.10 (d, 2H); 3.72 (m, 2H); 3.45-3.22 (m, 5H); 2.99 (t,/= 7.3 Hz, 2H); 2.33-2.13 (m,6H); 1.82 (m,2H). APCI-MS: m/z 395(MH+).
Example 24
//-(2-{f(2S)-2-Hydroxy-3-(2-oxo-l'//'-spiro[l-benzofuran-3,4'-piperidin]-r-yl)propyl]oxy}phenyl)acetamide
A mixture of spiro[l-benzofuran-3,4'-piperidin]-2-one (80 mg, 0.28 mmol) and N-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (60 mg, 0.28 mmol) in ethanol (2 mL) was kept on stirring at 80 C overnight. The volatiles were removed in vacuo and the residue
was purified by high pressure liquid chromatography (HPLC) to give the titled compound
(65 mg).
'H-NMR (OMSO-o^, 400 MHz): 8 9.03 (br.s, 1H); 7.95-7.90 (m, 1H); 7.44-7.39 (m, 1H);
7.32-7.24 (m, 3H); 7.05 (m, 2H); 6.94 (m, 1H); 6.09 (br.s, 1H); 4.41 (m, 1H); 4.07-3.9J
(m, 2H); 3.74-3.36 (m, 8H); 2.31-2.22 (m, 2H); 2.11 (s, 3H).
APCl-MS:m/z411(MH+).
Example 25
2-{[(2S)-3-(5-Chloro-l'//r,3//'-spiro[l-ben2ofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylloxy)-AcycIopropyI-4-hydroxybenzamide
Step I:
Methyl 2-hydroxy-4-(trityIoxy)benzoate
To a solution of methyl 2,4-dihydroxybenzoate (388 mg, 2.0 mmol) in dimethylformamide (5 mL) was added triethylamine, EtjN, (0.556 mL, 4.0 mmol) followed by trityl chloride (557.5 mg, 2.0 mmol) and 4-dimethyIaminopyridine (DMAP) (20 mg). The reaction mixture was kept on stirring at room temperature overnight, poured into a mixture of ice-water, the white precipitate was collected by filtration. This precipitate was subjected to silica gel flash chromatography (0-5% ethyl acetate in petroleum ether) to give the subtitled compound (350 mg).
'H-NMR (CDC13> 400 MHz); 5 10.65 (s, 1H); 7.58-7.22 (m, 16H); 6.38 (m, 2H); 3.89 (s,3H).
Step II: /V-Cyclopropyl-2-Jiydroxy-4-(trityIoxy)benzamlde
Methyl 2-hydroxy-4-(trityloxy)benzoate (340 mg, 0.83 mmol) was dissolved in cyclopropylamine (3 mL) and left at room temperature for a week. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-20% ethyl acetate in petroleum ether) to give the subtitled compound (210 mg).
'H-NMR (CDC13,400 MHz): 5 12.30 (s, IH); 7.48 (m, 6H); 7.35-7.22 (m, 9H); 6.92 (d, J = 9.0 Hz, IH); 6.31 (d, J = 2.4 Hz, IH); 6.24 (dd, J= 2.4, 8.8 Hz, IH); 6.08 (br. S, IH); 2.80 (m, IH); 0.85 (m, 2H); 0.60 (m, 2H).
Step III: jV-Cyclopropyl-2-((2S)-oxiran-2-ylmethoxy]-4-(trityIoxy)benzamide
A mixture of (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (119 mg, 0.459 mraoJ), //-cyclopropyl-2-hydroxy-4-(trityloxy)benzamide (200 mg, 0.459 mmol) and cesium carbonate, CszCOi, (186.2 mg, 0.573 mmol) in dimethylformamide (3 mL) was kept on stirring at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate, Na2SO4, filtered, concentrated and the residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum ether) to give the subtitled compound (160 mg). 'H-NMR (CDC13, 400 MHz): 5 8.04 (s, IH); 7.86 (d, J= 8.8 Hz, IH); 7.73 (br.d,-/ = 3.0 Hz, IH); 7.46-7.39 (m, 5H); 7.34-7.23 (m, 9H); 6.44 (dd, .7 = 2.2, 8.8 Hz, IH); 6.23 (d,7* 2.2 Hz, 1H); 4.03 (dd,/= 2.7, 10.8 Hz, IH); 3.68 (dd,/= 5.0, 10.8 Hz, !H);3.23(m, IH); 2.88 (m, 2H); 2.70 (dd, J= 2.7, 4.9 Hz, 1H); 0.80 (m, 2H); 0.58 (m, 2H).
Step IV:
2-{[(2S)-3-(5-Chloro-r//,3^r-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-
hydroxypropyljoxy}-/V-cycIopropyI-4-hydroxybenzamide
A mixture of Ar-cyclopropyl-2-[(2S)-oxiran-2-ylmethoxy]-4-(trityloxy)benzamide (152 mg, 0.307 mmol) and 5-chloro-3//-spiro[l-beazofuran-2,4'-piperidine] (69 rag, 0.307 mmol) in ethanol (3 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the residue was treated with 80% aqueous acetic acid (10 mL) at reflux for 90 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2%NH4OH) to give the titled compound (75 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.83 (d, /= 8.4 Hz, IH); 7.13 (m, IH); 6.94 (dd,7= 2.3, 8.4 Hz, IH); 6.65 (d, J= 8.4 Hz, IH); 6.51-6.45 (m, 2H); 4.21-4.13 (m, 2H); 4.08-4.02 (m,
1H); 3.01 (s, 2H); 2.90 (m, 1H); 2.75 (br.s, 4H); 2.58 (d, J= 6.2 Hz, 2H); 1.98 (m, 2H);
1.88 (m, 2H); 0.80 (m, 2H); 0.65 (m, 2H).
APCI-MS:m/z473(MH+).
Example 26 2-{[(2S)-3-(5-Chloro-l'/r,3//-spiro[l-benzofuran-2,4'-plperidin]-l'-yl)-2-hydroxy-2-
methy!propylJoxy)-,/V-cyclopropyl-4-hydroxybenzainide
Step I: Af-CycIopropyl-2-hydroxy-4-[(4-mcthoxybenzyI)oxy]benzamide
Methyl 2-hydroxy-4-[(4-methoxybenzyl)oxy]benzoate (Percec, V; Tomazos, D. /. Mater. Chem. 1993, 3, 643-650) (530 mg, 1.83 mmol) was dissolved in cyclopropyl amine (3 mL) and left at room temperature for a week. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum ether) to give the subtitled compound (407 mg).
'H-NMR (DMSO-d6, 400 MHz): S 13.20 (br.s, 1H); 8.56 (d, J-2.7 Hz, 1H); 7.72 (d, J = 8.7 Hz, 1H); 7.38-7.33 (m, 2H); 6.96-6.92 (m, 2H); 6.49-6.45 (m, 2H); 5.00 (s, 2H); 3.79 (s, 3H); 2.80 (m, 1H); 0.78 (ra, 2H); 0.58 (m, 2H).
Step II: [(2S)-2-Methyloxiranyl]rnethyl3-nitrobcnzenesulfonate
To an oven-dried 1000 mL three-necked flask was added powdered activated molecular sieves (8.0 g, 4A) and dichloromethane, CH2CI2) (440 mL), D-(-)-diisopropyl tartrate (4 mL, 14.2 mmol) and 2-methyl-2-propene-l-ol (20 mL, 240 mmol) was added and the mixture was cooled to -20 °C. Titanium tetraisopropoxide (3.5 mL, 11.9 mmol) was added with a few mL of dichloromethane and the mixture was stirred at -20 °C for 30 min. Cumene hydroperoxide (75 mL, 430 mmol) was added dropwise over 1.5 hours maintaining the temperature at-20 °C. The mixture was stirred at this temperature overnight. Trimethyl phosphite (40 mL, 340 mmol) was added dropwise over 5 hours maintaining the temperature at -20 °C. Triethyl amine (50 mL, 360 mmol) and
4-dimethylaminopyridine (DMAP) (3.48 g, 28.5 mmol) was added followed by a solution of 3-nitrobenzenesulphonyl chloride (47 g, 212 mmol) in dichloromethane (400 mL). The temperature was raised to -10 °C and the mixture was stirred at this temperature overnight. After removing the external cooling vessel, the reaction mixture was filtered through celite. The organic phase was washed with 10% tartaric acid (500 mL), saturated sodium hydrogencarbonate, NaHCCb, (300 mL) and brine (300 mL). The organic layer was dried over magnesium sulphate, MgSO4, and concentrated in vacuo to give 150 g of a yellow oil. The crude material was purified by silica gel flash chromatography (0-50% ethyl acetate in heptane) to give the subtitled compound (48.8 g).
'H-NMR (CDC13) 400 MHz): 8 8.79-8.75 (m, 1H); 8.52 (ddd, .7=1.1, 2.3, 8.3 Hz, 1H); 8.25 (ddd,J = 1.1, 1.8, 7.8 Hz, 1H); 7.81 (t,/ = 8.5 Hz, 1H); 4.28 (d,7= 11.3 Hz, 1H); 4.05 (d,y= 11.3 Hz, 1H);2.73 (d, J = 4.4 Hz, 1H); 2.67 (d, .7 =4.4 Hz, 1H); l.56(s,3H).
Step III:
A'-CyclopropyI-4-[(4-methoxybenzyl)oxy]-2-{((2S)-2-methloxiran-2-
yfjmethoxyjbenzainide
A mixture of [(2S)-2-methyloxiran-2-yl]methyl3-nitrobenzenesulfonate (218 mg, 0.797 mmol), Ar-cyclopropyl-2-hydroxy-4-[(4-methoxybenzyl)oxy]benzamide (250 mg, 0.797 mmol) and cesium carbonate, Cs2CC>3, (311 mg, 0.956 mmol) in dimethylformamide (5 mL) was kept on stirring at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate, Na2S04, filtered, concentrated and the residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum ether) to give the subtitled compound (260 mg).
'H-NMR (CDCi3,400 MHZ).- 88.19 (d, j=s.s HZ, IH); 7.90 (d,y= 3.0 HZ, IH); 7.38-
7.33 (m, 2H); 6.96-6.92 (m, 2H); 6.70 (dd, 7= 2.3, 8.8 Hz, 1H); 6.48 (d, /= 2.3 Hz, 1H); 5.02 (s, 2H); 4.14 (d,J= 10.3 Hz, 1H); 4.06 (d, J= 10.3 Hz, 1H); 3.80 (s, 3H); 3.04-2.98 (m, 1H); 2.94 (d, / = 4.7 Hz, 1H); 2.87 (d, 7= 4.7 Hz, 1H); 1.50 (s, 3H); 0.86 (m, 2H); 0.65 (m,2H).
Step IV: 2-{[(2S)-3-(5-ChIoro-l'/f,3^r-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxy-2-
methylpropyl]oxy}-Ar-cycIopropyW-[(4-methoxybenzyl)o*y]benzamide
A mixture of 5-chloro-3//-spiro[l-benzoftiran-2,4I-piperidine] (70 mg, 0,313 mmol) and A^-cyclopropyI-4-[(4-methoxybenzyl)oxy]-2-{[(2S)-2-methloxiran-2-yl] methoxyjbenzamide (120 mg, 0.313 mmol) in ethanol (3 mL) was kept on stirring at 80 °C for 6h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (100 mg).
'H-NMR (CDC13, 400 MHz): 5 8.22-8.15 (m, 2H); 7.39-7.34 (m, 2H); 7.13-7.06 (m, 2H); 6.97-6.92 (m, 2H); 6.72-6.66 (m, 2H); 6.50 (d,y= 2.3 Hz, IH); 5.08 (s, 2H); 3.88 (s, 3H); 3.05 (m, IH); 2.99 (s, 2H); 2.90 (m, 2H); 2.75 (m, IH); 2.66 (d, 7= 13.8 Hz, IH); 2.64 (m, IH); 2.49 (d, /= 13.8 Hz, IH); 1.99 (m, 2H); 1.82 (m, 2H); 1.60 (br.s, 2H); 1.33 (s, 3H); 0.86 (m, 2H); 0.65 (m, 2H). APCI-MS: m/z 607(MH+).
Step V:
2-{[(2S)-3-(5-Chloro-r/r,3/f-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-hydroxy-2-
methylpropylJoxyJ-yV-cyclopropyl^-hydroxybenzamide
2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxy-2-methylpropyl]oxy}-//-cyclopropyl-4-[(4-methoxybenzyl)oxy]benzamide (80 mg, 0.131 mmol) was treated with 10% trifluoroacetic acid in dichloromethane (10 mL) at room temperature for 15 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the titled compound (40 mg).
'H-NMR (CD3OD, 400 MHz): 6 7.83 (m, IH); 7.12 (m, IH); 7.03 (dd,J= 2.3, 8.5 Hz, IH); 6.64 (d, J= 8.5 Hz, IH); 6.49-6.45 (m, 2H); 4.09 (d,J= 9.2 Hz, IH); 3.90 (d, J= 9.2 Hz, IH); 2.99 (s, 2H); 2.92 (m, IH); 2.79 (m, 2H); 2.66 (m, 2H); 2.58 (d, J= 13.9 Hz, IH); 2.50 (d,y= 13.9 Hz, IH); 1.93-1.75 (m, 4H); 1.31 (s, 3H); .80 (m, 2H); 0.68 (m, 2H).
APCJ-MS: m/z 487(MH+).
Example 27 N-(4-hydroxy-2-{[(21S)-2-hydroxy-3-(r/f,4fr-spiro[chromene-354'-piperidin]-r-
yl)propyl]oxy}phenyl)acetamide
Step I (lZ)-l-(2,4-dihydroxyphenyl)ethanoneoxime
1-(2,4-dihydroxyphenyl)ethanone (4.5 g, 29.6 mmol) was dissolved in pyridin (17 mL). Hydroxylamine hydrochloride (2.1 g, 29.6 mmol) was added in small portions over 10 minutes. After stirring at room temperature over night the green-yellowish solution was partitioned between water and ethyl acetate, The organic phase was washed twice with water and once with 0.2 M hydrochloric acid, and was finally concentrated. The oily residue was treated with water, evaporated to yield a white semi solid residue, which was treated with toluene and evaporated to give the titled compound (4.8 g, 98%) as a white solid.
Step II 2-methyl-l,3-benzoxazol-6-oI
To a cooled (5°C) solution of (lZ)-l-(2,4-dihydroxyphenyl)ethanone oxime (9.7 g, 57.7 mmol) in acetonitrile (65 mL) and dimethylacetamide (11 mL) was added phosphorus oxychtoride (5.6 mL, 60.3 mmol) drop wise. The temperature was not allowed to exceed 10°C during the addition. After I hrs stirring at room temperature the yellow slurry was poured on a mixture of sodium hydrogen carbonate and ice. The resulting precipitate was filtered off and dried yielding 6.3 g (73%) the titled compound.
Step III 2-methyl-l,3-benzoxazoI-6-yl acetate
A slurry of2-methyI-l,3-benzoxazoI-6-ol (7.1 g, 47.8 mmol) in tetrahydrofuran was cooled to 10°C and triethylamine (5.8 mL, 81.3 mmol) was added in one portion, followed by the addition of acetyl chloride (11.3 mL, 81.6 mmol) in small portions. After stirring at room temperature over night the reaction mixture was partitioned between water and ethyl
acetate. The organic phase was washed twice with water and concentrated to give the titled compound (8.2 g, 90%) as a beige solid.
Step IV 4-(acetylamino)-3-hydroxyphenyl acetate
2-methyl-l,3-benzoxazol-6-yl acetate (8.1 g, 42.3 mmol) was dissolved in tetrahydrofuran (60 mL), and trifluoroacetic acid (4 mL, 53.2 mmol) was added. The light brown solution was stirred over night at room temperature. Sodium hydrogen carbonate (aq, sat) was added, and the solution was extracted twice with ethyl acetate. The combined organic layers were concentrated to the titled compound (8.0 g, 91%) as a beige solid.
Step V 4-(acerylamino)-3-[(2,S')-oxiran-2-yImethoxy]pheriyl acetate
A solution of 4-(acetylamino)-3-hydroxyphenyl acetate (669 mg, 3.2 mmol), (2i5)-oxiran-2-ylmethyI 3-nitrobenzenesulfonate (748 mg, 2,9 mol) and caesium carbonate (1.05 g, 3.2 mmol) in 1-methyl-pyrrolidinone (10 mL) was stirred overnight at room temperature, and then partitioned between water and ethyl acetate. The organic phase was washed twice with water and concentrated to an yellow oil, which was suspended in methanol/diethyl ether, !/j. The precipitated beige solid was filtered off and dried to give the titled compound (296 mg, 38%).
Step VI
N-(4-hydroxy-2-{[(2^)-2-hydroxy-3-(r/r,4/f-spiro[chromene-3,4'-piperidinJ-l'-yl)propyl]oxy}phenyl)acetamide
A solution of 4-(acetylamino)-3-[(ZSoxiran-2-ylmethoxy]phenyl acetate (56 mg, 0.21 mmo!) and 4//-spiro[chromene-3,4'-piperidine] (43 mg, 0.21 mmol) in methanol (1 mL) was stirred over night at 60°C, and then concentrated. The dark grey residue was purified by HPLC on CIS ("ICromasil" column, 5 um, acetonitrile/water 10/90 to 60/40 over 20 min with 0,1% trifluoroacetic acid) to give the title compound (39 mg, 33%) trifluoroacetate salt.
'H-NMR (acetone-d6, 400 MHz,) 5: 11.27 (1H, bs); 8.52 (1H, bs); 7.95 (1H, d); 7.10 (2H, t); 6.86 (IH, t); 6.78 (IH.d); 6.53 (1H, d); 6.40 (1H, dd); 4.55-4.48 (1H, m); 4.21 (1H, s);
4.09-4.01 (2H, m); 3.91 (1H, s); 3.83-3.65 (2H, m); 3.65-3.49 (2H, m); 3.49-3.35 (2H, m); 3.00 (1H, s); 2.70 (1H, s); 2.08 (3H, s); 2.02-1.74 (4H, m) APCi-MS: m/z 427 [MH+]
Example 28
2-{[(2S)-3-(5-Chloro-l'/f,3^r-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-2-hydroxy-2-methyIpropylJoxy}-4-hydroxy-A'-methyIbenzainide (trifluoroacerate)
Step I: 2-Hydroxy-4-{(4-metlioxybenzyl)oxy]-Ar-methylbenzanHde
To a suspension of methyl 2-hydroxy-4-[(4-methoxyben2yl)oxy]benzoate (500 mg, 1.73 mmol) in methanol (15 mL) was slowly added aqueous 40% methylamine (3 mL) at 0 C. After addition was complete the reaction mixture was kept on stirring at room temperature for 2 days. The volatiles were removed in vacuo to give the subtitled compound (500 mg). 'H-NMR (DMSO-d6, 400 MHz): 5 13.20 (br.s, 1H); 8.60 (m, 1H); 7.70 (d, J= 8.8 Hz, 1H); 7.35 (m, 2H); 6.96-6.92 (m, 2H); 6.50 (dd, J= 2.6, 8.8 Hz, 1H); 6.42 (d,J= 2.6 Hz, 1H)5.04 (s, 2H); 3.76 (s, 3H); 2.79 d,/= 4.6 Hz, 3H). APCI-MS: m/z 288(MH+).
Step II:
4-[(4-MethoxybenzyI)oxyJ-/V-methyI-2-{[(2S)-2-methyIoxiran-2-
yl]methoxy}benzamide
A mixture of f(2S)-2-methyloxiran-2-yl]methyl3-nitrobenzenesulfonate (133 mg, 0.487 mmol), 2-hydroxy-4-[(4-methoxybenzyl)oxy]-A'-methylbenzamide (140 mg, 0.487 mmol) and cesium carbonate, CsaCOj, (198 mg, 0.608 mmol) in dimethylformamide (5 mL) was kept on stirring at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate, Na2S04, filtered and concentrated. The residue was purified by silica gel flash :hromatography (0-60% ethyl acetate in petroleum ether) to give the subtitled compound 130 mg).
1H-NMR (CDC13,400 MHz): 5 8.18 (d,y= 8.8 Hz, 1H); 7.82 (m, IH); 7.37 (m, 2H); 6.97-6.92 (m, 2H); 6.71 (dd J= 2.3, 8.8 Hz, IH); 6.53 (d, J = 2.3 Hz, IH); 5.01 (s, 2H); 4.18 (d, J = 10.5 Hz, 1H); 4.10 (d, J = 10.5 Hz, IH); 3.85 (s, 3H); 3.02 (d, / = 4.9 Hz, 3H); 2.97 (d, 7= 4.6 Hz, IH); 2.80 (d, J= 4.6 Hz, IH); 1.50 (s, 3H). APCI-MS: m/z 358(MH+).

Step III:
2-(l(2S)-3-(5-Chloro-l'/r,3/r-spiro|l-bcn2ofiiran-2,4'-plpcridin]-r-yl)-2-hydroxy-2-
methytpropyl]oxy}-44(4-methoxybenzyl)oxy]-W-methylbenzanude
A mixture of 5-chloro-3tf-spiro[l-benzofuran-2,4'-piperidtne] (70 mg, 0.313 mraol) and 4-[(4-methoxybenzyl)oxy]-Ar-methyl-2-{[(2S)-2-methyloxiran-2-yl]methoxy}benzamide (112 mg, 0.313 mmoi) in ethanol (2 mL) was kept on stirring at 80 °C for 4.5 h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% ammonium hydroxide, NtUOH) to give the subtitled compound (135 mg).
'H-NMR (CDC13,4QO MHz): S 8.18 (d,J= 8.7 Hz, IH); 8.12 (m, IH); 7.39-7.35 (ra, 2H); 7.12 (m, 2H); 7.08 (dd,7=2.3, 8.5 Hz, IH); 6.97-6.92 (m, 2H); 6.72-6.66 (m, 2H); 6.52 (d, J = 2.3 Hz, IH); 5.05 (s, 2H); 3.90 (m, 2H); 3.82 (s, 3H); 3.0 (d, J = 4.9 Hz, 3H); 2.98 (s, 2.H); 2.94-2.84 (m, 2H); 2.73 (m, IH); 2.69 (d, J = 13.9 Hz, IH); 2.63 (m, IH); 2.49 (d, 7= 13.9 Hz, IH); 1.99 (m, 2H); 1.82 (m, 2H). APCI-MS: m/z 581 (MH+).
Step IV:
2-{[(2S)-3-(5-Chloro-l'//,3/ir-spJro(l-benzofuran-2,4'-piperidin]-l'-yl)-.2-hydroxy-2-methylpropyljoxyM-hydroxy-A^methylbenzamide (trifluoroacetate)
2-{[(2S)-3-(5-Chloro-]'//,3Ar-spiro[l-benzofuran-2,4'-piperidm]-r-yl)-2-hydroxy-2-methylpropyl]oxy}-4-[(4-methoxybenzyl)oxyJ-)V-methy[berzamide (125 mg, 0.215 mmol) was treated with 10% trifluoroacetic acid in dichloromethane (10 mL) at room temperature for 20 min. The volatiles were removed in vacuo and the residue was purified by HPLC
(acetonitrile/water (CH^CN/fyO), 0.1% trifluoroacetic acid) to give the titled compound
(50 mg).
'H-NMR (CD3OD, 400 MHz): 6 7.52-7.47 (m, IH); 7.20 /br.s, IH); 7.10 (dd, J = 2.3, 8.5
Hz, IH); 6.75 (d, /= 8.5 Hz, IH); 6.52 (br.s, IH); 6.49 (Jd, J = 2.1, 8.5 Hz, IH); 4.20 (m,
2H); 4.00 (m, IH); 3.62-3.35 (m, 4H); 3.18 (2xs, 2H); 3.90 (2xs, 3H); 2.60 (m, 2H); 2.32-
2.05 (m,3H); 1.39 (s,3H).
APCI-MS:m/z46l(MH+).
Example 29
2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzofuran-2,4'-piperidinj-l'-yI)-2-
hydroxy]oxy}-4-hydroxy-./V-methylberizamide
Step I: 4-[4-Methoxybenzyl)oxy]-Af-methyI-2-((2S)-oxiran-2-ylmethoxy]benzamide
A mixture of (2S)-oxiran-2-ylmethyl3-nitrobenzenesu]fonate (151 mg, 0.584 mmol), methyl 2-hydroxy-4-[(4-methoxybenzyl)oxy]benzoate (168 mg, 0.584 mmol) and cesium carbonate, Cs2CO3, (228 mg, 0.70 mmol) in dimethylformamide (4 mL) was kept on stirring at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate, NaaSO^, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-90% ethyl acetate in petroleum ether) to give the subtitled compound (150 mg). 'H-NMR (DMSO-d6, 400 MHz): 5 7.90 (m, IH); 7.75 (d, /= 8.7 Hz, IH); 7.37 (d, J= 8.6 Hz, 2H); 6.96-6.91 (m, 2H); 6.74 (d, J= 2.3 Hz, IH); 6.68 (dd,7 = 2.3, 8.7 Hz, IH); 5.08 (s, 2H); 4.48 (dd, J - 2.5, 11.5 Hz, IH); 4.04 (dd, J- 6.0, 11.5 Hz, IH); 3.78 (s, 3H); 3.45 (m, IH); 2.86 (t,.7-4.9 Hz, IH); 2.79 (d,7=4.7 Hz, 3H); 2.73 (dd,7=2.7, 5.0 Hz, IH). APC1-MS: m/z344(MH*).
Step II:
2-{[(2S)-3-(5-Chloro-rJHr)3JW-spiro1fl-benzofuran-2,4'-piperidm]-r-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]-A'-merhylberizamide
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidine] (70 mg, 0.313 mraol) and 4-[4-methoxyben2yi)oxy]-//-methyl-2-[(2S)-oxiran-2-ylraethoxy]benzamide (107.5 mg, 0.313 mmol) in ethanol (3 mL) was kept on stirring at 80 °C for 6h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (122 mg).
'H-NMR (CDClj, 400 MHz): 5 B.I8 (d,y= 8.8 Hz, 1H); S.IO (m, tH); 7.34 (d, J- 8.7 Hz, 2H); 7.14 (br.s, IH); 7.08 (m, 1H); 6.95 (d, 7= 8.7 Hz, 2H); 6.70 (m, 2H); 6.55 (d, 7= 2.1 Hz, IH); 5.08 (s, 2H); 4.22-4.12 (m, 2H); 3.98 (dd, /= 5.3, 9,3 Hz, IH); 3.85 (s, 3H}; 3.01 (s, 2H); 3.00 (d, J = 4.8 Hz, 3H); 2.95-2.87 (m, IH); 2.80 (m, IH); 2.65-2.50 (m, 4H); 2.01 (m, 2H); I.82(m,2H). APCl-MS:m/z567(MHf).
Step III:
2-{[(2S)-3-(5-Chloro-l'H,3H-spiro|l-benzofuran-2,4'-piperidin]-l)-yl)-2-
hydroxyJoxy)-4-hydroxy-N-methylbenzamide
2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzoruran-2,4'-piperidinJ-r-yi)-2-hydroxypropyl]oxy}-4-((4-methoxybenzyl)oxy]-W-methylbenzarmde (110 mg, 0.194 mmol) was treated with 10% trifluoroacetic acid in dichloromethane (10 mL) at room temperature for 20 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the titled compound (45 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.81 (d, /= 8.7 Hz, IH); 7.13 (m, IH); 7.04 (dd, 7= 2.3, 8.5 Hz, 1H); 6.66 (d, J = 8.5 Hz, 1H); 6.52 (d, J = 2.2 Hz, IH); 6.48 (dd, J - 2.2, 8.6 Hz, IH); 4.25-4.17 (m, 2H); 4.05 (m, IH); 3,02 (s, 2H); 2.92 (s, 3H); 2.70 (br.s, 4H); 2.60 (d,/ = 6.2 Hz, 2H); 1.94 (m, 2H); 1.84 (m, 2H). APCI-MS: m/z 447(MH+).
Example 30
-(2-{[(2J)-3-(5-Chloro-ll//-spiro[l,3-benzodioxoIe-2)4'-piperidinJ-ll-yI)-2-hydroxypropyI]oxy}-4-hydroxyphenyl)acetamide trifluoroacetate
Step I:
Ethyl 5-chIoro-l 'H-spirofl^-benzodioxole^/T-piperidineJ-l '-carboxylatc
A mixture of ethyl 4-oxopiperidine-l-carboxylate (1.71 g, 10 mmol), 4-chlorobenzene-l,2-diol (1.73 g, 12 mmol), and a catalytic amount of 4-methylbenzenesuIfonic acid hydrate in dry toluene (30 ml) were refluxed with water separator for 7 h. After cooling, the reaction mixture was washed with 2N sodium hydroxide (2 x 25 ml), and the solvent was removed in vacuo. Flash chromatography on silica gel (heptane/ethyl acetate, 2:1) of the residual semi-solid product afforded ethyl 5-chloro-I77-spiro[l,3-benzodioxole-2,4'-piperidine]-r-carboxylate as colourless crystals (0.43 g, 15 %). APCI-MS: m/z 298 [MH+].
'H-NMR (400MHz, CDCb): 6 6.77 (m, 2H), 6.67 (m, 1H), 4.16 (q, 2H, /= 7.1 Hz), 3.67 (t,4H, .7=5.7 Hz), I.98(t,4H,/=5.7Hz), 1.28 (t, 3H,7= 7.1 Hz).
Step II: 5-Chlorospiro[l,3-benzodioxole-2,4'-piperidine]
Ethyl 5-chloro-17/-spiro[l,3-benzodioxole-2,41-piperidine]-r-carboxylate (0.43 g, 1.45 mmol) was dissolved in ethanol (5 ml) and water (0.4 ml). Sodium hydroxide (0.2 g) was added followed by reflux for 2 days. After cooling, the solution was concentrated in vacuo, and acidified with 10 % HC1 to pH 'H-NMR (400MHz, CDC13): 5 6.6 - 6.9 (m, 3H), 3.06 (t, 4H, J = 5.0 Hz), 1.99 (t, 4H, / = 5.2 Hz).
Step III:
A^-(2-{[(2J)-3-(5-Chloro-l'/^-spiro[l,3-benzodioxoIe-2,4'-pipcridin]-r-yl)-2-hydroxypropyI|oxy)-4-hydroxyplienyI)acetamide trifluoroacetate
A solution of 5-cnlorospiro[l,3-benzodioxole-2,4'-piperidine] (45 mg, 0.2 mmol) and 4-(acetylamino)-3-[(26>oxiran-2-ylmethoxy]phenyl acetate (53 mg, 0.2 mmol) in methanol (5 ml) was refluxed for 15 h. The solvent was distilled off under reduced pressure. The residue was purified by preparative HPLC ("Kromasil" column; eluent: [acetonitrile + 0.1 % trifluoroacetic acid (TFA)Avater + 0.1 % TFAJ) to afford the titled compound as a colourless solid (37 mg, 0.07 mmol, 33 %). APCI-MS: nVz 449 [MH+].
'H-NMR (400MHz, acetone-dfi): 5 8.47 (br. s, IH), 7.93 (d, M,J » 8.7 Hz), 6.8 - 7.0 (m, 3H),6.53(d, I H, .7 = 2.6 Hz), 6.41 (dd, 1H,.7= 2.6 Hz,/= 8.7 Hz), 4.54 (m, IH), 4.08 (m, 2H), 3.66 (m, 2H), 2.51 (m, 4H), 2.08 (s, 3H), 2.06 (m, 4H).
Example 31
Ar-(2-{((2^)-3-(5-Chloro-l'//'-spiro[l,3-benzodioxole-2,4'-pipcridin]-r-yl)-2-hydroxy-2-methylpropylJoxy}-4-hydroxyphenyl)acetamide trifluoroacetate
The title compound was prepared as described in Example 9 from 5-chlorospiro[l,3-benzodioxole-2,4'-piperidine] (45 mg, 0.2 mmol) and 4-(acetylamino)-3-{[(21$>2-memyloxiran-2-yl]methoxy}phenyl benzoate (68 mg, 0.2 mmol) as a colourless solid (30 mg, 0.05 mmol, 26 %). APCJ-MS: m/z 463 [MH+].
'H-NMR (400MHz, acetone-d6): 5 8.59 (br. s, IH), 7.73 (d, IH, J - 8.7 Hz), 6.8 - 7.0 (m, 3H), 6.58 (d, IH, J = 2.6 Hz), 6.42 (dd, 1 H, J - 2.6 Hz, / - 8.7 Hz), 4.42 (d, IH, J = 9.7 Hz), 3.97 (d, IH,7 = 9.7 Hz), 3.71 (d, IH,/ = 14 Hz), 3.54 (d, lH,/= 14 Hz), 2.52 (m, 4H), 2.09 (s, 3H), 2.06 (m, 4H), 1.51 (s, 3H).
Example 32
Ar-(4-Hydroxy-2-{[(2iS')-2-hydroxy-3-(ll//'-spiro[l,3-benzjdloxole-254'-piperidin]-l'-yl)propyl]oxy}phenyl)acetamide trifluoroacetate
The title compound was prepared from spiro[l,3-benzodioxole-2,4'-piperidine] (E. K.
Moltzen, J. Perrengaard, E. Meier, J. Med. Chem. 1995, 38 (11), 2009 - 2007)
(38 mg, 0.2 mmol) as described Example 30. Yield 78 mg, 0.15 mmol, 74 %.
APCl-MS:m/z4l5[MH+].
'H-NMR (400MHz, acetone-d6): 5 7.90 (d, IH, J = 8.7 Hz), 6.87 (s, 4H), 6.53 (d, IH, J =
2.6 Hz), 6.75 (dd, IH, J = 2.6 Hz,,J= 8.7 Hz), 4.56 (m, IH, ), 4.08 (m, 2H), 3.69 (m,
2H), 2.46 (m, 4H), 2.09 (s, 3H), 2,07 (m, 4H).
Example 33
piperidin]-r-yl)propyl]oxy}phenyl}acetamide trifluoroacetate
The title compound was prepared from spiro[l,3-benzodioxole-2,4'-piperidine] (38 mg, 0.2
mmol) as described in Example 9. Yield 88 mg, 0.16 mmol, 81 %.
APCI-MS:m/z429[MH+j.
'H-NMR (400MHz, acetone-d6): 5 7.68 (d, IH, J = 8.7 Hz), 6.86 (s, 4H), 6.60 (d, IH, J =
2.5 Hz), 6.43 (dd, IH, J = 2.6 Hz, J = 8.7 Hz), 4.06 (d, IH, J = 9.7 Hz), 3.98 (d, IH, J =
9.7 Hz), 4.03 (d, IH.y = 9.7 Hz), 3.77 (d, lH,y= 13.6 Hz), 3.60 (d, lH,y = 13.6 Hz),
2.51 (m, 4H), 2.10 (s, 3H), 2.08 (m, 4H), 1.52 (s, 3H),
Intermediate Compound: 5-Chloro-3#-spiro(2-benzofuran-l,4'-pipendineJ
Step I: I'-Benzyl-S-chloro-S/f-spirop-beazofuran-l^'-piperidinJ-S-one
To a solution of 2-bromo-5-cblorobenzoic acid (2.35 g, 10.0 mmol) in tetrahydrofuran (THF) (15 mL) was added, a ,.6 M solution in hexane, n-buty] lithium (20 mL, 32.0 mmol) slowly at -78 C under nitrogen. After addition was complete the reaction mixture was kept on stirring at -78 °C for 3 h. Then a solution of l-ben2.ylpiperidin-4-one (3.78 g, 20.0 mmol) in THF (10 mL) was added slowly to the reaction mixture at -78 °C. After addition was complete the reaction temperature was raised to room temperature and the reaction mixture was kept on stirring at room temperature overnight. The reaction mixture was
poured into a mixture of water (60 mL) and diethyl ether (60 mL), layers were separated. The aqueous layer was extracted with diethyl ether (2 x 20 mL). The aqueous layer was acidified with aqueous 6M hydrochloric acid (HC1) to pH 2 and boiled for I h, cooled to 0 °C, pH was adjusted to 10.0 by addition of aqueous sodium hydroxide (NaOH) (6M) and rapidly extracted with trichioromethane (CHClj). The organic layer was washed with water, dried over sodium sulphate (NaiSO, filtered and concentrated in vacuo to give the subtitled compound (1.22 g) and it was pure enough for the next step. 'H-NMR (CDC13, 400 MHz): 5 7.85 (m, 1H); 7.65 (dd, J= 1.9, 8.2 Hz, 1H); 7.41-7.26-1.69 (m,2H). APCI-MS:m/z328(MH+).
Step II: r-Benzyl-5-chIoro-3H-spiro[2-benzofuran-l,4'-piperidineI
To a solution of 1 '-benzyl-5-chloro-3//-spiro[2-benzofuran-l,4'-piperidin]-3-one (I.I g, 3.35 mmol) in THF (12 mL) was added 1 M solution of borane complex in THF (7 mL, 7.0 mmol) slowly at 0 °C. After addition was complete reaction mixture was kept at room temperature for 30 min, then kept at reflux overnight, cooled to 0 °C and 6M aqueous HC1 (3,5 mL) was added slowly. The reaction mixture was kept at reflux for 5h, cooled to 0 °C, pH of the reaction mixture was adjusted to 10 by addition of aqueous NaOH (6M) and the whole was extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulphate (NaaSO^, filtered, and concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-30% ethyl acetate in petroleum ether) to give the subtitled compound (1.0 g).
'H-NMR (CDC13, 400 MHz): S 7.40-7.06 (m, 8H); 5.03 (Si 2H); 3.60 (s, 2H), 2.87 (m, 2H); 2.45 (m, 2H); 1.95 (m( 2H); 1.80 (m, 2H). APCl-MS:m/z314(MH*).
Step III: 5-Chloro-3/f-spiro[2-bcnzofuran-l,4'-piperidine]
To a solution of 11-benzyl-5-chloro-3//-spiro[2-benzoairan-l>4>-piperidine] (950 mg, 3.02 mmol) in dichloromethane (CH2C12) (6 mL) was added chloroethyl chloroformate (560.6 mg, 3.92 mraol) slowly at 0 °C. After addition was complete the reaction mixture was kept on stirring at 0 °C for 25 tnin. The volatiles were removed in vacuo, the residue was dissolved in methanol (6 mL) and kept at reflux for 40 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-5% methanol in dichloromethane, 0.2% ammonium hydroxide, KhUOH) to give the titled compound (300 mg) and r-benzyl-5-chloro-3//-spiro[2-benzofuran-l,4'-piperidin] was recovered (320 mg).
'H-NMR (COjOD, 400 MHz): 5 7.28-7.24 (m, 2H); 7.18-7.13 (m, 1H); 5.00 (s, 2H); 2.95 (m, 4H); 1.90-1.77 (m, 2H); 1.72-1.63 (m, 2H). APCI-MS: m/z 224(MH+).
Intermediate Compound: 5-Fluoro-3/?-spiro[l-benzofuran-2,45-piperidine]
Step I: r-Benzyl-5-fluoro-3^-spiro[l--benzofuran-2,4'-piperidine]
To a stirring suspension of magnesium strip (763 mg) in diethyl ether (7 mL) was added a crystal of iodine followed by 0.4 mL of 2-(bromomethyl)-l,4-difluorobenzene under nitrogen. The reaction was initiated with a high intensity heat gun, then 2-(bromomethyI)-1,4-difluorobenzene (5.0 g, 24.25 mmol) in diethyl ether (7 mL) was added at such a rate that a gentle reflux was maintained. After addition was complete the reaction mixture was kept on stirring at reflux for 100 min, cooled to room temperature. To this reaction mixture a solution of l-benzylpiperidin-4-one (4.57 g, 24.25 mmol) in diethyl ether (12 mL) was added dropwise with vigorous stirring. After addition was complete a white cake was formed which was left overnight at room temperature. The cake was hydrolized by treatment with aqueous ammonium chloride (NJ-LjCI) solution, extracted with diethyl ether. The organic layer was washed with water, dried over sodium sulphate (Na2SO4), filtered, concentrated and the residue was purified by silica gel flash chroma to graphy (0-1% methanol in dichloromethane, 0.1% ammonium hydroxide, NH4OH) to give intermediate
compound l-benzyl-4-(2,5-difiuorobenzyl)piperidin-4-ol (2.74 g) containing large amount of impurities. To a suspension of sodium hydride (NaH) (55%, 1.12 g, 26.0 mmol) in toluene (10 mL) was slowly added a solution of l-benzyl-4-(2,5-difluorobenzyl)piperidin-4-ol in toluene (15 mL). After addition was complete, the reaction mixture was kept on stirring at 110 °C (in a preheated oil bath), after 5 minutes dimethylformamide (9 mL) was added and stirring was continued at reflux for 2h. The reaction mixture was cooled to room temperature, water (20 mL) was added and extracted with ethyl acetate. The organic layer was dried over sodium sulphate (NajSO-O, filtered, concentrated and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.1% ammonium hydroxide, NH4OH) to give the subtitled compound (190 mg). 'H-NMR (CDC13, 400 MHz): 5 7.39-7.26 (m, 5H); 6.88-6.76 (m, 2H); 6.67 (dd, J = 4.2, 8.7 Hz, 1H); 3.59 (s, 2H); 2.99 (s, 2H); 2.68-2.47 (m, 4H); 2.03-1.94 8M, 2H); 1.86-1.76 (m, 2H). APCI-MS:m/z298(MH+).
Step II: 5-Fluoro-3//-spiro[l-benzofuran-2,4'-piperidine]
Ethyl chloroformate (65.6mg, 0.604 mmol) was added to a solution of 1 '-benzyl-5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (150 mg, 0.504 mmol) in toluene (2 mL) and the reaction mixture was refluxed overnight. The reaction mixture was cooled to room temperature, diluted by addition of toluene, washed successively with aqueous sodium hydrogencarbonate (NaHCOj) and water. The organic layer was dried over sodium sulphate (NajSO^ filtered and concentrated in vacuo. The residue was dissolved in ethanol (3.5 mL), aqueous potassium hydroxide (KOH) (SOOmg KOH in 0.8 mL water) was added and the reaction mixture was kept on stirring at reflux overnight, cooled to room temperature, extracted with ethyl acetate. The organic layer was well washed with water, dried over sodium sulphate (Na2SO4), filtered and concentrated. The residue was purified by HPLC (10% acetonitrile (CH3CN)-55% CH3CN in water containing 0.1% ammonium hydroxide, NH4OH) to give the titled compound (49 mg).
'H-NMR(CD3OD, 400 MHz): 5 6.92-6.87 (m, 1H); 6.81-6.75 (m, 1H); 6.64 (dd, 7=4.2, 8.7 Hz, 1H); 3.08-2.98 (m, 4H); 2.89-2.81 (rn, 2H); 1.92-1.83 (m, 2H); 1.78-1.71 (ra, 2H). APCI-MS:m/z208(MH+).
Intermediate Compound: 5-Chloro-3/f-spiro[l-benzofuran-2,3'-pyrroIidine]
Step 1: J-BenzyI-3-(5-chloro-2-fluorobenzyI)pyrrolidin-3-ol
To a stirring suspension of magnesium strip (1.39 g, 57.06 mmol) in diethyl ether (10 mL) was added a crystal iodine followed by 0.5 mLof 2-(bromomethyl)-4-chIoro-l-fluorobenzene under nitrogen. The reaction was initiated with a high intensity heat gun, then a solution of 2-(bromomethyl)-4-chloro-1-fluorobenzene (12.75 g, 57.06 mmol) in diethyl ether was added at such a speed that gentle reflux was maintained. After addition was complete the reaction mixture was kept on stirring at reflux for 3.5 h, cooled to room temperature and a solution of I-benzylpyrrolidin-3-one (10.0 g, 57.06 mmol) in diethyl ether (20 mL) was added dropwise with vigorous stirring. After addition was complete the reaction mixture was left overnight at room temperature. This reaction mixture was treated with aqueous ammonium chloride (NK^Cl) solution and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulphate (Na2SC>4), filtered, concentrated and the residue was purified by silica gel flash chromatogfaphy (0-2% methanol in dichloromethane, 0.2% ammonium hydroxide, NH^OH) to give the subtitled compound (650 mg).
'H-NMR(CDC13, 400 MHz): 5 7.39-7.23 (m, 6H); 7.21-7.15 (ra, 1H); 6.98 (t, 7= 9.0 Hz, 1H); 3.68 (d,y = 13.0 Hz, 1H); 3.63 (d,7= 13.0 Hz, 1H); 3.01-2.89 (m, 3H); 2.65 (d,/ = 9.5 Hz, 1H); 2.42-2.34 (m, 2H); 2.07-1.98 (m, 1H); 1.88-1.75 (m, 1H); 1.64 (br.s, 1H). APCI-MS: m/z 320(MH*).
Step II: l'-BenzyI-5-chloro-3J:/-spiro[l-benzofuran-2,3'-pyrroIidine
To a suspension of sodium hydride (NaH) (55%, 612 mg, 14.0 mmol) in toluene (10 mL) was added a solution of l-benzyl-3-(5-chIoro-2-fluorobenzyl)pyrrolidin-3-ol (1.3 g, 4.06 mmol) in toluene (20 mL) and the reaction mixture was kept on stirring at reflux, after 5 minutes dimethylformamide (10 mL) was added and the reaction mixture was refluxed for 90 minutes, cooled to room temperature, water (20 mL) was added and extracted with ethyl acetate. The organic layer was dried over sodium sulphate (Na:S04), filtered, concentrated and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (560 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.39-7.24 (m, 5H); 7.10 (s, 1H); 7.06 (dd, 7 = 2.3, 8.5 Hz, 1H); 6.68 (d, J =8.4 Hz, 1H); 3.73 (d, J= 13.0 Hz, 1H); 3.70 (d,7 = 13.0 Hz, lH);3.24(d,
7= 16.0 Hz, 1H); 3.20 (d,7= 16.0 Hz, 1H); 2.99 (d,7= 10.4 Hz, 1H); 2.95-2.88 (m, 1H);
2.74-2.64 (m, 2H); 2.43-2.34 (m, 1H); 2.11-2,02 (m, 1H).
APCI-MS: m/z 300(MH).
Step 111: 5-ChIoro-3#-spiro[l-benzofuran-2,3'-pyrroIidineJ
The experimental procedure is the same as described above for the corresponding piperidine derivative using 1 '-benzyl-5-chloro-3//-spiro[l-benzofuran-2,3'-pyirolidine] (555 mg, 1.85 mmol), ethyl chloroformate (261 mg, 2.4 mmol), toluene (5 mL), potassium hydroxide (KOH) (3.0 g), water (3 mL) and ethanol (6 mL) to give the titled compound (240 mg) after silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH).
'H-NMR (CDCI3> 400 MHz): 57.13 (s, 1H); 7.08 (dd, J = 2.3, 8.5 Hz, 1H); 6.65 (d, 7= 8.5 Hz, 1H); 3.32-3.16 (m, 4H); 3.07 (ddd,7= 4.8, 9.1, 11.2 Hz, 1H); 2.80 (d,7=12.3 Hz, 1H); 2.33-2.24 (m, IH); 1.93 (ddd, 7-7.3, 9.1, 13.7 Hz, 1H). APCI-MS:m/z 2 lO(MHf).
Example 34
hydroxypropyl]oxy}-4-liydroxyphenyl)acetamide
A mixture of 5-chloro-3//-spiro[2-berizofuran~l,4'-piperidin] (29.3 mg, O.I3I ramol) and 4-(acetyIamino)-3-[(2S)-oxiran-2-ylmethoxy]phenyl acetate (35 mg, 0.131 mmol) in ethanol (1.5 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by HPLC (acetonitrile (CH3CN) 10-55% in water, 0.1% trifluoroacetic acid, CF3COOH) to give the titled compound (35 mg). 'H-NMR (CDjOD, 400 MHz): 5 7.36 (m, 3H); 7.21 (d, J = 8.7 Hz, 1H); 6.50 (d, J = 2.4
Hz, 1H); 6.40 (dd,y=2.4, 8.7 Hz, 1H); 5.10 (s, 2H); 4.48 (m, 1H); 4.05 (d, 7=4.6 Hz,
2H); 3.78-3.63 (m, 2H); 3.56-3.35 (m, 4H); 2.40-2.21 (m, 2H); 2.13 (s, 3H); 2.08-1.95 (m,
2H).
APCI-MS: m/z 447(MH'f).
Example 35
Ar-(2-{[(2S)-3-(5-Chloro-r,3/f-spiro[2-benzofuran-l,4'-piPendin]-l'-y])-2-
hydroxypropyl]oxy}phenyl)acetamide
A mixture of 5-chIoro-3//-spiro[2-benzofuran-l,4'-piperidin] (35 mg, 0.156 mmol) and N-{2-[(2S>oxiran-2-ylmethoxy]phenyl}acetamide (32.3 mg, 0.156 mmol) in ethanol (1.5 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromalography (0-1 % methanol in dichloromethane, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (45 mg).
'H-NMR (CD3OD, 400 MHz): S 7.99 (dd,/= 1.3, 7.9 Hz, 1H); 7.29-7.25 (m, 2H); 7.18 (d, 7= 7.8 Hz, 1H); 7.12-7.01 (m, 2H); 6.06-6.91 (m, 1H); 5.00 (s, 2H); 4.25 (m, 1H); 4.13 (dd,y- 3.2, 9.9 Hz, 1H); 3.99 (dd, / = 6.4, 9.9 Hz, 1H); 3.00-2.89 (m, 2H); 2.67-2.50 (m, 4H); 2.20 (s, 3H); 2.08-1.96 (m, 2H); 1.73 (m, 2H). APC1-MS: m/z43i(MH+).
Example 36 2-{[(2S)-3-(5-ChIoro-l'J/,3-spiro(2-benzofuran-l)4'-piperidin|-l'-yl)-2-
hydroxypropylJoxyH-hydroxy-A'-methylbenzamide
Step I: 2-{[(2S)-3-(5-Chloro-l'/f,3/f-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyJ]oxy}-4-|(4-methoxybenzyI)oxy]-Ar-methylbenzamide
A mixture of 5-chloro-3//-spiro[2-benzofuran-lJ4'-piperidine] (26 mg, 0.116 mmol) and 4-[(4-methoxybenzyl)oxy]-A'-methyl-2-[(2S)-oxiran-2-ylmethoxy]ben2amide (40 mg, 0.116 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The voiatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.1% ammonium hydroxide, NH^OH) to give the subtitled compound (50 mg).
'H-NMR (CDCl], 400 MHz): 6 78.18 (d, /= 8.8 Hz, 1H); 8.14 (m, 1H); 7.37 (d, J = 8.7 Hz, 2H); 7.28 (m, 2H); 7.22 (s, 1H); 7.09 (d, J= 8.0 Hz, IH); 6.97-6.92 (m, 2H); 6.71 (dd, /= 2.3, 8.8 Hz, IH); 6.52 (d, J=2.3 Hz, IH); 5.08 (s, 2H); 5.05 (s, 2H); 4.25-4.15 (m, 2H); 3.85 (s, 3H); 3.00 (m, 4H); 2.88-2.75 (m, 2H); 2.66-2,46 (m, 3H); 2.06-1.90 (m, 2H); l.82(d,y=12.9Hz,2H). APCI-MS: m/z 567(MH+).
Step JI:
2-{((2S)-3-(5-ChIoro-r/f,3W-spiro{2-benzofuran-l,4'-pipcridin]-l'-yI).2-
hydroxypropyl]axy}-4-hydroxy-A^methyIbenzamide
2-{[(2S)-3-(5-Chloro-r//,3//-spiro[2-benzofuran-tI4'-piperidin]-r-yl)-2-hydrdxypropylJoxy}-4-[(4-methoxybenzyl)oxy]-/V-methylben2amide (45 mg, 0,079 mmol) was treated with 10% trifluoroacetic acid (CFjCOOH) in dichloromethane (CH2CI2) (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by HPLC (10-45% acetonitrile (CH3CN) in water, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (17 mg).

'H-NMR (CDjOD,400 MHz): 5 7.82 (d, J= 8.7 Hz, IH); 7.30-7.25 (m, 2H); 7.18 (d, /= 7.9 Hz, IH); 6.55 (d, /= 2.2 Hz, IH); 6.48 (dd, y- 2.2, 8.7 Hz, IH); 5.05 (s, 2H); 4.26-4.19 (ra, 2H); 4.09-4.04 (m, IH); 2.98-2.87 (m, 5H); 2.64-2.50 (m, 4H); 2.09-1.97 (m, 2H); l.73(d,y= 13.2 Hz, 2H). APCI-MS: m/z 447(MH+).
Example 37 2-{[(2S)-3-(5-Chloro-r/T,3/f-spiro[2-benzofuran-l,4'-piperidin]-l'-yI)-2-hydroxy-2-
methoxypropyIJoxy}-Ar-cyclopropyl-4-hydroxybenzanude
Step I:
2-{[(2S)-3-(5-ChIoro-riT,3^-spiro[2-benzofuran-l,4'-pipendinJ-r-yl)-2-hydroxy-2-
methylpropylJoxy)-A'-cyclopropyl-4-[(4-methoxybenzyl)oxy]benzamide
A mixture of 5-chloro-3//-spiro[2-benzofUran-l,4'-piperidinej (40 mg, 0.178 mmol) and A^-cyclopropyl-4-[(4-methoxybenzyl)oxy]-2-{[(2S)-2-methyioxiran-2-yl]methoxy}benzamide (68 mg, 0.178 mmol) in ethanol (2 mL) was stirred at 80 °C for 6h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-0.9% methanol in dichloromethane, 0.1% ammonium hydroxide, NH,fOH) to give the subtitled compound (45 mg).
'H-NMR (CDC13), 400 MHz): S 8.21 (br.s, IH); 7.99 (d, J= 8.7 Hz, IH); 7.36 (d3J= 8.7 Hz, 2H)7.27 (m, IH); 7.20 (s, IH); 7.03 (d,/= 8.0 Hz, IH); 6.92 (m, 2H); 6.70 (dd,/ = 2.3, 8.8 Hz, IH); 6.50 (d, / = 2.3 Hz, IH); 5.03 (s, 2H); 5.01 (s, 2H); 3.86 (s, 2H); 2.85 (s, 3H); 3.05 (m, IH); 2.91-2.80 (m, 3H); 2.75 (m, IH); 2.67 (d, J= 13.9 Hz, IH); 2.50 (d, J = 13.9 Hz, IH); 1.95 (m, 2H); 1.75 (m, 2H); 1.30 (s, 3H); 0.83 (m, 2H); 0.62 (m, 2H). APCI-MS: m/z 607(MH+).
Step II:
2-{I(2S)-3-(5-Chloro-l'/r,3J7-spiro[2-bcnzofuran-l,4'-pijendin]-l'-y!)-2-hydroxy-2-methoxypropyl]oxy}-/V-cyclopropyl-4-hydroxybenzaniide
2-{[(2S)-3-(5-chloro-l'/:/,3//-spiro[2-benzoruran-l)4'-piperidin]-r-yl)-2-hydroxy-2-methylpropyl]oxy}-Ar-cyclopropyl-4-[(4-methoxybenzyl)oxy]berizamide (40 mg, 0.065 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by HPLC (10-55% acetonitrile (CHjCN) in water, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (30 mg).
'H-NMR (CD3OD), 400 MHz): 5 7.84 (d, 7= 8.4 Hz, 1H); 7.25 (m, 2H); 7.J6 (d, J = 7.6 Hz, 1H); 6.45 (m, 2H); 5.00 (s, 2H); 4.11 (d, 7= 9.0 Hz, 1H); 3.93 (d, J= 9.0 Hz, 1H); 2.93 (m, 1H); 2.88 (m, 2H); 2.74-2.49 (m, 4H); 1.99 (m, 2H); 1.62 (m, 2H); 1.31 (s, 3H); 0.79 (m, 2H); 0.65 (m, 2H). APCI-MS: m/z 487(MH*).
Example 38
2-{[(2S)-3-(5-ChIoro-l'^,3/r-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-4-hydroxy-A'-(2-hydroxyethyl)benzamlde
Step I: MethyI-4-[(4-methoxybenzyI)oxy]-2-[(2S)-oxiran-2-ylmethoxy]benzoate
A mixture of 2(S)-oxiran-2-ylmethyl3-nitrobenzenesulfonate (518 mg, 2.0 mmol), methyl 2-hydroxy-4-[(4-methoxybenzyl)oxy]benzoate (576.6 mg, 2.0 mmol) and cesium carbonate (CsjCCh) (812.5 mg, 2.5 mmol) in dimethylformamide (10 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulphate, Na2SO4, filtered, concentrated in vacuo and the residue was purified by silica gel flash chromatography (0-30% ethyl acetate in petroleum ether) to give the subtitled compound (600 mg). 'H-NMR (CDCI3), 400 MHz): 6 7.87 (d, J = 8.7 Hz, 1H); 7.39-7.34 (m, 2H); 6.97-6.92 (m,
2H); 6.61 (dd, 7=2.4, 8.7 Hz, 1H); 6.59 (d, 7=2.2 Hz, 1H); 5.04 (s, 2H);4.31 (dd,7=
2.9, 11.1 Hz, 1H); 4.07 (dd, .7-4.8, 11.1 Hz, 1H); 3.88 (s, 3H); 3.85 (s, 3H); 3.40 (m, 1H);
2.92 (m, 2H).
APCI-MS: m/z 345(MH+).
Step II:
Methyl 2-{[(2S)-3-(5-chloro-r//,3^r-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate
A mixture of 5-ch[oro-3H-spiro[l-benzofuran-2,4'-piperidine] (150 mg, 0.67 ramol) and methyl-4-[(4-methoxybenzyl)oxy]-2-[(2S)-oxiran-2-yImethoxy]benzoate (230.5 mg, 0.67 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane) to give the subtitled compound (370 mg).
'H-NMR (CDC13), 400 MHz): 6 7.87 (d, J = 8.8 Hz, IH); 7.40-7.35 (m, 2H); 7.12 (m, IH); 7.07 (dd, J = 2.2, 8.4 Hz, IH); 6.98-6.93 (m, 2H); 6.69 (d, J = 8.4 Hz, IH); 6.63 (d, J = 2.2 Hz, IH); 6.60 (s, IH); 5.06 (s, 2H); 4.19 (m, 2H); 4.03 (m, IH); 3.89 (s, 3H); 3.85 (s, 3H); 3.00 (s, 2H); 2.80 (m, IH); 2.73-2.58 (m, 5H); 2.00 (m, 2H); 1.82 (m, 2H). APCI-MS.m/z568(MH*).
Step III:
2-{[(2S)-3-(5-Chloro-r/T,3jy-spirofl-benzofuran-2,4'-piperidinJ-r-yl)-2-
hydroxypropyl]oxy}-AH2-hydroxyethyl)-4-[(4-methoxybenzyI)oxy]benzamide
A mixture of methy[2-{[(2S)-3-(5-chloro-ry7r,3//-spiro[l-ben2oruran-2)4>-piperidinJ-J '-yl)-2-hydroxvpropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate (60 mg, 0.105 mmol) and 2-aminoethanol (0.256 mL, 4.2 mmol) in methanol (2 mL) was refluxed for 72h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% ammonium hydroxide, NH 'H-NMR (CDCI3), 400 MHz): 5 8.49 (t, J = 5.4 Hz, IH); 8.17 (d, y= 8.8 Hz, IH); 7.40-7.35 (m, 2H); 7.12 (s, IH); 7.09 (dd, /=2.2, 8.4 Hz, IH); 6.98-6.93 (m, 2H); 6.72 (dd, J-
2.2, 8.8 Hz, IH); 6.69 (d, /= 8.5 Hz, IH); 6.55 (d,J= 2.2 Hz, IH); 5.06 (s, 2H); 4.21 (m,
2H); 3.94 (dd, J = 7.2, 10.1 Hz, IH); 3.85 (s, 3H); 3.83 (d, /= 4.8 Hz, 2H); 3.70 (m, IH);
3.60 (m, IH); 3.00 (s, 2H); 2.91-2.76 (m, 2H); 2.68-2.53 (rh, 4H); 2.00 (m, 2H); 1.80 (m,
2H).
APCI-MS: m/z 597(MH).
Step IV:
2-{[(2S)-3-(5-Chloro-l'/f,3^-spiroH-benzofuran-2,4'-p!peridinJ-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-Ar-(2-hydroxyethyl)benzamide
2-{[(2S)-3-(5-Chloro-r//,3//-spiro[l-benzoftiran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy} -A^2-hydroxyethyl)-4-[(4-methoxybenzyl)oxy]benzamide (27 mg, 0.045 mmol) was treated with 10% trifluoroacetic acid (CFjCOOH) in dichloromethane (CH2C12) (3 mL) for 30 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-4% methanol in dichloromethane, 0,2% ammonium hydroxide, RUtOH) to give the titled compound (16 mg).
'H-NMR (CD3OD), 400 MHz): S 7,85 (d, J = 8.6 Hz, IH); 7.13 (m, IH); 7,19 (dd, J = 2.4, 8.5 Hz, IH); 6.65 (d,/ = 8.5 Hz, IH); 6.52 (d, J = 2.2 Hz, IH); 6.49 (dd, /= 2.2, 8.6 Hz, IH); 4.27-4.17 (m, 2H); 4.06 (dd, J= 5,9, 9.4 Hz, IH); 3.73 (t, J = 5.6 Hz, 2H); 3.53 (m, 2H); 3.00 (s, 2H); 2.70 (m, 4H); 2.62 (d, /= 6.4 Hz, 2H); 1.95 (m, 2H); 1.84 (m, 2H). APCI-MS: m/z 477(MH+).
Example 39
Af-(2-Aminoethyl)-2-{J(2S)-3-(5-chloro-l'^,3/f-spiro[l-benzofuran-2,4'-piperidin]-l'-
yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide
Step I:
yV-(2-Aminoethyl)-2-{[(2S)-3-(5-clrIoro-lW,3//'-spiro[l-bcnzofuran-2J4'-Piperidin]-l'-ylH-hydroxyprapylJoxyH-f^-met'hoxybenzyOoxyJbenzamide
A mixture of 2-{[(2S)-3-(5-chloro-r/7r,3//-spiro[l-benzorAjran-2,4'-piperidinJ-r-y[)-2-hydroxypropyl]oxy}-4-hydroxybenzo,c icid (50 mg, 0.084 rnmol) and N,N-carbonyldiimidazole (14 mg, 0.084 mrriol) in dimethylforrna;-nide (3 mL) was kept on stirring at room temperature for Ih. Then etbylenediamine (! 1 mg, 0.168 mmol) was added and the reaction mixture WE. stirred at room temperature overnight. The reaction
mixture was partitioned between ethyl acetate and water, the organic layer was dried over sodium sulphate, NazSO^, filtered, concentrated in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichioromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (22 rag). 'H-NMR (CD3OD), 400 MHz): 5 7.93 (d, J= 8.9 Hz, 1H); 7.45 (m, 2H); 7.12 (s, 1H); 7.04(ddjy=2.3,8.6Hz, 1H); 6.95-6.90 (m, 2H); 6.73 (s, 1H); 6.70 (d, /- 2.2 Hz, 1H); 6.64 (d, J= 8.5 Hz, 1H); 5.08 (s, 2H); 4.27 (dd, J= 2.7, 9.7 Hz, 1H); 4.23-4.15 (m, 1H); 4.05 (dd, y- 6.6, 9.8 Hz, 1H); 3.80 (s, 3H); 3.48 (t, J - 5.9 Hz, 2H); 2.96 (s, 2H); 2.86 (t, J = 6.1 Hz, 2H); 2.68 (m, 4H); 2.56 (d, J = 6.4 Hz, 2H); 1.90 (m, 2H); 1.80 (m, 2H). APC1-MS: m/z 596(MH+).
Step II:
jV-(2-Aminoethy!)-2-{](2S)-3-(5-chIoro-l'/f,3/f-spiro[I-benzofuran-2,4'-piperidin]-l'-
yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide
//-(2-Aminoethyl)-2-{[(2S)-3-(5-chloro-l'//,3//'-spiro|;[-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzamide ((22mg, 0.037 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (2 mL) for 20 rain at room temperature. The volatiles were removed in vacuo and the residue was purified by HPLC (10-60% acetonitrile (CHjCN) in water, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (8 mg).
'H-NMR (CD3OD), 400 MHz): 6 7.83 (d, /= 8.6 Hz, 1H); 7.14 (m, 1H); 7.04 (dd,y= 2.2, 8,4 Hz, 1H); 6.65 (d, J= 8.4 Hz, 1H); 6.50 (d, J = 2.1 Hz, 1H); 6.47 (dd, J= 2.2, 8.6 Hz, 1H); 4.27-4.19 (m, 2H); 4.04 (m, 1H); 3.50 (t, /= 6.0 Hz, 2H); 3.02 (s, 2H); 2.90 (t,J*> 6.0 Hz, 2H); 2,69 (m, 4H); 2.60 (d, J =-- 6.2 Hz, 2H); 1 .94 (m, 2H); 1.84 (m, 2H). APCI-MS:m/z476(MHt),
Example 40
I-JKaSJ-S-CS hydroxypropyljoxyl^-hydroxy-yV-methylbenzaimde
Step I: 2-{[(2S)-3-(5-Fluoro-l'//,3-spiroil-benzofuran-2,4'-piperldin]-r-yt)-2-
hydroxypropylJoxy}-4-[(4-methoxybenzyl)oxy]-Ar-methylbenzamide
A mixture of 5-fiuoro-3//-spiro[l-benzofuran-2,4'-piperidine] (20 mg, 0.096 mmol) and 4-[(4-methoxybenzyI)oxy]-A'-methyl-2-[(2S)-oxiran-2-ylmethoxy]benzamide(34.3mgJ 0.099 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-0,8% methanol in dichloromethane, 0.1% ammonium hydroxide, NH4OH) to give the subtitled compound (36 mg).
1H-NMR (CDC13), 400 MHz): 5 8.16 (d,J= 8.7 Hz, IH); 8.10 (m, IH); 7.36 (m, 2H); 6.96-6.91 (m, 2H); 6.89-6.77 (m, 2H); 7.72-6.64 (m, 2H); 6.54 (d, J» 2.3 Hz, IH); 5.00 (s, 2H); 4.20-4.10 (m, 2H); 3.96 (dd,7= 5.4, 9,4 Hz, IH); 3.83 (s, 3H); 3.01 (s, 3H); 3.00 (s, 2H); 2.90 (m, IH); 2.80 (m, IH); 2.64-2.50 (m, 4H); 2.00 (m, 2H); 1.83 (m, 2H). APCI-MS:m/z551(MH+).
Step II:
2-{[(2S)-3-(5-nuoro-l'//,3//-spiroIl-benzofuran-2,4'-piperidin]-l'-yI)-2-
hydroxypropyI]oxy}-4-I)ydroxy-7V-methylbenzamide
2-{[(2S)-3-(5-Fluoro-r//)3//-spiro[i-benzoruran-2,41-piPeridin>r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]-Af-methylbenzamide (32 mg, 0.058 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (2,5 mL) for 20 min at room temperature. The volatiles were removed in vacuo and the residue was purified byHPLC (10-50% acetonitrile (CH3CN) in water;0.1% ammonium hydroxide, NH4OH) to give the titled compound (11 mg).
lH-NMR(CDCl3),400MHz):57.82(d,/=8.6Hz, IH); 6.50 (dd,/= 2.7, 8.1 Hz, IH); 6.81-6.74 (m, IH); 6.62 (dd, J=4.2, 8,7 Hz, IH); 6.52 (d, J = 2.2 Hz, IH); 6.48 (dd,/= 2.2, 8.6 Hz, IH); 4.24-4.17 (m, 2H); 4.08-4.02 (m, IH); 3.01 (s, 2H); 2.92 (s, 3H); 2.77-2.63 (m, 4H); 2.60 (d, J= 6.2 Hz, 2H); 1.94 (m, 2H); 1.84 (m, 2H). APCI-MS:m/z43l(MH+).
Example 41 A'-(2-{[(2S)-3-(S-Fluoro-r/r,3//'-spiro[l-ben2ofuran-2,4'-plperidinJ-l)-yl)-2-
hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide
A mixture of 5-fluoro-3//-spiro[i-benzofuran-2,4'-piperidine] (20 mg, 0,096 mmol) and4-(acetylamino)-3-[(2S)-oxiran-2-ylmethoxy]phenyl acetate (2.5.5 mg, 0.096 mmol) in ethanol (2 mL) was kept on stirring at 80 °C over the weekend. The volatiles were removed in vacuo and the residue was purified by HPLC (10-35% acetonitrile (CH3CN) in water, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (14 mg). 'H-NMR (CD3OD), 400 MHz): 5 7.57 (d, J= 8.7 Hz, 1H); 6.90 (m, 1H); 6.81-6.74 (m, 1H); 6.63 (dd,J= 4.2, 8.7 Hz, 1H); 6.48 (d, J= 2.5 Hz, IH); 6.36 (dd, J = 2.6, 8.7 Hz, IH); 4.18 (m, IH); 4.05 (dd,J = 3.4, 9.8 Hz, IH); 3.93 (dd,/= 6.2, 9.8 Hz, IH); 3.01 (s, 2H); 2.70 (m, 4H); 2.61 (t, / = 7.0 Hz, 2H); 2.14 (s, 3H); 1.96 (m, 2H); 1.85 (m, 2H). APCl-MS:m/z431(MH+).
Example 42
Ar-(2-{((2S)-3-(5-Fluoro-l'/f,3//-spiro[l-benzofuran-2,4'-pipendin]-l'-yl)-2-
hydroxypropyl]oxy}phenyl)acetamide
A mixture of 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (8 mg, 0.038 mmol) and N-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (8 mg, 0.038 mmol) in ethanol (1.5 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by HPLC (10-70% acetonitrile (CH3CN) in water, 0.1% ammonium hydroxide, NH4OH) to give the titled compound (11 mg).
'H-NMR (CD3OD), 400 MHz): 5 7.99 (dd, J = 1.5, 8.1 Hz, IH); 7.08 (m, IH); 7.03 (m, IH); 6.94 (m, IH); 6.90 (m, IH); 6.77 (m, IH); 6.63 (dd,./-4.2, 8.8 Hz, IH); 4.19 (m, IH); 4.12 (dd, J = 3.2, 9.9 Hz, 1H); 3.98 (dd, 7- 6.4, 9.9 Hz, IH); 3.05 (s, 2H); 2.70 (m,
4H); 2.62 (m, 2H); 2.19 (s, 3H); 1.94 (m, 2H); 1.85 (m, 2H).
APCI-MS:m/z4l5(MH+).
Example 43
A mixture of 5-chloro-3#-spiro[l-benzoftiran-2,3'-pyrroIidine] (34.5 mg, 0.167 mmol) and Ar-{2-[(2S)-oxiran-2-ylmethoxy]phenyl}acetamide (35 mg, 0.167 mmol) in ethanol (1.5 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chiomatography (0-1% methanol (CHsOH) in dichloromethane (CHaCl?), 0.2% ammonium hydroxide, NHtQH) to give a mixture of two isomers (55 mg). This mixture was subjected to chiral HPLC to give the titled compound (17 mg) and other isomer (14 mg).
'H-NMR (CD3OD), 400 MHz): 5 7.99 (dd, J- 1.4, 8.0 Hz, IH); 7.15 (m, IH); 7.11-7.01 (m, 3H); 6.93 (m, IH); 6.66 (d, 7=8.5 Hz, IH); 4.18-4.11 (m, 2H); 3.99 (dd, .7=7.0, 10.6 Hz, IH); 3.25 (m, 2H); 3.11 (d,7= 10.8 Hz, IH); 3.00 (m, IH); 2.86-2.69 (m, 4H); 2.33-2.25 (m, IH); 2.18 (s, 3H); 2.13-2.05 (m, IH). APCI-MS:m/z417(MH).
Example 44
yV-(2-({(2S)-3[(2R)-5-Chloro-l'/r,3Jl7-spiro|l-benzofuran-2)3'-pyrrolidin]-l'-ylJ-2-hydroxypropyl}oxy)phenyl]acetamide
'H-NMR (CDjOD), 400 MHz): 5 7.99 (dd, 7= 1.4, 8.0 Hz, IH); 7.15 (m, IH); 7.11-7.01 (m, 3H); 6.93 (m, IH); 6.66 (d,7» 8.5 Hz, IH); 4.18-4.11 (m, 2H); 3.99 (dd, 7=7.0, 10.6 Hz, IH); 3.25 (m, 2H); 3.11 (d,7= 10.8 Hz, IH); 3.00 (m, IH); 2.86-2.69 (m, 4H); 2.33-2.25 (m, IH); 2.18 (s, 3H); 2.13-2.05 (m, IH). APCI-MS:m/z417(MH+).
Example 45
/V-[2-({(2S)-3-[(2S)-5-ChIoro-r/rj3//-spiro[l-benzofuran-2)3'-pyrroIidinJ-J'-ylJ-2-hydroxypropyl}oxy)-4-metnoxyphcnyljacetamide
A mixture of 5-chloro-3spiro[l-benzofuran-2,3'-pyrrotidine] (60 mg, 0.286 mmol) and //-{4-methoxy-2-[(2S)-oxiran-2-ylmetho?cy]phenyl}acetamide (68 mg, 0.286 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol (CH]OH) in dichloromethane (C^Clj), 0.2% ammonium hydroxide, NH4OH) to give a mixture of two isomers and this was subjected to chiral HPLC to give the titled compound (35 mg) and the other isorncr (35 mg).
'H-NMR (CD3OD), 400 MHz): 5 7.73 (d, J 8.8 Hz, IH); 7.14 (m, IH); 7.04 (dd,J = 2.2, 8.4 Hz, IH); 6.65 (d,/=» 8.5 Hz, IH); 6.60 (d, 7= 2.5 Hz, IH); 6.49 (dd, J = 2.6, 8.8 Hz, IH); 4.15-4.06 (m, 2H); 3.96 (dd, /= 6.2, 9.8 Hz, IH); 3.79 (s, 3H); 3.25 (m, 2H); 3.11 (dd, J- 10.7, 15.9 Hz, IH); 2.99 (m, IH); 2.85-2.64 (m, 4H); 2.25 (m, IH); 2.13 (s, 3H); 2.08 (m, IH). APCI-MS:m/z447(MH"f).
Example 46
^-[2-({(2S)-3-[(2R)-S-Cliloro-l'//,3//-spiro{l-benzofuran-2,3>-pyrrolidin]-r-yJ]-2-hydroxypropyl}oxy)-4-methoxyphenyl]acetamide
'H-NMR (CD3OD), 400 MHz): 6 7.73 (d, J- 8.8 Hz, IH); 7.14 (m, IH); 7.04 (dd, J = 2.2, 8.4 Hz, IH); 6.65 (d, J= 8.5 Hz, IH); 6.60 (d, J= 2.5 Hz, IH); 6.49 (dd, J = 2.6, 8.8 Hz, IH); 4.15-4.06 (m, 2H); 3.96 (dd,y= 6.2, 9.8 Hz, IH); 3.79 (s, 3H); 3.25 (m, 2H); 3.11
(dd, J= 10.7, 15.9 Hz, IH); 2.99 (m, IH); 2.85-2.64 (m, 4H); 2.25 (m, IH); 2.13 (s, 3H);
2.08 (m, IH).
APCI-MS: m/z 447(MH+).
Example 47
2-{[(2S)-3-(5~Chloro-r//,3flr-spiro[l-beuzofuran-2,3>-pyrrolidin]-l'-yI)-.2-hydroxypropyl]oxy}-4-hydroxy-A'-methylbenzamide
Step I:
2-{[(2S)-3-(5-Chloro-l'/f,37/-spiro[l-ben2ofuran-2,3'-pyrrolidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-mcthoxybenzyI)oxy]WV-rnethylbenzarnide
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,3'-pyrrolidine] (80 mg, 0.381 mmol) and 4-[(4-methoxybenzyl)oxy]-A^-methyl-2-[(2S)-oxiran-2-ylmethoxy]benzamide( 130.8 rag, 0.381 mmol) in ethanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (165 mg).
'H-NMR (CDC13), 400 MHz): 8 8.15 (d, y- 8.8 Hz, IH); 8.04 (m, IH); 7.36 (m, 2H); 7.13 (br,s, IH); 7.09 (m, IH); 6.93 (m, 2H); 6.72-6.66 (m, 2H); 6.54 (d,7= 2.2 Hz, IH); 5.05 (s, 2H); 4.17 (dd, /= 3,2, 9.5 Hz, IH); 4.09 (ra, IH); 3.98 (dd, J= 5.7, 9.5 Hz, IH); 3.83 (s, 3H); 3.30-2.83 (m, 9H); 2.72 (m, IH); 2.60 (dd, J= 3.4, 12.1 Hz, IH); 2.34 (m, 2H); 2.08 (m, 2H). APCI-MS: m/z 553(MH+).
Step II:
2-{I(2S)-3-(5-Chloro-r/T,3//'-spiro[l-benzofuran-2,3'-pyrrolidin]-r-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-./V-rnethylbenzarnide
2- {[(2S)-3-(5-Chloro-1 'H,3H-spiro[ l-benzofuran-2,3 '-pyrrolidin]- i'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]-Ar-methylbenzamide (160 mg, 0.289 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (CH2C12) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methano! (CHjOH) in dichloromethane (CHzCIa), 0.2% ammonium hydroxide, NHoOH) to give the titled compound (80 mg). APCI-MS: m/z 433 (MH+).
Example 48
2-{[(2S)-3-(5-Chloro-r//,3/f-spiro[l-benzofuran-2,4'-pipendin]-l'-yl)-2-hydroxypropyI]oxy}-4-hydroxybenzoic acid (trifluornacetate)
Step I: 2-{[(2S)-3-(5-ChJoro-JW,3^-spirofl-benzofuran-2,4'-piperidinl-l'-yl)-2-
hydroxypropyI]oxy}-4-[(4-methoxybenzyI]benzoicacid
To a solution of methyl 2-{[(2S)-3-(5-chIoro-l '//,3//-sptro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate (150 mg, 0.264 mmol) in ethanol (2 mL) was added aqueous solution of potassium hydroxide (KOH) (770 mg, KOH in 0.77 mL water) and the reaction mixture was stirred at reflux overnight, cooled to 0 °C and the pH was adjusted to 2.0 by addition of aqueous hydrochloric acid (HC1). The whole was extracted with ethyl acetate. The organic layer was dried over sodium sulphate, NajSO-t, filtered and concentrated to give the subtitled compound (145 mg). 'H-NMR (CD3OD), 400 MHz): 5 7.78 (d, J= 8.4 Hz, IH); 7.35 (m, 2H); 7.19 (m, IH); 7.09 (dd, J= 2.2, 8,4 Hz, IH); 6.93 (m, 2H); 6.75-6.65 (m, 3H); 5.09 (s, 2H); 4.40 (m, IH); 4.24 (dd,y = 4.0, 9,3 Hz, IH); 4.06 (dd, /= 5.5, 9.3 Hz, IH); 3.80 (s, 3H); 3.70-3,53 (m, 2H); 3.51-3.35 (m, 4H); 3.14 (s, 2H); 2.33 (m, 2H); 2.12 (d, J = 14.8 Hz, 2H). APC1-MS: m/z 554(MH*).
Step II:
hydroxypropyl|oxy}-4-hydroxybenzoic acid (trifluoroacetate)
2-{[(2S)-3-(5-Chloro-r//,J//-spiro[l-benzofliran-2)4'-piperidin]-l '-yl)-2-hydroxypropy!]oxy}-4-[(4-methoxybenzyl]beuzoic acid (31 mg, 0.052 mmot) was treated with 10% trifluoroacetic acid (CFjCOOH) in dichloromethane (CH2C12) (2 mL) at room temperature for 20 min. The volatiles were removed in vacuo and the residue was purified by HPLC (10-55% acetonitrile (CH3CN) in water, 0.1% trifluoroacetic acid (CF3COOH)) to give the titled compound (15 mg). APCI-MS: m/z 434(MH*).
Example 49
hydroxypropyl]oxy}-4-hydroxybenzoy])pyrro!idin-3-oI
Step I: (3S)-l-{2-{[(2S)-3-(5-ChJoro-r/T,3//-spiro(l-benzofuran-2,4'-piperidIjiJ-r-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxyjbenzoyI}pyrrolidin-3-oI
A mixture of 2-{[(2S)-3-(5-chloro-l V/,3//-spiro[l-benzofuran-2/T-piperidin]-] '-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoic acid (100 mg, 0.169 mmol) and N,N-carbonyldiimidazole (30 mg, 0.186 rnmol) in dimethylformamide (3mL) was stirred at room temperature for Ih. Then (3S)-pyrrolidin-3-ol (76.3 mg, 0.845 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water, the organic layer was dried over sodium sulphate, Na2SO4> filtered, concentrated in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% ammonium hydroxide, NH4OH) to give the subtitled compound (55 mg). APCI-MS:m/z623(MH*).
Step II:
3(S)-l-(2-{[(2S)-3-(5-Chloro-l'/f,3/r-spiro[l-benzofuran-2,4'-piperidinJ-l'-yI>2-hydroxypropyI]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ol
(3S)-l-{2-{[(2S)-3-(5-Chloro-l'//)3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxyben2yl)oxy]benzoyl}pyrrolidin-3-ol (50 mg, 0.08 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (CH2C12) (3 mL) at room temperature for 20 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-4.5% methanol (CH3OH) in dichloromethane (CH2C12), 0.2% ammor ium hydroxide, NH4OH) to give the titled compound (25 mg),
'H-NMR (CD3OD), 400 MHz): 57.13 (m, JH); 7.08 (dd,.7-2.5, 8.2 Hz, IH); 7.03 (dd,/ = 2.3, 8.5 Hz, IH); 6.65 (d, 7= 8.4 Hz, IH); 6.49 (m, IH); 6.44 (m, IH); 4.48 (m, 0.5 H);
4.35 (m, 0.5H); 4.10 (m, IH); 4.03 (m, IH); 3.96 (dd,y= 5.6, 9.7 Hz, IH); 3.67 (m, IH); 3.62-3.50 (m, 2H); 3.30 (m, IH); 3.00 (s, 2H); 2.78-2.52 (m, 6H); 2.12-1.77 (m, 6H). APCI-MS: m/z 503(MH*).
Example 50 3(R)-l-(2-{((2S)-3-(5-Chloro-r/f,3/T-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrrolidin-3-o]
Step I:
(3R)-l-{2-{[(2S)-3-(5-Chloro-l'//,3Jyr-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxyJbenzoyl}pyrrolidin-3-ol
A mixture of 2-{[(2S)-3-(5-chloro-r//,3//-spiro[l-ben2ofliran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoic acid (60 mg, 0.101 mmol) and N,N-carbonyldiimidazole (17.5 mg, 0.108 mmol) in dimethylformamide (3mL) was stirred at room temperature for Ih. Then (3R)-pyrrolidin-3-ol (47 mg, 0.540 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water, the organic layer was dried over sodium sulphate, NaaSO^, filtered, concentrated in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% ammonium hydroxide, NH-^OH) to give the subtitled compound (64 mg). APCI-MS: m/z 623(MH+).
Step II:
3(R)-J-(2-{[(2S)-3-(5-Chloro-l'//,3//-spiro[l-benzofuran-2,4'-piperidinH'-yl)-2-hydroxypropyIJoxy}-4-hydroxybenzoyi)pyrroIidin-3-oI
(3R)-l-{2-{[(2S)-3-(5-Chloro-r//,3//-spiro[l-ben2ofuran-2,4'-piperidinJ-r-yl)-2-hydroxypropyljoxy) -4-[(4-methoxybenzy!)oxy]benzoyl}pyrrolidin-3-ol (60mg, 0.096 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (CH2C12) (3 mL) at room temperature for 20 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-5% methanol (CH3OH) in
dichloromethane (CH2CIj), 0.2% ammonium hydroxide, NH4OH) to give the titled compound (8 mg).
'H-NMR (CD3OD), 400 MHz): 5 7.13 (m, 1H); 7.08 (dd, /- 2.5, 8.2 Hz, 1H); 7.03 (dd, J = 2.3, 8.5 Hz, 1H); 6.65 (d, ./= 8.4 Hz, 1H); 6.49 (m, 1H); 6.44 (m, 1H); 4.48 (m, 0.5 H); 4.35 (m, 0.5H); 4.10 (m, 1H); 4.03 (m, IH); 3.96 (dd, 7= 5.6,9.7 Hz, lH);3.67(m, 1H); 3.62-3.50 (m, 2H); 3.30 (m, 1H); 3.00 (s, 2H); 2.78-2.52 (m, 6H); 2.12-1.77 (m, 6H). APCl-MS: m/z 503(MH+).
Example 51
3-{[(2S)-3-(S-Chloro-l'Jflr,3//-spiro[l-benzofuran-2,4'-piperidinJ-r-yI)-2-
hydroxypropyl]oxy}-4-(morpholin-4-ylcarbonyl)phenol
Step I:
(2S)-l-(5-ChIoro-l'/f,3/r-spiro[l-benzofuran-2,4'-piperidin]-r-yI)-3-[5-[(4-
methoxybenzyl)oxyj-2-(morpholin-4-ylcarbonyI)phenoxyJpropan-2-ol
A mixture of 2-{[(2S)-3-(5-chloro-l'//,3//-spiro[l-benzofuran-2J4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoic acid (100 mg, 0.169 mmol) andN,N-carbonyldiimidazole (35 mg, 0.215 mmol) in dimethylformamide (3mL) was stirred at room temperature for Ih. Then morpholine (250 mg, 2.86 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetaSe and water, the organic layer was dried over sodium sulphate, Na2SO Step II:
3-{[(2S)-3-(5-Chloro-rjy,3/r-spiro[l-benzofuran-2)4'-piperidin]-l'-yI)-2-
hydroxypropyl]oxy}-4-(morpholin-4-ykarbonyI)phenoI
(2S)-l-(5-Chloro-r//,3//-sp!ro[i-benzofufan-2,4'-piperidin]-l'-yl)-3-[5-[(4-methoxybenzyl)oxy]-2-(morpho!in-4-ylcarbonyl)phenoxy]propan-2-ol (55 mg, 0.088 mmol) was treated with 10% trifluoroacetic acid (CF3COOH) in dichloromethane (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol (CHjOH) in dichloromethane (CH2Cl2), 0.2% ammonium hydroxide, NH4OH) to give the titled compound (24 mg).
'H-NMR (CD3OD), 400 MHz): 6 7.13 (m, IH); 7.07-7.01 (m, 2H); 6.65 (d, J = 8.5 Hz, IH); 6.50 (d, .7=2.1 Hz, IH); 6.45 (dd,/= 2.1, 8.2 Hz, IH); 4.15-3.92 (m, 3H); 3.87-3.37 (m, 8H); 3.00 (s, 2H); 2.78-2.49 (m, 6H); 1,94 (m, 2H); 1.83 (m, 2H). APCI-MS: m/z 503(MH+).
Example 52
I-ilCaS^-tS-chloro-l'H-spiroIl^-benzodioxole-a^'-piperidinJ-l'-yl)^-hydroxypropylJoxyj-N-methylbenzamide trifluoroacetate (salt)
Step I: 2-Hydroxy-yV-methylbenzamide
A solution of methyl salicylate (5.16 mL, 40 mmol) in methanol (10 mL) was added
dropwise to aqueous 40% methyfamine (18.1 mL, 210 mmol) at 0 °C. After addition was
complete the reaction mixture was kept on stirring at room temperature overnight. The
volatiles were removed in vacuo to give the subtitled compound (5.48 g).
'H-NMR (CDjOD, 400 MHz): 5 7.70 (dd, J = 1.5, 7.9 Hz, IH); 7.38-7.32 (, 2H); 6.90-6.83
(m,2H);2.85(s,3H).
Step II: ^/-Methyl-2-[(2S)-oxiran-2-ylmethoxyJbcnzamide
A mixture of (2S)-oxiran-2-ylmethyl-3-nitrobenzenesulfonate (388.5 mg, 1.50 mmol), 2-hydroxy-jV-methylbenzamide (226.5 mg, 1.50 mmol) and cesium carbonate (586 mg, 1,80 mmol) in dimethylfornia;nide (6 mL) was kept on stirring at room
temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was dried over sodium sulphate, Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-50% ethyl acetate in petroleum ether) to give the subtitled compound (284 mg). 'H-NMR (CDCb, 400 MHz): 6 8.39 (m, IH); 7.90 (br.s, IH); 7.06-6.98 (m, 2H); 6.95-6.89 (m, IH); 4.38 (dd,7 = 2.5, 11.4 Hz, IH); 3.98 (dd,/= 6.0, 11.4 Hz, lH);3.40(m, IH); 2.97 (t, J = 5.0 Hz, IH); 2.81 (dd, /= 2.7, 4.8 Hz, IH); 2.21 (s, 3H). APCI-MS: m/z 208 (MH+).
Step III:
2-{[(2S)-3-(5-chIoro-rH-spirofl,3-benzodioxoIe-2,4'-piperidinJ-l'-yl)-2-hydroxypropyIJoxy}-N-methyIbenzamide trlfluoroacetate (salt)
A mixture of 5-chlorospiro[l,3-benzodioxo[e-2,4'-piperidine] (22.5 mg, 0.1 mmol) and//-methyl-2-[(2S)-oxiran-2-ylmethoxy]benzamide (20.7 mg, 0.1 mmol) in ethanol (2 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by preparative HPLC (eluent: [acetonitrile /water -t- 0.1 % TFA]) to afford the titled compound as a colourless solid (28 mg, 51 %)
'H-NMR (acetone-de, 400 MHz).-5 7.94 (dd, 7=7.7, 1.7 Hz, IH), 7.46 (td,J= 7.8, 1.8 Hz, IH), 7.15 (d,/ = 8.3 Hz, IH), 7.07 (i,J= 7.5 Hz, IH), 6.93 - 6.86 (m, 3H), 4.73 (m, IH), 4.27 (m, 2H), 3.71 (dd, J = 13.4, 2.9 Hz, 2H), 3,58 (dd, /= 13.4, 9.5 Hz, 2H), 2.92 (s, 3H), 2.55 (br. s, 4H), 2.08 (m, 2H, covered by the signal of solvfent). APCl-MS:m/z433(MH+).
Example 53
N-(2-{[(2S)-3-(6-chIoro-3,4-dihydro-llH-spiro[chromene-2,4l-piperidin]-ll-yI)-2-hydroxypropyljoxy}phenyl)acctamide trifluoroacetate (salt)
A mixture of 6-chloro-3,4-dihydrospiro[chrornene-2,4'-piperidine] (23.8 mg, 0.1 mmol) and jV-{2-[(2S)-Oxiran-2-y!methoxy]phenyl}acetamide (20.7 mg, 0.1 mmol) in ethanol (3 mL) was kept on stirring at 80 °C overnight. The volatiles were removed in vacuo and the
Residue was purified by preparative HPLC (eluent: [acer.onitrile /water + 0.1 % TFA]) to
Afford the titled'compound as a colourless solid (40 mg, 71 %).
'H-NMR (acetone-d6, 400 MHz): 5 8.74 (br. s, 1H), 8.29 (d, J = 7.5 Hz, 1H), 7.15 (s, 1H),
7.11 (d, /= 8.8 Hz, 1H), 6.99 (d, J = 3.8 Hz, 2H), 6.97 - 6.85 (m, 2H), 4.54 (m, 1H), 4.11
(m, 2H), 3.81 - 3.43 (m, 6H), 2.88 (t, J= 6.8 Hz, 2H), 2.24 - 2.09 (m, 2H), 2.13 (s, 3H),
2.08 (m, 2H, covered by the signal of solvent), 1.95 (t,y= 6.8 Hz, 2H)
APCI-MS:m/z445(MH+).
Example 54
N-(2-{[(2S)-3-(6-chloro-3,4-dihyclro-l'H-spirolchromene-2,4'-piperidin]-r->'l)-2-hydroxypropyl]oxy}-4-fluorophenyl)acetamide trifluoroacetate (salt)
Prepared as described in Example 53 using 7V-{4-fluoro-2-[(2S)-oxiran-2-
ylmetoxy]phenyl}acetamide.
'H-NMR (acetone-d6, 400 MHz): 6 8.69 (br. s, 1H), 8.24 (m, 1H), 7.15 (s, 1H), 7.11 (dd, /
= 8.7, 2.6 Hz, 1H), 6.85 (m, 2H), 6.69 (td, J = 8.7, 2.8 Hz, 1H), 4.55 (m, 1H), 4.13 (m,
2H), 3.80 - 3,44 (m, 6H), 2.88 (t, /= 6.8 Hz, 2H), 2.29 - 2.05 (m, 4H, covered by the
signal of solvent), 2.12 (s, 3H), 1.95 (t, /= 6.6 Hz, 2H)
APCI-MS: m/z 463 (MH*).
Example 55
2-{[(2S)-3-(6-chIoro-3)4-dihydro-rH-spiro[chromene-2,4'-piperidinJ-l'-yI)-2-hydroxypropyl]oxy}-N-methylbenzamide trifluoroacetate (salt)
Prepared as described in Example 53 using //-methyI-2-[(2S)-oxiran-2-
yimedioxyjbenzamide.
'H-NMR (acetone-d6, 400 MHz): 5 8.08 (br. s, 1H), 7.96 (dd, J = 7.7, 1.5 Hz, 1H), 7.44
(ddd, J = 8.3, 7.3, 1.8 Hz, 1H), 7.15 - 7.05 (m, 4H), 6.86 (d, J= 8.7 Hz, 1H), 4.70 (m, 1H),
4.24 (m, 2H), 3.77 (m, 2H), 3.60 - 3.45 (m, 4H), 2.91 (d, J = 4.4 Hz, 3H), 2.87 (t, 7= 6.9
Hz, 2H), 2.24 (td,J= 14.5, 4.3 Hz, 2H), 2.1 1- 2.05 (m, 2H, covered by the signal of
solvent), t. 92 (m, 2H)
APCI-MS:m/z445(MH*).
Example 56
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro-l'H-spiro[chromene-2,4'-piperidlnJ-r-yI)-2. hydroxypropyl]oxy}-4-hydroxyphenyl)acetamlde trlfluoroacetate (salt)
Prepared from 6-chloro-3,4-dihydrospiro[chromene-2,4'-piperidine] as described in
Example 27.
'H-NMR (acetone-d6, 400 MHz): 6 7.92 (d, / = 8.7 Hz, IH), 7.14 (s, IH), 7.1 1 (dd, J - 8.7,
2.5 Hz, IH), 6.86 (d,/= 8.6 Hz, IH), 6.52 (d, J = 2.4 Hz, IH), 6.40 (dd, 7= 8.7, 2.5 Hz,
IH), 4.52 (m, IH), 4.06 (m, 2H), 3.83 - 3.41 (m, 6H), 2.87 (t,7= 6.8 Hz, 2H), 2.27 - 2.08
(m, 4H, covered by the signal of solvent), 2.08 (s, 3H), 1 .93 (t, J = 6.7 Hz, 2H)
APCl-MS:m/z461
Example 57
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro-rH-spirofchromerie-2,4'-piperidinJ-r-yl)-2-hydroxy-2-methylpropylJoxyH-hydroxyphenyI)acetamide trifluoroacetate
Prepared from 6-chIoro-3,4-dihydrospiro[chromene-2,4'-piperidine] as described in
Example 9.
'H-NMR (acetone-rig, 400 MHz): 5 7.72 (d, J = 7.3 Hz, IH), 7. 11 (m, 2H), 6.86 (d, / = 8.5
Hz, 2H), 6.58 (s, IH), 6,42 (d, J= 8.7 Hz, IH), 3.99 (dd, 7= 22.2, 9.3 Hz, 2H), 3.91 - 3.46
(m, 6H), 2.85 (t, J = 6.7 Hz, 2H), 2.29 (t, J = 12.6 Hz, 2H), 2.08 (s, 3H, covered by the
signal of solvent), 2.07 (m, 2H, covered by the signal of solvent), 1.90 (s, 28H), 1.50 (s,
3H)
APCI-MS: m/z 475 (MH+).
Example 58
hydroxypropyl}oxy)-4-hydroxyphenyl]acetamide
To a cold solution (ice-waterbath) of^-[2-({(2S)-3-[(2R)-5-chloro-l"//,3//-spiro[l-benzofuran-2)3'-pyrrolidin]-r-yl]-2-hydroxypropyl}oxy)-4-methoxyphenyl]acetamide(30 mg, 0.067 mmol) in CH2C12 (1.5 rnL) was slowly added 1 M solution of BBr3 in CH2Cl2 (0.2 mL). After addition was completed the reaction mixture was stirred at 0 °C for 3h. After addition of methanol (0.2 mL) the stirring was continued for another 10 min. The volatiles were removed in vacuo and the residue was dissolved in ethyl acetate, washed successively with aqueous NaHCCb solution and H2O. The organic layer was dried over Na2SO4) filtered and concentrated in vacuo. The residue was purified by HPLC (10-60% CH3CN in H20 in the presence of 0.1% NH4OH) to give the titled compound (14 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.57 (d,/= 8.7 Hz, IH); 7.15 (br.s, IH); 7.05 (dd, J = 2.3, 8.6 Hz, IH); 6.66 (d, J = 8.5 Hz, IH); 6.47 (d, J= 2.5 Hz, IH); 6.36 (dd, /= 2.5, 8.7
Hz, IH); 4.14-4.08 (m, IH); 4.05 (dd,7 = 3.5, 9.7 Hz, IH); 3.92 (dd, J= 6.2, 9.7 Hz, IH);
3.25 (m, 2H); 3.09 (d,/= 10.6 Hz, IH); 3.02 (2.92 (m, IH); 2.86-2.75 (m, 3H); 2.69 (dd, J
= 7.3, 12.2 Hz, 1H); 2.32-2.24 (m, IH); 2.13-2.05 (m, 4H).
APCI-MS: m/z 433(MHf).
Example 59
/V-[2-({(2S)-3--[(2S)-5-ch]oro-l'//,3//-spiro[l-benzofuran-2,3'-pyrrolidinJ-l'-yl]-2-hydroxypropyI}oxy)-4-hydroxyphenylJacetamide
To a cold solution (ice-water bath) of yV-[2-({(2S)-3-[(2S)-5-chloro-l "//,3//-spiro[l-benzoruran-2,3'-pyrrolidin]-r-yl]-2-hydroxypropyl}oxy)-4-methoxyphenyl]acetamide(30 mg, 0.067 mmol) in CH2C12 (1.5 rnL) was slowly added 1 M solution of BBr3 in CH2C12 (0.2 mL). After addition was. completed the reaction mixture was stirred at 0 °C for 3h. After addition of methanol (0.2 mL) the stirring was continued for another 10 min. The volatiles were removed in vacuo and the residue was dissolved in ethyl acetate, washed successively with aqueous NaHC03 solution and H20. The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue wss purified by HPLC (10-60% CH3CN in HiO in the presence of 0.1 % NH.|OH) to give the titled compound (15 mg).
'H-NMR (CD3OD, 400 MHz): 6 7.57 (d, /= 8.7 Hz, 1H); 7.15 (m, 1H); 7.05 (dd, /= 2.3, 8.5 Hz, 1H); 6.65 (d, J = 8.5 Hz, 1H); 6.47 (d, J = 2.5 Hz, 1H); 6.36 (dd, J = 2.5,8,5 Hz, 1H); 4.14-4.07 (m, 1H); 4.04 (dd,J= 3.7, 9.9 Hz, IH); 3.93 (dd,7= 6.1, 9.9 Hz, 1H); 3.25 (m, 2H); 3.13 (d,/= 10.7 Hz, IH); 3.03-2.96 (m, IH); 2.82-2.73 (m, 3H); 3.93 (dd,J= 6.1,9.9 Hz, IH); 2.32-2.24 (m, !H); 2.14-2.05 (m, 4H). APCI-MS: m/z 433(MH+).
Example 60
3-{[(2S)-3-(5-Chloro-r//,3/^-spiro[l-benzofuran-2,4'-piperidinl-l1-yl)-2-
hydroxypropyI]oxyj-4-(pyrrolidin-l-yIcarbonyI)phenol
Step I
(2S)-l-(5-Chloro-17/,3.tf-sPiro[I-benzoruran-2,4'-piperidin]-l'-yf)-3-{5-K4-
methoxybenzyl)oxyI-2-(pyrrolidin-l-ylcarbonyl)phenoxy]propan-2-ol
A mixture of 2-{[(2S)-3-(5-chloro-l '//^/Aspirotl-benzofuran^^'-pipertdinJ-r-yl)^-bydroxypropyI]oxy}-4-[(4-methoxybenzyI]benzoic acid (hydrochloride) (100 mg, 0.169 mmol) and AV^-carbonyldiimidazole (27.5 mg, 0.169 mmcl) in DMF (3 mL) was stirred at room temperature for Ih. Then, pyrrolidine (120 mg, 1.69 mmot) in DMF (1 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash chromalography (0-1% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (38 mg).).
'H-NMR (CDC13, 400 MHz): S 7.39-7.34 (m, 2H); 7.27-7.20 (m, IH); 7.13 (m, IH); 7.05 (dd, J = 2.3, 8.5 Hz, IH); 6.95 (m, IH); 6.69 (d,J= 8.4 Hz, IH); 6.64-6.59 (m, 2H); 4.13-3.98 (m, 3H); 3.87 (s, 3H); 3.64 (t, J = 6.9 Hz, 2H); 3.38 (m, 2H); 3.00 (s, 2H); 2.80 (m, IH); 2.73-2.49 (m, 5H); 2.03-1.76 (m, 8H). APCI-MS: m/z 607(MH*).
Step II
3-{l(2S)-3-(5-ChIoro-7'//,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-(pyrrolidin-l-ylcarbony!)phenol
(2S)-l-(5-Chloro-l'//,3//-spiro[l-benzofiiran-2,4>-piperidin]-r-yl)-3-[5-[(4-methoxybenzyl)oxy]-2-(pyrrolidin-l-ylcarbonyl)phenoxy]propan-2-ol (35 mg, 0.057 mmol) was treated with 10% CF3CO2H in CH2C12 (3 mL) at room temperature for 25 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (20 mg).
'H-NMR (CDjOD, 400 MHz): 5 7.09 (m, IH); 7.04-6.97 (m, 2H); 6.61 (d, / = 8.5 Hz, IH); 6.45 (d,/=2.2 Hz, IH); 6.39 (dd,7-2.0, 8.3 Hz, IH); 4.09-4.02 (m, IH); 3.97 (dd,J = 4.3, 9.7 Hz, IH); 3.91 (dd, .7-5.7, 9.7 Hz, IH); 3.51 (•:,./= 6.8 Hz, 2H); 3.30 (m, 2H); 2.99 (s, 2H); 2.74-2.46 (m, 6H); 1.98-1.74 (m, 8H). APCI-MS:m/z487(MH+).
Example 61
]-(2-{[(2S)-3-(5-Chloro-r/^,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-4-ol
Step I
l-{2-{[(2S)-3-(5-Chloro-r/f,377-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylloxy}-4-[(4-methoxybenzyl)oxy]benzoyl}piperidin-4-ol
Amixtureof2-{[(2S)-3-(5-chloro-r//,3//-spiro[l-benzofbran-2,4'-piperidin]-r-yi)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrocbloride) (100 mg, 0.169 mmol) and //.W-carbonyldiimidazole (27.5 mg, 0.169 mmol) in DMF (3 mL) was stirred at room temperature for Ih. Then piperidin-4-ol (20.5 mg, 0.202 mmol) in DMF was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (50 mg). APCI-MS: m/z 637(MH4).
Step II l-(2-{[(2S)-3-(5-Chloro-l'//,3jy-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-
hydroxypropylloxy}-4-hydroxybenzoyl)piperidin-4-ol
I - (2- {[(2S)-3-(5-Chloro-1 7/,3/f-spirof 1 -benzofuran-2,4'-piperidin]-1 *-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}piperidin-4-ol (45 mg, 0.07 mmol) was treated with 10% CF3C02H in CH2CI2 (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-4.5% methanol in dichloromethane, 0,2% NHjOH) to give the titled compound (20 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.09 (m, IH); 7.02-6.92 (m, 2H); 6.60 (d, J = 8.5 Hz, IH); 6.47-6.37 (m, 2H); 4.21-3.78 (m, 4H); 3.58-3.03 (m, 4H); 3.00 (s, 2H); 2.76-2.44 (m, 6H); 1.96-1.22 (m, 8H). APCI-MS:m/z637(MH+).
Example 62
(3S)-l-(2-{[(2S)-3-(5'Chloro-r/f,3^-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-2-
hydroxypropyl]oxy}benzoyl}pyrroIidin-3-ol
A mixture of 2-{[(2S)-3-(5-ch!oro-l '//,3//-spiro[l-benzofuran-2,4'-piperidinj-l '-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (60 mg, 0.132 mmol) and A^^V-carbonyldiimidazole (30 mg, 0.184 mmol) in DMF (1.5 mL) was stirred at room temperature for Ih. Then 3(S)-pyrrolidin-3-oI (57.5 mg, 0.66 mmol) in DMF (1 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04> filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NlijOH) to give the titled compound (13 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.45-7.39 (m, IH); 7.26 (br. d, J= 7.2 Hz, IH); 7.15-7.09 (m, 2H); 7.08-7.01 (m, 2H); 6.65 (d,/= 8.5 Hz, 1H); 4.50 (m, 0.5 H); 4.38 (m, 0.5H);
4.17-3.98 (m, 3H); 3.77-3.42 (m, 3H); 3.25 (ra, IH); 3.02 (s, 2H); 2.77-2.52 (m, 6H); 2.14-
1.77(m,6H).
APCI-MS: m/z 487(MH+).
Example 63
3-{[(2S)-3-(5-Chloro-l'/r,3/f-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-
hydroxypropyl]oxy}-4-(piperidin-l-ylcarbonyl)phenl
Step I
(2S)-l-(5-Chloro-l'/f,3/r-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-3-[5-[(4-
methoxybenzyl)oxy]-2-(piperidin-l-yIcarbonyl)phenoxy]propan-2-oI
A mixture of 2-{[(2S)-3-(5-chloro-l V/,3//-spiro[l-benzoftiran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybertzyI]benzoic acid (hydrochloride) (100 mg, 0.169 mmol) and AyV-carbonyldiimidazole (41 mg, 0.253 mmol) in DMF (1 .5 mL) was stirred at room temperature for Ih. Then piperidin (144 mg, 1.79 mmol) in DMF was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2SC>4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% MHjOH) to give the subtitled compound (24 mg). APCI-MS: m/z 62 1(MH*).
Step II
hydroxypropyIjoxy}-4-(piperidin-l-yIcarbonyl)phenoIi
2S)-l-(5-Chloro-r//)3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-3-(;5-[(4-methoxybenzyl)oxy]-2-(piperidin-l-ylcarbonyI)phenoxy]propan-2-ol (23 mg, 0.037 mmol) was treated with 10% CF3C02H in CH2C12 (3 mL) at room temperature for 30 min. The volatilles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NPL,OH) to give the titled compound (10 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.13 (m, 1H); 7.03 (dd, /= 2.2, 8.5 Hz, 1H); 7.00 (d, J = 8.2 Hz, 1H); 6.65 (d, J = 8.5 Hz, 1H); 6.50 (d, /= 2.1 Hz, 1H); 6.44 (dd,J = 2.1, 8.2 Hz, 1H); 4.10 (m, 1H); 4.07-3.93 (m, 2H); 3.80 (m, 1H); 3.58 (m, 1H); 3.30 (m, 2H, inside the methanol peak); 3.00 (s, 2H); 2.78-2.51 (m, 6H); 1.98-1.80 (m, 4H); 1.75-1.40 (m, 6H). APCl-MS:m/z503(MH+).
Example 64 (3S)-l-(2-{[(2S)-3-(5-Chloro-r/f,3//-spiro[2-benzofuran-l,4'-piperidinJ-l'-yJ)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ol
Step I
Methyl 2-{[(2S)-3-(5-chloro-lW,3#-spiro[2-benzofuran-l,4'-pipendinl-l '-yl)-2-
hydroxypropylJoxy}-4-((4-methoxybenzyl)oxy]benzoate
A mixture of 5-chloro-3H-spiro[2-benzofuran-l,4'-piperidin] (195 mg, 0.87 mmol) and methyl 4-[(4-methoxybenzyl)oxy]-2-[(2S)-oxiran-2-ylmethoxy]benzoate (300 mg, 0.87 mmol) in ethanol (4 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (450 mg). 'H-NMR (CDC13, 400 MHz): 5 7.89-7.85 M, 1H); 7,39-7.35 (m, 2H); 7.26 (dd, J = 1.8, 8.1 Hz, 1H); 7.20 (br.s, 1H); 7.08 (d, J = 8.0 Hz, 1H); 6.97-6.93 (m, 2H); 6.64-6.59 (m, 2H); 5.08 (s, 4H); 4.24-4.15 (m, 2H); 4.03 (dd, /= 5.8, 9.0 Hz, 1H); 3.88 (s, 3H); 3.84 (s, 3H); 2.98-2.85 (m, 2H); 2.75-2.46 (m, 4H); 2.03-1.90 (m, 2H); 1.77 (br, d,/= 13.5 Hz, 2H). APCI-MS: m/z 570(MH*).
Step II
2-{[(2S)-3-(5-Chloro-l'//,3//-!iPu--o[2-benzofuran-l,4'-pipendinJ-r-yl)-2-hydroxypropylJoxy}-4-[(4-methoxybenzyl)oxy]benzoicacid(hydrochloride)
Methyl 2-{[(2S)-3-(5-chloro-1 Y/,3//-spiro[2-benzofuran-1,4'-p'oeridinj-1 '-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate (450 rr,g, 0.792 mmol) was taken in ethanol (6 mL). Aqueous KOH (2.31 gm KOH in 2.3 mL of H2O) was added and the
reaction mixture was refluxed for overnight, cooled to 0 °C and the pH was made to 2.0 by addition of aqueous HCI, extracted with ethyl acetate. The organic layer was washed with H2O, dried over Na2SO4, filtered and concentrated to give the subtitled compound (370
'H-NMR (CD3OD, 400 MHz): 6 7.97-7.93 (m, 1H); 7.39-7.32 (m, 5H); 6.96-6.91 (m, 2H); 6.75-6.70 (m, 2H); 5.10 (s, 4H); 4.48-4.42 (m, 1H); 4.30 (dd, J = 4.0, 9.5 Hz, 1H); 4.1 1 (dd.y = 5.3, 9.5 Hz, 1H); 3';8l'(s, 3H); 3.80-3.42 (m, 6H); 2.55-2.41 (m, 2H); 1.98-1.88 (m, 2H). APC1-MS: m/z 554(MH+).
Step HI
(3S)-l-{2-{[(2S)-3-(5-Chloro-J',3-spiro[2-benzofuran-l,4'pipwridinJ-l'-yl)-
2hydroxypropyljoxy}-4-[(4-methoxybenzyI)oxy]benzoyl}pyrroUdin-3-ol
Amixtureof2-{[(2S)-3-(5-chIoro-r//,3//-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid (hydrochloride) (150 mg, 0.254 mmol) and A^-carbonyldiimidazoIe (54 mg, 0.33 mmol) in DMF (4 mL) was stirred at room temperature for 1 h, 3(S)-pyrrolidin-3-ol (1 1 1 mg, 1.27 mmol) in DMF (1.5 mL) was added and the reaction mixture was stirred at room temperature overnight, partitioned between ethyl acetate and water. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NrljOH) to give the subtitled compound (100 mg). APCI-MS:m/z623(MH+).
Step IV
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'^,3/r-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-4-hydroxybenzoyI)pyrroIidin-3-ol
(3S)-l-{2-{[(2S)-3-(5-ChIoro-r//,3//-sPiro[2-benzoruran-l,4'piperidin]-r-yl)-2-hydroxypropyljoxy}-4-[(4-methoxybenzyl)oxy]benzoyl)pyrrolidin-3-ol (95 mg, 0.152 mmol) was treated with 10% CF3C02H in CH2CI2 (4 mL) at room temperature for 25 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash
chromatography (0-5% methanol in dichloromethane, 0.2% NH4OH) to give the titled
compound (34 mg).
'H-NMRtCDjOD, 400 MHz): 6 7.31-7.27 (m, 2H); 7.20 (d,/ = 8,3 Hz, IH); 7,10 (d,/=
8.3 Hz, IH); 6.52 (t, J= 2.5 Hz, IH); 6.46 (dt, J= 2.0 Hz, IH); 5.02 (s, 2H); 4.49 (m, 0.5
H); 4.38 (m, 0.5 H); 4.20 (m, IH); 4.08-3.98 (m, 2H); 3.73-3.49 (m, 3H); 3.30 (m, IH);
3.12 (br.s, 2H); 2.95-2.70 (m, 4H); 2.18-1.75 (m, 6H).
APCI-MS: m/z 503(MH*).
Example 65
l-(2-{K2S>3-(5-ChIoro-l'//,3//-spiro[2-b€nzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)pipcridin-4-ol
Step 1
l-{[(2S)-3-(5-ChIoro-l'//r,3//-spiro[2-benzofuran-l,4'-pipendinJ-l'-yI)-2-
hydroxypropylJoxy}-4-f(4-methoxybenzyI)oxy]benzoyl}piperidin-4-oI
A mixture of 2-{[(2S)-3-(5-chloro-l '//,3//-spiro[2-ben2ofuran-l,4'-piperidin]-r-yl)-2-hydroxvpropyl]oxy}-4-[(4-memoxybenzyl)oxy]benzoic acid (hydrochloride) (150 mg, 0.254 mmol) and A^-carbonyldiirnidazole (54 mg, 0.33 mmol) in DMF (4 mL) was stirred at room temperature for 1 h, piperidin-4-ol (77 mg, 0.762 mmol) was added and the reaction mixture was stirred at room temperature overnight, partitioned between ethyl acetate and water. The organic layer was dried over Na2SC4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NH4OH) to give the subtitled compound (70 mg). APCI-MS: m/z 637(MH+).
Step II
l-(2-{[(2S)-3-(5-ChIoro-J'//,3//-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropylJoxy}-4-hydroxybenzoyl)piperidin-4-ol
l-{[(2S)-3-(5-Ch!oro-r//,3//-spiro[2-benzofuran-l,4'-pipendin]-l '-yl>2-hydroxypropyl]oxy}-4-[(4-methoxybenzyI)oxy]benzoyl}piperidin-4-oI (65 mg, 0.102
mmol) was treated with 1 0% CF3C02H in dichloromethane (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (26 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.30-7.25 (m, 2H); 7.19 (d, 7= 8.1 Hz, 1H); 7.07-6.98 (m, 1H); 6.53 (br.s, 1H); 6.45 (d, /= 8.2 Hz, 1H); 5.01 (s, 2H); 4.30-3.70 (m, 5H); 3.62-3.10 (m, 3H); 3.00 (br.s, 2H); 2.73-2.50 (m, 4H); 2.10-1.32 (m, 8H). APCI-MS:m/z517(MH*).
Example 66
A'-[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(trinuoromethyI)-r//,3/f-spiro(l-benzofuran-
2,4'-piperidin]-l'-yl]propyl}oxy)phenyIJacetamide
A mixture of 4-(acetylamino)-3-[(2S)-oxiran-2-ylmethoxy]phenyl acetate (41 mg, 0.155 mmol) and 5-(trifluoromethyI)-3H-spiro[l-benzofuran-2,4'-piperidine] (40 mg, 0.155 mmol) in ethanol (2 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (54 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.57 (d, J = 8.7 Hz, lH)i 7.45 (s, 1H); 7.39 (d, /= 8.5 Hz, 1H); 6.82 (d, J= 8.4 Hz, 1H); 6.48 (d, J= 2.5 Hz, 1H); 6.46 (dd, J = 2.6, 8.7 Hz, 1H);
4.20-4.14 (m, 1H); 4.05 (dd, /= 3.5, 9.9 Hz, 1H); 3.93 (dd, J = 6.2, 9.9 Hz, 1H); 3.08 (s,
2H); 2.80-2.55 (m, 6H); 2.13 (s, 3H); 2.02-1.83 (m, 4H).
APCI-MS:m/z481
Example 67
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'Jcr,3/T-spiro[l-benzofuran-2,4'-piPeridinJ-l'-yl)-2-hydroxypropylJoxy}-4-hydroxybenzoyl)pyrrolidin-3-ylbenzoate
Step I ter/-ButyI(3S)-3-(benzoyloxy)pyrrolidine-l-carboxylar.e
To a solution of (3S)-pyrrolidin-3-ol (0.87 g, 10.0 mmol) in THF (20 mL) was slowly added a solution of di-terr-buty! dicarbonate (2. 18 g, 10.0 mmol) in THF (10 ml) at room temperature. After addition was completed, the reaction mixture was stirred at room temperature overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane) to give intermediate /er/-Butyl (3S)-3-hydroxypyrrolidine-l-carboxyIate. To a solution of tert-butyl (3S)-3-hydroxypyrrolidine-l-carboxyIate (900 mg, 4.8 mmol) in CHjC^ (6 mL) was added Et3N (699 mg, 6.91 mmol) followed by benzoyl chloride (809 mg, 5.76 mmol) at 0 °C. After addition was completed, the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between GH^Cli and HaO. The organic layer was successively washed with aqueous NaHCOj and water, dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane) to give the subtitled compound (642 mg). 'H-NMR (CDCb, 400 MHz): 5 8.03 (d, /== 7.3 Hz, 2H); 7.59 (t, J = 7.3 Hz, 1H); 7.46 (t, J - 7.7 Hz, 2H); 5.58 (m, 1H); 3.75-3.45 (m, 4H); 2.20 (s, 2H); 1.50 (s, 9H). APCI-MS: m/z 1 92 (MH+-Boc).
Step II
(3S)-Pyrrol»din-3-yI-benzoate (trifluoroacetate)
/er/-Butyl (3S)-3-(benzoyloxy)pyrrolidine-l-carboxyIate (635 mg, 2.18 mmol) was treated
with 20% CFjCOaH in CHaCfo (20 mL) overnight at room temperature. The volatiles were
removed in vacuo to give the subtitled compound (800 mg).
'H-NMR (CDC13, 400 MHz): 5 9.29 (brd, 2H); 8.06 (m, 2H); 7.64-7.59 (m, 1H); 7.47 (t, J
= 7.9 Hz, 2H); 5.70 (m, 1 H); 3.72-3.50 (m, 4H); 2.40 (m, 2H).
APCI-MS: m/z 1 92
Step III
(3S)-l-{2-{[(2S)-3-(5-ChIoro-I>//.3/f-spiro[l-benzofuran-2,4'-pipendinJ-r-yl)-2-hydroxypropyljoxy}-4-[(4-metlioxybenzyl)oxyJbenzoyl}pyrrolidin-3-yl-benzoate
A mixture of 2-{[(2S)-3-(5-chloro-l '//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (218 mg, 0.369 mmol) and TvyV-carbonyldiimidazole (77.5 mg, 0.478 tnmol) in DMF (3 mL) was stirred at room temperature for 50 min. Then (3S)-pyrrolidin-3-yl-benzoate (trifluoroacetate) (225 mg, 0.738 mmol) in DMF (1 mL) was added followeed by, Et3N (0.102 mL, 0.738 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2SC>4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane) to give the subtitled compound (140 mg). APCJ-MS:m/z727(MH+).
Step IV
(3S)-l-(2-{[(2S)-3-(5-ChIoro-r^r,3//-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-2-
hydroxypropy!]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ylbenzoate
(3S)-l-{2-{[(2S)-3-(5-Chloro-l'//.3//-spiro[l-benzofuran-2>4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-[(4-rnethoxybenzyl)oxy]benzoyI}pyrrolidin-3-yl-benzoate(135mg,
0.185 mmol) was treated with 10% CF3C02H in CH2CI2 (3 mL) for 35 min. at room
temperature. The volatiles were removed in vacuo and the residue was purified by silica
gel flash chromatography (0-3.5% methanol in dichloromethane) to give the titled
compound (73 mg).
'H-NMR (CDCI3, 400 MHz): 5 8.06 (d, /= 7.4 Hz, 1H); 8.00 (d, J= 7.4 Hz, 1H); 7.61-
7.56 (m, 1H); 7.52-7.43 (m, 2H); 7.17-7.04 (m, 3H); 6.71 (dd, y= 2.4, 8.5 hz, 1H); 6.56-
6.45 (m, 2H); 5.16 (m, 0.5H); 5.50 (m, 0.5 H); 4.45 (m, 1H); 4.05-3.48 (m, 7H); 3.33-2.92
(m,8H); 2.40-1.95 (m,5H).
APCI-MS:m/z607(MH).
Example 68
(3S)-l-(2-{[(2S)-3-(5-Cli!oro-l'/A3//-spiroIl-benzofuran-2,4'-piperidinJ-l'-yl)-2-hydroxypropyl]oxy}-4-fluorob<:nzoyj> Step I
Methyl 4-fluoro-2-[(2S)-oxiran-2-ylmethoxy]benzoate
A mixture of methyl 4-fluoro-2-hydroxybenzoate (456.3 mg, 1.76 mmol), (2S)-oxiran-2-ylmethy! 3-nitrobenzenesulfonate (300 mg, 1.76 mmol) and Cs2C03 (687.4 mg, 2.11 mmol) in DMF (4.5 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H2O, organic layer was dried over Na2S04, filtered and concentrated in vacua. The residue was opurifted by silica gel flash chroma tography (0-30% ethyl acetate in petroleum spirit) to give the subtitled compound (385 mg).
'H-NMR(CDCI3, 400 MHz): 87.93-7.85 (m, IH); 6.77-6.69 (m, 2H); 4.36 (dd, 7= 2.6, ll.2 Hz, IH); 4.08 (dd, 7-4.9, l'l.2 Hz, IH); 3.90 (s, 3H); 3.44 (m, IH); 2.95 (m, 2H). APC1-MS: m/z 227 (MH*).
Step II
Methyl 2-{[(2S)-3-(5-chloro-l'//,3J/-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-fluorobenzoate
A mixture of 5-chloro-3tf-spiro[l-benzofuran-2,4'-piperidine] (224 mg, l.O mmol), methyl 4-fluoro-2-[(2S)-oxiran-2-ylmetboxy]benzoate (226 mg, l.O mmol) in ethanol (2 mL) was stirred at 80 C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane) to give the subtitled compound (290 mg).
'H-NMR (CDCI3,400 MHz): 5 7.90 (m, IH); 7.12 (s, IH); 7.07 (dd, 7= 2.2, 8.4Hz, IH); 6.77-6.67 (m, 3H); 4.25-4.14 (m, 2H); 4.06 (dd,7= 5.6, 9.0 Hz, IH); 3.90 (s, 3H); 3.00 (s, 2H); 2.90-2.60 (m, 6H); 2.00 (m, 2H); 1.86 (m, 2H). APC1-MS: m/z 452 (MH*).
Step HI
2-{[(2S)-3-(5-Chloro-l'Jtf,3//'-spiro{l-benzofuran-2,4'-PiperidinJ-r-yl)-2-hydroxypropyl]oxy}-4-fluorobcnzoic acid (hydrochloride)
Methyl 2-{[(2S)-3-(5-chloro-r/f,3//-spiro[t-benzofuran-2,4'-piperidin]-r-yI)-2-hydroxypropyl]oxy}-4-fluorobenzoate (286 mg, 0.635 mmol) in THF (3 mL) was treated with aqueous KOH (106 mg KOH in 1 mL H20) at room temperature for 7 h. The reaction mixture was cooled to 0 °C and pH was made to 2 by addition of aqueous HC1, extracted with ethyl acetate. The organic layer was washed with H2O, dried over NaaSdj, filtered and concentrated to give the subtitled compound (250 mg).
'H-NMR (CD3OD, 400 MHz): 8 7.98 (dd,J= 6.9, 8.8 Hz, IH); 7.20 (s, IH); 7.11 (dd,J = 2.0, 8.6 Hz, IH); 6.97 (dd, .7=2.3, 10.9 Hz, IH); 6.86-6.79 (m, IH); 6.74 (d, /= 8.5 Hz, IH); 4.50-4.43 (m, IH); 4.27 (dd, J = 4.0, 9.6 Hz, IH); 413 (dd,7 = 5.3, 9.6 Hz, IH); 3.80-3.43 (m, 6H); 3.15 (s, 2H); 2.10 (m, 2H); 2.18 (m, 2H). APCI-MS: m/z 436 (MH+).
Step IV
(3S)-l-(2-{[(2S)-3-(5-CUloro-l'^3^-spiro{l-ben2ofuran-2,4'-piPeridinj-r-yI)-2-
hydroxypropyI]oxy}-4-fluprobenzoy])pyrrolidin-3-oI
A mixture of 2-{[(2S)-3-(5-chloro-r//,3//-sptro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-hydroxypropyl]oxy}-4-fluorobenzoic acid (hydrochloride) (200 mg, 0.423 mmol) and N,N-carbonyldiimidazole (89.2 mg, 0.55 mmol) in DMF (3 mL) was stirred at room temperature for 50 min. Then (3S)-pyrrolidin-3-oI (184 mg, 2.11 mmol) in DMF (1 mL) was added and the reaction mixture was stirred at room temperature overnight, partitioned between ethyl acetate and H2O. The organic layer was dried overNa2SO Example 69
(3S)-l-(4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(trinuoromethyI)-l'//,3//-spiro[l-benzofuran-2,4'-piperidinJ-r-yLjpropyl}oxy)benzoyljpyrrolidin-3-ol
Step I Methy!-2-({(2S)-2-hydroxy-3-[5-(trinuoromethyl)-17/,3^-spiro[l-benzofuran-2,4'-
piperidinJ-l'-ylJpropyl}oxy)-4-[(4-methoxybenzyl)oxyJbenzoate
A mixture of 5-(trifluoromethyl)-3//-spiro[l-benzofuran-2,4'-piperidine] (107 rag, 0.416 'mmol) and methyl 4-[(4-methoxybenzyl)oxy]-2-[(2S)-oxiran-2-ylmethoxy]benzoate (143.25 mg, 0.416 mmol) in ethanol (2 mL) was stirred at 75 °C over the weekend. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2,5% methanol in dichloromethane) to give the subtitled compound (200 mg). APC1-MS: m/z 602 (MH+).
Step II
2-({(2S)-2-Hydroxy-3-[5-(trifluoromethyl)-l'jy,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl]propyl}oxy)-4-[(4-methoxybcnzyI)oxy]benzoicacid (hydrochloride)
Methyl-2-( {(2S)-2-hydroxy-3-[5-(trifluoromethyl)-l 7/,3//-spiro[ 1 -benzofuran-2,4 '-piperidin]-! '-ylJpropyI}oxy)-4-[(4-methoxybenzyl) oxyjbenzoate (190 mg, 0.3 15 mmol) was taken in ethanol (4 mL), aqueous KOH (918 mg KOH in 1 mL H20) was added and thereaction mixture was stirred at reflux temperature overnight, cooled to 0 °C and pH was made to 2 by addition of aqueous HC1, extracted with ethyl acetate. The organic layer was washed with H2O, dried over Na2S04, filtered and concentrated to give the subtitled compound (170 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.93 (d, /= 9.0 Hz, 1H); 7.52 (s, 1H); 7.45 (d, J= 8.6 Hz, 1H); 7.36 (d, /= 8.6 Hz, 2H); 6.96-6.88 (m, 3H); 6.75-6,69 (m, 2H); 5.10 (s, 2H); 4.44 (m, 1H); 4.28 (dd, 7=4.0, 9.5 Hz, 1H); 4.11 (dd,y= 5.3, 9.5 Hz, 1H); 3.80 (s, 3H); 3.77-3.43 (m, 6H); 3.22 (s, 2H); 2.38 (m, 2H); 2.20 (m, 2H). APCI-MS: m/z 588 (MH+).
Step III (3S)-l-{2-({(2S)-2-Hydroxy-3-[S-(trifluoromethyl)-r/f,3K-spiro{l-benzofuran-2,4)-
piperidin]-l'-yl]propyl}oxyH-{(4-methoxybenzyl)oxy]berizoyl}pyrrolidin-3-ol
A mixture of 2-({(2S)-2-hydroxy-3-[5-(trifluoromethyl)-l 7/,3//-spiroyM3etizofuran-2,4'-piperidin]-r-yl]propyl}oxy)-4-[(4-methoxybenzyl)oxy] benzoicacid(hydrochloride) (150 mg, 0.24 mrnol) and JV,//-carbonyldiimidazole (47 rag, 0.288 mmol) in DMF (3 mL) was stirred at room temperature for 50 rain. Then (3S)-pyrrolidin-3-ol (104.5 mg, 1.2 mmol) in DMF (1 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H2O. The organic layer was dried over Na2SO4) filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichlorometbane, 0.2% NH40H) to give the subtitled compound (80 mg). APCI-MS: m/z 657 (MtT).
Step IV
3S)-l-[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(trifiuoromethyl)-l'/7,3//-spiro[l-
benzofuran-2,4'-piperidinJ-l'-yl]propyI}oxy)benzoyI]pyrrolidin-3-ol
(3S)-l-{2-(((2S)-2-Hydroxy-3-[5-(trifluoromethyl)-l'jy,3//-spiro[l-benzofuran-2I41-piperidin]-r-yl]propyl}oxy)-4-[(4-methoxybenzy!)oxy]benzoyl}pyrro[idin-3-Ql (75 mg, 0.114 mmol) was treated with 10% CF3CO2H in CH2C12 (3 mL) for 20 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (26 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.45 (s, 1H); 7.39 (d, J - 8.5 Hz, 1H); 7.09 (dd, J= 2.4. 8.2 Hz, 1H); 6.82 (d, J = 8.4 Hz, 1H); 6.50 (ra, 1H); 6.45 (m, 1H); 4.48 (m, 0.5 H); 4.36 (m, 0.5H); 4.15-4.01 (m, 2H); 3.97 (dd, /= 5.6, 9.7 Hz, 1H); 3.72-3.50 (m, 3H); 3.38-3.23 (m, JH); 3.06 (s, 2H); 2.79-2.52 (m, 6H); 2.12-1.80 (m, 6H). APCI-MS: m/z 537 (MH+).
Example 70
(3S)-l-(4-FIuoro-2-{[(2S)-2-hydroxy-3-(l'^,3//-spiro[i-benzofuran-2,4'-piperidin]-r-yI)propylJoxy}benzoyl)pyrrolidin-3-oI
Step I Methyi-4-nuoro-2-{[(2S)-2-hydroxy-3-(l'/fr3-spiro[l-benzofuran-2,4'-piperidin]-r-
yl)propyl]oxy}benzoate
A mixture of 3//-spiroI-benzofuran-2,4'-piperidine] (55 mg, 0.29 mmol) and methyl 4-fluoro-2[(2S)-oxiran-2-ylmethoxy]benzoate (66 mg, 0.29 mmol) in ethanol (1.5 mL) was stirred at 78 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane) to give the subtitled compound (50 mg). APCI-MS:m/z4l6(MH+).
Step H
4-Fluoro-2-{[(2S)-2-hydroxy-3-(l',3'-splro[l-benzofuran-2,4'-piperidin]-l)-yl)propyl]oxy}benzoic acid (hydrochloridc)
Methyl4-fluoro-2-{[(2S)-2-hydroxy-3-(l'-spiro[l-berizbfuran-2l4'-piperidin] -1 '-yl)propyl]oxy}benzoate (50 mg, 0.12 mmol) was dissolved in THF (1.5 mL). Aqueous KOH (20 mg KOH in 0.5 mL H20) was added and the reaction mixture was stirred at room temperature for 24 h, cooled to 0 °C and pH was adjusted to 2 by addition of aqueous HC1, extracted with ethyl acetate. The organic layer was washed with HaO, dried overNa2SO4, filtered and concentrated to give the subtitled compound (37 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.96 (dd, J = 6.9, 8.8 Hz, 1H); 7.20 (d, J = 7.2 Hz, 1H); 7.12 (t, J = 7.5 Hz, 1H); 6.97 (dd.y = 2.4, 11.0 Hz, 1H); 6.88-6.78 (m, 2H); 6.76 (d,y= 8.0 Hz, 1H); 4.43 (m, 1H); 4.27 (dd,J= 4.1, 9.5 Hz, 1H); 4.13 (dd, 7= 5.3, 9.5 Hz, 1H); 3.79-3.42 (m, 6H); 3.14 (s, 2H); 2.30 (m, 2H); 2.16 (m, 2H). APCI-MS;m/z402(MH).
Step III
(3S)-l-(4-FIuoro-2-{[(2S)-2-hydroxy-3-(r,3//-spiro[l-benzofuran-2,4'-pipendinJ-l'-yl)propyl]oxy}benzoyl)pyrrolidin-3-oI
A mixture of 4-fluoro-2-{[(2S)-2-hydroxy-3-(l W,3//-spiro[l-benzofiiran-2,4'-piperidin]-l'-yl)propyl]oxy}benzoic acid (hydrochloride) (35 mg, 0.079 mmol) and N,N-carbonyldiimidazole (15.4 mg, 0.095 mmol) in DMF (1.5 mL) was stirred at room temperature for 45 min, (3S)-pyrrolidin-3-ol (34.4 mg, 0.395 mmol) in DMF (0.5 mL) was added and the reactiqn mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and HiO. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NHUOH) to give the titled compound (15 mg).
'H-NMR (CDjOD, 400 MHz): 8 7.32-7.26 (m, 1H); 7.13 (d, J= 7.3 Hz, 1H); 7.05 (t, J = 7.6 Hz, lH);6.94(dt,/=2.2Hz, 1H); 6.82-6.75 (m, 2H); 6.67 (d,/= 7.9 Hz, 1H);4.48 (m, 0.5H); 4.38 (m, 0.5H); 4.18-3.98 (m, 3H); 3.70 (dd,/= 5.3, 9.3 Hz, 1H); 3.66-3.46 (m, 2H); 3.37-3.18 (m, 1H); 3.00 (s, 2H); 2.78-2.51 (m, 6H); 2.15-1.78 (m, 6H). APCI-MS:m/z471(MH+).
Example 71
4-Fluoro-2-{[(2S)-3-(5-nuoro-r/r,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyljoxy}benzole acid (hydrochloride)
Step I
MethyI-4-fluoro-2-{((2S)-3-(5-fluoro-l '#,3^spiro[l-benzofuran-2,4'-piperidinJ-l '-
yl)-2-hydroxypropyl]oxy}benzoate
A mixture of 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (50 mg, 0.241 mmol) and methyl 4-fluoro-2-[(2S)-oxiran-2-ylmethoxy]benzoate (54.5 mg, 0.241 mmol) in ethanol (1.5 mL) was stirred at 77 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane) to give the subtitled compound (80 mg). APCI-MS: m/z 434 (MH+).
Step H 4-Fluoro-2-{[(2S)-3-(5-fluoro-rJff,3//'-spiro[l-benzofuran-2,4'-piperidinJ-ll-yl)-2-
hydroxypropyl]oxy}benzoic acid (hydrochloride)
To a solution of methyl4-fluoro-2-{[(2S)-3-(5-fluoro-r/jr,3//-spiro[l-benzofliran-2,4'-piperidinj-l '-yl)-2-hydroxypropyl]oxy}benzoate (80 mg, 0.184 mmol) in THF (1.5 mL) was added aqueous KOH solution (31 mg KOH in 0.5 mL of H20) and the reaction mixture was stirred at room temperature for 24 h, cooled to 0 °C and pH was adjusted to 2 by addition of aqueous HC1, extracted with ethyl acetate. The organic layer was washed with H20, dried over NajSO^, filtered and concentrated to give the titled compound (60
'H-NMR (CD3OD, 400 MHz): 5 7.97 (dd, J = 6.9, 8.7 Hz, IH); 6.97 (m, 2H); 6.88-6.79 (m, 2H); 6.72 (dd, J = 4.2, 8.8 Hz, IH); 4.45 (m, IH); 4.27 (dd, J= 4. 1, 9.6 Hz, IH); 4.13 (dd, J= 5,3, 9.6 Hz, IH); 3.78-3.42 (m, 6H); 3. 14 (s, 2H); 2.30 (m, 2H); 2.16 (m, 2H). APCI-MS: m/z 420 (MH+).
Example 72
(3SH-(4-Fluoro-2-{[(2S)-3-(5-fluoro-I'//f,3//-spiro[l-benzofuran-2,4'-pipcridin]-r-
yl)-2-hydroxypropyl]oxy}benzoyI)pyrrolidin-3-ol
A mixture of 4-fluoro-2-{[(2S)-3-(5-fluoro-l '//^//-spiroCl-benzofuran^^'-piperidinJ-r-yl)-2-hydroxypropy]]oxy}benzoic acid (hydrochloride) (50 mg, 0.109 mmol) and N,N-carbonyldiimidazole(21.2 mg, 0.131 mrno!) inDMF(1.5 mL) was stirred at room temperature for 1 h, (3S)-pyrrolidin-3-oI (47.5 mg, 0,545 mmol) in DMF (0.5 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H20. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NttjOH) to give the titled compound (21 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.29 (m, IH); 6.97-6.87 (m, 2H); 6.82-6.74 (m, 2H); 6.93 (dd, /= 4. 1 , 8.7 Hz, IH); 4.48 (m, 0.5.H); 4.37 (m, 0.5H); 4. 1 6-3.98 (m, 3H); 3,70 (dd, J =
5.3,9.4 Hz, 1H); 3.67-3.47 (m, 2H); 3.36-3.18 (m, 1H); 3.05 (s, 2H); 2.78-2.52 (m, 6H);
2.16-1.78(m,6H).
APCI-MS:ra/z489(MH+).
Example 73
7V-[(3S)-l-(2-{[(2S)-3-(5-Chloro-r/r3-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyljoxy}-4-hydroxybenzoyl)pyrrolidin-3-yl]acetamide
Step I
Af-((3S)-l-{[(2S)-3-(5-chloro-l'/?>3/r-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropylloxy}-4-((4-methoxybenzyl)oxy]benzoyI}pyrrolidin-3-yl)acetaraide
A mixture of2-{[(2S)-3-(5-chloro-lW,3/f-spiro[l-benzofuran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]ben2oic acid (hydrochloride) (150 mg, 0.254 mmol) and A^N-carbonyldiimidazole (50 mg, 0.308 mmol) in DMF (2 mL) was stirred at room temperature for 50 min. Then, JV-[(3S)-pyrrolidin-3-yI]acetamide (110 mg, 1.26 mmol) in DMF (0.5 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over NazSCXj, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane) to give the subtitled compound (100 mg). APCI-MS: m/z 664 (MH*).
Step II
J/V-[(3S)-l-(2-{[(2S)-3-(5-Chloro-r/f,3^-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)pyrrolidin-3-y!]acetamide
A^-((3S)-l-{[(2S)-3-(5-chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzy[)oxy]benzoyl}pyrrolidin-3-yl)acetamide(100 mg, 0.15 mmol) was treated with 10% CF3C02H in CH2C12 (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica
gel flash chromatography (0-4% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (22 mg).
'H-NMR (CDjOD, 400 MHz): 5 7.13 (m, IH); 7.09 (dd,y= 3.7, 8.2 Hz, 1H); 7.04 (dd, J= 1.7, 8.5 Hz, IH); 6.65 (d,J = 8.5 Hz, IH); 6.50 (t, /= 2.0 Hz, IH); 6.45 (dt, J= 2.2 Hz, IH); 4.44 (m, 0.5H); 4.26 (m, 0.5H); 4.16-3.77 (m, 3H); 3.74-3.58 (m, 2H); 3.52-3.14 (m, 2H); 3.00 (s, 2H); 2.77-2.52 (m, 6H); 2.28-2.10 (m, IH); 1.98-1.78 (m, 8H). APCI-MS: m/z 545 (MH+).
Example 74
2-{[(2S)-3-(5-CMoro-l '7/,3tf-spiro[l-benzofuran-2,4'-piperidin]-l >-yl)-2-
hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride)
Step I
Methyl 4-methyl-2-{(2S)-oxiran-2-ylmethoxy]benzoate
A mixture of (2S)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (777.7 mg, 3.0 mmol), methyl 2-hydroxy-4-raethylbenzoate ((498.5 mg, 3.0 mmol) and Cs2CO3 (1.17 g, 3.6 mmol) in DMF (10 mL) was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and HaO. The organic layer was dried overNa2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-20% ethyl acetate in petroleum spirit) to give the subtitled compound (500 mg). 1H-NMR (CDC13,400 MHz): 5 7.75 (d, /= 7,9 Hz, IH); 6.84 (d, J= 7.9 Hz, IH); 6.81 (s, IH); 4.33 (dd, / = 3.0, 11.2 Hz, IH); 4.12 (dd, /= 4.8, 11.2 Hz, IH); 3.89 (s, 3H); 3.42 (m, IH); 2.94 (m, 2H); 2.38 (s, 3H). APCI-MS: m/z 223 (MH*).
Step II
Methyl 2-{((2S)-3-(5-chloro-l '//,3/^spirofl-benzofuran-2,4'-piperidin]-l '-yl)-2-
hydroxypropyl]oxy}-4-methylbenzoate
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidin] (223.7 mg, 1.0 mmol) and methyl 4-methyl-2-[(2S)-oxiran-2-ylmethoxy]benzoate (222.24 mg, 1.0 mmol) in ethanol
(2 mL) was stirred at 80 °C for 5h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane) to give the subtitled compound (410 mg).
'H-NMR (CDC13,400 MHz): 5 7.76 (d, J= 8.4 Hz, IH); 7.13 (s, IH); 7.08 (dd,7= 2.2, 8.5 Hz, IH); 6.85 (m, 2H); 6.68 (d, /= 8.4 Hz, IH); 4.24 (m, IH); 4.19 (dd, J= 4.3, 9.2 Hz, IH); 4.08 (dd,J= 6.0, 9.1 Hz, IH); 3.90 (s, 3H); 3.02 (s, 2H); 2.94-2.67 (m, 6H); 2.40 (s, 3H); 2.06-1.86 (m, 4H). APCI-MS: m/z 448 (MH+).
Step III
2-{((2S)-3-(5-Chloro-l'//,3//-spiro[l-benzofuran-2,4'-piperidinI-l'yl)-2-hydroxypropyl]oxy}-4-methyIbenzoic acid (hydrochloride)
Methyl 2-{[(2S)-3-(5-chloro-l'//',3^-spiro[l-ben2oruran-214>-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-methylbenzoate (400 mg, 0.89 mmol) was taken in ethanol, aqueous KOH (2.6 g KOH in 2.6 mL H2O) solution was added and the reaction mixture was stirred at reflux temperature for 5h, cooled to 0 °C and the pH was made to 2 by addition of aqueous HCI, extracted with ethyl acetate. The organic layer was washed with HzO, dried over NajSO-t, filtered and concentrated to give the titled compound (330 mg). 1H-NMR (CD3OD, 400 MHz): 5 7.82 (d, y= 7.9 Hz, 1H); 7.20 (s, IH); 7.10 (dd, J = 2.2, 8.5 Hz, IH); 6.98 (s, IH); 6.90 (d, J = 8.1 Hz, IH); 6.74 (d, J= 8.5 Hz, IH); 4.44 (m, IH); 4.29 (dd,y= 4.0, 9.5 Hz, IH); 4.12 (dd,/ = 5.4, 9.6 Hz, IH); 3.78-3.42 (m, 6H); 3.14 (s, 2H); 2.40 (s, 3H); 2.30 )m, 2H); 2.16 (m, 2H). APCI-MS: m/z 432 (MH+).
Example 75
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'//,3//'-spiro[l-benzofuran-2,4'-piPeridin]-l)-yl)-2-
hydroxypropyI]oxy]}-4-methyIbenzoyl)pyrroIidin-3-ol
A mixture of 2-{[(2S)-3-(5-chloro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-l 'yi)-2-hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride) (150 mg, 0.32 mmol) and A'.A'-carbonyldiimidazole (65 mg, 0.4 mmol) in DMF (2.5 mL) was stirred at room temperature
for 45 min. Then (3S)-pyrrolidin-3-ol (139.4 mg, 1.6 mmol in DMF (0.5 mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and I-frO. The organic layer was dried over NaaSO^ filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NtitOH) to give the titled compound (90 mg). 'H-NMR (CD3OD, 400 MHz): 5 7.13 (m, 2H); 7.04 (dd, J= 2.1, 8.5 Hz, IH); 6.92 (s, IH); 6.85 (d, J = 7.6 Hz, IH); 6.60 (d, J = 8.5 Hz, IH); 4.47 (m, 0.5H); 4.35 (m, 0.5H); 4.17-3.96 (m, 3H); 3.74-3.44 (m, 3H); 3.37-3.18 (m, IH); 3.00 (s, 2H); 2.77-2.50 (m, 6H); 2.36 (s,3H);2.14-1.78(m,6H). APCI-MS:m/z501(MH*).
Example 76
2-{[(2S)-3-(5-FIuoro-l'//,3Jfir-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride)
Step I
Methyl2-{f(2S)-3-(5-nuoro-l'J/7,3/r-spiro[l-benzofuran-2J4'-piperidinl-l'-yl)-2-
hydroxypropyljoxy}-4-methylbenzoate
A mixture oF5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidin] (85 mg, 0.41 mmol) and methyl4-methyl-2-[(2S)-oxiran-2-ylmethoxy]benzoate-(91 mg, 0.41 mmol) in ethanol (2 mL) was stirred at 85 °C for 4.5 h. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane) to give the subtitled compound (136 mg). APCI-MS: m/z 430 (MH*).
Step II
2-{[(2S)-3-(5-Fluoro-l'//,3//'-spiro[l"benzofuran-2,4'-piperidin]-lI-yl)-2-hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride)
Methyl2- {[(2S)-3-(5-fluoro-11//,3#-spiro[ 1 -benzofuran-2,4 '-piperidin]-1 '-yl)-2-hydroxypropyl]oxy}-4-methylbenzoate (133 mg, 0.309 mmol) was taken in ethanol (2.5
mL), aqueous K.OH (902 mg KOH in 1 mL H2O) was added. The reaction mixture was srirred at reflux temperature for 5 h, cooled to 0 °C and the pH was adjusted to 2 by addition of aqueous HC1, extracted with ethyl acetate. The organic layer was washed with H20, dried overNa2SC>4, filtered and concentrated to give the titled compound (50 mg). 'H-NMR (CD3OD, 400 MHz): 8 7.74 (d, /= 7.9 Hz, IH); 6.96 (m, 2H); 6.89 (d, J = 8.0 Hz, IH); 6.84 (m, IH); 6.71 (dd,7 = 4.1, 8.7 Hz, IH); 4.43 (m, IH); 4.28 (dd,J= 4.0, 9.4 Hz, IH); 4.11 (dd, J= 5.6,9.5 Hz, IH); 3.75-3.40 (m, 6H); 3.14 (s, 2H); 2.39 (s, 3H); 2.32 (m,2H);2.14(m,2H). APCI-MS:m/z4I6(MH*).
Example 77
(2S)-l-(5-Chloro-l'/T,3^-spiro[l-benzofuran-2,4'-pipcridin]-l'-yl)-3-(2-{[2-
(hydroxymethyI)morpholin-4-yl]carbonyI}-5-rnethylphenoxy)propan-2-ol
Step I 4-(ter/-Butyl)2-mcthyl2,4-morphoIinedicarboxylate
Methyl iodide (9.38 mL, 150 mmol) was added to a suspension of 4(ter 'H-NMR(CDC13, 400 MHz): 54.07 (dd, 2H); 3.99 (m, IH); 3.77 (s, 3H); 3.73 (m, IH); 3.55 (m, IH); 3.07 (m, 2H); 1.45 (s, 9H).
Step II 7er/-ButyI2-(hydroxymethyI)-4-morpholinecarboxylate
4-(tert-Butyl)2-methyl 2,4-morpholinedicarboxylate (62.6 mmol) was dissolved in dry THF (100 mL) and added drop wise at 0 °C to a suspension of lithium borohydride (2.5 g, 115 mmol) in dry THF (100 mL). After addition was completed the reaction mixture was
stirred at room temperature overnight. Water (10 mL) was added and stirred at room temperature for 1 h. The volatiles were removed in vacuo and the residue was partitioned between ethyl acetate and HjO. The organic layer was washed successively with 0.5M aqueous HC1, saturated aqueous NaHCO} and h^O. The organic layer was dried over NaaSO-t, filtered and concentrated to give the subtitled compound (13.3 g). 'H-NMR (CDC13> 400 MHz): 6 3.88 (m, 3H); 3.46-3.42 (m, 4H); 2.93 (m, 1H); 2.75 (m, lH);2.09(m, 1H); 1.46(s,9H).
Step III
Morpholin-2-ylmethyI trifluoroacetate (trifluoroacctic acid salt)
Tert-Butyl 2-(hydroxymethyl)-4-morpholinecarboxylate (5,13 g, 23.61 mmol) was treated with CFjCChH (20 mL) in CH2C12 (50 mL) at room temperature for 3 h. The volatiles were removed in vacuo to give the subtitled compound (7.6 g).
'H-NMR (DMSO-d6, 400 MHz): 8 9.25 (br.s, 2H); 3.86 (dd, /= 3.3, 12.6 Hz, 1H); 3.62 (m, 2H); 3.39 (m, 2H); 3.19 (m, 2H); 2.96 (t, J= \ 1.2 Hz, 1H); 2.76 (t,/= 1 1.2 Hz, 1H).
Step IV
2S)-l-(5-ChIoro-l'/f>3//-spiro{l-benzofuran-2,4'-piperidin]-l'-yl)-3-(2-{[2-
(hydroxymethyl)morphoIin-4-yI]carbonyl}-5-methylphenoxy)propan-2-oI
A mixture of 2-{[(2S)-3-(5-chloro-l '//,3//-spiro[l-benzofuran-2,4'-piperidin]-ryl)-2-hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride) (100 mg, 0.213 mmol) and Ar,A^-carbonyldiimidazole (41.5 mg, 0.255 mmol) in DMF (2.5 mL) was stirred at room temperature for 50 min, morpholin-2-ylmethyl trifluoroacetate (trifluoroacetic acid salt) (347 mg, 1.06 mmol) in DMF (I mL) was added followed by Et3N (0.3 mL) and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was partitioned between ethyl acetate and HzO. The organic layer was dried over NazSO^, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (58 mg). APCI-MS:ra/z531
Example 78
(3S)-l-(2-{[(2S)-3-(5-F]uoro-l'//,3//-sp[ro{l-benzofuran-2,4'-piperidinl-r-yO'2-
hydroxypropyl]oxy}-4-methylbenzoyl)pyrrolidin-3-ol
A mixture of 2-{[(2S)-3-(5-fluoro-r^,3//r-spiro[l-benzofuran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}-4-methylbenzoic acid (hydrochloride) (45 mg, 0.099 mmol) and NJ/-carbonyldiimidazole (20 mg, 0.123 mmol) in DMF (2 mL) was stirred at room temperature for 50 min, (3S)-pyrrolidin-3-ol (43 mg, 0.495 mmol) in DMF (I mL) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and HaO. The organic layer was dried over Na^SO-t, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NtLjOH) to give the titled compound (35 mg). 'H-NMR(CD3OD, 400 MHz): 5 7.14 (dd,J= 1.0, 7.6 Hz, 1H); 6.94-6.84 (m, 3H); 6.77 (m, 1H); 6.62 (dd, J = 4.2, 8.8 Hz, 1H); 4.48 (m, 0.5H); 4.35 (m, 0.5H); 4.16-3.96 (m, 3H); 3.73-3.43 (m, 3H); 3.38-3.18 (m, IH); 3.00 (s, 2H); 2.76-2.52 (m, 6H); 2.35 (s, 3H); 2.12-1.77 (m, 6H). APCI-MS:m/z485(MH+).
Example 79
2-{((2S)-3-(5-Chloro-l'//,3Jy-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-hydroxypropyl]oxy}-W-{[(4R)-2,5-dioxoimidazoUdin-4-yl]methyl}-4-hydroxybenzamide
Step I
2-{{(2S)-3-(5-Chloro-l1/f,3^-spiro[l-benzofuran-2,4'-piperidinl-l'-yl)-2-hydroxypropyl]oxy}-Ar-{l(4R)-2,5-dioxoimidazolidin-4-yI]methyl}-4-[(4-methoxybenzyl]oxy]benzamide
A mixture of 2-{[(2S)-3-(5-chloro-rj/13//-spiro[l-benzofuran-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (125 mg, 0.211 mmol) and ./vyv-carbonyldiimidazole (43 mg, 0.264 mmol) in DMF (3 mL) was stirred at room temperature for 40 min. Then, (5R)-5-(aminomethyl)imidazolidine-2,4-dione
(hydrochloride) (150 rag, 0.906 mmol) was added followed by Et3N (0.54 mL (3.62 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NfyOH) to give the subtitled compound (30
mg)-APCI-MS:m/z665(MH+).
Step II
hydroxypropyl]oxy}-JV-{[(4R)-2,5-dioxoimidazoIidin-4-yIJmethyl}-4-hydroxybenzamide
2-{[(2S)-3-(5-Chloro-r//;3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-A/-{[(4R)-2,5-dioxoimidazolidin-4-yl]methyl}-4-[(4-methoxybenzyl]oxy]benzamide (28 mg, 0.042 mmol) was treated with 10% CFjCChH in CHzCfo (3 mL) at room temperature for 25 min. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-5% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (9 mg). 'H-NMR (CD3OD, 400 MHz): S 7.83 (d, J= 8.6 Hz, IH); 7.14 (s, IH); 7.04 (dd, y= 1.9, 8.3 Hz, IH); 6.65 (d, J= 8.5 Hz, IH); 6.53 (s, IH); 6.48 (m, IH); 4.37-4.17 (m, 3H); 4.07 (m, IH); 3.90-3.64 (m, 2H); 3.03 (s, 2H); 2.85-2.59 (m, 6H); 2.02-1.82 (m, 4H). APC1-MS: m/z 545 (MH+).
Example 80
l-(2-{[(2S)-3-(5-Chloro-l'^,3/ir-spiro[l-benzofuran-2,4'-piperidinI-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyI)-3-(trifluoromethyl)pyrrolidin-3-oI
Stepl /er/-Butyl3-hydroxy-3-(trifluoromethyl)pyrrolidine-l-carboxyJate
tert-Butyl 3-oxopyirolidine-l-carboxylate (926 mg, 5.0 mmol) was dissolved in THF (10 mL) and the solution was cooled to 0 °C, trimethyl (trifluoromethyl)silane (0.872 mL) and tetrabutylammonium fluoride (TBAF) (176 mg, 0.557 mmol) were added. The ice-bath was removed and the reaction mixture was stirred at room temperature overnight. Saturated aqueous NHoCl solution (8 mL) was added and stirring was continued. After 15 rain TBAF (2.36 g TBAF in 7.5 mL THF) was added and the reaction mixture was stirred at room temperature for Ih. The reaction mixture was extracted with ethyl acetate, washed with fyO, dried overNa2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum spirit) to give the subtitled compound (800 mg).
'H-NMR (CDC13, 400 MHz): 8 3.78-3.38 (m, 4H); 2.25 (m, IH); 2.00 (m, IH); 1.40 (s, 9H).
Step II 3-(Trifluoromethyl)pyrrolidin-3-ol(trifluoroacetate)
/er/-Butyl 3-hydroxy-3-(trifluoromethyl)pyrrolidine-l-carboxylate (310 mg, 1.21 mmol)
was treated with 20% CFsCOjH in C^Cla for 4h at room temperature. The volatiles were
removed in vacuo to give the subtitled compound (330 mg).
'H-NMR (CD3OD, 400 MH2): 8 3.72-3.59 (m, 4H); 2.38 (m, IH); 2.22 (m, IH).
APCI-MS:m/zl56(MH*).
Step III
l-{2-{[(2S)-3-(5-Chloro-lWs3^-spiro[l-benzofuran-2,4'-PiPeridin]-l'-yl)-2-hydroxypropyI]oxy}-4-((4-methoxybenzyl)oxyJbenzoyl}-3-(trifluoromethyl)pyrrolidin-3-ol
A mixture of 2-{[(2S)-3-(5-chloro-l'//)3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (150 mg, 0.254 mmol) and A^/V-carbonyldumidazole (51.5 mg, 0.317 mmol) in DMF (3 mL) was stirred at room temperature for 40 min. Then (3-(trifluoromethyl)pyrrolidin-3-ol (trifluoroacetate) (326 mg, 1.21 mmol) was added followed by Et3N (0.337 mL. 2.42 mmol) and the reaction
mixture was stirred at room temperature for 20 h. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was dried over Na2S04) filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2.0% methanol in dichloromethane, 0.2% NFLtOH) to give the subtitled compound (83 mg). APCI-MS: m/z 691 (MH*).
Step IV
l-(2-{[(2S)-3-(5-Chloro-r//,3//r-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyIJoxy}-4-hydroxybenzoyl)-3-(trifluoromethyl)pyrroIidin-3-ol
l-{2-{[(2S)-3-(5-Ghloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-3-(trifluoromethyl)pyrrolidin-3-ol (83 mg, 0.12 mmol) was treated with 10% CF3CO2H in CH2C12 (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% NH4OH) to give the titled compound (15 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.16-7.09 (m, 2H); 7.05 (ra, IH); 6.66 (d, J = 8.5 Hz, IH); 6.50 (s, IH); 6.46 (d,/= 8.3 Hz, IH); 4.12 (m, IH); 4.00 (m, 2H); 3.89-3.40 (m, 4H); 3.02 (s, 2H); 2.87-2.60 (m, 6H); 2.35-1.80 (m, 6H). APCI-MS: m/z 571 (MH+).
Example 81
3-{[(2S)-3-(5-Chloro-l'//,3/f-spiro(l-benzofuran-2,4'-piperidinJ-l'-yl>2-hydroxypropyl]oxyH-{[3-(trifluoromethyl)pyrrolidin-l-ylJcarbonyl} phenol
Step I /grt-Buryl3-(trifluoromethyl)pyrrolidine-l-carboxylate
To a solution of rert-butyl3-hydroxy-3-(trifluoromethyl)pyrrolidine-l-carboxylate (468 mg, 1.83 mmol) in pyridine (10 mL) was added SOClz (1.71 mL) and the reaction mixture was stirred at reflux temperature under nitrogen for 25 min, cooled to room temperature, H20 (20 mL) was added, extracted with ethyl acetate. The combined organic layer was
washed with dilute aqueous HCI, saturated aqueous NaHC03 and HzO successively. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was dissolved in ethanol (10 mL), Pd/C (10%) (300 mg) was added and it was hydrogeneted at room temperature over the weekend. The catalyst was removed by filtration. The filtrate was concentrated in vacuo to give the subtitled compound (100 mg). APCI-MS: m/z 140 (MH*-Boc).
Step H 3-(Trifluoromethyl)pyrrolidine(trifluoroacetate)
/erf-Butyl 3-(trifluoromethyl)pyrrolidine-l-carboxyIate (100 mg, 0.42 mmol) was treated with 20% CF3C02H in Ct^C^ at room temperature overnight. The volatiles were removed in vacuo to give the subtitled compound (106 mg). APCI-MS: m/z 140 (MH*).
Step III
(2S)-l-(5-Chloro-l'^,3/T-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-3-(5-I(4-methoxyben2yI)oxy]-2-{(3^trifluoromethyl)pyrrolidin-I~yl]carbonyI} phenoxy)propan-2-ol
A mixture of 2-{[(2S)-3-(5-chloro-l '/f,3//-spiro[l-benzofuran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (177 mg, 0.3 mmol) and yV^V-carbonyldiimidazole (61 mg, 0.375 mmol) in DMF (3 mL) was stirred at room temperature for 45 min, 3-(trifluoromethyl) pyrrolidine (trifluoroacetate) (106 mg, 0.42 mmol) in DMF (1 mL) was added followed by Et3N (0.17 mL, 1.2 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H20. The organic layer was dried over Na2SC>4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.2% NHtOH) to give the subtitled compound (89 mg). APCI-MS: m/z 675 (MH+).
Step IV
3-{[(2S)-3-(S-Chloro-l'//,3//-spiro[l-benzofuran-2,4'-pipendin)-l'-yl)-2-hydroxypropyljoxy}-4-{[3-(trifluoromethyl)pyrrolidin-l-yl]carbonyl} phenol
[2S)- 1 -(5-Chloro-l '#,3//-spiro[ I -benzofuran-2,4 '-piperidin]- 1 '-yl)-3-(5-[(4-nethoxybenzyl)oxy]-2-{[3-(trifluoromethyl)pyiTolidin-l-yl]carbonyl} phenoxy) propan-2-3! (88 rag, 0.13 mmol) was treated with 10% CF3C02H in CH2C12 (3 mL) for 25 min at
room temperature. The volatiles were removed in vacuo and the residue was. purified by
silica gel flash chromatography (0-3% methanol in dichloromethane, 0.2% NtiUOH) to
give the titled compound (22 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.14 (s, 1H); 7.08 (dd, J= 4.3, 8.3 Hz, 1H); 7.05 (m, 1H);
6.66 (d, /= 8.5 Hz, 1H); 6.51 (m, 1H); 6.46 (m, 1H); 4.15-3.42 (m, 7H); 3.18 (m, 1H);
3.02 (s, 2H); 2.78-2.52 (m, 6H); 2.34-1.80 (m, 6H).
APCI-MS: m/z 555 (MH+).
Example 82
yV-[2-(Acctylamino)ethyl]-2-{[(2S)-3-(5-chloro-l'JHrJ3//-spiroIl-benzofuran-2,4>-
piperidinJ-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide
Step I
piperidinJ-lJ-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl) oxy] benzamide A mixture of 2-{[(2S)-3-(5-chIoro-r//,3//'-spiro[l-benzoruran-2,41-piperidin]-r-yl)-2-hydroxypropylJoxy}-4-[(4-methoxybenzyl]benzoic acid (hydrochloride) (100 mg, 0.169 mmol) and A^-carbonyldiimidazole 834 mg, 0.2 1 1 mmol) in DMF (3 mL) was stirred at room temperature for 45 min, /V-(2-aminoethyl) acetamide (86 mg, 0.845 mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and H2O. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanot in dichloromethane, 0.2% NH4OH) to give the subtitled compound (77 mg).
'H-NMR (CDC13,400 MHz): 5 8.38 (t, y= 5.6 Hz, IH); 8.10 (d, y = 8.8 Hz, IH); 7.36 (d, J = 8.6 Hz, 2H); 7.13 (m, 2H); 7.07 (dd, J= 2.1, 8.4 Hz, IH); 6.94 (d,y- 8.6 Hz, 2H); 6.73-6.65 (m, 3H); 6.57 (d,y= 2.2 Hz, IH); 5.02 (s, 2H); 4.34 (m, IH); 4.22 (dd,y= 3.0, 9.7 Hz, IH); 4.00 (dd, J = 6.3, 9.7 Hz, IH); 3.83 (s, 3H); 3.65 (m, 2H); 3.48 (m, 2H); 3.06-2.67 (ra, 8H); 2.08 (m, 4H); 1.97 (s, 3H). APCI-MS: ra/z 638 (MH+).
Step II
Ar-[2-(Acetylaraino)ethyl]-2-{[(2S)-3-(5-chloro-l'//,3^r-spiro[l-bcnzofuran-2,4'-
piperidinl-l'-yI)-2-hydroxypropyIJoxy}-4-hydroxybenzamide
A42-(Acetylamino)ethyl]-2- {[(2S)-3-(5-chlpro-r/f,3 #-spiro[ 1 -benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl) oxy] benzarnide (72 mg, 0.112 mmol) was treated with 10% CF3CO2H in CH2C12 (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-3.5% methanol in dichloromethane, 0.2% NH^OH) to give the titled compound (32 mg).
'H-NMR (CD3OD, 400 MHZ): 5 7.82 (d, y= 8.7 HZ, IH); 7.14 (s, IH); 7.04 (dd, y= 2.2,
8.5 Hz, IH); 6.66 (d,y= 8.5 Hz, IH); 6.53 (d,y= 2.1 Hz, IH); 6.49 (dd, J= 2.1, 8.7 Hz, IH); 4.23 (m, 2H); 4.07 (dd, J = 7.0,10.7 Hz, IH); 3.51 (t, J = 6.1 Hz, 2H); 3.39 (t, J = 6.1 Hz, 2H); 3.02 (s, 2H); 2.74 (br. s, 4H); 2.64 (d, J = 6.0 Hz, 2H); 1.99-1.82 (m, 7H). APCI-MS: m/z 518 (MH+).
Example 83
N-(5-chloro-2-{[(25)-3-(5-chloro-rjy,3£r-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-methoxyphenyl)acetamide
Step I: N-(5-chloro-2-hydroxy-4-methoxyphenyl)acetamide
This compound was prepared as described by Kun Hoe Chung; Kyong Mahn Kim; Jae NyoungKim and Eung Kul Ryu, Synth.Comm., 1991, 21 (18&19), 1917-1922, usingN-(2-hydroxy-4-methoxyphenyl)acetamide as starting material. APCI-MS: m/z 216 [MH+]
Step II:
N-{5-chloro-4-methoxy-2-[(2S)-oxiran-2-ylmethoxylphenyI}acetamide To a slurry of N-(5-chloro-2-hydroxy-4-methoxyphenyl)acetamide (227 mg, 1.05 mmol) and caesium carbonate (376 rag, 1.25 mmol) in l-methyl-2-pyrrolidinone (2 mL) was added (2S)-oxirane-2-ylmethyl 3-nitrobenzenesulfonate (301 mg, 1.16 mmol) dissolved 2-methyl-2-pyrrolidine (2 mL) drop wise. The resulting brown slurry was stirred over night, at room temperature. The mixture was partitioned between water and ethyl acetate. The organic phase was dried over magnesium sulphate, filtered and concentrated to yield crude 280 mg (98%) of the titled compound. APCI-MS: m/z 272 [MH+]
Step III:
N-(S-chloro-2-{[(25)-3-(S-chloro-l'/r^/r-apiro(l-benzofuran-2,4'-piperidIn1-l'-yl>2-
hydroxypropyl]oxy}-4-methoxyphenyl)acetamide
A solution of N-{5-chloro-4-methoxy-2-[(2,S)-oxiran-2-ylmethoxy]phenyl}acetamide (101 mg, 0.37 mmol) and 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidine] (83.5 mg, 0.37 mmol) in ethanol (10 mL) was refluxed over night, and then concentrated. The crude material was purified on C18 ("Kromasil" column, 10 um, acetonitrile/water 25/75 to 50/50 over 30 min with 0.1% trifluoroacetic acid). Pure fractions were pooled and freeze-dried to give 116 mg (51%) of the title compound as the trifluoroacetate salt. 'H-NMR (400 MHz, (CD3)2CO) 5: 8.36 (1H, s); 7.24 (1H, bs); 7.14 (1H, dd); 6.87 (1H, s); 6.76 (IH, d); 4.59-4.52 (1H, m); 4.25-4.15 (2H, m); 3.89-3.40 (6H, m); 3.88 (3H, s); 3.20 (2H, bs); 2.45-2.19 (4H, m); 2.12 (3H, s) APCI-MS: m/z 495 [MH+]
Example 84
(5S)-N-(5-chloro-2-{[(ZS>3-(5-chioro-l '#,3.ff-spiro{l-benzofuran-2,4 '-piperidin]-! '-
yl)-2-hydroxypropyl]oxy}phenyl)-3-hydroxypyrroHdine-l-carboxamide
Step I: (S^-^S-chloro^-hydroxyphenyO-S-hydroxypyrrolidine-l-carboxaraide
*
5-chloro-l,3-benzoxazole-2(3#)-one (577 mg, 0.34 mmol) and (3S)-pyrrolidin-3-ol (0.6 mL, 0.74 mmol) was heated to 90°C for 2 hrs. The resulting red solidified oil was purified on silica (dichloromethane/methanol) to give the titled compound (768 mg, 88%). APCI-MS: m/z 257 [MH+]
Step II:
(35)-yV-{5-chIoro-2-I(25)-oxiran-2-ylmethoxyJphenyl}-3-hydroxypyrrolidine-l-
carboxamide
A solution of (3S)-jV-(5-chloro-2-hydroxyphenyl)-3-hydroxypyrrolidine-l -carboxamide (232 mg, 0.90 mmol), (2S)-oxiran-2-ylmethyI 3-nitrobenzenesuIfonate (234 rag, 0.90 mmol) and caesium carbonate (369 mg, 1.13 mmol) in dimethylformamide (9 mL) was stirred at room temperature, over night. The mixture was partitioned between water and ethyl acetate, and the organic phase was washed twice with water and once with brine, and finally concentrated. The crude material was purified by HPLC on CIS ("Kromasil" column, 10 um, acetonitrile/water 35/65 to 85/15 over 30 min), yielding the titled compound (82 mg, 29%). APCI-MS: m/z 3 13 [MH+]
yl)-2-hydroxypropyI]oxy}phenyl)-3-hydroxypyrroIidine-l-carboxamide
A solution of (3S)-N- {5-chloro-2-[(2.S)-oxiran-2-ylmethoxy]phenyl} -3-hydroxypyrrolidine-1 -carboxamide (63.2 mg, 0.20 mmol) and 5-chloro-3H-spiro[l-benzofuran-2,4'-piperidine] (45.4 mg, 0.20 mmol) in isopropanol (8 mL) was stirred at 80°C over night. The concentrated crude material was purified by HPLC on CIS
("Kromasil" column, 10 urn, acetonitrile/water 50/50 to 85/15 over 45 min, with 0.1% trifluoroacetic acid). Pure fractions were pooled and freeze-dried to give the title compound (83 mg, 65%) as the trifluoroacetate salt.
'H-NMR (400 MHz, DMSO-40 5: 9.69 (1H, bs); 9.60 (1H, bs); 8.00 (1H, d); 7.39 (1H, bs); 7.29 (1H, bs); 7.16 (1H, d); 7.06 (IH, d); 7.00 (1H, dd); 6.78 (IH, d);4.41-4.34 (1H, m); 4.32 (IH, bs); 4.09-3.97 (2H, m); 3.62-3.40 (7H, m); 3.36-3.16 (4H, m); 3.10 (2H, s); 2.22-2.03 (3H, m); 2.03-1.90 (IH, m); 1.88-1.79 (IH, m) APCI-MS: m/z 536 [MH+]
Example 85
(35)-^-(2-{[(2tS')-3-(5-chIoro-rf,3-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-2-
hydroxypropyIloxy}phenyl)-3-hydroxypyrrolidine-l-carboxamide
The title compound was prepared using l,3-benzoxazo!e-2(3//)-one by methods analogous
to the methods described in Example 84.
'H-NMR (400 MHz, DMSO-40 S: 9.70 (IH, bs); 9.62 (IH, bs); 7.82 (IH, d); 7.36 (IH, s);
7.29 (IH, bs); 7.00 (2H, dt); 6.91 (IH, t); 6.80 (IH, d); 4.41-4.34 (IH, m); 4.32 (IH, bs);
4.09-3.97 (2H, m); 3.62-3.41 (7H, m); 3.35-3.15 (4H, m); 3.10 (2H, s); 2.22-2.03 (3H, m);
2.03-1.90 (IH, m); 1.88-1.79 (IH, m)
APCI-MS: m/z 502 [MH+]
Example 86
N-(2-{[(2S)-3-(5-chloro-l 'H,3H-spiro(l-benzofuran-2,4 '-piperidinj-l '-y!)-2-
hydroxypropyl]oxy}phenyI)-4-hydroxypiperidine-l-carboxamide
The title compound was prepared using l,3-benzoxazole-2(3#)-one and 4-hydroxypiperidine by methods analogous to the methods described in Example 84, 'H-NMR (400 MHz, DMSO-^j) 5: 9.67 (IH, bs); 9.60 (IH, bs); 7.81 (IH, s); 7.63 (IH, d); 7.30 (IH, d); 7.15 (IH, d); 7.06-6.98 (2H, m); 6.91 (IH, dt); 6.80 (IH, d); 4.41-4.28 (2H,
m); 4.08-3.95 (2H, ra); 3.84-3.75 (2H, m); 3.69 (1H, sept); 3.63-3.41 (3H, m); 3.32-3.04 (4H, m); 3.10 (2H, s); 2.22-1.98 (4H, m); 1.80-1.71 (2H, m); 1.41-1.29 (2H, m) APCI-MS:m/z5l6[MH+]
Example 87
Ar-(2-{[(25)-3-(S-Chloro-l'//,3fl-spiro[l-benzofuran-2,4'-piperidinJ-l(-yl)-2-hydroxypropyl]oxy}phenyl)urea trifluoroacetate (salt)
Step I:
(25)-3-(2-Aminophenoxy)-l-(5-chloro-l'//,3/f-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)propan-2-ol bis(hydrochloride) (salt)
AH2- {[(2,S>3-(5-Chloro-1 '#,3//-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-
hydroxypropyl]oxy}phenyl)acetamide (117 rag, 0.27 mmol) was stirred in 1M
hydrochloric acid (2 mL) at 100°C for 2h. The solution was diluted with water and freeze
dried to give the subtitled compound as a white amorphous solid (112 mg).
'H-NMR (MeOH-,, 400 MHz): 5 7.49-7.44 (m, 1H); 7.40 (d, J = 8.0 Hz, 1H);
7.25 (d, J= 8.4 Hz, 1H); 7.21 (bs, 1H); 7.15-7.09 (m, 2H); 6.75 (d, J= 8.4 Hz, 1H); 4.64-
4.52 (m, 1H); 4.21 (d, J = 4.8 Hz, 2H); 3.84-3.65 (m, 2H); 3.49 (dd, /= 10.3,13.1 Hz,
2H); 3.62-3.38 (ra, 2H); 3.16 (bs, 2H); 2.33-2.15 (m, 4H)
APCI-MS:m/z389(MtT)
Step H:
A^-(2-{[(2^-3-(5-Chloro-lt/f,3-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}phenyl)urea trifluoroacetate (salt)
To(21S)-3-(2-aminophenoxy)-l-(5-chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-ll-yI)propan-2-ol bis(hydrochloride) (46.2 mg, 0.1 mmol) dissolved in acetic acid / water (1 / 1 mL) potassium cyanate (16.2 mg, 0.2 mmol) dissolved in water (0.5 mL) was added. The mixture was stirred at ambient temperature overnight. After purification by preparative HPLC using acetonitrile/water containing 0.1% TFA as mobile phase and freeze drying the titled compound was obtained as a white amorphous solid (43 mg, 78%).
8.34 (m, 1H); 7.83 (bs, 1H); 7.25 & 7.21 (s, 1H); 7.14(d,y=8.4Hz, 1H); 6.93-6.81 (m, 3H); 6.77 (d, J = 8.4 Hz, IH); 5.95 (bs, 2H);4.60-4.52 (m, lH);4.18(d,y=9.6Hz, 1 H); 4.07-4.00 (m, IH); 3.92-3.71 (m,3H); 3.70-3.40 (ra, 3H); 3.30 & 3.22 (s, 2H); 2.44-2.19 (m, 4H) APCI-MS: m/z 432 (MH+)
Example 88
Ar-(2-{[(25)-3-(5-chloro-l1JT,3^-spiro[l-benzofuran-2,4l-piperidin]-r-yl)-2-hydroxypropylJoxy}-4-hydroxyphenyl)urea trifluoroacetate (salt)
Step I:
4-Amino-3-{[(2,S)-3-(5-chloro-l',3/f-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}phenol bis(trifluoroacetate) (salt)
The compound was prepared analogous to the compound Example 87 Step I from ^-(2-{[(25)-3-(5-ChIoro-l'//)3//-spiro[l-benzofuran-2J4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)acetamide (135 mg, 0.3 mmol) and 1M hydrochloric acid (3 mL). After purification by preparative HPLC using acetonitrile/ water containing 0. 1% TFA as mobile phase and freeze drying the subtitled compound was obtained as a white amorphous solid (150 mg).
'H-NMR (MeOH-^, 400 MHz): 8 7.21 (bs, IH); 7.18.(d, J= 8.8 Hz, IH); 7.1 1 (dd, J= 2.0, 8.4 Hz, IH); 6.74 (d, / = 8.4 Hz, IH); 6.62 (d, J = 2.4 Hz, IH); 6.49 (dd, J= 2.4, 8.8 Hz, IH); 4.58-4.49 (m, IH); 4.13 (d, 7=4.8 Hz, 2H); 3.8-3.6 (m, 2H); 3.6-3.4 (m, 2H); 3.48 (d, J = 13.2 Hz, IH); 3.45 (d, J = 13.2 Hz, IH); 3.16 (s, 2H); 2.31-2.17 (m, 4H) APCI-MS: m/z 405 (MH+)
Step II:
hydroxypropyl]oxy)-4-hydroxyphenyI)urea trifluoroacetate (salt)
The compound was prepared analogous to the compound Example 87 Step II from
4-amino-3- {[(2,S>3-(5-chloro-1 'H,3H-spiio[ I -benzofuran-2,4'-piperidinj-1 '-yl)-2-
hydroxypropyljoxy) phenol bis(hydrochloride) (63.3 mg, O.I mmol) and potassium cyanat
(16.2 mg, 0.2 mmol). After purification and freeze drying the titled compound was
obtained as a white amorphous solid (51 mg, 90%).
'H-NMR (400 MHz, acetone-d*): 5 8.01 (d,/= 8.8 Hz, 1H); 7.60 (s, 1H);
7.25 & 7.21 (s, 1H); 7.14 (dd, J = 2.2, 8.4 Hz, 1H); 6.77 (d, / = 8.4 Hz, IH);
6.45 (d, J = 2.5 Hz, IH); 6.37 (dd, J = 2.5, 8.8 Hz, IH); 4.57-4.49 (m, IH);
4.12 (dd,y= 9.7, 2.6 Hz, IH); 4.01 (dd,y = 9.7, 5.1 Hz, IH); 3.95-3.65 (m, 3H);
3.62-3.40 (m, 3H); 3.33 & 3.21 (s, 3H); 2.44-2.20 (m, 4H)
APCI-MS:m/z448(MH+)
Example 89
-(2-{[(25)-3-(5-Chloro-l'/r,3-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-fluorophenyl)urea trifluoroacetate (salt)
Step I:
(2,S)-l-(2-Amino-5-fluorophenoxy)-3-(5-chloro-l'/^3J:f-spiro[l-benzofuran-2,4'-piperidin]-r-yI)propan-2-ol bis(hydrochloride) (salt)
The subtitled compound was preparad analogous to the compound Example 87 Step I from
A^-(2-{[(2^-3-(5-chloro-ll//,3//-spiro[l-benzofuran-2,4p-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-fluorophenyl)acetamide (150 mg, 0.27 mmol) and 1M hydrochloric
acid (2 mL).
APCI-MS: m/z 407 (MH+)
Step II:
A^(2-{[(25)-3-(5-Chloro-r/r,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-fluorophenyl)urea trifluoroacetate (salt)
The reaction solution obtained from Step I was buffered with ammonia acetate (200 mg) dissolved in acetic acid (1 mL). Potassium cyanate (44 mg, 0.54 mmol) dissolved in water [0.5 mL) was added and the mixture was stirred at ambient temperature over night. After
purification of the reaction mixture by preparative HPLC using acetonitrile/water containing 0.1% TFA as mobile phase and freeze drying the titled compound was obtained as a white amorphous solid (105 mg).
'H-NMR (MeOH- Example 90
M{[(2-{[(21y)-3-(5-Chloro-llH>3/f-splro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)aminojcarbonyl}methancsulfonamide trifluoroacetate (salt)
To a solution of 4-nitrophenyl chloroformate (50 mg, 0.25 mmol) in DCM (3 mL) DMAP (30 mg, 0.25 mmol) was added. After stirring the mixture for 5 min methanesulfonamide (24 mg, 0.25 mmol) and TEA (25 uL, 0.25 mmol) was added and the stirring continued for Ih. 4-Amino-3-{[(2ly)-3-(5-chloro-l'//,3//'-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenol (78 mg, 0.12 mmol) dissolved in DCM (2 mL) and TEA (75uL, 0.75 mmol) was added and the stirring continued at ambient temperature. The reaction was complete after 2h as monitored by LCMS. After evaporation of the solvent the crude product was purified by preparative HPLC using acetonitrile/water containing 0.1% TFA as mobile phase. The titled compound was obtained as a white amorphous solid (7 mg) after freeze drying.
'H-NMR (Acetone-rfd, 300 MHz): 5 8.32 (bs, IH); 7.91 (d,7= 8.7 Hz, IH); 7.24 (bs, IH); 7.14 (dd,7= 8.4,2.2 Hz, IH); 6.78 (d,7=8.6 Hz, IH); 6.51 (d,7 = 2.4 Hz, IH); 6.43 (dd, 7= 8.6, 2.6 Hz, IH); 4.61-4.52 (m, IH); 4.11 (dd, 7= 9.5, 3.8 Hz, IH); 3.98 (dd, 7= 9.5, 6.4 Hz, IH); 4.01-3.78 (m, 2H); 3.65 (d, 7= 9.4 Hz, IH); 3.74-3.42 (m, 4H); 3.27 (s, 3H); 3.30-3.15 (m, 2H); 2.43-2.20 (m, 4H) APCI-MS:m/z526(MH*)
Example 91
(4ly)-2-(2-{[(25)-3-(5-Chloro-l'^,3//-spiro{l-benzofuran-2,4.'.piperidinJ-r-yl)-2-hydroxypropyI]oxy}-4-hydroxybenzoyl)isoxazoIidin-4-ol trifluoroacetate (salt)
Step I:
(^-Methyl 2-[4-hydroxylsoxazoIidin-2-yl]carbonylbenzoate
Triethylamine (0.28 ml) was added to a solution of /V-hydroxyphthalimide (5.00 g, 30 mmol) and (/?)-(-)-epichlorohydrin (2.40 ml, 30.6 mmol) in anhydrous dioxane (10ml) under nitrogen. The mixture was stirred at 50°C for 48h, further (2R}-2-(chloromethyl)oxirane (0.24 ml) and triethylamine (0.28ml) were added and stirring continued at 50°C for 24 h. Methanol (10ml) and further triethylamine (4.27 ml) were added and stirring continued at 50°C for 2 h. The mixture was evaporated under reduced pressure, the residue dissolved in saturated aqueous sodium bicarbonate solution (100 ml) and extracted with ethyl acetate (6 x 100 ml). Combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was recrystallised from ethyl acetate to give the sub-title compound (3.4 g). 'H-NMR (CDCI3; 400 MHz): 5 3.66 (1H, d, br), 3.79 (1H, d, br), 3.89-3.99 (1H, m), 3.99-4.10 (1H, m), 4.74-4.81 (1H, m), 7.46 (1H, d), 7.49 (1H, t),, 7.62 (1H, t), 7.99 (IH, d) MS(ESI): m/2 252 [M+H]*
Step II:
(iS>4-Isoxazolidinol hydrochloride
Hydrochloric acid (4M, 15ml) was added to (S)-Methy\ 2-[4-hydroxyisoxazoIidin-2-yljcarbonylbenzoate (1.87 g, 7.4 mmol) and the solution heated under reflux for 3 h. The mixture was cooled to room temperature, filtered and evaporated under reduced pressure. The residue was recrystallised from propan-2-ol to give the sub-title compound as white needles (0.78 g).
'H-NMR (jDMSO-df, 400 MHz): 6 335 (IH, d), 3.47 (IH, dd), 4.03 (IH, dd), 4.07 (IH, d), 4.78-4.8 l(!H,m).
Step HI: (45)-2'{2-{[{25)-3-(5-Chloro-l'-spiro[l-benzofuran-2,4'-pipcridinl-ll-yl)-2-
hydroxypropylJoxy}-4-[(4-methoxybenzyl)oxylbenzoyl}isoxazoIidin-4-ol
After stirring PS-carbodiimide (1.28 mmol/g) (312 mg, 0.4 mmol) in DCM (5 mL) for 15 min2-{[(250-3-(5-chloro-r//)3//-spiro[l-benzorAiran-2)4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid (118 mg, 0.2 mmol) dissolved in DCM (2 mL) was added and stirring continued for 30 min. A solution of (5)-4-isoxazolidinol hydrochloride (25 mg, 0.2 mmol) and TEA (70 uL, 0.5 mmol) in DCM (I mL) was added and stirring continued at ambient temperature over night. The reaction was complete as monitored by LCMS. All solids were filtered off and the filtrate evaporated in vacuo. The residue was partitioned between ethylacetate and water, the organic phase washed with water, dried and evaporated in vacuo leaving an oil (93 mg). APCI-MS: m/z 625 (MH*)
Step IV:
(4ly)-2-(2-{I(25)-3-(5-Chloro-l'^,3J^-spiro[l-benzofuran-2,4l-piperidin]-lp-yl)-2-hydroxypropyljoxy}-4-hydroxybenzoyl)isoxazolidin-4-ol trifluoroacctate (salt)
(45)-2- {2-{[(2S)-3-(5-Chloro- l'H,3H-splro[ l-benzofuran-2,4'-piperidin]- l'-yl>2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}isoxazolidin-4-ol (93 mg, 0.15 mmot) was dissolved in a mixture of TFA/DCM 1/9(10 mL) and the solution stirred at ambient temperature for 30 min. After evaporation of the solvent in vacuo the residue was purified by preparative HPLC using acetonitrile / water containing 0.1% TFA as mobile phase. The titled compound was obtained as a white amorphous solid (18 mg) after freeze drying.
'H-NMR (Acetone- 3.70 (d, J= 11.7 Hz, 2H); 3.56-3.40 (bs, 2H); 3.41 (dd, J = 13.5, 9.2 Hz, 1H); 3.17 (bs, 2H); 2.48-2.14 (m,4H) APCI-MS: mJz 505 (MH4)
Example 92
(^^^-{((a^O^S-Chloro-l'^ajy-spiroll-benzofuran^^'-piperidinJ-l'-yl)^-hydroxypropyl]oxy}-4-hydroxybenzoyl)isoxazo!idin-4-oI trifluoroacetate (salt)
Step I:
(/?)-Mcthyl 2-[4-hydroxyisoxa2olidin-2-ylJcarbonylben2oate
Prepared from (2.S)-2-(chloromethyl)oxirane by the method of described in Example 91 Step I.
'H-NMR (CDC13; 400 MHz): 8 3.66 (1H, d, br), 3.79 (1H, d, br), 3.89-3.99 (1H, m), 3.99-4.10 (1H, m), 4.74-4.81 (1H, m), 7.46 (1H, d), 7.49 (1H, t), 7.62 (1H, t), 7.99 (1H, d). MS(ESI): m/z 252 [M+Hf
Step II:
(ft)~4-lsoxazolidinol hydrochloridc
Prepared from (/?)-Methyl 2-[4-hydroxyisoxazolidin-2-yl]carbonylbenzoate following the procedure of Example 91 Step II.
'H-NMR (CDCi3; 400 MHZ): 5 3.35 (m, d), 3.47 (m, dd), 4.03 (in, dd), 4.07 (in, d),
4.78-4.8 l(lH,m).
Step III:
(4^)-2-{2-{[(25)-3-(S-Chloro-lljy)3J5r-spiro(l-benzofuran-2,4t-piperidin]-r-yl>2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyI)oxy]benzoyl}isoxazolidin-4-ol
The subtitled compound was prepared analogous to the compound Example 91 Step III from2-{[(2lT)-3-(5-chloro-l'^3^'-spiro[l-benzofliran-2,41-piperidin]-l1-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid (118 mg, 0.2 mmol) and (fl)-4-isoxazolidinol hydrochloride (25 mg, 0.2 mmol).
APC1-MS: m/z 625 (MH)
Step IV:
(4^)-2-(2.{[(25)-3-(5-Chloro-l'^,3/f-spiro[l-bcnzofuran-2,4'-piperidin]-r-y])-2-hydroxypropyljoxyH-hydroxybenzoyl)isoxazolidin-4-ol trifluoroacetate (salt)
The titled compound was prepared analogous to the compound Example 91 Step IV from
(4/?)-2-{2-{[(25)-3-(5-Chloro-r//,3//-spiro[l-benzofuran-2,4'-pipendin]-l1-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}isoxazolidin-4-ol
and TFA/DCM 1/9. After purification and freeze drying the titled compound was obtained
as a white amorphous solid (26 mg).
'H-NMR (Acetone- 8.5, 2.4 Hz, IH); 6.78 (d, J = 8.5 Hz, IH); 6.61 (d, J= 2.0 Hz, IH); 6.50 (dd, J = 8.3,2.0
Hz, IH); 4.88-4.81 (m, IH); 4.60-4.48 (m, IH); 4.15 (dd,y = 9.5,4.5 Hz, IH); 4.02 (dd,/=
9.5, 6.3 Hz, IH); 3.97 (dd, /= 11.7, 5.9 Hz, IH); 3.94-3.87 (m, 2H); 3.86-3.72 (bs, 2H);
3.70 (d,7= 11.7 Hz, 2H); 3.56-3.40 (bs, 2H); 3.41 (dd, J= 13.5, 9.2 Hz, IH); 3.17 (bs,
2H); 2.48-2.14 (m,4H)
APCI-MS: m/z 505 (MH+)
Example 93
(45)-2-(2-{[(2iS)-3-(5-Chloro-lt//)3/f-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-methyHsoxazolidin-4-ol trifluoroacetate (salt)
Step I: 2-[[(25)-2-MethyloxiranyI]methoxyl-l/f-isoindole-l,3(2B)-dione
A mixture of N-hydroxypthalimide (5.3 g, 32.5 mmol), [(2lS)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate (5.9 g, 21.6 mmol) and triethylamine (10.6ml) in dichloromethane (15ml) was stirred under nitrogen at ambient temperature for 24 h. The reaction mixture was poured onto a silica column and eluted with dichloromethane to give the sub-title compound as a colourless solid (3.Ig).
'H-NMR (CDCb; 400 MHz): 5 1.63 (3H, s), 2.69 (1H, d), 2.76 (IH, d), 4.17 (1H, d), 4.21 (1H, d), 7.73-7.78 (2H, m), 7.82-7.87 (2H, m) MS (APCI) 234 [M+H]+
Step II: 2-{[(2J?)-3-Chloro-2-hydroxy-2-methylpropyl]oxy]-l^-isoindole-l,3(2/Jr)-dione
2-[[(25)-2-MethyIoxiranyl]methoxy]-l//-isoindole-l,3(2//)- 'H-NMR (CDC13; 400 MHz): 8 1.29(3H, S), 3.67 (1H, d), 3.76 (1H, d), 4.09 (1H, d), 4.15 (lH,d), 7.86 (4H,s), 5.24 (lH,s)
Step III:
2-[[(45)-4-Hydroxy-4-methyI-2-isoxazoIidinyIJcarbonylJ- benzole acid methyl ester
A solution of 2-[[(2J?)-3-Chloro-2-hydroxy-2-methylpropyl]oxy]- l//-isoindole-l,3(2//)-
i
dione (3.3 g, 12.2 mmol) in methanol (25 ml) was treated with triethylamine (3.4 ml) and heated under nitrogen at reflux for 1 h. The mixture was concentrated to dryness and purified by chromatography eluting with a gradient from dichloromethane to 5% methanol in dichloromethane. The chiral purity of the product was enhanced by recrystallising twice from acetonitrile to give the sub-title compound as a colourless solid (1.92 g). 1H-NMR (CDC13; 400 MHz): 5 1.52 (3H, s), 3.59 (IH, d), 3.81 (1H, d), 3.88 (1H, d), 4.04 (1H, s), 4.34 (IH, d), 3.92 (3H, s), 7.45 (IH, d), 7.49 (IH, t), 7.62 (IH, t), 8.00 (IH, d). HPLC: (9010THIP.M) 50mm chiracel AD column, ee >99%
Step IV: (45)-4-Methyl-4-isoxazoIidtnolhydrochIoride
A solution of 2-[[(4iS)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]- benzoic acid methyl ester (4.9 g, 19.5 mmol) in 2N hydrochloric acid (30 ml) was heated under nitrogen
at reflux for 4 h. After cooling the precipitate was removed by filtration and the liquors concentrated to dryness under vacuo. The residue was triturated with acetonitrile to give the sub-title compound as a white solid (1.79 g).
'H-NMR (CDC13; 400 MHz): 5 1.42 (3H, s), 3.29 (IH, d), 3.41 (IH, dD), 3.87 (IH, d), 4.05 (IH, dd)
Step V:
(45)-2-{2-{[(2lS)-3-(5-chloro-ll/f,3flr-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyI}-4-methyIisoxazolidin-4-ol
The subtitled compound was prepared analogous to the compound Example 91 Step III from2-{[(2lS)-3-(5-chloro-l'/f,3//'-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid (118 mg, 0.2 mmol) and (4.S1)-4-methyl-4-isoxazolidinol hydrochloride (28 mg, 0.2 mmol). APC1-MS: m/z 639 (MH+)
Step VI:
(45)-2-(2-{[(21S)-3-(5-Chloro-l'/f,3^-spiro[l-benzofuran-2,4'-piperidin]-lI-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-methylisoxazolidin-4-oltrifluoroacetate (salt)
The titled compound was prepared analogous to the compound Example 91 Step IV from (4lS)-2-{2-{[(21y)-3-(5-chloro-l'//,3^-spiro[l-benzofuran-2)41-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-4-raethylisoxazolidin-4-ol (crude product from (45)-2-{2-{[(24S)-3-(5-chloro-l'//,3Ar-spiro[l-benzofuran-2)4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-4-methylisoxazoIidin-4-ol and TFA/DCM 1/9. After purification and freeze drying the titled compound was obtained as a white amorphous solid (33 mg).
'H-NMR (Acetone-rftf, 300 MHz): 8 7.23 (bs, IH); 7.22 (d, J = 8.2 Hz, IH); 7.14 (dd, /-8.5, 2.4 Hz, IH); 6.78 (d, J= 8.5 Hz, IH); 6.61 (d, J = 2.0 Hz, IH); 6.50 (dd,./- 8.3,2.0 Hz, IH); 4.59-4.47 (m, IH); 4.15 (dd, 7=9.8, 5.1 Hz, IH); 4.06 (dd, J= 9.8, 5.6 Hz, IH); 3.92 (d,7= 8.3 Hz, IH); 3.86-3.74 (bs, 2H); 3.85 (d, 7= 11.2 Hz, IH); 3.77 (d, /= 8.3 Hz,
1H); 3.66 (d, J = 11.2 Hz, 1H); 3.65-3.56 (m, 2H); 3.50 (d, J = 9.0 Hz, 1H); 3.55-3.40 (m, 2H); 3.46 (d,/= 9.0 Hz, 1H); 3.16 (bs, 2H); 2.48-2.14 (m,4H); 1.48 (s, 3H) APCl-MS:m/z5I9(MH*)
Example 94
(4J?)-2-(2-{[(25)-3-(5-Chloro-l'flr,3/f-spiro[l-benzofuran-2,4'-piperidin]-lt-yI)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-methyIisoxazolidin-4-ol trifluoroacetate (salt)
Step I: 2-[[(2/?)-2-MethyIoxiranyl]methoxy]-lJyr-isoindole-l,3(2/0-dione
Prepared from N-hydroxyphthalimide and [(2^?)-2-methyloxiran-2-yl]methyI 3-
nitrobenzenesulfonate (Chen, J.; Shurn, W., Tetrahedron Letters, 1993, 34(48), 7663-6)
by the method of Example 93 Step I.
1H-NMR (CDC13; 400 MHz): 8 1.63 (3H, s), 2.69 (1H, d), 2.76 (1H, d), 4.17 (1H, d),
4.21 (1H, d), 7.73-7.78 (2H, m), 7.82-7.87 (2H, m)
MS (APCI) 234 [M+Hf
Step II: 2-[[(2^)-3-Chloro-2-hydroxy-2-methylpropyIJoxy]-l/r-isoindole-l,3(2fl)-dione
Prepared from 2-[[(2^)-2-Methyloxiranyl]methoxy]-l//-isoindoIe-l,3(2//)-dione by the method of Example 93 Step II.
'H-NMR (CDCh; 400 MHz): 5 1.29(3H, S), 3.67 (1H, d), 3.76 (1H, d), 4.09 (1H, d), 4.15 (1H, d), 7.86 (4H, s), 5.24 (IH.s)
Step III:
2-[[(4J?)-4-Hydroxy-4-methyI-2-isoxazolidinyl]carbonylJ- benzole acid methyl ester
Prepared from 2-[[(2/?)-3-Chloro-2-hydroxy-2-methylpropyl]oxy]- l//'-isoindole-l,3(2//)-dione by the method of Example 93 Step III.
'H-NMR (CDC13; 400 MHz): 5 1.52 (3H, s), 3.59 (1H, d), 3.81 (IH, d), 3.88 (1H, d), 4.04 (IH, s), 4.34 (IH, d), 3.92 (3H, s), 7.45 (IH, d), 7.49 (IH, t), 7.62 (IH, t), 8.00 (IH, d)
Step IV:
(4K)-4-Methyl-4-isoxazoIidinol hydrochloride
Prepared from 2-[[(4£)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]- benzole acid methyl ester by the method of Example 93 Step IV.
'H-NMR (CDC13; 400 MHz): 8 1.42 (3H, s), 3.29 (IH, d), 3.41 (IH, dD), 3.87 (IH, d), 4.05 (IH, dd)
Step V:
(4/?)-2-{2-{[(2lSr)-3-(5-chIoro-r/f)3JHr-spiro[l-benzofuran-2,4'-piperidin]-ll-yI)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-4-rnethylisoxazolidin-4-ol
The subtitled compound was prepared analogous to the compound Example 91 Step 111 from2-{[(2,S)-3-(5-chloro-l1//',3^-spiro[I-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid (118 mg, 0.2 mmol) and (47?)-4-methyl-4-isoxazolidinol hydrochloride (28 mg, 0.2 mmol). APCI-MS: m/z 639 (MH*)
Step VI:
(4JR)-2-(2-{l(25)-3-(5-Chloro-r7/,3/r-spiro(l-benzofuran-2,4'-piperidinJ-ll-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-methyHsoxazolidin-4-ol trifluoroacetate (salt)
The titled compound was prepared analogous to the compound Example 91 Step IV from (4R)-2- (2- {[(2S)-3-(5-chloro-1 '#;3//-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyljoxy} -4-[(4-methoxybenzyl)oxy]benzoyl} -4-methylisoxazolidin-4-ol and TFA/DCM 1/9. After purification and freeze drying the titled compound was obtained as a white amorphous solid (30 mg).
'H-NMR (Acetone-^, 300 MHz): 5 7.23 (bs, IH); 7.22 (d,7= 8.2 Hz, IH); 7.14 (dd, 7= 8.5, 2.4 Hz, IH); 6.78 (d, J = 8.5 Hz, IH); 6.61 (d, J= 2.0 Hz, IH); 6.50 (dd, J= 8.3, 2.0
Hz, 1H); 4.60-4.48 (m, IH); 4.15 (dd,/= 9.5,4.5 Hz, 1H); 4.03 (dd,y= 9.5, 6.3 Hz, 1H); 3.92 (d, y= 8.4 Hz, IH); 3.87-3.72 (bs, 2H); 3.82 (d, J = 10.9 Hz, IH); 3.75 (d, J= 8.4 Hz, 1H); 3.69 (d,y= 10.9 Hz, IH); 3.66 (bs, IH); 3.56-3.38 (m, 2H); 3.42 (dd,J= 8.8, 13.5 Hz, IH); 3.17 (bs, 2H); 2.48-2.14 (m, 4H); 1.48 (s, 3H) APCI-MS:m/z519(MH+)
Example 95
2-{[(26}-3-(S-chloro-l'/r,3flr-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy}-/V-(methyIsulfonyl)benzamide trifluoroacetate
Step I:
tert-butyl 2-[(25)-oxiran-2-ylmethoxy]benzoate
A mixture of terf-butyl salicylate (2.01 g, 10.3 mmol), (25)-oxiran-2-yIraethyl 3-nitrobenzenesulfonate (2.69 g, 10.4 mmol) and cesium carbonate (4.05 g, 12.4 mmol) in dimethylformamide (20 mL) was stirred at'room temperture overnight. The reaction mixture was partitioned between ethyl acetetate and water. The organic layer was dried over sodium sulphate, Na2S04, filtered, concentrated in vacuo. The residue was purified by silica gel flash chromatography (ethyl acetate 40%, heptane 60%) and gave the subtitle compound (2.3 g, 89 %).
'H-NMR (CDci3,400 MHZ): 5 7.71 (dd, y= i.g, 7.7 HZ, IH); 7.41 (dd, j= u, 7.8 HZ,
IH); (dd, y = 0.8, 7.5 Hz, IH); 6.98 (d, J - 8.4 Hz, IH); 4.29 (dd, J= 3.2, 11.0 Hz, IH); 4.06 (dd, y= 5.2,11.0 Hz, IH); 3.42-3.37 (m, IH); 2.93-2.89 (m, IH); 2.86-2.83 (m, IH) APCI-MS:m/z251(MH+)
Step U:
-buryl2-{[(2-3-(S-chloro-r3-spiro[l-benzofuran-2,4'-piperidin]-r-yI)-2-
hydroxypropyljoxyjbenzoate
A mixture of 5-chloro-3//-spiro[l-ben2ofuran-2,4'-piperidine] (390 mg, 1.6 mmol) and tert-butyl 2-[(25)-oxiran-2-ylmethoxy]benzoate (350 mg, 1.6 mmol) in ethanol was heated
at reflux overnight. The volatiles were removed in vacuo, the residue was used without
further purification.
APCl-MS:m/z474(MrT)
Step III:
methoxybenzyl)oxy]propyl}oxy)benzoicacid
To a suspension of sodium hydride (170 mg, 4.2 mmol) in THF (10 mL) under argon at 0 °C, was added tert-butyl 2-{[(25)-3-(5-chloro-r/f13//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}benzoate (750 mg, 1.6mmol) in THF (10 mL) and 1-(chloromethyl)-4-methoxybenzene (250mg, 1.6mmol) in THF (10 mL). The mixture was stirred at room temperture overnight, poured over ice and pH adjusted to 1 with HC1 (aq). It was then extracted with ethyl acetate, the organic layer was dried over sodium sulphate (NajSO^, the volatiles were removed in vacuo. The residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave the subtitle compound (91 mg) APCI-MS: m/z 538 (MH*)
Step IV:
2-({(250-3-(5-!/-spiro[l-benzofuran-2>4l-piperidin]-lI-y])-2-((4-
methoxybenzyl)oxy]propyl}oxy)-W-(methylsulfonyl)benzamide
A mixture of 2-({(2,S)-3-(5-chloro-r//,3//'-spiro[l-benzofuran-2)4l-piperidin]-ll-yl)-2-[(4-methoxybenzyl)oxy]propyl}oxy)benzoic acid (90 mg, 0.17 mmol), Af,A/-dimethylpyridin-4-amine (22 mg, 0.18 mmol), methanesulfonamide (18 mg, 0.19 mmol) and //-[3-(dimethylamino)propyl]-A/t-ethylcarbodiimide hydrochloride (35 mg, 0.18 mmol) in dichloromethane (5 mL) was stirred under argon at room temperture overnight. The mixture was poured in 1M HC1 (aq), the two layers were separated, the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over sodium sulphate, the volatiles were removed in vacuo, the residue (117 mg) was used without further purification.
APCI-MS:m/z615(MH+)
Step V:
hydroxypropyI]oxy}WV-(methylsuIfonyl)benzamide
2-({(2lS)-3-(5-chioro-l'//)3//-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-[(4-methoxyben2yl)oxy]propyl}oxy)-Ar-(methyIsulfonyl)benzamide (104 mg, 0.17 mmol) was stirred in a mixture of trifluoroacetic acid (500 p.L) and dichloromethane (3 mL), at room temperature for 1 hour. The volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave the subtitle compound (31 mg, overall yield Steps II-V 3.9 %).
'H-NMR (acetone-d6,400 MHz): 5 7.92 (dd, J = 1.8, 7,8 Hz, 1H); 7.62 (dd, /= 1.8, 8.3 Hz, 1H); 7.28-7.22 (m, 2H); 7.19-7.11 (m, 2H); 6.77 (d, /= 8.5 Hz, 1H); 4.76-4.69 (m, 1H); 4.42-4.32 (m, 2H); 3.98-3.44 (m, 6H); 3.42 (s, 3H); 3.19 (br.s, 2H); 2.41-2.19 (m, 4H) APCI-MS:m/z495(MH)
Step VI:
Z^KlS'J-SS-chloro-l'/r/i'-spiroIl-benzofuran-a-piperidinl-l'-ylH-
hydroxypropyl]oxy}T/V-(methyIsulfonyl)benzamldetrifluoroacetate
2- {[(2,S>3-(5-chloro-l 7/,3//-spiro[ l-benzofuran-2,4'-Piperidin]-l '-yl)-2-hydroxypropylJoxyj-^methylsulfonyObenzamide (31 mg, 0.06 mmol) was dissolved in dichloromethane, trifluoroacetic acid (100 jaL) was added. Volatiles were removed in vacuo and the subtitle compound (35 mg) was obtained. APCI-MS:m/z495(MH*)
Example 96
2-{((21S)-3-(5-chloro-l'jyr,3/f-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyI|oxy}-A'-U/-tetrazoI-5-ylbenzamide bis(trifluoroacetate)
Step 1:
2-{l(21S)-3-(5-chloro-r//,3Jtf-spiroll-benzofuran-2,4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride
A mixture of (erf-butyl 2-{[(25)-3-(5-chloro-r//)3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoate (200 mg, 0.42 mmol) and cone, aqueous HC1 (3 mL) in dichloromethane (25 mL) was stirred at room temperture for 48 hours. Volatiles were removed in vacuo, the brown residue was used without further purification APCI-MS:m/z418(MH+)
Step II:
2-{[(25)-3-(5-chIoro-l'flr,3H-spiro(l-benzofuran-2,4'-piperidin]-l1-yl)-2-hydroxypropyljoxyJ-A'-lH-tetrazol-S-ylbenzamide bis(trifluoroacetate)
A mixture of 2-{[(25)-3-(5-chloro-r//J3//-spiro[l-benzoruran-2I4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride (110 mg, 0.24 mmol), l//-tetrazol-5-amine (27 mg, 0.26 mmol) and PS-Carbodiimid (850 mg, 1 mmol) was stirred in dichloromethane (10 ml) at room temperature overnight. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.1% trifluoroacetic acid), and gave the subtitle compound (23 mg, overall yield Steps I-II 11 %).
1H-NMR (acetone-d6,400 MHz): 5 11.43 (br. s, IH); 8.03 (dd,y = 1.7, 7.8 Hz, 1H); 7.65 (dd, y= 1.9, 7.1 Hz, IH); 7.32 (d, J= 8.3 Hz, 1 H); 7.25-7.17 (m, 2H); 7.14 (dd, J- 2.4, 8.5 Hz, IH); 6.79 (d, y » 8.5 Hz, IH); 4.85-4.78 (m, IH); 4.52-4.39 (m, 2H); 3.98-3.76 (m, 2H); 3.75-3.67 (m, 2H); 3.66-3.50 (m, 2H); 3.22 (br. s, 2H); 2.47-2.32 (m, 2H); 2.31-2.20 (m,2H) APCI-MS: m/z 485 (MH+)
Example 97
3-{[(251)-3-(5-chIoro-rF,3flr-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-{[(3)-3-(dimethylamino)pyrroIidin-l-yI]carbonyl}phenol bis(trifluoroacetate) (salt)
Step I:
(25)-l-(S-chloro-l'^,3Ja"-spiro[l-ben2ofuran-2)4'-piperidin]-r-yI)-3-{2-{[(3J?)-3-(dimethylamino)pyrrolidin-l-yl]carbonyl}-5-[(4-methoxybenzyl)oxy]phenoxy}propan-2-ol
A mixture of PS-carbodiimide (530 mg, 0.68 mmol) and dichloromethane (6 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(2S)-3-(5-chloro-17/,3//-spirofl-benzofuran-piperidinJ-l'-yO-l-hydroxypropylloxy}methoxybenzyl)oxy]benzoic acid hydrochloride (200 mg, 0.32 mmol) inNMP (1 mL) and dichloromethane (2 mL) was added, the mixture was stirred for 30 minutes, a solution of (3/?)-AyV-dimethylpyrrolidin-3-amine (48 mg, 0.42 mmol) in dichloromethane (2 mL) was added. The mixture was stirred at room temperture overnight, filtrated, the filtrate was washed with brine, dried with sodium sulphate. Volatiles were removed in vacuo, the residue was used without further purification APCI-MS: m/z 650 (MH*)
Step II:
3-{[(25)-3-(5-chIoro-lIH,3W-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-{[(3^)-3-isopropylpyrrolidin-l-yl]carbonyl}phenol bis(trifluoroacetate)
To a solution of (25)-l-(5-chloro-l'//,3//'-spiro[l-benzofuran-2,41-piperidm]-ll-yl)-3-{2-{[(3/?)-3-isopropylpyrrolidin-l-yl]carbonyl}-5-[(4-methoxybenzyl)oxy]phenoxy}propan-2-ol (crude product from the previous step) and dichloromethane (3 mL) was added trifluoroacetic acid (600 \iL). The mixture was stirred at room temperature for I h, votatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.1% trifluoroacetic acid) and gave (60 mg, overall yield Steps MI 25 %) of the subtitle compound.
'H-NMR (acetone-d6) 400 MHz): 5 7.22 (s, 1H); 7.15-7.11 (m, 2H); 6.77 (d,J= 8.5 Hz, 1H); 6.64-6.60 (m, IH); 6.53-6.49 (m, 1H); 4.63-4.49 (m, 2H); 4.17-3.96 (m, 4H); 3.96-3.72 (m, 4H); 3.71-3.38 (m, 6H); 3.17 (br. s, 2H); 3.00 (br. s, 3H); 2.94 (br. s, 3H); 2.60-2.18(m,6H). APC1-MS: mJz 530 (MH*)
Example 98
3-{l(2lS)-3-(5-chloro-rH,3//'-spiro[l-benzofuran-2,4I-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-{[(35)-3-(diraethylamino)pyrrolidin-l-yl]carbonyl}phenol bis(trifluoroacetate)
The title compound was prepared using (3.S3-N^-dimethylpyrrolidin-3-amine as described
in Example 97.
'H-NMR (Acetone-^, 300 MHz): 5 7.25-7.20 (m, IH); 7.16-7.11 (m, 2H); 6.77 (d, 7= 8.5
Hz, IH); 6.63-6.58 (m, IH); 6.54-6.48 (m, IH); 4.70-4.52 (m, IH); 4,20-3.98 (m, 3H);
3.96-3.72 (m, 4H); 3.70-3.36 (m, 6H); 3.17 (bs, 2H); 3.00 (s, 3H); 2.95 (s, 3H); 2.62-2.16
(m,6H)
APCI-MS: m/z 530 (MH*)
Example 99
(S^-l-CS-chloro-I^lCZ^O-CS-chloro-l'^S/f-spirotl-benzofuran-I^'-plperidin]-!1-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyI)pyrrolidin-3-ol trifluoroacetate
Step I:
Methyl 5-chloro-2,4-dihydroxybenzoate
Prepared from methyl 2,4-dihydroxybenzoate using the procedure described by Anderson, W. K., et aL, J. Med. Chem. 1996,39,46 - 55.
'H-NMR (CDCb, 400 MHz): 5 10.85 (s, IH), 7.84 (s, IH), 6.63 (s, IH), 5.99 (s, IH), 3.95 (s, 3H)
Step II:
Methyl 5-chIoro-2-hydroxy-4-[(4-methoxybenzyl)oxy]benzoate
To a solution of methyl 5-chloro-2,4-dihydroxybenzoate (0.41 g, 2 mmol) in acetone were added l-(chloromethyl)-4-methoxybenzene (0.32 g, 2 mmol) andKjCOj (0.28 g, 2 mmol). The reaction mixture was heated with reflux for 3 days, than cooled to room temperature. The inorganic material was removed by filtration. The solvent was distilled in vacuo, and the residue was recrystallized from methanol to afford white solid (0.37 g, 60 %). 'H-NMR (CDC13,400 MHz): 5 10.89 (s, 1H), 7.82 (s, IH), 7.37 (d, J = 8.7 Hz, 2H), 6.92 (d,J = 8.7 Hz, 2H), 6.56 (s, IH), 5.09 (s, 2H), 3.92 (s, 3H), 3.82 (s, 3H)
Step III:
Methyl 5-chloro-4-[(4-methoxybenzyl)oxy]-2-[(25)-oxiran-2-ylmethoxy]benzoate
A solution of methyl 5-chloro-2-hydroxy-4-[(4-methoxybenzyl)oxy]benzoate (0.37 g, 1.16 mmol), (2S)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (0.30 g, 1.16 mmol) and caesium carbonate (0.45 g, 1.4 mmol) in dimethylformamide (15 mL) was stirred at room temperature overnight. The mixture was partitioned between water and ethyl acetate, and the organic phase was washed twice with water and once with brine, and finally concentrated. The crude material was purified by flash chromatoghrphy on silica gel (eluent: ethyl acetate/n-heptane), yielding the titled compound (0.33, 74%). 'H-NMR (CDC13,400 MHz): 6 7.91 (s, IH), 7.37 (d, / = 8.7 Hz, 2H), 6.92 (dd, J= 6.7, 2.0 Hz, 2H), 6.66 (s, IH), 5.14 (m, 2H), 4.33 (dd, /= 11.4, 2.6 Hz, IH), 3.98 (dd, J= 11.5, 5.1 Hz, IH), 3.86 (s, 3H), 3.82 (s, 3H), 3.36 (m, IH), 2.93 - 2.87 (m, 2H) APCI-MS: m/z 379 (MH+)
Step IV
Methyl 5-chloro-2-{[(2JS)-3-(5-chloro-ll//J3J7-spiro[l-benzofuran-2,4'-piperidin]-l'-
yI)-2-hydroxypropyl]oxy}-4-((4-methoxybenzyl)oxy]benzoate trifluoroacetate (salt)
A solution of 5-chloro-3//-spiro[l-benzoruran-2,4'-piperidine] (100 mg, 0.45 mmol) and methyl 5-chloro-4-[(4-methoxybenzyl)oxy]-2-[(25)-oxiran-2-ylmethoxy]benzoate (170 mg, 0.45 mmol) in ethanol (5 mL) was refluxed for 6 h. The solvent was distilled off under
reduced pressure. The residue was purified by HPLC (eluent: (acetonitrile /water + 0.1 % TFA]) to afford a colourless solid (218 mg, 67 %). APCI-MS: m/z 602 (MH*)
Step V:
5-chIoro-2-{[(25)-3-(5-chloro-l'//,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-{(4-methoxybenzyl)oxy]benzoic acid hydrochloride
To a mixture of methyl 5-chloro-2-{[(25)-3-(5-chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate trifluoroacetate (220 mg, 0.3 mmol) in ethanol (10 mL) was added a solution of potassium hydroxide (4 g) and water (4 mL). The mixture was stirred at room temperture for 3 hours, pH was adjusted to I with aqueous HCl (37 %), extracted with ethyl acetate, dried with sodium sulphate. Volatiles was removed in vacuo, the subtitle compound (180 mg) required no further purification. APCI-MS: m/z 588 (MH)
Step VI:
(3.S)-l-{5-chloro-2-{((25)-3-(5-chloro-ll/r,3-spiro[l-benzofuran-2,4'-piperldin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]bcnzoyl}pyrrolidin-3-ol trifluoroacetate
A mixture of PS-carbodiimide (250 mg, 0.32 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 5-chloro-2-{[(2S)-3-(5-chloro-] 7f,3//-spiro[ 1 -benzoruran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (100 mg, 0.16 mmol) in NMP (0.5 mL) and dichloromethane (1 mL) was added, the mixture was stirred for 30 minutes, a solution of (S^-pyrrolidin-S-ol (18 mg, 0.21 mmol) in dichloromethane (1 mL) was added. The mixture was stirred at room temperture overnight, filtrated, the filtrate was washed with brine, dried with sodium sulphate. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid), and gave (45 mg) of the subtitle compound.
APCI-MS: m/z 657 (MH*)
Step VII:
(35)-l-(5-chloro-2-{[(25)-3-(5-chloro-rjY,3/f-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyi]oxy}-4-hydroxybenzoyl)pyrrolidin-3-ol trifluoroacetate
To a solution of (35)-l-{5-chloro-2-{[(2^)-3-(5-chloro-lI//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}pyrrolidin-3-ol trifluoroacetate (45 rag, 0.05 rnmol) in dichloronvethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperature for 20 minutes, volatiles was removed in vacuo. The residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid), and gave (22 mg, overall yield Steps V-VII11 %) of the subtitle compound.
'H-NMR (acetone-d6l 400 MHz): 6 7.24-7.22 (m, 2H); 7.13 (d, J = 8.4 Hz, 1H); 6.87 (d,/ = 13.7 Hz, IH); 6.77 (d, J= 8.5 Hz, IH); 4.56-4.46 (m, 2H); 4.44-4.39 (m, 1H); 4.17-4.02 (m, 2H); 3.87-3.72 (m, 2H); 3.70-3.60 (m, 2H); 3.60-3.26 (m, 7H); 3.16 (br. s, 2H); 2.45-2.16 (m, 4H); 2.03-1-80 (m, 2H). APCi-MS: m/z 537 (MH+)
Example 100
3-{[(2,y)-3-(5-chloro-l'/ir,3flr-spiro[l-benzofuran-2,41-piperidin]-l'-yO-2-hydroxypropyl]oxy}-4-{[(35)-3-methoxypyrrolidin-l-yl]carbonyl}phenol trifluoroacetate
Step I:
(21y)-l-(5-chloro-llflr,3H-spiro[l-benzofuran-2J4'-piperidin]-l'-yl)-3-(5-I(4-methoxybenzyl)oxy]-2-{[(3S)-3-methoxypyrroHdin-l-yI]carbonyl}phenoxy)propan-2-ol
A mixture of PS-carbodiimide (277 mg, 0.35 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(2S)-3-(5-ch\Qio-\'H,3H-spiro[l-benzoruran-2,4'-piperidin]-r-yl)-2-hydimypropyl]oxy}-4-[(4-
methoxybenzyl)oxy]benzoic acid hydrochloride (100 mg, 0.16 mmol) in NMP (0.5 raL) and dichloromethane (1 mL) was added, the mixture was stirred for 30 minutes, a solution of (3.S)-3-methoxypyrrolidine (27 mg, 0.27 mmol) in dichloromethane (1 mL) was added. The mixture was stirred at room temperture overnight, filtrated, the filtrate was washed with brine, dried with sodium sulphate. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave (35 mg) of the subtitle compound. APCI-MS: m/2 637 (MH*)
Step 11:
3-{[(2^)-3-(5-chloro-lfH,3/f-spiro(l-bcnzofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropylJoxy}-4-{((35)-3-methoxypyrrolidin-l-yI]carbonyl}phenol trifluoroacetate
To a solution of (25)-l-(5-chloro-r/f,3/f-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-3-(5-[(4-methoxybenzyl)oxy]-2- {[(3S)-3-methoxypyrrolidin-l -yl]carbonyl} phenoxy)propan-2-ol (35 mg, 0.05 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 2 hours, volatiles were removed and the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 25 mg (overall yield S teps I-II 25 %) of the title compound.
'H-NMR (acetone-dfi, 400 MHz): 6 7.23 (s, 1H); 7.16-7.10 (m, 2H); 6.77 (d, J = 8.7 Hz, 1H); 6.64-6.61 (m, 1H); 6.52 (dd, J =2.1, 8.2 Hz, 1H); 4.54-4.45 (m, 1H); 4.17-3.95 (m, 3H); 3.88-3.70 (m, 2H); 3.69-3.60 (m, 2H); 3.60-3.42 (m,4H); 3.40-3.31 (m, 3H); 3.26 (s, 2H); 3.17 (br. s, 2H); 2.46-2.17 (m, 4H); 2.10-1.92 (m, 2H). APCI-MS:
Example 101
3-{[(2kS)-3-(5-chloro-l'//,3^-spiro[l-benzofuran-2J4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-{[(2/?)-2-(hydroxymethyI)pyrrolidin-l-yl]carbonyl}phenol trifluoroacetate
Step I:
(25)-l-(5-chIoro-rJff,3J7-spiro[l-benzofuran-2,4'-piperidin}-l'-yl)-3-{2-{[(2J?)-2-(hydroxymethyl)pyrroIidin-l-yl]carbonyl}-5-[(4-methoxy benzyl)oxyl p henoxy} propan-2-ol
A mixture of PS-carbodiimide (280 rag, 0.36 mmol) and dichloromethane (2.5 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(25)-3-(5-chloro-l'//33//-spiro[ 1 -benzofuran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (100 mg, 0.16 mmol) in NMP (0.6 mL) and dichloromethane (1 mL) was added, the mixture was stirred for 30 minutes, a solution of (2^?)-pyrrolidin-2-ylmethanol (30 mg, 0.30 mmol) in dichloromethane (I mL) was added. The mixture was stirred at room temperture overnight and filtered. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave (51 mg) of the subtitle compound. APCI-MS: m/z 637 (MH4)
Step II:
3-{[(25)-3-(S-chloro-l'/r,3/f-spiro(l-benzofuran-2,4'-piperidinJ-l'-yl)-2-hydroxypropylJoxy}-4-{[(2/Z)-2-(hydroxymethyl)pyrroIidin-l-yllcarbonyl}phenol trifluoroacetate
To a solution of (21S)-l-(5-chloro-lW,3//-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-3-{2-{[(2/?)-2-(hydroxvmethyl)pyrrolidin-1 -yljcarbonyl} -5-[(4-
methoxybenzyl)oxy]phenoxy} propan-2-ol (51 mg, 0.08 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 30 minutes, volatiles were removed, the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 20 mg (overall yield Steps Ml 20 %) of the title compound.
'H-NMR (acetone-d6,400 MHz): 6 7.23 (s, 1H); 7.15-7.10 (m, 2H); 6.77 (d, 7= 8.6 Hz, 1H); 6.60-6.57 (m, 1H); 6.50 (dd, J = 2.1, 8.2 Hz, 1H); 4.58-4.48 (m, 1H), 4.32-4.24 (m,
1H); 4.14-4.06 (m, 2H); 3.90-3.60 (m, 4H); 3.60-3.40 (m, 4H); 3.32-3.20 (m, 2H); 3.16 (br. s, 2H); 2.46-2.16 (m, 4H); 1.95-1.66 (m, 2H); 1.35-1.29 (m, 2H). APCI-MS:m/z517(MH+)
Example 102
3-{[(25)-3-(5-chIoro-l'/f,3/f-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-{[(2,S)-2-(hydroxymethyl)pyrrolidin-l-yl]carbonyl}phenol trifluoroacetate
The title compound was prapared as described in Example 101 using (2/Z)-pyrrolidin-2-
ylmethanol.
'H-NMR (acetone-ds, 400 MHz): 6 7.23 (s, 1H); 7.16-7.05 (m, 2H); 6.77 (d, J - 8.5 Hz,
1H); 6.64-6.57 (m, 1H); 6.50 (dd, 7-2.2, 8.4 Hz, 1H); 4.60-4.51 (m, 1H), 4.30-4.22 (m,
1H); 4.14-4.10 (m, 2H); 3.90-3.72 (m, 2H); 3.70-3.24 (m, 8H); 3.17 (br. s, 2H); 2.44-2.14
(m,4H); 1.92-1.68 (m,4H).
APCI-MS:m/z517(MH+)
Example 103
3-{[(2lSO-3-(5-chloro-l1.ftr,3flr-spiro[l-benzofuran-2J4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-{[3-(hydroxymethy!)pyrrolidin-l-yl]carbonyl} phenol trifluoroacetate
The title compound was prapared as described in Example 101 pyrrolidin-3-ylmethanol
hydrochloride .
'H-NMR (acetone-dfi, 400 MHz): 6 7.23 (s, 1H); 7.16-7.08 (m, 2H); 6.80-6.75 (m, 1H);
6.67-6.62 (m, 1H); 6.53-6.48 (m, IH); 4.52-4.44 (m, 1H), 4.17-4.02 (m, 2H); 3.90-3.10 (m,
15H); 2.50-2.16 (m, 4H); 2.02-1.68 (m, 2H).
APCl-MS:m/z517(Mtf')
Example 104
l-(2-{[(21y)-3-(5-chloro-r/fJ3//-spiro[l-benzofuran-2,4t-piperidin]-l'-yl)-2-hydroxypropyljoxy}-4-hydroxybenzoyl)-D-prolinumide trifluoroacetate
Step i: l-{2-{[(21S}-3-(5-chloro-l'/f,3H-spiro[l-benzofuran-2,4'-ptperidinJ-l'-yl)-2-
hydroxypropylloxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-D-prolinamide
A mixture of PS-carbodiimide (280 mg, 0.36 mmol) and dichloromethane (2.5 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(2S)-3-(5-chloro-17f,3//-spiro[ 1 -benzofuran-2,4'-piperidm]-1 '-yl)-2-hydroxypropyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (100 mg, 0.16 mmol) in NMP (0.6 mL) and dichlorornethane (1 mL) was added, the mixture was stirred for 30 minutes, a solution of D-prolinamide (29 rag, 0.25 mmol) in dichloromethane (1 mL) was added. The mixture was stirred at room temperture overnight and filtrated. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave (68 mg) of the subtitle compound. APCI-MS:m/z650(MH+)
Step II:
i-(2-{[(25)-3-(S-chloro-rJflr,3^r-spiro[l-benzofuran-2J4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyI)-D-prolinarnide trifluoroacetate
To a solution of l-{2-{[(25)-3-(5-chloro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-D-prolinamide (68 mg, 0.10 mmol) in dichloromethane was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 30 minutes, volatiles were removed, the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 28 mg (overall yield Steps I-II27 %) of the title compound.
'H-NMR (acetone-de, 400 MHz, 2 rotamers): 5 7.23 (s, 1H); 7.22-7.16 and 6.64-6.54 (m, 3H); 7.15-7.10 and 7.06-7.02 (m,2H); 6.77 (d,J = 8.4 Hz, 1H); 6.53-6.48 and 6.46-6.41 (m, 1H); 4.62-4.47 (m, 2H); 4.16-4.02 (m, 2H); 3.92-3.42 (m, 8H); 3.34-3.22 (m, 2H); 3.16 (br. s, 2H); 2.46-2.14 (m, 4H); 2.12-1.76 (m, 2H). APCI-MS: m/z 530 (MH+)
Example 105
N-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(rH,3H-spiro[l-benzofuran-2,4r-piperidin]-lf-yl)propyl]oxy}phenyl)acetamide trifluoroacetate (salt)
The title compound was prepared from 3#-spiro[l-benzofuran-2,4'-piperidine] as
described in Example 27.
'H-NMR(acetone-de, 400 MHz): 5 8.52 (s, IH), 7.93 (d, J = 8.7 Hz, IH), 7.21 (d, J = 7.2
Hz, IH), 7.12 (t, .7 = 7.7 Hz, IH), 6.86 (t,/= 7.3 Hz, IH), 6.75 (d,J= 7.9 Hz, IH), 6.53 (d,
J = 2.4 Hz, IH), 6.40 (dd, /- 8.8,2.4 Hz, IH), 4.53 (m, IH), 4.08 (m, 2H), 3.94 - 3.39 (m,
6H), 3.15 (s, 2H), 2.45 - 2.15 (m, 4H), 2.09 (s, 3H)
APCl-MS:m/z413(MH+).
Example 106
N-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(5-methyl-llH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)propyl]oxy}phenyl)acetamide trifluoroacetate (salt)
The title compound was prepared from 5-Methyl-3//-spiro[l-benzofuran-2,4'-piperidine]
as described in Example 27.
'H-NMR (acetone-d 6.92 (d, /= 8.1 Hz, IH), 6.63 (d, /« 8.1 Hz, IH), 6.53 (d, J = 2.4 Hz, IH), 6.41 (dd, J=
8.7, 2.4 Hz, IH), 4.52 (s, IH), 4.07 (d, J = 3.8 Hz, 2H), 3.92 - 3.38 (m, 6H), 3.09 (s, 2H),
2.42 - 2.13 (m, 4H), 2.24 (s, 3H), 2.10 (s, 3H)
APCl-MS:m/z427(MH+).
Example 107
N-(5-chIoro-2-{[(2S)-2-hydroxy-3-(l'H,3H-splro[l-benzofuran-2,4l-piperidin]-l'-yl)propyl]oxy}-4-methoxyphenyl)acetamide trifluoroacetate (salt)
om 3/f-spiro[l-benzofuran-2,4'-piperidine] as
described in Example 83.
'H-NMR (DMSO-d6,400 MHz): 8 9.61 (br. s, 1H), 9.02 (m, 1H), 7.91 (s, 1H), 7.21 (d, /=
7.3 Hz, 1H), 7.11 (m, 1H), 6.85 (m, 2H), 6.77 (d, 7= 7.9 Hz, 1H), 4.38 (m, 1H), 4.06-(rn,
2H), 3.85 (s, 3H), 3.66 - 3.12 (m, 6H), 3.08 (s, 2H), 2.23 -1.94 (m, 7H)
APCI-MS:m/z461(MH).
Example 108
N-(5-chloro-4-hydroxy-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidinj-lr-yl)propyljoxy}phenyl)acetamide trifluoroacetate (salt)
To a stirred solution of N-(5-chloro-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)propyl]oxy}-4-methoxyphenyl)acetamide trifluoroacetate (116 mg, 0.2 mmol) in dichloromethane (50 ml) at 0 °C was added a solution of BBrj (1 M in dichloromethane, 2 ml, 2 mmol) under argon. The stirring was continued at 0 °C for 6 h, then the reaction mixture was quenched with methanol. The solvent was removed in vacuo, the resudue purified by HPLC (eluent: [acetonitrile / water + 0.1 % TFA]) to afford colourless solid (12 mg, 10 %).
'H-NMR (acetone-d6) 400 MHz): 8 8.62 (s, 1H), 8.26 (s 1H), 7.21 (d, J = 7.3 Hz, 1H), 7.12 (t,y = 7.7 Hz, 1H), 6.86 (t,7= 7.4 Hz, 1H), 6.75 (m, 2H),4.55 (m, 1H), 4.10 (m, 2H), 3.93 - 3.19 (m, 8H), 3.16 (s, 2H), 2.43 - 2.15 (m, 4H), 2.11 (s, 3H) APCi-MS:m/z447(MH4>
Example 109
(3S)-N-(2-{[(2S)-3-(5-chloro-ltH,3H-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-methoxyphenyl)-3-hydroxypyrrolidine-l-carboxamide trifluoroacetate (salt)
The title compound was prepared using 6-methoxy-l,3-benzoxazol-2(3/^)-one as described in Example 84.
'H-NMR (acetone-d6,400 MHz): 5 7.74 (m, 1H), 7.23 (s, 1H), 7.13 (dd, J= 8.5,2.2 Hz, 1H), 7.03 (s, IH), 6.77 (d, y- 8.5 Hz, 1H), 6.61 (d,/= 2.7 Hz, 1H), 6.49 (dd, J = 8.8,2.7 Hz, 1H), 4.59 (m, IH), 4.47 (m, IH), 4.14 (m, 2H), 3.80 (m, 2H), 3.75 (s, 3H), 3.64 - 3.40 (m, 8H), 3.16 (s, 2H), 2.44 - 2.16 (m, 4H), 2.09 -1.89 (m, 2H) APCI-MS: m/z 532 (MH*).
Example 110
(3S)-N-(2-{l(2S)-3-(5-chloro-l'H^H-spiro[l-benzofuran-2,4'-piperidin]-lf-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)-3-hydroxypyrrolidine-l-carboxamide trifluoroacetate (salt)
To a stirred solution of (3S)-N-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzoruran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy} -4-methoxyphenyl)-3-hydroxypyrrolidine-1 -carboxamide trifluoroacetate (59 mg, 0.09 mmol) in dichloromethane (50 ml) at 0 °C was added a solution of BBrs (1 M in dichloromethane, 1.8 ml, 1.8 mmol) under argon. The stirring was continued at 0 °C for 4 h, then the reaction mixture was quenched with methanol. The solvent was removed in vacuo, the resudue purified by HPLC (eluent: [acetonitrile / water + O.I % TFA]) to afford colourless solid (30 mg, 53 %). 'H-NMR (acetone-dfi, 400 MHz): 8 7.52 (m, IH), 7.23 (s, IH), 7.13 (dd, /= 8.5,2.3 Hz, IH), 6.99 (s, IH), 6.77 (d,y- 8.5 Hz, IH), 6.57 (d, J- 2.5 Hz, IH), 6.39 (dd, J= 8.6, 2.6 Hz, IH), 4.56 (m, IH), 4.46 (m, IH), 4.07 (m, 2H), 3.90 - 3.21 (m, 10H), 3.16 (s, 2H), 2.42 - 2.16 (m, 4H), 2.09 -1.90 (m, 2H) APCI-MS: m/z 518 (MH*).
Example 111
(3S)-l-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(rHJ3H-spiro(l-benzofuran-2,4'-pipcridin]-r-yl)propyI]oxy}benzoyl)pyrroIidin-3-ol trifluoroacetate (salt)
Step I:
Methyl 2-{((25)-2-hydroxy-3-(l'^3H-spiro[l-benzofuran-2,41-piperidin]-l'-yI)propyljoxy}-4-[(4-methoxybenzyl)oxy]benzoate trifluoroacetate (salt)
A solution of 3#-spiro[l-benzofuran-2,4'-piperidine] (50 mg, 0.26 mmol) and methyl methyl 4-[(4-methoxybenzyl)oxy]-2-[(25)-oxiran-2-ylmethoxy]benzoate (91 mg, 0.26 mmol) in ethanol (3 mL) was refluxed for 6 h. The solvent was distilled off under reduced pressure. The residue was purified by HPLC (eluent: [acetonitrile /water + 0.1 % TFA]) to afford a colourless solid (103 mg, 61 %). APCI-MS: m/z 534 (MH+)
Step II:
2-{[(25')-2-hydroxy-3-(rflr,3Jar-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)propyl]oxy}-4-{(4-methoxybenzyl)oxy)benzoic acid hydrochloride
To a mixture of methyl 2-{[(25)-2-hydroxy-3-(l'//,3//-spiro[l-benzofuran-2,4'-piperidin]-
l'-yl)propyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoate trifluoroacetate
(103 mg, 0.16 mmol) in ethanol (5 mL) was added 10 N aq. NaOH solution (1 ml) and
water (1 ml). The mixture was stirred at room temperture overnight, pH was adjusted to 1
with aqueous HC1 (2 M), extracted with ethyl acetate, dried with sodium sulphate.
Volatiles was removed in vacuo to afford the subtitle compound, which was used without
purification.
APCI-MS: m/z 520 (MH+)
Step III:
(3S)-l-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)propyl]oxy}benzoyI)pyrrolidin-3-oI trifluoroacetate (salt)
A mixture of PS-carbodiimide (250 mg, 0.32 mmol) and dichloromethane (5 mL) was stirred at room temperature for 15 minutes, then 2-{[(25)-2-hydroxy-3-(r//,3^/'-spiro[l-benzofuran-2)4'-piperidin]-r-yl)propyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (89 mg, 0.16 mmol) was added, and the mixture was stirred for 30 minutes. A solution of (3i$)-pyrrolidin-3-ol (14 mg, 0.16 mmol) in dichloromethane (1 mL) was added. The mixture was stirred at room temperture for 24 h, and filtered. Trifluoroacetic
acid (10 % in dichloromethane, 5 ml) was added, and the stirring was continued for 1 h at room temperature. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.1% trifluoroacetic acid) and gave (14 mg, overall yield Steps II-III15 %) of the title compound.
'H-NMR (acetone-dfi, 400 MHz): 6 7.20 (d, J = 7.2 Hz, 1H), 7.12 (m, 2H), 6.85 (t, J= 7.4 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 6.60 (dd, J - 7.4,2.0 Hz, IH), 6.51 (dt, J= 8.2, 2.4 Hz, 1H), 4.49 (s, 2H), 4.40 (m, IH), 4.17 - 4.00 (m, 3H), 3.87 - 3.25 (m, 8H), 3.12 (s, 2H), 2.45 - 2.12 (m,4H), 2.10- 1.85 (m,2H) APCI-MS:m/z469(MH+).
Example 112
2-{[(2S)-3-(5-chloro-l'H)3H-spiro[l-benzofuran-2)4'-piperidin]-l(-yl)-2-hydroxypropyi]oxy}-5-methylbenzoic acid hydrochloride
Step I:
Methyl 5-methyI-2-[(2£)-oxiran-2-ylmethoxy]benzoate
A solution of methyl 2-hydroxy-5-methylbenzoate (0.166 g, 1 mmol), (2S)-oxiran-2-yimethyl 3-nitrobenzenesulfonate (0.26 g, 1 mmol) and caesium carbonate (0.39 g, 1.2 mmol) in dimethylformamide (5 mL) was stirred at room temperature overnight. The mixture was partitioned between water and ethyl acetate, and the organic phase was washed twice with water and once with brine, and finally concentrated. The crude material was purified by flash chromatoghrphy on silica gel (eluent: ethyl acetate/n-heptane), yielding the titled compound (0.16 g, 72%) as colourless oil.
'H-NMR (CDClj, 400 MHz): 8 7.61 (d, J = 2.0 Hz, IH), 7.25 (d, J - 9.9 Hz, IH), 6.89 (d, /= 8.4 Hz, 1H),4.28 (dd, J= 11.2, 3.0 Hz, IH), 4.07 (dd, J= 11.2,4.9 Hz, IH), 3.89 (s, 3H), 3.38 (m, IH), 2.89 (m, 2H), 2.30 (s, 3H)
Step II:
Methyl 2-{[(21S)-3-(5-chloro-l'//,3/f-spiro[l-ben2ofuran-2,4'-piperldin]-l'-yl)-2-
hydroxypropyl]oxy}-5-methylbenzoate trifluoroacctate (salt)
A solution of 5-chloro-3#-spiro[l-benzofuran-2,4'-piperidine] (112 rag, 0.5 mmol) and methyl 5-methyl-2-[(2lS}-oxiran-2-ylmethoxy]benzoate (111 mg, 0.5 mmol) in ethanol (5 raL) was refluxed for 6 h. The solvent was distilled off under reduced pressure. The residue was purified by HPLC (eluent: [acetonitrile /water + 0.1 % TFA]) to afford a colourless solid (153 mg, 54 %). APCI-MS:m/z446(MH+)
Step III:
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyI]oxy}-5-methylbcnzoic acid hydrochloride
To a mixture of methyl 2-{[(25)-3-(5-chloro-ll^J3//-spiro[l-beri2ofuran-2)41-piperidin3-r-yl)-2-hydroxypropyl]oxy} -5-methylbenzoate trifluoroacetate
(153 mg, 0.27 mmol) in ethanol (5 mL) was added ION aq. NaOH solution (1 ml) and water (1 ml). The mixture was stirred at room temperture for 3 hours, pH was adjusted to 1 with aqueous HC1 (2 M), extracted with ethyl acetate, dried with sodium sulphate. Volatiles was removed in vacuo to afford the subtitle compound (123 mg, 96 %). 'H-NMR (acetone-d6,400 MHz): 5 7.68 (d,7= 2.1 Hz, 1H), 7.36 (dd,7= 8.6, 2.1 Hz, IH), 7.22 (s, IH), 7.11 (m, 2H), 6.76 (d, J= 8.5 Hz, IH), 4.68 (m, IH), 4.27 (m, IH), 4.17 (m, IH), 3.72 (br. s, 2H), 3.67 (d,J= 13.7 Hz, IH), 3.51 (br. s, 2H), 3.43 (dd,J= 13.5, 8.8 Hz, IH), 3.19 (s, 2H), 2.47 (br. s, 2H), 2.30 (s, 3H), 2.22 (br. s, 2H) APC1-MS: m/z 423 (MH+)
Example 113
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4t-piperidLn]-l'-yl)-2-hydroxypropyl]oxy}-4-methoxybenzoic acid hydrochloride
The title compounds was prepared using methyl 2-hydroxy-4-methoxybenzoate as described in Example 112.
'H-NMR (acetone-dfi, 400 MHz): 5 7.89 (d, /= 8.8 Hz, IH), 7.23 (m, IH), 7.12 (dd, J= 8.5, 2.3 Hz, IH), 6.76 (d,/= 8.6 Hz, 2H), 6.74 (d, J = 2.3 Hz, 2H), 6.65 (dd,7= 8.8, 2.3
Hz, 1H), 4.70 (m, IH), 4.31 (m, 1H), 4.22 (ra, IH), 3.89 (s, 3H), 3.73 (br. s, 2H), 3.67 (dd, J= 13.4, 1.9 Hz,, IH), 3.58 - 3.45 (m, 2H), 3.41 (dd, 7= 13.5, 8.7 Hz, 1H), 3.19 (s, 2H), 2.49 (m, 2H), 2.24 (br. d, J = 14.0 Hz, 2H) APCI-MS: m/z 448 (MH*)
Example 114
(3S)-l-(2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperldin]-l'-yl)-2-hydroxypropylIoxy}-5-methylbenzoyl)pyrrolidin-3-oI trifluoroacetate (salt)
A mixture of PS-carbodiimide (78 mg, 0.1 mmol) and dichloromethane (5 raL) was stirred at room temperature for 15 minutes, then2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-5-rnethytbenzoic acid hydrochloride (23 mg, 0.05 mmol) was added, and the mixture was stirred for 30 minutes. A solution of (35)-pyrrolidin-3-ol (5 mg, 0.05 mmol) in dichloromethane (1 mL) was added. The mixture was stirred at room temperture for 24 h, and filtered. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.1% trifluoroacetic acid) and gave (6 mg, 21 % ) of the title compound.
1H-NMR (acetone-d Example 115
(3S)-l-(2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin)-l'-yl)-2-hydroxypropyIloxy}-4-methoxybenzoyl)pyrrolidin-3-ol trifluoroacetate (salt)
The title compound prepared from 2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-methoxybenzoic acid hydrochloride as described in Example 114.
'H-NMR (acetone-d^ 400 MHz): 5 7.23 (s, 1H), 7.19 (dd,J= 8.4, 3.1 Hz, IH), 7.13 (d, J== 8.6 Hz, IH), 6.77 (d, J- 8.5 Hz, 1H), 6.67 (t, J- 2.4 Hz, IH), 6.60 (dt, /= 8.4,2.2 Hz, 1H), 4.51 (m, 2H), 4.39 (m, IH), 4.22 - 4.12 (m, 2H), 4.08 (m, IH), 3.83 (s, 3H), 3.85 -3.25 (m, 8H), 3.16 (s, 2H), 2.35 (br. s, 2H), 2.21 (br. s, 2H) APCI-MS:m/z517(MH*)
Example 116
5-chloro-2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-lt-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride
The title compounds was prepared using methyl 5-chloro-2-hydroxybenzoate as described in Example 112.
'H-NMR (acetone-rig, 400 MHz): 87.81 (d, J = 2.8Hz, 1H),7.57 (dd, J =9.0,2.8Hz, IH), 7.26 (d, J= 9.0 Hz, IH), 7.23 (s, IH), 7.13 (dd, J= 8.5,2.2 Hz, IH), 6.77 (d,/= 8.5 Hz, IH), 4.66 (m, 2H), 4.32 (m, IH), 4.19 (m, IH), 3.73 (br. s, 2H), 3.69 (d, J= 13.3 Hz, IH), 3.54 (br. s, 2H), 3.45 (dd,y = 13.5, 8.9 Hz, IH), 3.20 (s, 2H),2.46 (br. s, 2H),2.24 (br. d, J = 12.3 Hz, 2H) APCl-MS:m/z452(MH*)
Example 117
(3S)-l-(5-chIoro-2-{[(2S)-3-(5-chloro-ltHJ3H-spiro[l-benzofuran-2,4'-piperidin]-l1-yl)-2-hydroxypropyI]oxy}benzoy!)pyrrolidin-3-ol trifluoroacetate (salt)
The title compound prepared from 5-chloro-2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-
benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride as
described in Example 114.
'H-NMR (acetone-d6, 400 MHz): 6 7.39 (dt,J= 8.8, 2.4 Hz, IH), 7.25 (dd,/=4.1, 2.8 Hz,
IH), 7.23 (s, IH), 7.15 (d, /= 8.7 Hz, IH), 7.12 (s, IH), 6.77 (d, J= 8.5 Hz, IH), 4.53 (m,
2H), 4.42 (m, IH), 4.23 - 4.06 (m, 3H), 3.76 - 3.14 (m, 12H), 2.33 (br. s, 2H), 2.23 (br. s,
2H)
APCI-MS:m/z521
Example 118
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-5-fluorobenzoic acid hydrochloride
The title compounds was prepared using methyl 5-fluoro-2-hydroxybenzoate as described in Example 112.
'H-NMR (acetone-d*, 400 MHz): S 7.56 (dd, J= 8.9,3.2 Hz, 1H), 7.35 (m, 1H), 7.27 (dd, J= 9.2,4.4 Hz, 1H), 7.13 (dd, J= 8.4,2.1 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 4.68 (m, 1H), 4.29 (m, 1H), 4.18 (m, 1H), 3.72 (br. s,2H), 3.68 (br. d,7- 13.1 Hz, 3H), 3.51 (br. s, 1H), 3.41 (dd,y= 13.4, 9.0 Hz, 3H), 3.19 (s, 2H), 2.53 (br. s, 2H), 2.22 (br. s, 2H) APC1-MS: m/z 436 (MHf)
Example 119
(3S)-l-(2-{((2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-5-fluorobenzoyl)pyrrolidin-3-ol trifluoroacetate (salt)
The title compound prepared from 5-fluoro-2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-
benzoruran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoic acid hydrochloride as
described in Example 114.
'H-NMR (acetone-d^, 400 MHz): 5 7.23 (s, 1H), 7.16 (m, 2H), 7.12 (s, 1H), 7.04 (m, 1H),
6.77 (d, 7=8.5 Hz, 1H), 4.51 (m,2H),4.41 (m, 1H), 4.19-4.04 (m, 3H), 3.70 - 3.13 (m,
12H), 2.32 (br. s, 2H), 2.23 (br. s, 2H)
APCI-MS: m/z 505 (MH*)
Example 120
N-(2-{l(2S)-3-(S-chloro-l'H,3H-spLro[l-benzofuran-2,4I-piperidin]-r-yl)-2-hydroxypropyl]oxy}phenyl)pyrrolidine-l-carboxamlde trifluoroacetate (salt)
The title compound was prepared using l,3-benzoxazol-2(3#)-one and pyrrolidine as
described in Example 84.
'H-NMR (acetone-d6) 400 MHz): 6 8.14 (ra, 1H), 7.23 (s, 2H), 7.13 (dd, J = 8.5, 2.2 Hz,
1H), 6.99 (ra, 1H), 6.90 (m, 2H), 6.76 (d, /= 8.6 Hz, 1H), 4.64 (m, 1H), 4.13 (m, 1H), 3.82
(br. s, 2H), 3.61 (br. d,J= 13.1 Hz, 2H), 3.55 - 3.42 (m, 8H), 3.18 (s, 2H), 2.35 (br. s, 2H),
2.25 (br. s,2H), 1.93 (m,4H)
APCI-MS:m/z486(MH+).
Example 121
Methyl 4-(acetyIamino)-3-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-
piperidin]-l'-yl)-2-hydroxypropyl]oxy}benzoate trifluoroacetate (salt)
Step I:
Methyl 4-(acetylamino)-3-hydroxybenzoate
A solution of methyl 3-hydroxy-4-nitrobenzoate (0.78 g, 3.96 mmol) in THF (40 ml) with Pd on charcoal (10 %, 0.15 g) was stirred in the atmosphere of hydrogen at atmospheric pressure overnight. The mixture was filtered through celite. The solvent was removed in vacuo. The residue was taken into water (20 ml), and acetic anhydride (0.5 ml, 5.29mmol) was added. The mixture was vigorously stirred at 65 °C for 30 min. After cooling to room temperature, the precipitate was collected by filtration, washed with water, and dried. White powder (0.64 g, 77%).
Step II:
Methyl 4-(acetyIamino)-3-[(25)-oxiran-2-ylmethoxy]benzoate
A solution of methyl 4-(acetylamino)-3-hydroxybenzoate (0.209 g, \ mmol), (2S)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (0.26 g, 1 mmol) and caesium carbonate (0.39 g, 1.2 mmol) in dimethylformamide (5 mL) was stirred at room temperature overnight. The mixture was partitioned between water and ethyl acetate, and the organic phase was washed twice with water and once with brine, and finally concentrated. The crude material
was purified by flash chromatoghrphy on silica gel (eluent: ethyl acetate/n-heptane),
yielding the subtitle compound (96 mg, 36%) as colourless oil.
'H-NMR (CDC13, 400 MHz): 5 8.45 (d, J= 8.5 Hz, IH), 8.12 (s, IH), 7.69 (dd, J= 8.5,1.6
Hz, IH), 7.54 (d,7- 1.7 Hz, 1H), 4.43 (dd,7 = 11.3,2.3 Hz, IH), 3.96 (dd, 7= 11.3,6.3
Hz, IH), 3.89 (s, 3H), 3.41 (m, IH), 2.96 (t, J = 4.5 Hz, IH), 2.79 (dd, J = 4.7,2.6 Hz, IH),
2.24 (s, 3H)
APCI-MS: m/z 266 (MH+).
Step III:
Methyl 4-(acetylamino)-3-{[(2S)-3-(S-chloro-l'H,3H-spiro[l-benzofuran-2,4r-
piperidinj-1 '-yI)-2-hydroxypropyl]oxy}benzoate trifluoroacetate (salt)
A solution of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidine] (81 mg, 0.36 mmol) and methyl 4-(acetylamino)-3-[(26)-oxiran-2-ylmethoxy]benzoate (96 mg, 0.36 mmol) in ethanol (5 mL) was refluxed for 5 h. The solvent was distilled off under reduced pressure. The residue was purified by HPLC (eluent: [acetonitrile /water + 0.1 % TFA]) to afford a colourless solid (177 mg, 82%).
'H-NMR (acetone-dd, 400 MHz): 5 8.97 (s, IH), 8.49 (d, J= 8,5 Hz, IH), 7.64 (dd,y= 8.6, 1.7 Hz, IH), 7.57 (d,y= 1.4 Hz, IH), 7.24 (s, IH), 7.13 (dd,J= 8.5,2.0 Hz, IH), 6.76 (d, y= 8.5 Hz, IH), 4.60 (m, IH), 4.22 (m, 2H), 3.93 - 3.69 (m, 6H), 3.85 (s, 3H), 3.21 (s, 2H), 2.44 - 2.22 (m, 4H), 2.20 (s, 3H) APCI-MS: m/z 489 (MH*).
Example 122
4-(acetylamino)-3-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyljoxy}benzoic acid trifluoroacetate (salt)
To a stirred solution of methyl 4-(acetylamino)-3-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-ptperidin]-r-yl)-2-hydroxypropyl]oxy}benzoate trifluoroacetate salt (175 mg, 0.29 mmol) in ethanol (4 ml) was added 2 M aq. NaOH (4 ml). The reaction mixture was stirred at room temperature overnight. Then pH was adjusted to 5 by addition of TFA.
The mixture was concentrated in vacuo and purified by HPLC (eluent: [acetonitrile / water
+ 0.1 % TFA]) to afford colourless solid (114 mg, 67 %).
'H-NMR (acetone-d6,400 MHz): 8 8.96 (s, 1H), 8.48 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 8.5,
1.6 Hz, 1H), 7.58 (d,/= 1.1 Hz, 1H), 7.24 (s, 1H), 7.13 (dd,/= 8.5,2.1 Hz, 1H), 6.76(d,
7= 8.5 Hz, 1H), 4.61 (m, 1H), 4.23 (m, 2H), 3.96 - 3.42 (m, 6H), 3.21 (s, 2H), 2.48 - 2.21
(m, 4H), 2.20 (s, 3H)
APCI-MS:m/z475(MH+).
Example 123
Ar-(2-{[(25)-3-(5-chIoro-3'-nuoro-l'^J3/Jr-spiro[l-benzofuran-2,4'-pipcridinJ-l'-yl)-2-
hydroxypropyI]oxy}-4-hydroxyphenyl)acetamide
The title compound was prepared as described in Example 27 from 5-chloro-3'-fhioro-3H-spiro(l-ben2ofuran-2,4'-piperidine) (57.3 mg, 0.212 rhmol) and 4-{(acetylamino)-3-(2S)-oxiran-2-y!methoxy]phenyl acetate (51.2 mg, 0.216 mmol) and to give 18 mg (18%) of the title compound. APCI-MS: m/z 465 (M+H)*
Example 124
2-{[(2S)-3-(5-chloro-l'HJ3H-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxypropyI)benzamide
Resin-bound carbodiimide (60 mg, 0.08 mmol) was allowed to swell in dichloromethane (0.5 mL) for 30 minutes. 2-{[(25)-3-(5-chloro-r/f,3//-spiro[l-ben2ofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoicacid (24.7 mg, 0.045 mmol, 0.3 M in l-methyl-2-pyrrolidinone) was added and after additionally 30 minutes 1-aminopropan-2-ol (0.21 ml, 0.3 M in l-methyl-2-pyrrolidinone) was added. After reaction over night at room temperature the resin was filtered off, and washed with several portions of dichloromethane. The organic layers were combined and evaporated. The crude material of2-{[(2^)-3-(5-cli[oro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-AK2-hydroxypropyl)-4-[(4-me1hoxybenzyl)oxy]benzamide was dissolved in trifluoroacetic acid/dichloromethane (1.2 mL 70/30) and stirred overnight at room temperature. The solvents were evaporated and the resulting crude material was purified on CIS with acetonitrile/water 0.1% trifluoroacetic acid as mobile phase. Pure fractions were collected, pooled and evaporated to give the title compound as the trifluoroacetate. APCI-MS ra/z: 490 [MH+]
The following compounds in Examples 125 to 166 were prepared by methods analogous to the method described in Example 124.
Example 125
2-{[(2S)-3-(S-chloro-llH,3H-spiro(l-benzofuran-2,4r-piperidin]-l1-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxy-l,l-dimethylethyl)benzamide
APCI-MS m/z: 505 [MH+]
Example 126
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2J4l-piperidinl-l(-yI)-2-
hydroxypropyl]oxy}-N-cyclopentyl-4-hydroxybenzaniide
APCI-MS m/z: 501 [MH+]
Example 127
2-{[(2S)-3-(S-chloro-llH,3H-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyI]oxy}-4-hydroxy-N-(2-methoxyethyl)benzamide
APCI-MS m/z: 491 [MH*]
Example 128
2-{[(2S)-3-(S-chloro-rH53H-spSro[l-benzofuran-2)4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxyphenyl)benzamide
APCI-MS m/z: 525 [MH*]
Example 129
N-(tcrt-butyl)-2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-
2-hydroxypropyl]oxy}-4-hydroxybenzamide
APCI-MS m/z: 489 [MH*]
Example 130
2-{((2S)-3-(5-chloro-l'H,3H-spiro[l-ben2ofuran-2,4'-piperidm]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxy-l-methylethyI)benzamide
APCI-MS m/z: 491 [MH+]
Example 131
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-Piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-isobutylbenzamide
APCI-MS m/z: 489 [MH*]
Example 132
2-{((2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2J4'-piperidinI-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(4-hydroxycyclohexyI)benzamide
APCI-MS m/z: 530 [MH*]
Example 133
2-{[(2S)-3-(5-chIoro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-
hydroxypropy!]oxy}-N-(2,3-dihydroxypropyl)-4-hydroxybenzamide
APCI-MS m/z: 507 [MH+]
Example 134
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxyethyl)-N-methyIbenzamide
APCI-MS m/z: 491 [MH+]
Example 135 methyl N^-
hydroxypropyl]oxy}-4-hydroxybenzoyl)serinate
APCI-MS m/z: 535 [MH*]
Example 136
hydroxypropylloxy}-N-(l-ethylpropyl)-4-hydroxybenzamide
APCI-MS m/z: 503 [MH+]
Example 137
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2J4l-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(tetrahydrofuran-2-ylmethyl)benzamide
APCI-MS m/z: 517 [MH*]
Example 138
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-214l-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-[l-(hydroxymethyl)-2,2-dimethylpropyl]benzaraide
APCI-MS m/z: 533 [MH+]
Example 139
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidinl-ll-yl)-2-hydroxypropyI]oxy}-N-{l(lS,2R,5S)-6,6-dimethylbicyclo(3,l.l]hept-2-yl]methyl}-4-hydroxybenzamide
APCI-MS m/z: 569 [MH*]
Example 140
2-{[(2S)-3-(5-chloro-llH,3H-sptro(l-benzofuran-214'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-[l-(hydroxymcthyl)-2-methylpropyl]benzamide
APCI-MS m/z: 519 [MH+]
Example 141
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidinj-l'-yl)-2-
hydroxypropylloxy}-4-{[4-(2-hydroxyethyl)piperazin-l-yl]carbonyl}phenol
APCI-MS m/z: 546 [MH*]
Example 142
3-{[(2S)-3-(S-chIoro-l'H,3H-spiro[l-bcnzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-{[3-(hydroxymethyl)pipcridin-l-yl]carbonyl}phenol
APCI-MS m/z: 531 [MH*]
Example 143
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-N-[5-(l,l-dimethylpropyl)-2-hydroxyphenyl]-4-hydroxybenzamide
APCI-MS m/z: 595 [MH+]
Example 144
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-
hydroxypropyI]oxy}-4-hydroxy-N-|3-(l-hydroxyethyl)phenyl]benzarnide
APCI-MS m/z: 553 [MH+]
Example 145
2-{[(2S)-3-(5-chIoro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-
hydroxypropyI]oxy}-N-(cyclopropylmethyI)-4-hydroxybenzamide
APCI-MS m/z: 487 [MH*]
Example 146
2-{|(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-ll-yl)-2-hydroxypropylloxy}-4-hydroxy-N-pyrrolidin-l-ylbenzamide
APCI-MS m/z: 502 [MH+]
Example 147
N-[(lR,4S)-bicyclo[2.2.1Jhept-2-yI]-2-{l(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-
2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzamide
APCI-MS m/z: 527 [MH*]
Example 148
4-(4-chlorophcnyl)-l-(2-{[(2S)-3-(S-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-
l'-yl)-2-hydroxypropyIloxy}-4-hydroxybenzoyl)piperidin-4-ol
APCI-MS m/z: 627 [MH+]
Example 149
2-{I(2S)-3-(5-chloro-rH,3H-spiroll-benzoruran-2,4'-piperidinl-l'-yl)-2-
hydroxypropy!Joxy}-4-hydroxy-N-(2-hydroxy-l-phenyIethyl)benzamide
APCI-MS nVz: 553 [MH+]
Example ISO
l-(2-{((2S)-3-(5-chloro-l'H,3H-spiroll-benzofuran-2,4'-piperidin]-l'-yI)-2-
hydroxypropyI]oxy}-4-hydroxybenzoyl)-4-phenylpiperidln-4-ol
APCI-MS m/z: 593 [MH*]
Example 151
3-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-
hydroxypropyI]oxy}-4-(3,4-dihydroisoquinolin-2(lH)-ylcarbonyl)pheno!
APCI-MS m/z: 549 [MH+]
Example 152
hydroxypropyI]oxy}-4-{(2-(hydroxymethyI)piperidin-l-yl]carbonyl}phenol
APCI-MS m/z: 531 [MH*]
Example 153
l-{2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-ben2ofuran-2,4I-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)-N,N-dimethylprolinamide
APCI-MS m/z: 558 [MH+]
Example 154
methyl (4R)-l-(2-{[(2S)-3-(5-chloro-llH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl>
2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-hydroxyprolinate
APCI-MS m/z: 56 1
Example 155
(3R)-l-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidinJ-r-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-3-ol
APCI-MS m/z: 517 [MH+]
Example 156
2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxycyc!ohexyl)benzamide
APCI-MS m/z: 53 1 [MH*]
Example 157
3-{((2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4?-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-((4-phenylpiperidin-l-yl)carbonyl]phenol
APCI-MS m/z: 577
Example 158
3-{[(2S)-3-(S-chloro-llH)3H-spiro(l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-(thiomorpholin-4-ylcarbonyl)phenol
APCI-MS m/z: 519 [MH+]
Example 159
l-(2-{((2S)-3-(5-chIoro-l(H3H-spiro[l-benzofuran-2,4r-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)piperidin-3-ol
APCI-MS m/z: 517 [MH+]
Example 160
2-{[(2S)-3-(5-chloro-llH,3H-spiro[l-benzofuran-2,41-piperidin]-lr-yl)-2-
hydroxypropyl]oxy}-N-(cyclopropylmethyl)-4-hydroxy-N-propyIbenzamide
APCI-MS m/z: 529 [MH+]
Example 161
2-{[(2S)-3-(S-chloro-llH,3H-spiro[l-benzofuran-2,4'-piperidinJ-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N,N-diisobutylbenzamide APCI-MS m/z: 545 [MH*J
Example 162
3-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyIJoxy}-4-(l,3-dihydro-2H-isoindol-2-ylcarbonyl)phenol
APCI-MS ra/z: 535 [MH*]
Example 163
N-(2-tert-butoxyethyO-2-{[(2S)-3-(5-chloro-rH,3H-spiro[l-benzofuran-2,4'-
piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-isobutyIbenzamide
APCI-MS m/z: 589 [MH*]
Example 164
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyljoxy}-4-[(4-fluoropiperidin-l-yI)carbonyl]phenol
APCI-MS m/z: 5 19 [MH*]
Example 165
3-{l(2S)-3-(5-chloro-rH,3H-spiro{l-benzofuran-2,4'-piperidin]-l'-yl>2-
hydroxypropyl]oxy}-4-[(4,4-difluoropiperidin-l-yl)carbonyl]pheno!
APC1-MS m/z: 537 [MH*]
Example 166
2-{l(2S)-3-(5-chloro-l'H,3H-spiro{l-benzofuran-214'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-N-phenylbenzamide
APCI-MS m/z: 493 [MH+]
The following compounds in Examples 167 to 21 1 were prepared as described in Example 124 using 6-Chloro-3#-spiro[2-benzofuran-l,4'-piperidine] as starting material
Example 167
hydroxypropyl]oxy}-4-({(2JR)-2-[hydroxy(diphenyl)methyl]pyrrolidin-l-yl}carbonyl)phenol
APCI-MS m/z: 669 [MH+]
Example 168
2-{[(2i)-3-(5-chloro-ll/r,3^-spiro[2-benzofuran-l,4'-piperidin]-l'-yI)-2-
hydroxypropyl]oxy}-4-hydroxy-Ar-(2-hydroxyethyl)-Ar-tnethylbenzarnide
APCI-MS m/z: 49 1 [MH+]
Example 169
3-{[(25)-3-(5-chloro-l(//r}-spiroI2-benzofuran-l,4l-piperidinl-l'-yl)-2-hydroxypropyl]oxyH-(pyrrolidin-l-ylcarbonyl)phenoI
APC1-MS m/z: 487 [MH*]
Example 170
3-{[(250-3-(S-ch!oro-l'H,3//-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-{[4-(2-hydroxyethyl)piperazin-l-yl]carbonyl}pheno!
APCI-MS m/z: 546 [MH+]
Example 171
3-{[(24y)-3-(5-chioro-lI//,3^-spiro[2-benzofuran-l)4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-{[3-(hydroxymethyl)piperidin-l-yl]carbonyl}phenol
APCI-MS m/z: 531 [MH+]
Example 172
4-(4-chlorophenyI)-l-(2-{[(2lS}-3-(5-chloro-l'//,3^/-spiro[2-benzofuran-l,4'-piperidinI
l'-yl)-2-hydroxypropylJoxy}-4-hydroxybcnzoyI)piperidin-4-ol
APCI-MS m/z: 627 [MH*J
Example 173
3-{I(25)-3-(5-chloro-ll^,3//-spiro[2-benzofuran-l,4l-piperidinl-l'-yl)-2.
hydroxypropyl]oxy}-4-{[4-(hydroxymethyl)piperidin-l-yI]carbonyl}phenol
APCI-MS m/z: 531 [MH*]
Example 174
l-(2-{[(21S)-3-(5-chloro-r^,3/f-spiro[2-benzofuran-l,4I-PipcridinJ-lt-yl)-2-
hydroxypropyljoxy}-4-hydroxybenzoyl)-4-phenyIpiperidin-4-ol
APCI-MS m/z: 593 [MH+]
Example 175
3-{[(2iS)-3-(5-chloro-l'/f,3fl'-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-(3,4-dihydroisoquinoHn-2(l^)-ylcarbonyl)phenoI
APCI-MS m/z: 549 [MH+]
Example 176
3-{[(25)-3-(5-chloro-l1^,3iT-spiro[2-benzofuran-l,4I-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-{[2-(hydroxymethyl)piperidin-l-yl]carbonyl}phenol
APCI-MS m/z: 531 [MH+]
Example 177
3-{l(25)-3-(S-chloro-l'//,3/^-spiro{2-benzofuran-l,4'-piperidin]-lt-yl)-2-
hydroxypropyl]oxy}-4-{[3-(dimethylamino)pyrrolidin-l-yl]carbonyl}phenol
APCI-MS m/z: 530 [MH+]
Example 178
l-(2-{((25')-3-(S-chloro-lW)3Jff-spiro[2-benzofuran-l,4l-piperidin]-lf-yl)-2-
hydroxypropylloxyJ^-hydroxybenzoyO-^^V-dimethylprolinamide
APCI-MS m/z: 558 [MH"]
Example 179
2-{[(21S)-3-(5-chloro-l'/f,3//'-spiro[2-benzofuran-l,4I-piperidin]-lf-yl)-2-
hydroxypropyl]oxy}-A':-cycIohexyl-4-hydroxy-Ar-(2-hydroxyethyl)benzamide
APCI-MS m/z: 559 [MH+]
Example 180
methyl (4/Z)-l-(2-{[(25)-3-(5-chloro-l rjy,3/f-spiro[2-benzofuran-l,4'-piperidin]-l »-yl).
2-hydroxypropyl]oxy}-4-hydroxybenzoyI)-4-hydroxyproUnate
APCI-MS m/z: 561 [MH+]
Example 181
(3JR)-l-(2-{[(2^)-3-(5-chJoro-l'-Hr,3/r-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-hydroxypropyljoxy}-4-hydroxybenzoyl)piperidln-3-ol
APCI-MS m/z: 517 [MH*]
Example 182
3-{[(2iy)-3-(5-chloro-l'jyj3JHr-spiro{2-ben2ofuran-l,4'-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-((4-phenylpiperidin-l-yl)carbonyl]phenol
APCI-MS ra/z: 577 [MH+]
Example 183
3-{[(25}-3-(5-chloro-l'^,3^-spiro[2-benzofuran-l,4'-piperidin]-l1-yl)-2-
hydroxypropy!Joxy}-4-(thiomorpholin-4-ylcarbonyl)phenol
APCI-MS m/z: 519 [MH*]
Example 184
l-(2-{[(2,y)-3-(5-chloro-ll//,3/ir-spiro[2-benzofuran-l,4'-piperidin]-l'-yl>2-
hydroxypropyI]oxy}-4-hydroxybenzoyl)piperidin-3-oI
APCI-MS m/z: 517 [MH+]
Example 185
2-{[(25)-3-(5-chloro-r^,3^-spiro[2-benzofuran-l,4'-piperidinJ-l'-yl)-2-
hydroxypropylloxyJ-A^^ycIopropylmethyO^-hydroxy-jV-propylbenzamide
APCI-MS m/z: 529 [MH+]
Example 186
2-{[(2S)-3-(5-chloro-l'/f,3/r-spiro[2-benzofuran-l,4'-piperidin]-ll-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-AVV-diisobutylbenzamide
APCI-MS ra/z: 545 [MH+]
Example 187
3-{l(2lS)-3-(5-chloro-r^,3fr-spiro[2-benzofuran-lJ4l-piperidin]-r-yl)-2-hydroxypropyl]oxy}^-(l,3-dihydro-2#-isoindol-2-ylcarbonyl)phenol
APCI-MS m/z: 535 [MH*]
Example 188
Ar-(2-/ert-butoxyethyl)-2-{[(25)-3-(5-chloro-l'fir,3H-spiroI2-benzofuran-l,4l-
piperidin]-r-yl)-2-hydroxypropyl)oxy}-4-hydroxy-Af-isobutylbenzaraide
APCI-MS m/z: 589 [MH*]
Example 189
3-{[(21S)-3-(5-chloro-r^r3^-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-[(4-fluoropiperidin-l-yI)carbonyI]phenol
APCI-MS m/z: 519 [MH*]
Example 190
3-{[(2^)-3-(5-chIoro-l'Jff,3£r-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-4-[(4,4-difluoropiperidin-l-yl)carbonyI]phenol
APCI-MS m/z: 537 [MH4"]
Example 191
2-{[(25)-3-(5-chloro-l'J&,3fi'-spiro[2-benzofuran-l,4f-piperidin]-ll-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-Ar-(2-hydroxypropyI)benzamide
APCI-MS m/z: 491 [MH*]
Example 192
2-{[(2S)-3-(5-chloro-p,3-spiro[2-benzofuran-l,4l-piperidin]-r-yl)-2-
hydroxypropylloxyJ-hydroxy--hydroxy-ljl-dimethylethylJbenzamide
APCI-MS m/z: 505 [MH+]
Example 193
2-{[(25)-3-(S-chIoro-l'/f,3H-spiro(2-benzofuran-l,4'-piperidinl-r-yI)-2-hydroxypropy!Joxy}-Ar-cyclopentyl-4-hydroxybenzamide
APCI-MS m/z: 50 1 [MH+]
Example 194
2-{[(2.S)-3-(5-chloro-lI//,3H-spiro[2-benzofuran-l,4'-piperidin]-ll-yI)-2-
hydroxypropyl]oxy}-4-hydroxy-A/-(2-methoxyethyl)benzamide
APCI-MSm/z:491
Example 195
2-{[(25)-3-(5-chloro-r/f,3/ir-spiro[2-benzofuran-l,4'-piperidin]-ll-yl)-2-
hydroxypropylJoxy^-hydroxy-AH^-hydroxyphenyObenzamide
APCI-MS m/z: 525 [MH+]
Example 196
2-{[(2lS)-3-(S-chIoro-lt,3Jff-spiro[2-benzofuran-l,4t-piperidin]-l'-yl)-2-
hydroxypropylJoxyJ-hydroxy-A-hydroxy-l-methylethylJbenzamide
APCI-MS m/z: 491 [MH*]
Example 197
2-{[(25)-3-(5-chloro-l'//,3/ir.spiro[2-benzofuran-l,4l-piperidin]-ll-yl)-2-
hydroxypropylJoxy}-4-hydroxy-A'-isobutylbenzamide
APCI-MS m/z: 489 [MH+]
Example 198
2-{[(2lS)-3-(5-chloro-l'/r,3JHr-spiro[2-benzofuran-l,4l-piperidin]-r-yl)-2-
hydroxypropyI]oxy}-4-hydroxy-Ar-(2-hydroxyethyl)benzamide
APCI-MS m/z: 477 [MH*]
Example 199
hydroxypropyl]oxy}-4-hydroxy-AK4-hydroxycyclohexyl)benzamide
APCI-MS m/z: 531 [MH]
Example 200
2-{[(25)-3-(5-chIoro,3F-spiroI2-ben2ofuran-l,4I-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-./V-(2,3-dihydroxypropyl)-4-hydroxybenzamide
APCI-MS ro/z: 507 [MH]
Example 201
methyl Ar-(2-{[(25)-3-(5-chloro-ltjy,3JHr-spJro[2-benzofuran-l,4l-piperidin]-l1-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)serinate
APCI-MS m/z: 535 [MH]
Example 202
2-{[(25)-3-(5-chloro-l'fi,3ff-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-Ar-(l-ethylpropyl)-4-hydroxybenzamide
APCI-MS m/z: 503 [MH]
Example 203
2-{[(25)-3-(5-chloro-l'/,3/f-spiro[2-benzofuran-l,41-piperidin]-ll-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-A-(tetrahydrofuran-2-ylmethyl)benzamide
APCI-MS m/z: 517 [MH]
Example 204
2-{[(2lS)-3-(5-chloro-l1jy,3H-spiro[2-benzofuran-l)4I-piperidin]-r-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-Ar-[l-(hydroxymethyI)-2,2-dimethylpropyl]benzamide
APCI-MS m/z: 533 [MH+]
Example 205
2-{[(25)-3-(5-chloro-l'/f,3//'-spiro[2-benzofuran-l34I-piperidin]-r-yi)-2-hydroxypropyl]oxy}-4-hydroxy-/V-(l-(hydroxymethyl)~2-methylpropyl]benzamide
APCI-MS m/z: 519 [MHJ
Example 206
2-{[(2lS)-3-(5-chIoro-rH,3-spiro(2-benzofuran-l,4'-piperidin]-l'-yI)-2-
hydroxypropyl]oxy}-4-hydroxy-Ar-13-(l-hydroxyethyl)phenylJbenzamide
APCI-MS m/z: 553 [MH+]
Example 207
2-{[(25)-3-(5-chloro-lI,3-spiro(2-benzofuran-l>41-piperidin]-l'-yl)-2-
hydroxypropylJoxy}-AKcyclopropyImethyI)-4-hydroxybenzamide
APCI-MS m/z: 487 [MH+]
Example 208
2-{[(21y)-3-(5-chloro-ll/r,3//-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-
hydroxypropyljoxyJ-hydroxy-Apyrrolidin-l-ylbenzamidc
APCI-MS m/z: 502 [MH+]
Example 209
/V-[(l/?,45)-bicyclo[2.2.1jhept-2-ylJ-2-{[(25)-3-(5-chIoro-l1/r,3/f-spiro[2-benzofuran-
M'-piperidmJ-l'-yO-hydroxypropylloxyJ-hydroxybenzamide
APCI-MS m/z: 527 [MH]
Example 210
2-{[(25)-3-(5-chloro-lI3/r-spiro{2-benzofuran-l,4'-PiPcridin]-r-yl)-2-
hydroxypropyl]oxy}-4-hydroxy-A':(2-hydroxy-l-phenyIethyl)benzamide
APCI-MS m/z: 553 [MH+]
Example 211
2-{l(2,5)-3-(S-chloro-rflr,3Jflr-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-hydroxyT/V-(2-hydroxycyclohexyl)benzamide
APCI-MSra/z:531[MHJ
Example 212
l-(2-{[(2lS)-3-(5-chloro-l'/ir>3//-spiro[l-benzofuran-2,4'-piperidin]-ll-y!)-2-hydroxypropyl]oxy}-4-hydroxyben2oyl)pyrrolidine-3-carboxamide trifluoroacetate
Step I:
l-{2-{((25)-3-(5-chloro-l'//,3H-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-
hydroxypropyI]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}pyrrolidine-3-carboxamide
A mixture of PS-carbodiimide (425 mg, 0.54 mmol) and dichloromethane (5 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(2,$')-3-(5-chloro-r.£/',3//-spiro[l-ben2ofuran-2,4l-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (160 mg, 0.27 mmol) in NMP (2.5 mL) and dichloromethane (2.5 mL) was added. The mixture was stirred for 30 minutes, and a mixture of pyrrolidine-3-carboxamide hydrochloride (73 mg, 0.48 mmol) and triethylamine (73 u,L, 52 mmol) in dichloromethane (2.5 mL) was added. The mixture was stirred at room temperture overnight and filtrated. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave (55 mg, yield 31%) of the subtitle compound. APCI-MS: m/z 650 (MH*)
Step II:
l-(2-{[(2lS)-3-(5-chloro-lt//)3J3r-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyI]oxy}-4-hydroxybenzoyl)pyrrolidine-3-carboxamide trifluoroacetate
To a solution of l-{2-{[(2ly)-3-(5-chloro-l1//)3//-spiro[l-benzofuran-2,41-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}pyrrolidine-3-carboxamide (55 mg, 0.084 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 1 h, volatiles were removed, the residue
was purified by HPLC (acetonitrtle/water, 0.1 % trifluoroacetic acid) to give 23 mg (42 %)
of the title compound.
'H-NMR (acetone-dfi) 400 MHz): 5 7.28-7.22 (m, 1H); 7.18-7.07 (m, 2H); 6.83-6.75 (m,
1H); 6.67-6.57 (m, 1H); 6.56-6.48 (m, 1H); 4.62-4.46 (m, 1H); 4.21-3.92 (m, 2H); 3.91-
3.44 (m, 8H); 3.44-3.26 (m, 2H); 3.26-3.06 (m, 3H); 2.50-2.01 (m, 6H).
APCI-MS: m/z 530 (MtT)
Example 213
l-(2-{[(25)-3-(5-chloro-l'^,3^-spiro[l.benzofuran-2,4'-piperidinl-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-L-prolinamide trifluoroacctate
Step I:
l-{2-{[(2lS)-3-(5-chloro.l'/f,3^/-spiro(l-benzofuran-2,4'-piperidin]-r-yI)-2-
hydroxypropyI]oxy}-4-[(4-methoxybenzyl)oxy|benzoyl}-L-prolinamide
A mixture of PS-carbodiimide (425 mg, 0.54 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 2-{[(21S)-3-(5-chloro-l'//,3//-sp iro[ I -benzo ruran-2,4'-piperidin] -1 *-yl)-2-hydrox ypropyl] oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (160 mg, 0.27-mmol) in NMP (1.5 mL) and dichloromethane (2 mL) was added. The mixture was stirred for 30 minutes, and a mixture of L-prolinamide (46 mg, 0.40 mmol) in dichloromethane (2 raL) was added. The mixture was stirred at room temperture overnight and filtrated. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave 85 mg (48 %) of the subtitle compound. APCI-MS: m/z 650 (MH*)
Step II:
l-(2-{((25)-3-(5-chloro-l'//,3//-spiro[l-benzofuran-2,4t-pipendin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-L-prolinamide trifluoroacetate
To a solution of !-{2-{[(25)-3-(5-chloro-l'/:rj3//-spiro[l-benzofiiran-2,41-piperidm]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl}-L-prolinamide (85 mg, 0.13 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 1 h, volatiles were removed, the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 37 mg (44 %) of the title compound.
'H-NMR (acetone-^, 400 MHz): 8 7.23 (s, 1H); 7.19-7.10,7.06-7.03 and 6.61-6.54 (m, 5H); 6.77 (d,J = 8.3 Hz, 1H); 6.53-6.48 and 6.46-6.42 (m, 1H); 4.61-4.55 (m, 1H); 4.55-4.47 (m, 1H); 4.17-4.08 (m, 1H); 4.05-3.94 (ra, 1H); 3.88-3.70 (m, 2H); 3.70-3.28 (m, 6H); 3.16 (br. s, 2H); 2.47-2.14 (m, 4H); 2.10-1.77 (m, 4H). The compound exists in solution as a mixture of 2 rotamers. APC1-MS: m/z 530 (MH+)
Example 214
2-chloro-5-{[(25)-3-(5-chloro-l'//,3/ir-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hyd roxypropyl]oxy}-4- {[(3J?)-3-(dirnethylamino)pyrrolidin-l-ylJcarbonyl} phenol bis(trifluoroacetate)
Step 1:
methyl 5-chloro-2-hydroxy-4-[(4-methoxybenzyOoxy]benzoate
A mixture of l-(chloromethyl)-4-methoxybenzene (1.53 g, 9.8 mmol), methyl 5-chloro-2,4-dihydroxybenzoate (1.98 g, 9.8 mmol) and potassiumcarbonate (1.35 g, 9.8 mmol) in acetone (15 mL) was stirred at reflux overnight. The mixture was filtered, solvent was removed in vacuo, the residue was dissolved in ethyl acetate and was washed with brine two times. The organic layer was dried over sodium sulphate, solvent was removed in vacuo and the residue was purified by recrystillaziation from methanol. (1.46 g, 46 %) of the title compound was obtained.
'H-NMR (CDClj, 400 MHz): 5 10.90 (s, 1H); 7.84 (s, 1H); 7.39 (d, 7-8.5 Hz, 2 H); 6.94 (d,J =8.7 Hz, 2H); 6.57 (s, 1H); 5.10 (s, 2H); 3.93 (s, 3H); 3.83 (s, 3H).
Step II:
methyl 5-chIoro-4-[(4-methoxybenzyl)oxy]-2-[(2.y)-oxiran-2-ylinethoxy]ben2oate
A mixture of methyl 5-chloro-2-hydroxy-4-[(4-methoxybenzyl)oxyJbenzoate (1.78 g, 5.5 mmol), (2,S)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (1.43 g, 5.5 mmol) and cesiumcarbonate (2.15 g, 6.6 ramol) in NMP (15 mL) was stirred at room temperture overnight. Water was added to the mixture and it was then extracted with with ethyl acetate three times. The combined organinc layers was washed with water, dried over sodium sulphate and solvent was removed in vacuo. The residue was purified by silica gel flash chromatography (ethyl acetate / heptane 10-30 %), (1.66 g, 79 %) of the title compound was obtained.
'H-NMR (CDC13, 300 MHz): 5 7.92 (s, 1H); 7.39 (d, J - 8.8 Hz, 2H); 6.93 (d, J- 8.7 Hz, 2H); 6.67 (s, 1H); 5.15 (s, 2H); 4.35 (dd, J = 2.5, 11.5 Hz, 1H); 4.02-3.96 (m, 1H); 3.87 (s, 1H); 3.83 (s, 3H); 3.41-3.35 (m, 1H); 2.95-2.88 (m, 2H). APCI-MS: m/z 379 (MH*)
Step III:
methyl 5-chloro-2-{[(2iS)-3-(5-chloro-l'//,3Jy-spiro(l-benzofuran-2,4l-piperidin]-ll-
yl)-2-hydroxypropyl]oxy}-4-((4-methoxybenzyl)oxy]benzoate
A mixture of 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidine] (420 mg, 1.9 mmol) and methyl 5-chloro-4-[(4-methoxybenzyl)oxy]-2-[(2,S)-oxiran-2-ylmethoxy]benzoate (710 mg, 1.9 mmol) in ethanol (15 mL) was stirred and heated at reflux overnight. Solvent was removed in vacuo, the residue required no further purification, (1.13 g, 100%) of the title compound was obtained. APCI-MS: m/z 602 (MH+)
Step IV:
5-chloro-2-{[(2lS)-3-(5-chloro-l13//-spiro[l-benzofuran-2)41-piperidin]-lr-y])-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride
A mixture of methyl 5-chloro-2-{[(25)-3-{5-chloro-l'//,3//'-spiro[l-benzofliran-2J4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]ben2oate (1.13 g, 1.9 mrnol), potassium hydroxide (15 g), water (15 mL) and ethanol (50 mL) was stirred att room temperture for two hours. Ethanol was removed in vacuo, aqueous hydrochloric acid (37 %) was added until pH = 1, the mixture was extracted with ethyl acetate, washed with brine and dried with sodium sulphate. Solvent was removed in vacuo, no further purification was needed, (1.05 g, 89 %) of the title compound was obtained. APC1-MS: m/z 588 (MH+)
Step V;
(25)-l-{4-chloro-2-{[(3J?)-3-(dimethylamino)pyrrolidin-l-ylJcarbonyl}-5-[(4-methoxybenzyl)oxyJphenoxy}-3-(5-chloro-l'^,3^-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)propan-2-ol
A mixture of PS-carbodiimide (380 mg, 0.49 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 5-chloro-2-{((25}-3-(5-chIoro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (150 mg, 0.24 mmol) in NMP (0.5 mL) and dichloromethane (2.5 mL) was added. The mixture was stirred for 30 minutes, and a mixture of (3/?)-^V,A/'-dimethylpyrrolidin-3-arnine (56 mg, 0.49 mmol) in dichloromethane (2.5 mL) was added. The mixture was stirred at room temperture overnight and filtrated. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave 110 mg, (67%) of the subtitle compound. APCI-MS: m/z 684 (MH4)
Step VI:
2-chloro-5-{[(21y)-3-(5-chloro-l1flrJ3/f-spiro[l-benzofuran-2,4'-piperidin]-l'-yI)-2-hydroxypropyl|oxy}-4-{[(3J?)-3-(dimethyIamino)pyrrolidin-l-yI]carbonyl}phenoI bis(trifluoroacetate)
To a solution of (25)-l-{4-chloro-2-{[(3^)-3-(dimethylamino)pyrrolidin-l-yl]carbonyl}-5-[(4-methoxybenzyl)oxy]phenoxy}-3-(5-chloro-r//,3//-spiro[l-ben2ofuran-2,4'-piperidin]-l'-yl)propan-2-ol (110 mg, 0.16 tnmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperture for 1 hour, volatiles were removed, the residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 45 mg (35 %) of the title compound. 'H-NMR (acetone-d6, 400 MHz,): 8 7,24-7.21 (m, 2H); 7.13 (d,J = 8.9 Hz, 1H); 7.07 and 6.98 (m, 1H); 6.77 (d, J= 8.5 Hz, 1H); 4.66-4.50 (m, 1H); 4.20-3.96 (m, 2H); 3.94-3.70 (m, 2H); 3.68-3.46 (m, 4H); 3.44-3.35 (m, IH); 3.19 (br. s, 2H); 2.97 (s, 3H); 2.93 (s, 3H); 2.58-2.19 (m, 6H). The compound exists in solution as a mixture of 2 rotamers. APC1-MS: m/z 564 (MH+)
Example 215
2-chloro-5-{[(21S)-3-(5-chloro-r/f,3H-spiro[l-benzofuran-2,4'-pipcridin)-l'-yl)-2-hydroxypropyl]oxy}-4-{[(3^)-3-(hydroxymethyl)pyrrolidin-l-yl]carbonyl}phenoI trifluoroacetate
Step I:
(2ly)-l-{4-chloro-2-{[(3/?)-3-(hydroxymethyl)pyrrolidin-l-yI]carbonyl}-5-[(4-methoxybenzyI)oxy]phenoxy}-3-(5-chloro-l'/f,3jF/-spiro[l-benzofuran-2,4'-piperidIn]-l'-yI)propan-2-ol
A mixture of PS-carbodiimide (380 mg, 0.49 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 5-chloro-2-{[(2,S)-3-(5-chloro-1 '#,3//-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxypropyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (150 mg, 0.24 mmol) inNMP (1 mL) and dichloromethane (2.5 mL) was added. The mixture was stirred for 30 minutes, and a mixture of (3^)-pyrrolidin-3-ylmethanol (82 mg, 0.59 mmol) and triethylamine (85 u,L, 61 mmol) in dichloromethane (2.5 mL) was added. The mixture was stirred at room temperture for 48 h and was then filtered. Volatiles were removed in vacuo, the residue
was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave 87 mg (54 %) of the subtitle compound. APCI-MS: m/z 671 (MH*)
Step II:
hydroxypropyl]oxy}-4-{[(3^)-3-(hydroxymethyl)pyrrolidin-l-yljcarbonyI}phenol trifluoroacetate
To a solution of (2,J)-l-{4-chloro-2-{[(3/?)-3-(hydroxymethyl)pyn:olidin-l-yl]carbonyl}-5-
[(4-methoxybenzyI)oxy]phenoxy}-3-(5-chloro-rH,3//-spiro[l-ben2ofuran-2)4l-piperidin]-
l'-yl)propan-2-ol (87 mg, 0.13 mmol) in dichloromethane (3 mL) was added trifluoroacetic
acid (0.3 mL). The mixture was stirred at room temperture for 1 hour, volatiles were
removed, the residue was purified by HPLC (acetonitrile/water, 0. 1 % trifluoroacetic acid)
and gave 23 mg (26 %) of the title compound.
'H-NMR (acetone-d6) 300 MHz): 6 7,24-7.21 (m, 2H); 7.13 (dd, /= 2.4, 8.6 Hz, 1H); 6.97-
6.92 (m, 1H); 6.77 (dd,J = 1.2, 8.6 Hz, 1H); 4.57-4.46 (m, 1H); 4.18-4.04 (m, 2H); 3.92-
3.70 (m, 2H); 3.70-3.30 (m, 10H); 3.29-3.12 (m, 3H); 2,52-2.16 (m, 4H); 2.10-1.68 (m,
2H).
APCI-MS: m/z 55 1 (MH*)
Example 21 6
hydroxypropyl]oxy}-4-{[(3.S)-3-(hydroxymethyl)pyrroHdin-l-yl]carbonyl}phenol trifluoroacetate
The title compound was prepared using (35)-pyrrolidin-3-ylmethanol as described in
Example 2 1 5.
'H-NMR (acetone-d6, 300 MHz): 5 7,26-7.21 (m, 2H); 7.13 (dd, /= 2.3, 8.5 Hz, 1H); 6.97-
6.90 (m, 1H); 6.77 (dd,/ = 1.2, 8.4 Hz, 1H); 4.56-4.46 (m, 1H); 4.17-4.03 (m, 2H); 3.92-
3.70 (m, 2H); 3.70-3.33 (m, 10H); 3.30-3.22 (m, 1H); 3.17 (br. s, 2H); 2,52-2.16 (m, 4H);
2.10-1.68(m,2H).
APCI-MS: m/z 55 l(MrT)
Example 217
2-chloro-5-{((25)-3-(5-nuoro-ll^,3H-spiro[l-benzofuran-2,4r-piperidin]-r-yl)-2-hytiioxypropylJoxy}-4-(pyrrolidin-l-yIcarbonyl)phenoI trifluoroacetate
Step I:
methyl 5-chloro-2-{[(25)-3-(5-fluoro-l'f/,3/f-spiro[l-bcnzofuran-2,4'-piperidin]-r-
yl)-2-hydroxypropyI]oxy}-4-[(4-methoxybenzyI)oxy]benzoate
A mixture of 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (390 mg, 1.9 mraol) and methyl 5-chloro-4-[(4-methoxybenzyl)oxy]-2-[(2.S1)-oxiran-2-ylmethoxy]benzoate (710 mg, 1.9 mmol) in ethanol (15 mL) was stirred and heated at reflux overnight. Solvent was removed in vacuo, the residue was purified by silica gel flash chromatography (dichloromethane / methanol 0-3 %), and gave the subtitle compound, APCI-MS: m/z 586 (MH+)
Step II:
5-chloro-2-{((25)-3-(5-nuoro-ll//>3Jy-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoicacid hydrochloride
A mixture of methyl 5-chloro-2-{[(2lS)-3-(5-fluoro-r//,3/f-spiro[l-benzofliran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate (910 mg, 1.5 mmol), potassium hydroxide (15 g), water (15 mL) and elhanol (50 mL) was stirred att room temperture for three hours. Ethanol was removed in vacuo, aqueous hydrochloric acid (37 %) was added until pH = 1, the mixture was extracted with ethyl acetate, washed with brine and dried with sodium sulphate. Solvent was removed in vacuo, no further purification was needed. 0.91 g (80 % overall yield for Steps I-II) of the title compound were obtained. APCI-MS: m/z 572 (MH4)
Step III;
(2iS)-l-[4-chloro-5-[(4-methoxybenzyl)oxy]-2-(pyrrolidin-l-ylcarbony!)phenoxy]-3-(5-fluoro-l'Jflr,3//-spiro[l-benzofuran-2,4l-piperidinJ-r-yI)propan-2-oI
A mixture of PS-carbodiimide (380 mg, 0.49 mmol) and dichloromethane (3 mL) was stirred at room temperature for 15 minutes, a solution of 5-chloro-2-{[(2^)-3-(5-fluoro-17/,3//-spiro[ I -benzofuran-2,4'-piperidin]-1 -yl)-2-hydroxypropy I] oxy } -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (150 mg, 0.25 mmol) in NMP (0.5 mL) and dichloromethane (2.5 mL) was added. The mixture was stirred for 30 minutes, and a mixture of pyrrolidine (56 mg, 0.49 mmol) in dichloromethane (2,5 mL) was added. The mixture was stirred at room temperture for 48 hours and was then filtrated. Volatiles were removed in vacuo, the residue was purified by HPLC (acetonitrile/water, 0.025% ammonium hydroxid) and gave (45 mg, yield 29 %) of the subtitle compound. APCI-MS: m/z 625 (MH*)
Step IV:
2-chloro-5-{[(2.S)-3-(5-nuoro-l'^,3//r-spiro[l-ben2ofuran-2,4'-piperidin]-ll-yl)-2-hydroxypropyl]oxy}-4-(pyrroIidin-l-yIcarbonyl)phenol trifluoroacetate
To a solution of (2i)-l-[4-chloro-5-[(4-methoxybenzyl)oxy]-2-(pyrrolidin-l-
ylcarbonyl)phenoxy]-3-(5-fluoro-1 7/,3//-spiro[l -benzoruran-2,4'-piperidin]-1 '-yQpropan-
2-ol (45 mg, 0.07 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.3
mL). The mixture was stirred at room temperture for 1 hour, volatiles were removed, the
residue was purified by HPLC (acetonitrile/water, 0.1 % trifluoroacetic acid) and gave 38
mg (87 %) of the title compound.
'H-NMR (acetone-d6,300 MHz): 6 7.24 (s, IH); 7.04-6.98 (m, IH); 6.97-6.94 (m, IH);
6.94-6.84 (m, IH); 6.77-6.72 (m, IH); 4.56-4.45 (m, IH); 4.17-4.06 (m, 2H); 3.90-3.69 (m,
2H); 3.60-3.44 (m, 4H); 3.44-3.28 (m, 4H); 3.16 (br. s, 2H); 2.46-2.14 (m, 4H); 2.00-1.82
(m,4H).
APCI-MS: m/z 505 (MH*)
Example 218 hydroxypropyl]oxy}-4-methoxyphenyl)acetamide
Step I (2R)-2-[(5-Methoxy-2-nitrophenoxy)methyl]oxirane
To a mixture of (2S)-oxiran-2-ylmethanol (296.3 mg, 4.0 mmol), 5-methoxy-2-nitrophenol (676.6 mg, 4.0 mmol) and triphenyl phosphine (1.05 g, 4.0 mmol) in THF (10 mL) was added diethyl azodicarboxylate (DEAD, 704.6 mg, 4.0 mmol) in THF (5 raL) dropwise at room temperature. After addition was completed the reaction mixture was stirred at room temperature overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-40% ethyl acetate in petroleum spirit) to give the subtitled compound (650 mg).
'H-NMR (CDC13) 400 MHz): 5 8.00 (d, J = 9.0 Hz, IH), 6.60 (d, J = 2.5 Hz, IH); 6.55 (dd, J= 2.5, 9.2 Hz, IH); 4.41 (dd, J = 2.7, 11.3 Hz, IH); 4.12 (dd, J = 5.0, 11.3 Hz, IH); 3.90 (s, 3H); 3.41 (m, IH); 2.93 (m, 2H).
Step II Ar-{4-Methoxy-2-[(2R)-oxiran-2-ylmethoxyJphenyl}acetamide
A mixture of (2R)-2-[(5-methoxy-2-nitrophenoxy)methyl]oxirane (620 mg, 2.75 mmol), Pd on charcoal (10%) (250 mg), A^-ethyldiisopropylamine (0.941 mL), acetic anhydride (0.52 mL, 5.5 mmol) in ethyl acetate (25 mL) was hydrogenated at normal pressure for 40 min. The catalyst was filtered off and the filtrate was concentrated. The residue was purified by silica gel flash chromatography (0-60% ethyl acetate in petroleum spirit) to give the subtitled compound (155 mg).
'H-NMR (CDC13,400 MHz): S 8.21 (d,/= 8.7 Hz, IH); 6.52 (m, 2H); 4.35 (dd, J=2.5, 11.4 Hz, IH); 3.93 (dd, /= 6.0,11.4 Hz, IH); 3.80 (s, 3H); 3.40 (m, IH); 2.96 (t,J= 4.6 Hz, IH); 2.78 (dd,7=2.7,4.8 Hz, IH). APCI-MS: m/2 238(MH+).
Step III
7V-(2-{[(2R)-3-(5-Fluoro-r//,3//-spiro[l-benzofuran-2J4'-piperidin]-r-yl)-2-
hydroxypropyljoxy}-4-methoxyphenyl)acetamide
A mixture of 5-fluoro-3tf-spiro[l-benzoftiran-2,4'-piperidine]hydrochloride (154 mg, 0.632 mmol), A^4-Methoxy-2-[(2R)-oxiran-2-ylmethoxy]phenyl}acetamide (150 mg, 0.632 mmol) and K2C03 (87 mg, 0.632 mmol) in ethanol (3 ml) was stirred at 80 °C for 3h. The reaction mixture was partitioned between ethyl acetate and h^O. The organic layer was dried over Na2SC4, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NKjOH) to give the titled compound (100 mg).
'H-NMR (CDC13,400 MHz): 5 8.18 (d, /= 8.6 Hz, 1H); 8.02 (br.s, 1H); 6.87 (m, 1H); 6.80 (m, 1H); 6.66 (dd, J= 4.2, 8.7 Hz, 1H); 6.56-6.51 (m, 2H); 4.18 (m, 1H); 4.04 (dd,/= 3.3, 10.1 Hz, 1H); 3.96 (dd, J= 5.1, 10.1 Hz, 1H); 3.79 (s, 3H); 3.01 (s, 2H); 2.91 (m, 2H); 2.78-2.57 (m, 4H); 2.20 (s, 3H); 2.07-1.84 (m, 4H). APCI-MS: m/z 445(MH*).
Example 219
Methyl 2-{[(2S)-3-(5-nuoro-l'Jflr,3/f-spiro{l-benzofuran-2,4'-piperidin]-r-yI)-2-
hydroxypropyl]oxy}benzoate
A mixture of 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (155.4 mg, 0.75 mmol) and methyl 2-[(2S)-oxiran-2-yImethoxy]benzoate (157 mg, 0.75 mmol) in methanol (4 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1% methanol in dichloromethane, 0.1% NH4OH) to give the titled compound (250 mg).
'H-NMR (CDC13, 400 MHz): 6 7.83 (dd,/= 1.9, 4.1 Hz, 1H); 7.48 (m, 1H); 7.02 (m, 2H); 6.86 (m, 1^:6.79(01, 1H); 6.66 (dd, J =4.2, 8.7 Hz, 1H); 4.26-4.16 (m, 2H); 4.09 (dd,/= 5.7, 9.2 Hz, 1H); 3.90 (s, 3H); 3.00 (s, 2H); 2.90-2.68 (m, 6H); 2.00 (m, 2H); 1.90 (m, 2H). APCI-MS:
Example 220
2-{[(2S)-3-(5-FIuoro-l'//,3-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}benzoic acid (hydrochloride)
Methyl 2-{[(2S)-3-(5-fluoro-r//,3//-spiro[l-benzofuran-2,4I-piperidin]-r-yl)-2-hydroxypropyl]oxy}benzoate (240 mg, 0.58 mmol) was dissolved in THF (4 mL), aqueous KOH (67 mg KOH in 1 mL HaO) was added and the reaction mixture was stirred at room temperature overnight. The pH of the reaction mixture was adjusted to 2.0 by addition of aqueous HC1, extrated with ethyl acetate. The organic layer was washed with hkO, dried over NajSO,!, filtered and concentrated to give the titled compound (210 mg). 'H-NMR(CD3OD,400MHz):57.93(dd,J= 1.8,7.8 Hz, lH);7.57(m, IH); 7.18 (d,J=
8.4 Hz, 1H); 7.10 (t, 7= 7.6 Hz, IH); 6.97 (dd, 7=2.6, 8.1 Hz, 1H); 6.85 (m, IH); 6.73
(dd,7 = 4.2, 8.8 Hz, IH); 4.46 (m, IH); 4.31 (dd,7=4.0, 9.5 Hz, IH); 4.15 (dd, 7 = 5.4,
9.4 Hz, IH); 3.76-3.40 (m, 6H); 3.16 (s, 2H); 2.30 (m, 2H); 2.19 (m, 2H).
APCI-MS:m/z403(MH+).
Example 221
(3S)-l-(2-{[(2S)-3-(5-Fluoro-l'/f,3/r-spiro(l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}benzoyl)pyrroIidln-3-ol
A mixture of 2-{[(2S)-3-(5-fluoro-r//,3//-spiro[l-benzofuran-2,4'-piperidin]-l '-yl)-2-hydroxypropyl]oxy}benzoic acid (hydrochloride) (200 mg, 0.456 mmol) and WTV-carbonyldiimidazole (89 mg, 0.548 mmol) in DMF (3 mL) was stirred at room temperature for 40 min, a slution of 3(S)-pyrrolidin-3-ol (199 mg, 2.28 mmol) in DMF (1 mL) was added and the reaction mixture was stirred at room temperature overnight. The mixture was partitioned between ethyl acetate and HaO, organic layer was dried overNa2SO4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-2% methanol in dichloromethane, 0.2% NH-tQH) to give the titled compound (96 mg). 'H-NMR (CD3OD, 400 MHz): 6 7.42 (m, IH); 7.27 (d, J= 7.4 Hz, IH); 7.11 (dd, J = 2.8, 8.4 Hz, IH); 7.04 (t, 7= 7.4 Hz, IH); 6.90 (dd,7= 2.5, 8.0 Hz, IH); 6.78 (m, IH); 6.63 (dd, 7= 4.2, 8.7 Hz, IH); 4.50 (m, 0.5 H); 4.38 (m, 0.5H); 4.17-4.00 (m, 3H); 3.72 (m IH);
3.63 (m, 1H); 3.50 (m, 1H); 3.373.18 (m, 1H, under methanol peak); 3.02 (s, 2H); 2.77-'2.54(m,6H);2.18-1.78(m,6H). APCI-MS:m/z471(MH+).
Example 222
3-{[(2S)-3-(5-Fluoro-riT,3ff-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-(pyrrolidin-l-ylcarbonyl)phenol
Step I
Methyl 2-{((2S)-3-(5-nuoro-l'fr,3-spiro{l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate
A mixture of 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] (119 rag, 0.577 mmol) and methyl 4-[(4-methoxybenzyl)oxy]-2-[(2S)-oxiran-2-ylmethoxy] benzoate (199 mg, 0.577 mmol) in methanol (3 mL) was stirred at 80 °C overnight. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NtLjOH) to give the subtitled compound (228 mg). 'H-NMR (CDC13, 400 MHz): 5 7.85 (d, J = 8.6 Hz, 1H); 7.36 (d, J = 8.6 Hz, IH); 6.94 (m, 2H); 6.89-6.77 (m, 2H); 6.66 (dd, J=4.1, 8.7 Hz, IH); 6.62-6.57 (m, 2H); 4.28 (m, 1H); 4.12 (dd, J= 4.7, 9.3 Hz, IH); 4.06 (dd, 7= 5.9, 9.3 Hz, IH); 3.88 (s, 3H); 3.85 (s, 3H); 3.00 (s, 2H); 2.98-2.74 (m, 6H); 2.00 (br,s, 4H). APCI-MS: m/z 552(MH+).
Step II
2-{[(2S)-3-(5-FIuoro-l'/f,3^-spiro[l-benzofuran-2,4'piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoicacid (hydrochloride)
Methyl 2-{[(2S)-3-(5-fluoro-r//,3//-spiro[l-benzoruran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoate (220 mg, 0.398 mmol) was taken in ethanol (3 mL), aqueous KOH (224 mg, KOH in 1 mL HaO) was added and the mixture was stirred at reflux temperature overnight, cooled to 0 °C, aqueous HC1 was added until
pH became 2.0, extracted with ethyl acetate, washed with HjO, dried over Na^SC),), filtered
and concentrated to give the subtitled compound (180 mg).
'H-NMR (CD3OD, 400 MHz): 6 7.90 (d, /= 9.1 Hz, 1H); 7.36 (d,y= 8.7 Hz, 2H); 6.98-
6.91 (m, 3H); 6.83 (m, 1H); 6.74-6.68 (m, 3H); 5.10 (s, 2H); 4.44 (m, 1H); 4.27 (dd,J =
4.0, 9.4 Hz, 1H); 4.10 (dd, /= 5.4,9.4 Hz, 1H); 3.80 (s, 3H); 3.77-3.40 (m, 6H); 3.12 (s,
2H);2.30(m,2H);2.15(m,2H).
APCI-MS: m/z 538(MH*).
Step III
(2S)-i-(5-Fluoro-l'//,3.ff-spiro[l-benzofuran-2,4>-piperidin]-l>yO-3-[5-[(4-
methoxybenzyI)oxy]-2-(pyrrolidin-l-ylcarbonyl)phenoxy]propan-2-ol
2-{[(2S)-3-(5-Fluoro-l'//,3//-spiro[l-benzofuran-2,4'piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoicacid (hydrochloride) (136 mg, 0.237 mmol) and //,W-carbonyldiimidazole (46 mg, 0.284 mmol) was taken in DMF (3 mL) and stirred at room temperature for 55 min, pyrrolidine (168.5 mg, 2.37 mmol) was added and stirred at room temperature overnight. The reaction mixture was partitioned between ethyl acetate and HjO. The organic layer was dried over Na2SO,i, filtered and concentrated. The residue was purified by silica gel flash chromatography (0-1.5% methanol in dichloromethane, 0.2% NHjDH) to give the sub titled compound (70 mg). APCI-MS: m/z 552(MH+).
Step IV
3-{|(2S)-3-(5-Fluoro-l'lf,3Jy-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyIJoxy}-4-(pyrrolidin-l-ylcarbonyI)phenol
(2S)-l-(5-Fluoro-l'//,3//-spiro[l-benzoruran-2,4I-piperidin]-ryl)-3-[5-((4-methoxybenzyl)oxy]-2-(pyrrolidin-l-ylcarbonyl)phenoxy]propan-2-ol (65 mg, 0.11 mmol) was treated with 10% CF3C02H in CH2C12 (3 mL) for 25 min at room temperature. The volatiles were removed in vacuo and the residue was purified by silica gel flash chromatography (0-2.5% methanol in dichloromethane, 0.2% NHjOH) to give the titled compound (28 mg).
'H-NMR (CD3OD, 400 MHz): 5 7.07 (d, /= 8.2 Hz, IH); 6.90 (dd, J = 2.6, 8.2 Hz, IH); 6.77 (m, IH); 6.63 (dd, .7=4.2, 8.7 Hz, IH); 6.50 (d, .7=2.1 Hz, IH); 6.44 (dd,7 = 2.1, 8.3 Hz, IH); 4.10 (m, IH); 4.03 (dd,/= 4.3, 9.7 Hz, IH); 3.96 (dd, J = 5.6, 9.7 Hz, 1H);3.56 (t, J = 7.0 Hz, 2H); 3.34 (m, 2H, inside methanol peak);3.01 (s, 2H); 2.70 (br.s, 4H); 2.56 (m,2H);2.01-1.78(m,8H). APCI-MS:m/z47l(MH+).
Example 223
A^-(4-fluoro-2-{[(2^)-3-(5-nuoro-l'/f,3JHr-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2-hy droxy p ropylj oxy} p heny l)acetamide
The title compound was prepared using 5-fluoro-3//-sptro[l-benzofuran-2,4'-piperidine] as
described in Example 2.
'H-NMR (acetone-dfi, 300 MHz): 5 8.63 (br. s, IH); 8.26-8.17 (m, IH); 6.99-6.88 (m, 2H);
6.87-6.76 (m, IH); 6.74-6.62 (m, 2H); 4.25-4.19 (m, IH); 4.19-4.09 (m, IH); 4.07-3.99 (m,
IH); 3.03 (s, 2H); 2.85 (br. s, IH); 2.78-2.60 (m, 4H); 2.60-2.54 (m, 2H); 2.10 (s, 3H);
1.97-1.76 (m,4H).
APCI-MS: m/z 433 (MH+)
Example 224
N-{5-chloro-2-[3-(5-chloro-7'/r,J£r-spiro[l-benzofuran-2,4'-piperidinJ-r-yI)-2-
hydroxypropoxy]-4-hydroxyphenyl}cyclopentanecarboxamide
Step 1: 5-chloro-6-[(triisopropylsiIyI)oxy]-l,3-benzoxazol-2(J//)-one
5-chloro-6-hydroxy-l,3-benzoxazol-2(lff)-°ne (0-93 g, 5 mmol) and imidazole (1.00 g, 15 mmol) were dissolved in dimethylforraarnide (10 mL) with stirring under inert atmosphere. Triisopropylsilylchloride (1.15 g, 6 mmol) was added and the resulting solution was stirred for 3 days. The reaction mixture was partitioned between water and heptane. The organic
layer was washed with water and dried over magnesium sulphate, filtrated and concentrated, to give 1.45 g (85%) of the subtitled compound as a grey solid. APCI-MS: m/z 342 [MH+]
Step II: N-{5-chIoro-2-hydroxy-4-((triisopropylsiIyI)oxy]phenyl}cyclopentanecarboxamide
Bromo(cyclopentyl)magnesium (0.58 mL, 1.16 mmol, 2 M in diethylether) was added under inert atmosphere to a solution of 5-chloro-6-[(triisopropylsilyl)oxy]-l,3-benzoxazol-2(3#)-one (66 mg, 0.19 mmol) in tetrahydroftlran (3 mL). After stirring over night at 70°C, the solution was evaporated and dissolved in ethylacetate. The organic layer was washed with water and IM hydrochloric acid, dried and finally concentrated to give 68 mg (89%) of the subtitled compound as a brown solid. APCI-MS: m/z 412 [MH+]
Step III:
N-{5-chIoro-2-(oxiran-2-yImethoxy)-4-[(triisopropylsilyl)oxy]phenyl}-
cyclopentanecarboxamide
N-{5-chloro-2-hydroxy-4-[(triisopropylsilyl)oxy]phenyl}cyclopentanecarboxamide(140 mg, 0.3 mmol) was dissolved in 1,4-dioxane (20 mL). Caesium carbonate (170 mg, 0.5 mmol) was added, followed by (2S)-oxiran-2-y-methyl 3-nitrobenzenesulfonate (90 mg, 0.3 mmol). After stirring over night at room temperature the mixture was partitioned between ethyl acetate and water. The organic layer was washed with water and concentrated. Purification by HPLC on CIS (Xterra, 5 um, 19x50 mm; acetonitrile/water 60/40 to 100/0 over 15 min) yielded 25 mg (17%) of the titled intermediate compound. 1H-NMR (300 MHz, (CDC13) 5: 8.45 (1H, s); 7.70 (1H, bs); 6.51 (1H, s); 4.27 (IH, dd); 3.88 (IH, dd); 3.39-3.34 (IH, m); 2.98-2.95 (IH, m); 2.80 (IH, dd); 2.79-2.67 (IH, m); 2.02-1.61 (8H, m); 1.36-1.22 (3H, m); 1.17-1.05 (18H, m) APCI-MS: m/z 468 [MH+]
Step IV:
N-{5-chloro-2-[3-(5-chloro-/'H,5jy-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropoxy]-4-hydroxyphenyl}cyclopentanecarboxainide
A solution of5-chloro-3//-spiro[I-benzofuran-2,4'-piperidine] (11 mg, 0.05 mmol) andN-{5-chIoro-2-(oxiran-2-ylmethoxy)-4-[(triisopropylsilyl)oxy]phenyl}cyclopentane-carboxamide (25 mg, 0.05 mmol) in isopropanol (15 tnL) was stirred over night at 65°C, and then concentrated to give 34 mg (98%) of N-{5-chloro-2-[3-(5-chloro-7 T/iJ/f-spirofl-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropoxy]-4-t(triisopropylsilyl)oxy]phenyl}-cyclopentanecarboxamide as a light brown solid, which was dissolved in dimethylformamide (15 mL) and water (1.5 mL). Caesium carbonate (32 mg, 0.10 mmol) was added. The solution was stirred over night at room temperature, and then partitioned between water and ethyl acetate. The organic layer was washed several times with water, dried and concentrated. The residue was purified by HPLC on CIS (Kromasil, 5 urn, acetonitrile/water 10/90 to 60/40 over 20 min) to give the titled compound. APCI-MS: m/z 535 [MH+]
Example 225
N-{5-chloro-2-[3-(5-fluoro-Jr77,J/r-spiro[l-ben2ofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropoxy]-4-hydroxyphenyl}cyclopentanecarboxamide
The title compound was prapered as described in Example 224 using 5-fluoro-3//-spiro[l-benzofuran-2,4 '-piperidine]. APCI-MS: m/z 519 [MH+]
Example 226
N-{5-chloro-4-hydroxy-2-[2-hydroxy-3-(7'jy,J//-spiro[l-benzofuran-2,4'-piperidin]-
l'-yl)propoxy]phenyl}cyclopentanecarboxamide
The title compound was prapered as described in Example 224 using 3//-spiro[l-benzofuran-2,4'-piperidine]. APCI-MS: m/z 501 [MH+]
Example 227
A'-(5-Chloro-2-{[(25^-3-(5-chIoro-l'/f)3/r-spiro[l-benzofuran-2,4'-piperidinJ-ll-yl)-2-hydroxypropyI]oxy}-4-hydroxyphenyI)benzamide trifluoroacetate (salt)
Step I: AX5-Chloro-2,4-dimethoxyphenyI)bcnzamide
To a stirred solution of (5-chloro-2,4-dimethoxyphenyl)amine (1.88 g, 10 mmol) and triethylamine (2.1 mL, 15 mraol) in DCM (50 mL) benzoylchloride (1.3 mL, 11 mmol) was added dropwise while cooled. The reaction was complete in 5. The solution was washed consecutively with 1M sodium hydrogencarbonate solution (10 mL) and water (3 x 10 mL), dried and concentrated in vacua leaving a solid, which was recrystallized from ethylacetate (25 mL) to give a pale gray solid (1.975 g, 67%). APCI-MS: m/z 292 (MH*)
Step II: /V-(5-Chloro-2,4-dihydroxyphenyI)benzamide
To a stirred solution of Ar-(5-chloro-2,4-dimethoxyphenyl)benzamide (292 mg, 1 mmol) in DCM (10 mL) 1M boron tribrornide in DCM (3 mL, 3 mmol) was added dropwise at ambient temperature. A precipitate was formed after 30 min. The stirring was continued over night. The mixture was quenched with methanol (5 mL) and concentrated in vacua leaving an oil which was used without further purification. APCI-MS: m/z 264 (MH+)
Step III:
4-(Benzoylamino)-2-chloro-5-hydroxyphenyl benzoate
To crude //-(5-chloro-2,4-dihydroxyphenyl)benzamide (1 mmol) in acetone (10 mL) potassium carbonate (280 mg, 2 mmol) and benzoylchloride (140 mg, 1 mmol) was added. The mixture was stirred at ambient tempearature over night. The solvent was removed in
vacua and the residue purified by flash chromatography on silica using DCM and methanol
in gradient. The pure compound was obtained as a white solid (153 mg, 42%).
'H-NMR (AcetonA 400 MHz): 8 9.81 (bs, 1H); 9.39 (bs, 1H); 8.21 (d, J = 7.3 Hz, 2H);
8.16 (s, 1H); 8.06 (d,7= 7.3 Hz, 2H); 7,77 (t, 7= 7.6 Hz, 1H); 7.68-7.55 (ra, 5H); 7.07 (s,
1H)
APCI-MS: m/z 368 (MH+)
StepIV: 4-(Benzoylamino)-2-chloro-5-[(2^-oxiran-2-yImethoxy]phenyl benzoate
To a stirred solution of 4-(benzoylamino)-2-chloro-5-hydroxyphenyl benzoate (103 mg, 0.28 mmol) and [(25)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate (73 mg, 0.28 mmol) in DMF (3 mL) cesium carbonate (98 mg, 0.3 mmol) was added. The stirring was continued at ambient temperature over night. The mixture was poured into water and partitioned between water and ethylacetate. The organic phase was washed with water, dried and concentrated in vacua to give a white solid (117 mg, 98%). The solid was used without further purification.
'H-NMR (Aceton-rffc 400 MHz): 8 9.06 (bs, 1H); 8.66 (s, 1H); 8.22 (d, J= 7.5 Hz, 2H); 8.02 (d, J= 7.5 Hz, 2H); 7.77 (t,7= 7.7 Hz, 1H); 7.64 (t, J= 7.7 Hz, 2H); 7.57 (t, J= 7.7 Hz, 2H); 7.30 (s, 1H); 4.57 (dd,J= 2.4, 11.5 Hz, 1H);4.11 (dd, 7-6.2, 11.5 Hz, 1H); 3.49-3.43 (m, 1H); 2.90-2.87 (m, 1H); 2.81-2.78 (m, 2H) APCI-MS: m/z 424 (MH+)
Step V:
Ar-(5-Chloro-2-{[(2lS)-3-(5-chloro-l'/JrJ3jyr-spiro[l-benzofuran-2,4'-piperidin]-lI-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)benzamide trifluoroacetate (salt) A solution of S-chloro-S/f-spirofl-benzofuran^'-piperidine (29 mg, 0.13 mmol) and 4-(benzoylamino)-2-chloro-5-[(25)-oxiran-2-ylmethoxy]phenyl benzoate (55 mg, 0.13 mmol) in ethanol (3 mL) was stirred at 80°C for 2h. 1M NaOH (0.15 mL, 0.15 mmol) was added and the stirring continued at 80°C for Ih. The solvent was evaporated in vacuo and the crude product purified by flash chromatography (silica, DCM and methanol in
Gradient leaving an oil (32 mg), which was dissolved in acetic acid and acified with TFA. After freeze drying the titled compound was obtained as an amorphous solid (36 mg, 42%) 'H-NMR (Aceton^, 400 MHz): 5 9.01 (s, IH); 8.95 (bs, IH); 8.24 (s, IH); 8.23 (s, IH); 8.03-7.98 (m, 2H); 7.59-7.49 (m, 3H); 7.24-7.22 (m, IH); 7.14 (dd, J= 8.5,2.3 Hz, IH); 6.92 (s, IH); 6.76 (d,/= 8.5 Hz, IH); 4.66-4.58 (m, IH); 4.21-4.12 (m, 2H); 3.80-3.53 (m, 3H); 3.53-3.36 (m, 3H); 3.17 (s, 2H); 2.38-2.16 (m, 4H) APCI-MS:m/z543(MH*)
Example228
(S-Chloro-l-iKl^-SKS-fluoro-lT-spiroIl-benzofura'-piperidinJ-l'-ylH-hydroxypropyl]oxy}-4-hydroxyphenyl)benzamide trifluoroacetate (salt)
The compound was prepared using 5-fluoro-3/f-spiro[l-benzoruran-2)4'-pipertdine] as
described in Example 227.
'H-NMR (Acetoiwfo 400 MHz): 5 9.02 (bs, 2H); 8.23 (s, IH); 8.22 (s, IH); 8.01 (d, J =
7.3 Hz, 2H); 7.59-7.49 (m, 3H); 7.01 (d,J= 8.3 Hz, IH); 6.94 (s, IH); 6.88 (ddd, J= 9.0,
2.3 Hz, IH); 6.73 (dd,y= 8.7,4.2 Hz, IH); 4.69-4.59 (m, IH); 4.21-4.12 (m, 2H); 3.86-
3.57 (m, 3H); 3.57-3.36 (m, 3H); 3.17 (s, 2H); 2.40-2.14 (m, 4H)
APCI-MS: m/z 527 (MH*)
Example 229
Wr-(5-Chloro-2-{[(21S)-3-(5-chIoro-l'/f,3flr-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl]oxy}-4-hydroxyphenyl)urca trifluoroacetate (salt)
Step I:
5-ChIoro-2-{[(2,S)-3-(5-chloro-l'/r,3//-spiro[l-benzofuran-2,4'-pIperidin]-r-y0.2-hydroxypropyl]oxy}-4-[(4-raethoxybenzyl)oxy] benzoyl azide
To a stirred slurry of 5-chloro-2-{[(25)-3-(5-chloro-ll//,3//'-spiro[t-benzofuran-2)41-piperidin]-1 '-yl)-2-hydroxypropyl]oxy} -4-[(4-methoxybenzyl)oxy]benzoic acid hydrochloride (235 mg, 0.4 mmol) in DCM (10 mL) triethylamine (60uL, 0.4 mL) was
added to obtain a solution. To the solution diphenyl phosphoryl azide (90 uL, 0.4 mmol) and triethylamine (60uL, 0.4 mmol) were added. The mixture was stirred at ambient temperature over night. The solvent was evaporated in vacuo and the residue purified by flash chromatography (silica, DCM) leaving the subtitled compound as an impure colourless oil (235 mg), which was used in the next step without wurther purification. APCI-MS: m/z 585 (MH+, isocyanate)
Step II:
Ar-(5-ChIoro-2-{[(2^)-3-(5-chloro-l1/f,3-spiro[l-benzofuran-2,4'-piperidin]-lt-yO-2-hydroxypropyIJoxy}-4-hydroxyphenyI)urea trifluoroacetate (salt)
Cmde5-chloro-2-{[(2150-3-(5-chloro-r//,3//'-spiro[l-benzofuran-2)4l-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4-methoxybenzyl)oxy]benzoyl azide (235 mg, 'H-NMR (Aceton-4j, 400 MHz): 5 8.35 (s, IH), 7.70 (br. s, IH), 7.25 (s, IH), 7.14 (dd, y-8.5, 2.0 Hz, IH), 6.77 (d, /= 8.5 Hz, IH), 6.65 (s, IH), 5.92 (br. s, 2H), 4.54 (m, IH), 4.14 (d, /« 9.7 Hz, IH), 4.02 (dd, J= 9.4, 5.1 Hz, IH), 3.95 - 3.65 (m, 2H), 3.60 - 3.39 (m, 4H), 3.21 (s, 2H), 2.43 - 2.18 (m, 4H) APCI-MS: m/z482 (MH*)
Example 230
Af-(5-Chloro-2-{((25}-3-(5-fluoro-r^J3/f-spiro[l-benzofuran-2J4l-piperidinJ-l'-yl)-2-hydroxypropyI]oxy}-4-hydroxyphenyI)urea trifluoroacetate (salt)
The compound was prepared from 5-chloro-2-{[(2iS)-3-(5-chloro-l'//,3//-spiro[l-ben2oruran-2J4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-[(4methoxybenzyl)oxy]-benzoic acid as described in Example 229. APCI-MS: m/z 466 (MH+)
Example 231
Af-(5-chloro-2-{[(2lSO-3-(5-fluoro-l'r,3//-spiro(l-benzofuran-2,41-piperidinJ-r-yl)-2-
hydroxypropyl]oxy}phenyl)urea
Step 1: AHS-chloro-l-hydroxyphenyOurea
2-amino-4-chlorophenol (1.3 g, 8.9 mmol) was dissolved in 1M HC1 (10 mL). Ammonium acetate was added to the solution to adjust pH to 5. The stirred mixture was treated with a suspension of potassium cyanate (0.80 mg, 9.8 mmol) in water, and than kept overnight at room temperature. Water was removed by evaporation and the residue was recrystallized from water to afford pink precipate (0.9 g, 55 %). APCI-MS: m/z 187 [MH+]
Step II: 7V-{5-chloro-2-[(2.5')-oxiran-2-ylrnethoxy]phenyl}urea
A solution of //-(5-chloro-2-hydroxyphenyl)urea (0.9 g, 4.9 mmol) and (2iS)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (1.0 g, 3.8 mmol) in dimethylformamide were stirred under nitrogen. Cesium carbonate (1.9 g, 5.7 mmol) was added to the mixture and the reaction was stirred under nitrogen at room temperature over night. The mixture was partitioned between water and dichloromethane, and the organic phase was washed with water. After drying, filtration and evaporation of the solvent 0.48g, (52 %) of subtitle compound was obtained. APCI-MS: m/z 243 [MH].
Step HI:
A^-(5-chIoro-2-{[(2,S)-3-(5-fluoro-rH,3/ir-spiro[l-benzofuran-2,4I-piperidinl-l'-yl)-2-hydroxypropyl]oxy}phcnyl)urea
A^5-chloro-2-[(2^-oxiran-2-ylmethoxy]phenyl}urea (0.48 g, 2.0 mmol) and 5-fluoro-3#-spiro[l-benzofuran-2,4'-piperidine] (0.49 g, 2.0 mmol) were dissolved in 3 mL ethanol. The reaction mixture was stirred at 80°C over night. Ethanol was removed by evaporation and the mixture was purified by column chromatography (dichloromethane/methanol) and HPLC on CIS (Xterra) to afford 35 rag (39 %) of the title compound. 'H-NMR (DMSO-rfrf, 400 MHz): 6 8.18 (d, 7= 2.6 Hz, 1H); 7.92 (s, 1H); 7.07-6.97 (m, 2H); 6.91-6.84 (m, 2H); 6.73-6.68 (m, 1H); 6.33 (s, 2H); 4.88 (br.s, 1H); 4.15-3.98 (m, 2H); 3.97-3.85 (m, 1H); 3.00 (s, 2H); 2.76-2.30 (br.m, 6H, partially covered with the signal of solvent); 1.94-1.65 (br.m,4H). APCI-MS:m/z450[MH+]
Example 232
^-(5-chloro-2-{[(25)-3-(5-chloro-l'^,3/r-spiro[l-benzofuran-2,4'-piperidin]-r-yI)-2-hydroxyp ropyl]oxy} phenyl)urea
The title compound was prepared using 5-chloro-3//-spiro[l-benzofuran-2,4'-piperidine] as described in Example 231. APCI-MS: m/z 466 [MH+]
Example 233
yV-(2-{[(2^-3-(5-nuoro-l'/r,3JH'-spiro[l-benzofuran-2)4l-piperidin]-lt-yl)-2-
hydroxypropyl]oxy}phenyl)urea
The title compound was prepared from 2-aminophendl as according to the procedure described in Example 231.
'H-NMR (DMSO-rftf, 400 MHz): 5 8.08-8.01 (m, 1H); 7.77 (s, 1H); 7.08-7.03 (m, 1H); 7.00-6.95 (m, IH); 6.92-6.80 (m, 3H); 6.75-6.69 (m, 1H); 6.16 (s, 2H); 4.90 (br.s, 1H);
4.20-4.00 (br.m, 2H); 3.97-3.86 (m, IH); 3.02 (s, 2H); 2.86-2.35 (br.m, 6H, partially covered with the signal of solvent); 2.02-1.67 (br.m, 4H). APCI-MS: m/z 416.2 [MH+]
Example234 yl)propyl]oxy}phenyl)urea
The title compound was prepared from 2-aminophenol and 3//-spiro[l-benzoruran-2,4'-
piperidine] according to the procedure described in Example 23 1 .
'H-NMR (acetone-^, 400 MHz): 5 8.25-8.21 (m, IH); 7.81 (br.s, IH); 7.17-7.13 (m, IH);
7.10-7.04 (m, IH); 7.02-6.96 (m, IH); 6.92-6.84 (m, 2H); 6.81-6.75 (m, IH); 6.69 (d,7 =
7.6 Hz, IH); 5.60 (br.s, 2H); 4.18-4.09 (m, 2H); 4.02-3.94 (m, IH); 3.01 (s, 2H); 2.82-2.53
(m, 6H, partially covered with the signal of solvent); 1.95-1.77 (m, 4H).
APCI-MS: m/z 398 [MH+]
Example 235
Ar-(4-fluoro-2-{[(25)-3-(5-nuoro-ll//,3J/-spiro[l-benzofuran-2,4'-piperidin]-lI-yl)-2-
hydroxypropyl]oxy}phenyl)urea
The title compound was prepared from 2-amino-5-fluorophenol and 5-fluoro-3//-spiro[l-benzofuran-2,4'-piperidine] according to the procedure described in Example 231. 'H-NMR (acetone-^, 400 MHz): 6 8.17 (dd, J = 9.0, 6.4 Hz, IH); 7.75 (br.s, IH); 6.97-6.92 (m, IH); 6.87-6.79 (m, 2H); 6.69-6.60 (m, 2H); 5.68 (br.s, 2H); 4.21-4.12 (m, 2H); 4.06-3.97 (m, IH); 3.04 (s, 2H); 2.81-2.55 (m, 6H, partially covered with the signal of solvent); 1.97-1.79 (m, 4H). APCI-MS: m/z 434.2 [MH+]
Example 236
Ar-(4-fluoro-2-{[(25)-2-hydroxy-3-( -spiro[l-ben2ofuran-2,4'-piperidin]-l1-
yl)propyl]oxy}phenyl)urea
The title compound was prepared from 2-amino-5-ftuorophenol and 3//-spiro[l-benzofuran-2,4'-piperidine] according to the procedure described in Example 231. 'H-NMR (acetone-^, 400 MHz): 8 8.21-8.15 (m, IH); 7.71 (br.s, 1H); 7.15 (d, 7=7.3 Hz, 1H); 7.07 (t, J= 7.7 Hz, IH); 6.88-6.82 (m, IH); 6.79 (t, /= 7.4 Hz, IH); 6.69 (d, /= 7.9 Hz, IH); 6.67-6.60 (m, IH); 5.64 (br.s, 2H); 4.22-4.11 (m, 3H); 4.05-4.00 (m, IH); 3.02 (s, 2H); 2.90-2.57 (m, 6H, partially covered with the signal of solvent); 1.97-1.79 (m, 4H). APCI-MS: m/z 416.2 [MH+]
THP-1 Chemotaxis Assay
Introduction
The assay measured the chemotactic response elicited by MlP-la chemokine in the human monocytic cell line THP-1. The compounds of the Examples were evaluated by their ability to depress the chemotactic response to a standard concentration of MlP-la chemokine.
Methods
Culture of THP-1 cells
Cells were thawed rapidly at 37°C from frozen aliquots and resuspended in a 25 cm flask containing 5 ml of RPMI-1640 medium supplemented with Glutamax and 10% heat inactivated fetal calf serum without antibiotics (RPMI+10%HIFCS). At day 3 the medium is discarded and replaced with fresh medium.
THP-1 cells are routinely cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum and glutamax but without antibiotics. Optimal growth of the
cells requires that they are passaged every 3 days and that the minimum subculture density
is 4x10 cells/ml.
Chemotaxis assay
Cells were removed from the flask and washed by centrifugation in RPMl+10%HIFCS+glutamax. The cells were then resuspended at 2x10 cells/ml in fresh medium (RPMI+10%HIFCS+glutamax) to which was added calcein-AM (5 ul of stock solution to 1 ml to give a final concentration of 5x10 M). After gentle mixing the cells were incubated at 37°C in a C02 incubator for 30 minutes. The cells were then diluted to 50 ml with medium and washed twice by centrifugation at 400xg. Labelled cells were then resuspended at a cell concentration of 1x10 cells/ml and incubated with an equal volume of MIP-la antagonist (10 M to 10 M final concentration) for 30 minutes at 37°C in a humidified 2 incubator.
Chemotaxis was performed using Neuroprobe 96-well chemotaxis plates employing 8 urn filters (cat no. 101-8). Thirty microlitres of chemoattractant supplemented with various concentrations of antagonists or vehicle were added to the lower wells of the plate in triplicate. The filter was then carefully positioned on top and then 25ul of cells preincubated with the corresponding concentration of antagonist or vehicle were added to the surface of the filter. The plate was then incubated for 2 hours at 37°C in a humidified CC>2 incubator. The cells remaining on the surface were then removed by adsorption and the whole plate was centrifuged at 2000 rpm for 10 minutes. The filter was then removed and the cells that had migrated to the lower wells were quantified by the fluorescence of cell associated calcein-AM. Cell migration was then expressed in fluorescence units after subtraction of the reagent blank and values were standardized to % migration by comparing the fluorescence values with that of a known number of labelled cells. The effect of antagonists was calculated as % inhibition when the number of migrated cells were compared with vehicle.





WE CLAIM:
1. A tricyclic spiropiperidine or spiropyrrolidines of formula

(Formula Removed)
wherein
misO, 1, 2,3 or 4;
each R1 independently represents halogen, cyano, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, Ci-Ce alkoxy or sulphonamido;
either X represents a bond,-CHa-,-O-or-C (O)- and Y represents a bond,-GHz-, -O- or -C(O)-, or X and Y together represent a group-CH=C (CHa)- or-C (CHa) =CH-, and Z represents a bond,-O-,-NH-or-CH2-, provided that only one of X, Y and Z can represent a bond at any one time and provided that X and Y do not both simultaneously represent-O-or-C (O)- ; n is 0, 1 or 2;
each R2 independently represents halogen or C1-C6 alkyl; q is 0 or 1;
R3 represents -NHC(O)R10,-C(O)NRUR12 or-COOR12a;
R4, R5, R6, R7 and R8 each independently represent a hydrogen atom or a Ci-C6 alkyl group; t is 0, 1 or 2;
each R9 independently represents halogen, cyano, hydroxyl, carboxyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 haloalkyl, or C1-C6 alkyl optionally substituted by at least one substituent selected from carboxyl and C1-C6 alkoxycarbonyl; R10 represents a group C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, adamantyl, C5-C6 cycloalkenyl, phenyl or a saturated or
unsaturated 5-to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more substituents independently selected from nitro, hydroxyl, oxo, halogen, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, phenyl and -NHC(O)-R13, or R10 represents a group -NR14R15 or -O-R16;
R11 and R12 each independently represent (i) a hydrogen atom, (ii) a 3- to 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, C1-C6 alkyl, C1-C6 hydroxyalkyl and C:-Ce haloalkyl, (iii) a C1-C6 alkyl group optionally substituted by at least one substituent selected from halogen, amino, hydroxyl, C1-C6 haloalkyl, carboxyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonylamino and a 3-to 6-membered saturated or unsaturated ring optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur and optionally further comprising a bridging group, the ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo (=O), C1-C6 alkyl, C1-C6 hydroxyalkyl and C1-C6 haloalkyl, or (iv) C1-C6 alkylsulphonyl, or
R11 and R12 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom and that is optionally fused to a benzene ring to form a 8- to 11- membered ring system, the heterocyclic ring or ring system being optionally substituted with at least one substituent selected from halogen, hydroxyl, amido, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 haloalkyl, C1-C6 alkylamino, di- C1-C6 alkylamino, C1-C6 alkylcarbonyl, C1-C6 alkylcarbonylamino, C1-C6 alkylaminocarbonyl, di- C1-C6 alkylaminocarbonyl, phenyl, halophenyl, phenylcarbonyl, phenylcarbonyloxy and hydroxydiphenylmethyl;
R12a represents a hydrogen atom or a C1-C6 alkyl group; R13 represents a C1-C6 alkyl, amino or phenyl group;
R14 and R15 each independently represent a hydrogen atom, or a group C1-C6 alkyl, C1-C6 alkylsulphonyl, phenyl or a saturated or unsaturated 5-to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted as defined above for R10, or R14 and R15 together with the nitrogen atom to which they are attached form a 4- to 7- membered saturated heterocyclic ring that optionally further comprises a ring nitrogen, oxygen or sulphur atom, the heterocyclic ring being optionally substituted by at least one hydroxyl; and
R16 represents a hydrogen atom, or a group C1-C6 alkyl, phenyl or a saturated or unsaturated 5-to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each group being optionally substituted as defined above for R10; or a pharmaceutically acceptable salt or solvate thereof.
2. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in
claim 1, wherein
m is 0, 1, 2, 3 or 4;
each R1 independently represents halogen, cyano, hydroxyl, C1-C6 alkyl, C1-C6
alkoxy or sulphonamido;
either X represents a bond,-CH2-,-O-or-C(O)- and Y represents a bond,-CH2-, -
O- or -C(O)-, or X and Y together represent a group-CH=C (CHa)- or-C (CHs)
=CH-, and Z represents a bond, -O-, -NH- or -CHa-, provided that only one of X,
Y and Z can represent a bond at any one time and provided that X and Y do not
both simultaneously represent-O-or-C (O)- ;
n is 0, 1 or 2;
each R2 independently represents halogen or C1-C6 alkyl;
q is 0 or 1 ;
R3 represents -NHC(O)R10, -C(O)NRnR12 or -COOR12a;
R4, R5, R6, R7 and R8 each independently represent a hydrogen atom or a C1-C6
alkyl group;
t is 0, 1 or 2;
each R9 independently represents halogen, cyano, hydroxyl, C1-C6 alkoxy, Ci-
Ce haloalkyl, or C1-C6 alkyl optionally substituted by at least one substituent
selected from carboxyl and Ci-C6 alkoxycarbonyl;
R10 represents a group C1-C6 alkyl, Ca-Ce alkenyl, Ca-Ce cycloalkyl, adamantyl,
Cs-Ce cycloalkenyl, phenyl or a saturated or unsaturated 5-to 10-membered
heterocyclic ring system comprising at least one ring heteroatom selected from
nitrogen, oxygen and sulphur, each of which may be optionally substituted by
one or more substituents independently selected from nitro, hydroxyl, oxo,
halogen, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6
alkyloarbonyl, C1-C6 alkoxycarbonyl, phenyl and -NHC (O)-R13, or .....
R10 represents a group -NR14R15 or -O-R16;
R11 and R12 each independently represent (i) a hydrogen atom, (ii) a 3-to 6-
membered saturated or unsaturated ring optionally comprising at least one
ring heteroatom selected from nitrogen, oxygen and sulphur, the ring being
optionally substituted with at least one substituent selected from halogen,
methyl and trifluoromethyl, or
(iii) a C1-C6 alkyl group optionally substituted by at least one substituent
selected from halogen, amino, hydroxyl, trifluoromethyl, carboxyl, C1-C6
alkoxycarbonyl and a 3-to 6- membered saturated or unsaturated ring
optionally comprising at least one ring heteroatom selected from nitrogen,
oxygen and sulphur, the ring being optionally substituted with at least one
substituent selected from halogen, methyl and trifluoromethyl, or
R11 and R12 together with the nitrogen atom to which they are attached form a
4-to 7- membered saturated heterocyclic ring optionally further comprising a
ring oxygen atom, the heterocyclic ring being optionally substituted with at
least one substituent selected from hydroxyl and C1-C6 alkoxy;
R12a represents a hydrogen atom or a C1-C6 alkyl group;
R13 represents a C1-C6 alkyl, amino or phenyl group;
R14 and R15 each independently represent a hydrogen atom, or a group C1-C6
alkyl, phenyl or a saturated or unsaturated 5-to 10-membered heterocyclic ring
system comprising at least one ring heteroatom selected from nitrogen, oxygen
and sulphur, each group being optionally substituted as defined above for R10,
or
R14 and R15 together with the nitrogen atom to which they are attached form a
4- to 7- membered saturated heterocycle; and
R16 represents a hydrogen atom, or a group C1-C6 alkyl, phenyl or a saturated
or unsaturated 5-to 10-membered heterocyclic ring system comprising at least
one ring heteroatom selected from nitrogen, oxygen and sulphur, each group
being optionally substituted as defined above for R10 ;
or a pharmaceutically acceptable salt or solvate thereof.
3. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in claim 1 or claim 2, wherein X and Y have the meanings:
X is a bond, Y is O, X is O and Y is a bond, X is CH2 and Y is a bond, X is a bond and Y is CH2, X is CH2 and Y is O, X is O and Y is CH2, X is C(0) and Y is O, X is O and Y is C(O), X is CH2 and Y is CH2, or X and Y are -CH=C(CH3)-.
4. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in any one of claims 1 to 3, wherein Z represents a bond, -0- or-CHa-.
5. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in
any one of claims 1 to 4, wherein R3 represents -NHC (O) R10 or-C (O) NR11 R12.
6. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in
any one of claims 1 to 5, wherein t is 0, 1 or 2.
7. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in
any one of claims 1 to 5, wherein each R9 independently represents halogen,
hydroxyl, carboxyl, Ci-C4 alkoxy, Ci-C4 alkoxycarbonyl, Ci-C4 haloalkyl or Ci-
C4 alkyl.
8. The tricyclic spiropiperidine or spiropyrrolidines compounds as claimed in
claim 1 selected from:
N (2- { [ (2S)-3- (5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) acetamide,
N-(2- { [(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-fluorophenyl) acetamide,
N-(2- { [(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methoxyphenyl) acetamide,
N-(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) acetamide,
N-[2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-5-(trifluoromethyl) phenyl] acetamide,
2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-cyclopropylbenzamide,
2- { [(2S)-3-(5-Chloro-l'H, 3H-spirof l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-cyclopropyl-4-fluorobenzamide,
2-{[(2S)-3-(5-Chloro-lIH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-cyclopropyl-4-methoxybenzamide,
N (2- { [ (2S)-3- (5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxy- 2-methylpropyl] oxy}-4-hydroxyphenyl) acetamide trifluoroacetate,
N-(5-Chloro-2-{[(2s)-3-(6-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)- 2-hydroxypropyl] oxy} phenyl) acetamide,
N-(2-{[(2S)-3-(6-Chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l1-yl)-2-hydroxypropyl] oxy}-4-fluorophenyl) acetamide,
N (2- { [ (2S)-3- (6-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) acetamide,
N-(2-{[(2S)-3-(6-Chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methoxyphenyl) acetamide,
2- { [(2S)-3-(6-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy)-N-cyclopropyl-4-fluorobenzamide,
N-(2{[(2S)-3-(5-Fluoro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] phenyl) acetamide,
N-(4-Chloro-2-{[(2S)-2-hydroxy-3-(3-oxo-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl) propyl] oxy} phenyl) acetamide,
N-Cyclopropyl-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-1'- yl) propyl] oxy} benzamide,
N-(4-Chloro-2-{[(2S)-2-hydroxy-3-(l'-H,3H-spiro[2-benzofuran-l,4'-piperidin]-1'- yl) propyl] oxy} phenyl) acetamide,
N-(5-Chloro-2 {[ (2S)-2-hydroxy-3- (I'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-1'- yl) propyl] oxy} phenyl) acetamide,
N-(2-{[(2S)-2-hydroxy-2-methyl-3-(l'H,3H-spiro[2-benzoufuran-l,4'-piperidin]-1'- yl) propyl] oxy}-4-methoxyphenyl) acetamide,
N-[2-{[(2S)-2-Hydroxy-3-(l'H,3H-spjro[2-benzofuran-l,4l-piperidin]-l'-yl) propyl] oxy}-5-(trifluoromethyl) phenyl] acetamide,
N-(2-{[(2S)-2-Hydroxy-3-(2-methyl-1 'H-spiro[indene-l,4'-piperidin]-1'- yl) propyl] oxy} phenyl) acetamide,
N-(2-{[(2S)-3-(2,3-Dihydro-l'H-spiro[indene-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) acetamide,
N-(2-{[(2S)-2-Hydroxy-3-(2-oxo-1 'H-spiro[l -benzofuran-3,4'-piperidin]-1 '-yl) propyl] oxy} phenyl) acetamide,
2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-cyclopropyl-4-hydroxybenzamide,
2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxy-2- methylpropyl] oxy}-N-cyclopropyl-4-hydroxybenzamide,

N-(4-hydroxy-2- { [(259-2-hydroxy-3-(l'H, 4H-spiro [chromene-3, 4'-piperidin]-1'- yl) propyl] oxy} phenyl) acetamide,
2-{[(2S)-3-(5-Chloro-1 'H,3H-spiro[ 1 -benzofuran-2,4'-piperidin]-1 '-yl)-2-hydroxy-2- methylpropyl] oxy}-4-hydroxy-N-methylbenzamide (trifluoroacetate),
2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxy] oxy}-4-hydroxy-N-methylbenzamide,
N (2- {[ (2S)-3- (5-Chloro-I'H-spiro [1, 3-benzodioxole-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) acetamide trifluoroacetate,
N-(2- { [(2S)-3-(5-Chloro-I'H-spiro [1, 3-benzodioxole-2, 4'-piperidin]-lL-yl)-2-hdyroxy- 2-methylpropyl] oxy}-4-hydroxyphenyl) acetamide trifluoroacetate,
N- (4-Hydroxy-2-{[(2S)-2-hydroxy-3- (I'H-spiro [1, 3-benzodioxole-2, 4'-piperidin]-!'- yl) propyl] oxy} phenyl) acetamide trifluoroacetate,
N-(4-Hydroxy-2-{[(2S)-2-hydroxy-2-methyl-3- (I'H-spiro [1, 3-benzodioxole-2,4'-piperidin]-l'-yl) propyl] oxy} phenyl) acetamide trifluoroacetate,
N-(2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) acetamide,
N-(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-r-yl)-2-hydroxypropyl] oxy} phenyl) acetamide,
2-{[(2S)-3- (5-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-methylbenzamide,
2- { [(2S)-3-(5-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxy-2- methoxypropyl] oxy}-N-cyclopropyl-4-hydroxybenzamide,
2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxyethyl) benzamide,
N (2-Aminoethyl)-2-{](2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]- l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzamide,
2- {[(2S)-3-(5-Fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-methylbenzamide,
N-(2-{[(2S)-3-(5-Fluoro-l'H, 3H-spiro [l-benzqfilran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) acetamide,
N-(2- { [(2S)-3-(5-Fluoro-l'H, 3H-spiro [l-benzofilran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) acetamide,
N-[2-{(2S)-3-[(2S)-5-Chloro-l'H,3H-spiro[l-benzofuran-2,3'-pyrrolidin]-l'-yl]-2-hydroxypropyl} oxy) phenyl] acetamide,
N-[2-({(2S)-3[(2R)-5-Chloro-l'H,3H-spiro[l-benzofuran-2,3t-pyrrolidin]-r-yl]-2-hydroxypropyl} oxy) phenyl] acetamide,
N-[2-({(2S)-3[(2S)-5-Chloro-l'H,3H-spiro[l-benzofuran-2,3'-pyrrolidin]-l'-yl]-2-hydroxypropyl} oxy)-4-methoxyphenyl] acetamide,
N- {(2S)-3-[(2R)-5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 3'-pyrroHdin]-l'-yl]-2-hydroxypropyl} oxy)-4-methoxyphenyl] acetamide,
2-{[(2S)-3-(5-Chloro-rH,3H-spiro[l-benzofuran-2,3'-pyrrolidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-methylbenzamide,
2-{[(2S)-3-(5-Chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidm]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoic acid (trifluoroacetate),
3 (S)-l-(2- {[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-ol,
3 (R)-l- {[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-ol,
3-{[(2S)-3-(5-Chloro-l'Hr3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- (morpholin-4-ylcarbonyl)phenol,
2-{[(2S)-3-(5-chloro-l'H-spiro[l,3-benzodioxole-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-methylbenzamide trifluoroacetate,
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro- 1'H-spiro [chromene-2, 4'-piperidinj-l'-yl)-2-hydroxypropyl] oxy} phenyl) acetamide trifluoroacetate,
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro-l'H-spiro [chromene-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-fluorophenyl) acetamide trifluoroacetate,
2-{[(2S)-3-(6-chloro-3, 4-dihydro-l'H-spiro [chromene-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-methylbenzamide trifluoroacetate,
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro-l'H-spiro [chromene-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) acetamide trifluoroacetate,
N-(2-{[(2S)-3-(6-chloro-3,4-dihydro-l'H-spiro [chromene-2, 4'-piperidin]-l'-yl)-2-hydroxy-2-methylpropyl] oxy}-4-hydroxyphenyl) acetamide trifluoroacetate,
N-[2-({(2S)-3-[(2R)-5-chloro-l1H,3H-spiro[l-benzofuran-2J3I-pyrrolidin]-l'yl]-2-hydroxypropyl} oxy) -4-hydroxyphenyl] acetamide,
N-[2-( {(2S)-3-[(2S)-5-chloro-l'H, 3H-spiro [l-benzofuran-2, S'-pyrrolidinJ-l'-yl]-2- hydroxypropyl} oxy) -4-hydroxyphenyl] acetamide,
3-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-(pyrrolidin-l-ylcarbonyl) phenol,
L-(2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-4-ol,
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} benzoyl) pyrrolidin-3-ol,
3-{[(2S)-3-(5-Chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4- (piperidin-1-ylcarbonyl) phenol,
(3S)-l-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-ol,
l-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-4-ol,
N-[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5-(trifluoromethyl)-rH,3H-spiro[l-benzofuran- 2, 4'-piperidin]-l'-yl] propyl} oxy) phenyl] acetamide,
(3S)-l-(2- {[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-ylbenzoate,
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,41-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-fluorobenzoyl) pyrrolidin-3-ol,
(3S)- 1 -[4-Hydroxy-2-({(2S)-2-hydroxy-3-[5 (trifluoromethyl)- 1 'H,3H-spiro[ 1 -benzofuran-2, 4'-piperidin]-l'-yl] propyl} oxy) benzoyl] pyrrolidin-3-ol,
(3S)-l-(4-Fluoro-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidin]- I'-yl) propyl] oxy} benzoyl) pyrrolidin-3-ol,
4-Fluoro-2-{[(2S)-3-(5-fluoro-l'H, 3H-spirp[l-benzofuran-2,4'-piperidm]-l'-yl)-2-hydroxypropyl] oxy} benzole acid (hydrochloride),
)-1- (4-Fluoro-2-{[(2S)-3-(5-fluoro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin] 1'- yl) -2-hydroxypropyl] oxy} benzoyl) pyrrolidin-3-ol,
N-[(3 S)-l-(2- { [(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l '-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-yl] acetamide,
2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methylbenzoic acid hydrochloride,
(3S)-l-(2-{[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy]}-4-methylbenzoyl) pyrrolidin-3-ol,
2-{[(2S)-3-(5-Fluoro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methylbenzoic acid hydrochloride,
(2S)-l-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-3-(2- {[2-(hydroxymethyl) morpholin-4-yl] carbonyl}-5-methylphenoxy) propan-2-ol,
(3S)-l-(2-{[(2S)-3-(5-Fluoro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methylbenzoyl) pyrrolidin-3-ol, 2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N { [ (4R)-2, 5-dioxoimidazolidin-4-yl] methyl}-4-hydroxybenzamide,
l-(2-{[(2S)-3-(5-Chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-3-(trifluoromethyl) pyrrolidin-3-ol,
3-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4- {[3-(trifluoromethyl) pyrrolidin-1-yl] carbonyl} phenol,
N-[2-(Acetylamino) ethyl] -2- {[(2S)-3-(5-CHLORO-rH,3H-spiro[l-benzofuran-2, 4'- piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzarnide,
N-(5-chloro-2- {[(2S)-3-(5-chloro-l H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-methoxyphenyl) acetamide,
(3S)-N-(5-chloro-2- {[(25)-3-(5-chloro-l H, 3H-spiro [l-benzofuran-2, 4'-piperidin] -1 '-yl) -2 -hydroxypropyl] oxy}phenyl) -3-hydroxypyrrolidine-1 -carboxamide,
(3S)-N-(2- { [(2S)-3-(5-chloro-l H, 3H-spiro [l-benzofuran-2, 4-piperidin]-l'-yl)-2- hydroxypropyl] oxy}phenyl)-3-hydroxypyrrolidine-l-carboxamide,
N-(2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl)-4-hydroxypiperidine-l-carboxamide,

N (2-{[(2S)-3- (5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) urea trifluoroacetate,
N-(2-{[(2S)-3-(5-chloro-l'H, 3H-spirot l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) urea trifluoroacetate,
N-(2-{[(259-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-fluorophenyl) urea trifluoroacetate,
N-{[(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxyphenyl) amino] carbonyl} methanesulfonamide trifluoroacetate,
(4S)-2-(2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4l-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) isoxazolidin-4-ol trifluoroacetate,
(4R)-2-(2- {[(2S)-3-(5-Chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) isoxazolidin-4-ol trifluoroacetate,
(4S)-2-(2-{[(2S)-3-(5-Chloro-rH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-rnethylisoxazolidin-4-ol trifluoroacetate,
(4R)-2- (2-{[(2S)-3-(5-Chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}-4-hydroxybenzoyl)-4-methylisoxazolidin-4-ol
trifluoroacetate,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-(methylsulfonyl) benzamide trifluoroacetate,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-l H-tetrazol-5-ylbenzamide bis (trifluoroacetate),
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy)-4-{[(3R)-3-(dimethylamino)pyrrolidin-l-yl]carbonyl} phenol bis (trifluoroacetate),
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- { [ (3S)-3- (dimethylamino) pyrrolidin-1-yl] carbonyl} phenol bis (trifluoroacetate),
(3(S)-l-(5-chloro-2-{[(2(S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-!'- yl) -2-hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidin-3-ol trifluoroacetate,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}- 4- { [ (3S)-3-methoxypyrrolidin-l-yl] carbonyl} phenol trifluoroacetate,
3-[(2S)-3-(5-chloro-I'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}- 4- { [(2R)-2-(hydroxymethyl) pyrrolidin-1-yl] carbonyl} phenol trifluoroacetate,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}- 4-{[(2S)-2-(hydroxymethyl)pyrrolidin-1 -yl]carbonyl}phenol trifluoroacetate,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-
hydroxypropyl]oxy}~{[3-(hydroxymethyl)pyrrolidin-1 -yljcarbonyl} phenol
trifluoroacetate,
l-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-D-prolinarnide trifluoroacetate,
N-(4-hydroxy-2- {[(2S)-2-hydroxy-3-(l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'- yl) propyl] oxy} phenyl) acetamide trifluoroacetate,
N-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(5-methyl-l'H, 3H-spiro [l-benzofuran-2, 4'- piperidin]-l'-yl) propyl] oxy} phenyl) acetamide trifluoroacetate,
N-(5-chloro-2- { [(2S)-2-hydroxy-3-(l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-1'- yl) propyl] oxy}-4-rnethoxyphenyl) acetamide trifluoroacetate,
N-(5-chloro-4-hydroxy-2- { [(2S)-2-hydroxy-3-(l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl) propyl] oxy} phenyl) acetamide trifluoroacetate,
(3S)-N-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,41-piperidin]-l'-yl)2-hydroxypropyl] oxy}-4-methoxyphenyl)-3-hydroxypyrrolidine- 1-carboxarnide trifluoroacetate,
(3S)- N- (2- { [ (2S)-3- (5-chloro- I'H, 3H-spiro [l-benzofuran-2,4'-piperidin]-l'-yl) -2 -hydroxypropyl] oxy}-4-hydroxyphenyl) -3-hydroxypyrrolidine-1 -carboxamide trifluoroacetate,
(3S)-l-(4-hydroxy-2-{[(2S)-2-hydroxy-3-(l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]- l'-yl) propyl] oxy} benzoyl) pyrrolidin-3-ol trifluoroacetate,
2-{[(2S)-3- (5-chloro-I'H, 3H-spiro[ l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-5-methylbenzoic acid hydrochloride,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methoxybenzoic acid hydrochloride,
(3S)-1- (2- {[ (2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-5-methylbenzoyl) pyrrolidin-3-ol trifluoroacetate,
(3S)-l-(2- {[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-methoxybenzoyl) pyrrolidin-3-ol trifluoroacetate,
5-chloro-2- {[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy} benzoic acid hydrochloride,
(3S)-l-(5-chloro-2- {[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-!'- yl)-2-hydroxypropyl] oxy}benzoyl)pyrrolidin-3-ol trifluoroacetate,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-5-fluorobenzoic acid hydrochloride,
(3S)-1- (2- { [ (2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2,4'-piperidin]l'-yl)-2 hydroxypropyl] oxy}-5-fluorobenzoyl) pyrrolidin-3-ol trifluoroacetate,
N-(2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) pyrrolidine-1-carboxamide trifluoroacetate,
Methyl 4-(acetylamino)-3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} benzoate trifluoroacetate,
4-(acetylamino)-3-{[(2S)-3-(5-chloro-l'H, 3H-spirof l-benzofuran-2, 4'-piperidin]-l'-yl) -2-hydroxypropyl] oxy} benzoic acid trifluoroacetate,
N-(2-{[(25)-3-(5-chloro-3'-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxyphenyl) acetatnide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spi.ro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-hydroxypropyl) benzamide,
2-{[(2S)-3-(5-chloro-l1H,3H-spiro[l-benzofuran-2,4'-piperidin]-l-'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxy-l,l-dimethylethyl) benzamide,
2- {[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidm]-l'-yl)-2-hydroxypropyl]oxy}-N-cyclopentyl-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,41-piperidin]-lI-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-methoxyethyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-hydroxyphenyl) benzamide,
N-(tert-butyl)-2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2,4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-hydroxy-l-methylethyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2,4'-piperidin]-l'-yl)-2-
hydroxypropyl] oxy}-4-hydroxy-N-isobutylbenzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydrox-N-(4-hydroxycyclohexyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N- (2, 3-dihydroxypropyl) -4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-I'H, 3H-spiro [l-benzofuran-2, 4'-pipendin]-l'-y !)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-hydroxyethyl)-N-raethylbenzamide,
Methyl N (2-{[(2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) serinate,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N- (1 -ethylpropyl) -4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (tetrahydrofuran-2-ylmethyl) benzamide,
2-{[(2S)-3- (5-chloro- I'H, 3H-spiro [l-benzofilran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- [1- (hydroxymethyl)-2, 2-dimethylpropyl] benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [I-benzofuran-2, 4'-piperidin]- I'-yl)-2-hydroxypropyl] oxy}-N- { [(IS, 2R, 5S)-6, 6-dimethylbicyclo [3.1. 1] hept-2-yl] methyl}-4- hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- [1- (hydroxymethyl)-2-methylpropyl] benzamide,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- {[4-(2-hydroxyethyl) piperazin-1-yl] carbonyl} phenol,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] 0x7} -4- {[3-(hydroxymethyl)piperidin-l-yl]carbonyl}phenol,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2,4'-piperidm]-l'-yl)-2-hydroxypropyl] oxy}-N- [5- ( 1, l-dimethylpropyl)-2-hydroxyphenyl]-4-hydroxybenzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- [3- ( 1-hydroxyethyl) phenyl] benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-(cyclopropylmethyl)-4-hydroxybenzainide,
2-{[(2S)-3-(5-chloro-lIH,3H-spiro[l-benzofuran-2,4I-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-pyrrolidin- 1-ylbenzamide,
N-[(1R, 4S) -bicyclo [2.2. 1] hept-2-yl]-2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [1-benzofuran- 2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzamide,
4-(4-chlorophenyl)-2-(2- { [(2S)-3-(50chlorol'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]- l'-yl)-2-hydrox:ypropyl] oxy}-4-hydroxybenzoyl) piperidin-4-ol,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N-(2-hydroxy-1 -phenylethyl) benzamide,
l-(2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [ l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] ox7}-4-hydroxybenzoyl)-4-phenylpiperidin-4-ol,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-(3,4-dihydroisoquinolin-2(lH)-hlcarbonyl) phenol,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- { [2-(hydroxymethyl) piperidin-1-yl] carbonyl} phenol,
l-(2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}- 4-hydroxybenzoyl)-N, N-dimethylprolinamide,
Methyl (4R)-l-(2- { [ (2S)-3- (5-chloro-I'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-1 '-yl-)- 2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-4-hydroxyprolinate,
(3R)-l-(2-{[(2S)-3-(5-chloro-rH, 3H-spiro [l-benzofuran-2, 41-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-3-ol,
2-{[(2S)-3- (5-chloro- FH, 3H-spiro [l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N- (2-hydroxycyclohexyl) benzamide,
3-{[(2S)-3-(5^chloro-l'H, 3H-spiro [l-benzofuran-2,4'piperidin]-l'-yl)-2-
hydroxypropyl] oxy}-4-[(4-phenylpiperidin-l-yl)carbonyl] phenol,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-(thiomorpholin-4-ylcarbonyl) phenol,
l-(2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [ l-benzofuran-2, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-3-ol,
2-{[(2S)-3-(5-chloro- 1'H, 3H-spiro [l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-(cyclopropylmethyl)-4-hydroxy-N-propylbenzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl]oxy}-4-hydroxy-N, N-diisobutylbenzamide,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-(l, 3-dihydro-2H-isoindol-2-ylcarbonyl) phenol,
N (2-tert-butoxyethyl)-2- { [ (2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-1 '-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-isobutylbenzamide,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- [ (4-fluoropiperidin-l-yl) carbonyl] phenol,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- [ (4, 4-difluoropiperidin-1-yl) carbonyl] phenol,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-phenylbenzamide,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- ({(2R)-2-(hydroxy (diphenyl) methyl] pyrrolidin-1 - yl} carbonyl) phenol,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N (2-hydroxyethyl)-N-rnethylbenzamide,
3-{[(2S)-3-(5-chloro-l'H,3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-(pyrrolidin-1-ylcarbonyl) phenol,
3-{[(25)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-{[4-(2-hydroxyethyl)piperazin-l-yl]carbonyl}pyenol,
3-{[(25)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-{[3-(hydroxymethyl)piperidin-1 -yljcarbonyl} phenol,
4-(4-chlorophenyl)-1 -(2-{[(2S)-3-(5-chloro-1 'H,3H-spiro[2-benzofuran-1, 4'-
piperidin]- l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-4-ol,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- {[4-(hydroxymethyl)piperidin-l-yl]carbonyl} phenol,
l-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4l-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) -4-phenylpiperidin-4-ol,
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-lr-yl)-2-hydroxypropyl]oxy}-4-(3,4-dihydroisquinoHn-2(lH)-ylcarbonyl) phenol,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- {[2-(hydroxymethyl)piperidin-l-yl]carbonyl} phenol,
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- {[3-(dimethylamino)pyrrolidin-l-yl]carbonyl} phenol,
l-(2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-N,N-dimethylprolinamide,
2-{[(2S)-3-(5-chloro-rH,3H-spiro[2-benzofuran-l,4I-piperidin]-r-yl)-2-hydroxypropyl] oxy}-N-cyclohexyl-4-hydroxy-N-(2-hydroxyethyl) benzamide,
Methyl (4R)-1- (2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)- 2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-4-hydroxyprolinate,
(3R)-l-(2- {[(2S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-3-ol,
3-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- [ (4-phenylpiperidin-l-yl) carbonyl] phenol,
3-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- (thiomorpholin-4-ylcarbonyl) phenol,
l-(2-{[(2(S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidm]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl) piperidin-3-ol,
2-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-N (cyclopropylmethyl)-4-hydroxy-N-propylbenzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N, N-diisobutylbenzamide,
3-{[(2S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-(l, 3-dihydro-2H-isoindol-2-ylcarbonyl) phenol,
N-(2-ter-butoxyethyl)-2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-1 r-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-isobutylbenzamide,
3-{[(25)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4- [ (4-fluoropiperidin-l-yl) carbonyl] phenol,
3-{[(2S')-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-[(4,4-difluoropiperidin-l-yl)carbonyl] phenol,
2-{[(25)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxypropyl) benzamide,
2-[ [ (2S)-3- (5-chloro- 1'H, 3H-spiro [2-benzofuran- 1, 4'-piperidin]- l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydrox7-l, 1-dimethylethyl) benzamide,
2-[[(2S)-3- (5-chloro- I'H, 3H-spiro [2-benzofuran- 1, 4'-piperidin]- l'-yl)-2-hydroxypropyl] oxy}-N-cyclopentyl-4-hydroxybenzamide,
2-{[(2S)-3- (5-chloro-I'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-methoxyethyl) benzamide,
2-{[(2(S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxyphenyl) benzamide,
2-{[(2S)-3-(5-chloro-1 'H,3H-spiro]2-benzofuran-1,4'piperidin]-1 '-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxy-l-methylethyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-isobutylbenzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxyethyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H,3H-spiro[2-benzofuran-l,4'-piperidin]-lr-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(4-hydroxycyclohexyl) benzamide,
2-{[(2S)-3- (5-chloro-I'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-(2, 3-dihydroxypropyl)-4-hydroxybenzamide,
Methyl N-(2- { [(2S)-3-(5-chloro-l1H,3H-spiro[2-benzofuran-l,4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxybenzoyl) serinate,
2-{[(2S)-3- (5-chloro-I'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-N-( 1 -ethylpropyl)-4-hydroxybenzamide,
2-{[(2(S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N (tetrahydrofuran-2-ylmethyl) benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-[l-(hydroxymethyl)-2, 2-dimethylpropyl] benzamide,
2-{[(2S)-3-(5-chloro-1 'H,3H-spiro[2-benzofuran- l,4'-piperidin-1,4'-piperidin]-1'-yl)-2- hydroxypropyl] oxy}-4-hydroxy-N-[l-(hydroxymethyl)-2-methylpropyl] benzamide,
2-{[(2(S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N [3- (1-hydroxyethyl) phenyl] benzamide,
2-{[(2S)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-N- (cyclopropylmethyl) -4-hydroxybenzamide,
2-{[(2S)-3- (5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-pyrrolidin-l-ylbenzamide,
N-[(1R, 4S-bicyclo [2.2. 1] hept-2-yl]-2-{[(25)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran- 1, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzamide,
2-[[(2S)-3- (5-chloro-I'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yi)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxy-l-phenylethyl) benzamide,
2-{[(25)-3-(5-chloro-l'H, 3H-spiro [2-benzofuran-l, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-hydroxy-N-(2-hydroxycyclohexyl) benzamide,
l-(2-{[(2S)-3-[5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-
hydroxypropyl] oxy}-4-hydroxybenzoyl) pyrrolidine-3-carboxamide
trifluoroacetate,
l-(2-{[(2S)-3-[5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-r-yl)-2-hydroxypropyl] oxy}-4-hydroxybenzoyl)-L-prolinamide trifluoroacetate,
2-chloro-5- {[(2S)-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4- { [ (3R)-3- (dimethylamino) pyrrolidin-1-yl] carbonyl} phenol bis (trifluoroacetate),
2-chloro-5- { [(22-3-(5-chloro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-
2-hydroxypropyl] oxy}-4-{[(3R)-3-(hydroxymethyl)pyrrolidin-l-yl]carbonyl}
phenol trifluoroacetate,
2-chloro-5-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropyl] oxyl-4-1 [ (3S)-3- (hydroxymethyl) pyrrolidin- I-yl] carbonyl} phenol trifluoroacetate,
2-chloro-5- { [ (2S)-3- (5-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-(pyrrolidin-l-ylcarbonyl) phenol trifluoroacetate,
N-(2-{[(2R)-3-(5-Fluoro-I'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-methoxyphenyl) acetamide,
Methyl 2- { [ (2S)-3- (5-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} benzoate,
2-{[(2S)-3-(5-Fluoro-l'H, 3H-spirot l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} benzoic acid (hydrochloride),
(3S)-l-(2- { [ (2S)-3- (5-Fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy} benzoyl) pyrrolidin-3-ol,
3-{[(2S)-3-(5-Fluoro-l'H, 3H-spiro [l-benzofuran-2, 41-piperidin]-l'-yl)-2-hydroxypropyl] oxy}-4-(pyrrolidin-l-ylcarbonyl) phenol,
N-(4-fluoro-2- { [(2S)-3-(5-nuoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy} phenyl) acetamide,
N-{5-chloro-2-[3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropoxy]-4-hydroxyphenyl} cyclopentanecarboxamide,
N-{5-chloro-2-[3-(5-nuoro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2-hydroxypropoxy] -4-hydroxyphenyl} cyclopentanecarboxamide,
N-{5-chloro-4-hydroxy-2-[2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidin]- l'-yl) propoxy] phenyl} cyclopentanecarboxamide,
N-(5-Chloro-2- { [ (2S)-3- (5-chloro-1'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxyphenyl) benzamide trifluoroacetate,
N-(5-Chloro-2-{[(2S)-3-(5-fluoro-ltH,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxyphenyl) benzamide trifluoroacetate,
N- (5-Chloro-2-l [ (2S)-3- (5-chloro-I'H, 3H-spiro [I-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxyphenyl) urea trifluoroacetate,
N-(5-Chloro-2- { [(2S)-3-(5-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy}-4-hydroxyphenyl) urea trifluoroacetate,
N-(5-chloro-2- { [(2S)-3-(5-fluoro-l'H,3H-spiro[l-benzofuran-2,4'-piperidm]-l'-yl)-2- hydroxypropyl] oxy} phenyl) urea,
N-(5-chloro-2-{[(2S)-3-(5-chloro-l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-ll-yl)-2- hydroxypropyl] oxy} phenyl) urea,
N-(2-{[(2S)-3- (5-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2-hydroxypropyl] oxy} phenyl) urea,
N-(2-{[(259-2-hydroxy-3-(l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'- yl) propyl] oxy} phenyl) urea,
N-(4-fluoro-2- {[(259-3-(5-fluoro-l'H, 3H-spiro [l-benzofuran-2, 4'-piperidin]-l'-yl)-2- hydroxypropyl] oxy} phenyl) urea,
N-(4-fluoro-2-{[(2S)-2-hydroxy-3-(l'H,3H-spiro[l-benzofuran-2,4'-piperidin]-l'-yl) propyl] oxy} phenyl) urea,
and pharmaceutically acceptable salts and solvates of any one thereof.
9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which comprises,
(b) reacting a tricyclic spiropiperidine or spiropyrrolidines of formula
(Formula Removed)
wherein m, R1, n, R2, q, X, Y and Z are as defined in formula (I), with a tolyloxyethyloxirane of formula

(Formula Removed)
wherein R3, R4, R5, R6, R7, R8, t and R9 are as defined in formula (I)
using an organic solvent alcohol (e.g. methanol or ethanol), a hydrocarbon (e.g. toluene) or tetrahydrofuran, dimethylformamide, N-methylpyrrolidinone or acetonitrile, at a temperature of 20 to 12CTC.
10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 in weight % of 0.1 to 50% in association with a pharmaceutically acceptable adjuvant, diluent or carrier adding up to 100%.
11. The tricyclic spiropiperidine or spiropyrrolidines compounds of formula (1) or a pharmaceutically-acceptable salt or solvate thereof as claimed in any one of claims 1 to 9 for use in treatment of chronic obstructive pulmonary disease, asthma, rheumatoid arthritis and multiple sclerosis.




Documents:

4014-DELNP-2004-Abstract(24-1-2008).pdf

4014-DELNP-2004-Abstract-(14-07-2008).pdf

4014-delnp-2004-abstract.pdf

4014-DELNP-2004-Claims(24-1-2008).pdf

4014-DELNP-2004-Claims-(14-07-2008).pdf

4014-delnp-2004-claims.pdf

4014-DELNP-2004-Correspondence-Others(24-1-2008).pdf

4014-DELNP-2004-Correspondence-Others-(14-07-2008).pdf

4014-delnp-2004-correspondence-others.pdf

4014-delnp-2004-description (complete)-14-07-2008.pdf

4014-delnp-2004-description (complete).pdf

4014-DELNP-2004-Form-1(24-1-2008).pdf

4014-delnp-2004-form-1.pdf

4014-delnp-2004-form-18.pdf

4014-DELNP-2004-Form-2(24-1-2008).pdf

4014-delnp-2004-form-2.pdf

4014-DELNP-2004-Form-3(24-1-2008).pdf

4014-delnp-2004-form-3.pdf

4014-delnp-2004-form-5.pdf

4014-DELNP-2004-GPA(24-1-2008).pdf

4014-delnp-2004-gpa.pdf

4014-delnp-2004-pct-210.pdf

4014-delnp-2004-pct-304.pdf

4014-delnp-2004-pct-409.pdf

4014-DELNP-2004-Petition-137(24-1-2008).pdf

abstract.jpg


Patent Number 222108
Indian Patent Application Number 4014/DELNP/2004
PG Journal Number 32/2008
Publication Date 08-Aug-2008
Grant Date 21-Jul-2008
Date of Filing 16-Dec-2004
Name of Patentee ASTRAZENECA AB
Applicant Address S-151 85 SODERTALJE, SWEDEN.
Inventors:
# Inventor's Name Inventor's Address
1 NAFIZAL HOSSAIN ASTRAZENECA R & D LUND, S-221 87 LUND, SWEDEN.
2 SVETLANA IVANOVA ASTRAZENECA R & D LUND, S-221 87 LUND, SWEDEN.
3 MARGUERITE MENSONIDES-HARSEMA ASTRAZENECA R & D LUND, S-221 87 LUND, SWEDEN.
PCT International Classification Number C07D 491/10
PCT International Application Number PCT/SE2003/001185
PCT International Filing date 2003-07-07
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 0202133-5 2002-07-08 Sweden